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effectiveness of the key absorbent product designs to
provide a more solid basis for guiding selection and
purchase. Also to carry out the first stage in the
development of a quality of life (QoL) instrument for
measuring the impact of absorbent product use on
users’ lives. 
Design: Three clinical trials focused on the three
biggest market sectors. Each trial had a similar
crossover design in which each participant tested all
products within their group in random order. 
Setting, participants and interventions: In Trial 1,
85 women with light urinary incontinence living in the
community tested three products from each of the
four design categories available (total of 12 test
products): disposable inserts (pads); menstrual pads;
washable pants with integral pad; and washable inserts.
In Trial 2a, 85 moderate/heavily incontinent adults
(urinary or urinary/faecal) living in the community (49
men and 36 women) tested three (or two) products
from each of the five design categories available (total
of 14 test products): disposable inserts (with mesh
pants); disposable diapers (nappies); disposable pull-ups
(similar to toddlers’ trainer pants); disposable T-shaped
diapers (nappies with waist-band); and washable
diapers. All products were provided in a daytime and a
(mostly more absorbent) night-time variant. In these
first two trials, the test products were selected on the
basis of data from pilot studies. In Trial 2b, 100
moderate/heavily incontinent adults (urinary or
urinary/faecal) living in 10 nursing homes (27 men and
73 women) evaluated one product from each of the
four disposable design categories from Trial 2a.
Products were selected on the basis of product
performance in Trial 2a and, again, day time and 
night-time variants were provided. The first phase of
developing a QoL tool for measuring the impact of
using different pad designs was carried out by
interviewing participants from Trials 1 and 2a.
Main outcome measures: Product performance 
(e.g. comfort, discreetness) was characterised using a
weekly validated questionnaire. A daily pad change and
leakage diary was used to record severity of leakage,
numbers of laundry items and pads. Skin health changes
were recorded weekly. At a final interview preferences
were ranked, acceptability of each design recorded,
and overall opinion marked on a visual analogue scale
(VAS) of 0–100 points. This VAS score was used to
estimate cost-effectiveness. In addition, a timed pad
changing exercise was conducted with 10 women from
Trial 2b to determine any differences between product
designs. 
Results: Disposable inserts are currently the mainstay
of management for lightly incontinent women (Trial 1)
and they were better for leakage and other variables
(but not discreetness) and better overall than the other
three designs. However, some women preferred
menstrual pads (6/85) or washable pants (13/85), both
of which are cheaper to use. Washable inserts were
worse both overall and for leakage than the other
three designs (72/85 found them unacceptable). 
For disposable inserts and disposable diapers, findings
from the community (Trial 2a) and nursing home trials
(Trial 2b) were broadly similar. Leakage performance of
disposable inserts was worse than that of the other
designs for day and night. Pull-ups were preferred over
Health Technology Assessment 2008; Vol. 12: No. 29
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not better overall than the traditional disposable one.
However, there were important differences in
performance and preference findings for men and
women from both trials. Pull-ups (the most expensive)
were better overall than the other designs for women
during the day and for community-dwelling women
during the night. Although disposable diapers were
better for leakage than disposable inserts (the
cheapest), women did not prefer them (except in
nursing homes at night), but for men the diapers were
better both overall and for leakage and were the most
cost-effective design. No firm conclusions could be
drawn about the performance of designs for faecal
incontinence. Nursing home carers found pull-ups and
inserts easier to apply (in the standing position) and
quicker (in the pad change experiment) than the diaper
designs; the ability to stand was associated with
preference for pull-ups or inserts. The T-shaped diaper
was not easier or quicker to change than the diaper.
The washable products (Trial 2a) gave diverse results:
they were better for leakage at night, but were worse
overall for daytime than the other designs. Three-
quarters of the women (27/36) found them
unacceptable, but nearly two-thirds of men (31/49)
found them highly acceptable at night. Findings from
the two community trials (Trials 1 and 2a) showed that
there were many practical problems in dealing with
washable products but, together with the less effective
and less expensive products, such as menstrual pads,
they were more acceptable at home (and, in the case
of washables, at night). This suggests that cost-effective
management may involve combining products by using
more effective (for a given user) but more expensive
designs (e.g. pull-ups) when out and less effective but
less expensive designs when at home. The interviews
examining the impact of pad use on QoL provided
themes and domains that can be further developed into
a tool for further evaluation of absorbent products. 
Conclusions: This study showed that there were
significant and substantial differences between the
designs of absorbent products and for moderate/heavy
incontinence some designs are better for men/women
than others. There was considerable individual
variability in preferences and cost-effective
management may best be achieved by allowing users to
choose combinations of designs for different
circumstances within a budget. Further research is
needed into the feasibility of providing choice and
combinations of designs to users, as well as into the
development of more effective washables and of
specifically male disposable products. QoL
measurement tools are needed for users of absorbent
products, as are clinical trials of designs for community-
dwelling carer-dependent men and women with
moderate/heavy incontinence. 
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Background 
The UK health service, nursing homes and public
spend around £94 million per year on
incontinence pads (absorbent products) to contain
urine and/or faeces, but the research base for
making informed choices between different
product designs is very weak. 
Objectives
The aim of this trial was to compare the
performance and cost-effectiveness of the key
absorbent product designs to provide a more solid
basis for guiding selection and purchase. 
A further aim was to carry out the first stage in 
the development of a quality of life instrument for
measuring the impact of absorbent product use on
users’ lives. 
Design
The work involved three clinical trials focusing on
the three biggest market sectors. Each trial had a
similar crossover design in which each participant
tested all products within their group in random
order. 
Settings, participants and
methods 
In Trial 1, 85 women with light urinary
incontinence living in the community tested three
products from each of the four design categories
available (total of 12 test products): disposable
inserts (pads); menstrual pads; washable pants
with integral pad; and washable inserts. In Trial
2a, 85 moderate/heavily incontinent adults
(urinary or urinary/faecal) living in the community
(49 men and 36 women) tested three (or two)
products from each of the five design categories
available (total of 14 test products): disposable
inserts (with mesh pants); disposable diapers
(nappies); disposable pull-ups (similar to toddlers’
trainer pants); disposable T-shaped diapers
(nappies with waist-band); and washable diapers.
All products were provided in a daytime and a
(mostly more absorbent) night-time variant. In
these first two trials, the test products were
selected on the basis of data from pilot studies. In
Trial 2b, 100 moderate/heavily incontinent adults
(urinary or urinary/faecal) living in 10 nursing
homes (27 men and 73 women) evaluated one
product from each of the four disposable design
categories from Trial 2a. Products were selected on
the basis of product performance in Trial 2a and,
again, daytime and night-time variants were
provided. The first phase of work to develop a
quality of life tool for measuring the impact of
using different pad designs was carried out by
interviewing participants from Trials 1 and 2a.
Outcome measures
Product performance was characterised using
validated questionnaires, which asked the
participants (in Trials 1 and 2a) or carers (all
participants in Trial 2b, except for the few who
could report for themselves) to evaluate various
aspects of pad performance (leakage, ease of
putting on, discreetness, etc.) using a five-point
scale (very good–very poor) at the end of the week
(or 2 weeks for Trial 2b) of product testing. In
addition, participants/carers were asked to save
individual used pads in bags for weighing and to
indicate the severity of any leakage from them on
a three-point scale (none, a little, a lot). These
data were used to determine differences in leakage
performance. Numbers of laundry items and pads
used were recorded to estimate costs, and skin
health changes were recorded by the participant
or by the researchers (Trial 2b). At the end of
testing, participants were interviewed and ranked
their preferences (with and without costs), stated
the acceptability of each design (highly
acceptable–totally unacceptable) and recorded
their overall opinion on a visual analogue scale
(VAS) of 0–100 points (worst design–best design).
This VAS score was used with product costs to
estimate cost-effectiveness. In addition, a timed
pad changing exercise was conducted with 10
women from Trial 2b to determine any differences
between product designs. 
Executive summaryx
Results
Results presented are for statistically and clinically
significant findings. 
Trial 1
Disposable inserts are currently the mainstay of
management for lightly incontinent women and
they were better for leakage and other variables
(but not discreetness) and better overall than the
other three designs. However, some women
preferred menstrual pads (6/85) or washable pants
(13/85), both of which are cheaper to use.
Washable inserts were worse both overall and for
leakage than the other three designs (72/85 found
them unacceptable). 
Trials 2a and 2b
Disposable inserts and disposable diapers are the
designs currently most commonly used by
moderate/heavily incontinent adults. Findings
from the community (Trial 2a) and nursing home
trials (Trial 2b) were broadly similar. The leakage
performance for the disposable inserts was worse
than that of the other designs for day and night
and pull-ups were preferred over inserts for the
daytime. The new T-shaped diaper was not better
overall than the traditional disposable diaper.
However, there were important differences in
performance and preference findings for men and
women from both trials and the community-
dwelling men had more severe urinary
incontinence than the women – mean daytime
urine mass 375 g for men and 215 g for women
[difference 148 g, 95% confidence interval (CI)
79.8 to 217.7]. Pull-ups (the most expensive) were
better overall than the other designs for women
during the day and for community-dwelling
women during the night also. Although disposable
diapers were better for leakage than disposable
inserts (the cheapest), women did not prefer them
(except in nursing homes at night) but for men
the diapers were better both overall and for
leakage and were the most cost-effective design.
No firm conclusions could be drawn about the
performance of designs for faecal incontinence
and there was no firm evidence that there were
differences in skin health problems between
designs.
In the nursing home trial, the carers found pull-
ups and inserts easier to apply (in the standing
position) and quicker (in the pad change
experiment) than the diaper designs, and 
ability to stand was associated with preference 
for pull-ups or inserts. Despite being designed 
for ease of changing, the T-shaped diaper 
was not easier or quicker to change than the
diaper. 
The washable products (Trial 2a) gave diverse
results. The washables were better for leakage at
night than the other designs, but were worse
overall for daytime than the other designs. Three-
quarters of the women (27/36) found them
unacceptable, but nearly two-thirds of men (31/49)
found them highly acceptable at night. 
Findings from the two community trials (Trials 1
and 2a) showed that there were many practical
problems in dealing with washable products but,
together with the less effective and less expensive
products, such as menstrual pads, they were more
acceptable at home (and, in the case of washables,
at night). This suggests that cost-effective
management may involve combining products by
using more effective (for a given user) but more
expensive designs (e.g. pull-ups) when out and less
effective but less expensive designs when at home. 
The interviews examining the impact of pad use
on quality of life provided themes and domains
(such as hiding the problem, perceptions of
normality, coping with incontinence) that can be
further developed into a tool for further
evaluation of absorbent products. 
Conclusions
This study showed that there were significant 
and substantial differences between the designs 
of absorbent products and for moderate/heavy
incontinence some designs are better for
men/women than others. There was considerable
individual variability in preferences, and cost-
effective management may best be achieved by
allowing users to choose combinations of 
designs for different circumstances within a
budget.
Implications for healthcare
There is evidence that:
• A range of disposable and washable designs
need to be provided to cost-effectively meet
the needs of men and women with
incontinence.
• Men may require more, or more absorbent,
products than women.
• Although some users prefer washables, current
products have important limitations and a
blanket policy of providing only washables is
not recommended.
Executive summary• Allowing men and women to choose
combinations of designs for day and night 
and for different circumstances, within a limited
budget, is likely to be economical for the NHS.
Recommendations for research
The following areas need to be addressed.
• Translational research: to pilot the feasibility of
providing choice and combinations of designs
to users
• Development of more effective washables for
women with light incontinence and more
effective and appealing (particularly to 
women) washables for moderate/heavy
incontinence.
• Development of specifically male disposable
products for moderate/heavy incontinence.
• Further development of a tool to measure
quality of life for users of absorbent 
products.
• Clinical trial of designs for community-dwelling
carer-dependent men and women with
moderate/heavy incontinence.
Health Technology Assessment 2008; Vol. 12: No. 29
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Despite advances in treatments and therapies for
incontinence, completely reliable bladder or bowel
control is not an attainable goal for everyone. Many
people need support from products to achieve
‘contained incontinence’1 to enable them to carry
out their everyday lives confidently and to maintain
their quality of life (QoL). Successful management
with continence products can help people avoid
the stigmatising consequences of incontinence,
which can otherwise threaten social and working
lives, and also personal relationships.2,3
Absorbent products for incontinence are the most
common type of continence product in use and
account for the majority of NHS expenditure on
continence aids and appliances (estimated to be
around £94 million per annum4). They are
available in a wide range of designs, sizes and
absorbencies encompassing light through to heavy
incontinence. Users of products also vary widely,
from children with special needs through to
independent adults and to older people with
multiple disabilities living in nursing homes. 
In the UK, these products are available to people
living at home and in residential settings through
the NHS, although local provision may be
restricted and varies widely between primary care
trusts. Product selection is usually carried out by
nurses in consultation with patients, but there is
little evidence to support the efficacy of the
different designs of products for different patient
groups and to provide a firm basis for making
choices for individual patients.
Designs
Absorbent products may be classified into two
broad categories based on the incontinence
severity of the user: light, and moderate/heavy
incontinence. Within these categories are
disposable (single-use) and reusable (washable)
products, which are subdivided into different
body-worn designs and different underpad
designs, the latter being used mainly for
moderate/heavy incontinence. There are only two
absorbent products on the market designed
specifically for faecal incontinence (both inserts
without superabsorber; see below) and pads
designed for urinary incontinence are frequently
used for this purpose.5,6 Table 1 shows a
classification of absorbent products.
Body-worn absorbent products can be divided into
several main design groups. Inserts (sometimes
called two-piece system, liners or, in the case of
small pads, shields) are made in a wide range of
sizes suitable for light through to very heavy
incontinence. They are held in place by close-
fitting underwear or stretch mesh briefs (Figure 1)
and sometimes have an indicator that changes
colour when wet to signal the need for a pad
change. They may have longitudinal, elasticated
standing gathers of hydrophobic material
intended to impede lateral leakage of urine and
Health Technology Assessment 2008; Vol. 12: No. 29
1
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Chapter 1
Introduction
TABLE 1 Classification of absorbent continence productsa
Method of use Body-worns Underpads
Designs for moderate/heavy incontinence Inserts Bedpads
Diapers Chairpads
T-shaped diapers
Pull-ups
Design for light incontinence Inserts
Menstrual pads (W) (disposable only)
Pouches (M)
Leafs (M)
Pants with integral pad
a Most products may be used by women or men. (W) and (M) denote products specifically designed for women and men,
respectively. All designs have disposable and washable variants.faeces. Generally, they are shaped to fit the body
more snugly and elastication at the legs may also
be used to enhance fit.
Disposable inserts for light incontinence (Figure 2)
usually have an adhesive strip on the back to help
secure them. Washable inserts (Figure 3) are usually
more simply designed than disposable inserts,
with no elastication, and are either shaped or a
simple rectangle. 
Diapers (or one-piece system/all-in-ones) are
adult-sized versions of babies’ diapers (nappies).
Disposable diapers (Figure 4) usually have
elasticated waist and legs and self-adhesive tabs
(usually resealable), and often a wetness indicator
and standing gathers. Washable diapers are usually
elasticated at the waist and legs and are fixed with
Velcro or press-studs (Figure 5). Diapers are
intended for moderate to very heavy incontinence.
T-shaped diapers have recently been introduced
that fasten round the waist before the front is
pulled into position and secured, to enable users
to apply the diaper while standing (Figure 6).
Pull-ups are similar in construction to trainer
pants for toddlers. The absorbent material is built
into a pull-up pant and is either limited to the
crotch area or distributed throughout the pants.
Disposable pull-ups (Figure 7) are usually
elasticated throughout the pants to give a close fit.
Washable pull-ups are usually made in terry
towelling with an outer waterproof layer (Figure 8).
Both disposable and washable pull-ups have
versions for different levels of incontinence.
Washable pull-ups for light incontinence are often
known as pants with integral pad (Figure 9). 
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2
FIGURE 1 Stretch mesh briefs and disposable insert pad
FIGURE 2 Disposable insert pads (light) 
 
FIGURE 3 Washable insert pads (heavy and light) Health Technology Assessment 2008; Vol. 12: No. 29
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FIGURE 4 Disposable diaper
FIGURE 5 Washable diaper
FIGURE 7 Disposable pull-up
FIGURE 8 Washable pull-up
FIGURE 6 Disposable T-shaped diaper FIGURE 9 Washable pant with integral pad (light)Male pouches are for lightly incontinent men and
are designed to fit over the penis (Figure 10).
Larger pouches (often called leafs) are designed to
fit around the scrotum also. All are worn with
close-fitting underwear or stretch mesh briefs. An
adhesive strip is often provided on the disposable
versions to help hold them in place.
Underpads are usually simple rectangles of
different sizes to be used on the bed or chair
(Figure 11). Washable underpads may have a high
friction backing or have ‘wings’ for tucking
beneath the mattress of single beds to help keep
them in place. Underpads vary widely in
absorbency, with less absorbent products being
used as ‘back-up’, with body-worn absorbents and
more absorbent products being used as sole
protection on the bed at night. 
Materials
Absorbent products – disposable or washable –
usually comprise three main layers: an absorbent
core sandwiched between a waterproof backing
beneath and a water-permeable coverstock (or
topsheet) above, next to the wearer’s skin. 
The main component in disposable absorbent
cores is invariably some kind of fluffed wood pulp
fibres, but most also now contain some powdered
superabsorber [sometimes referred to as
superabsorbent polymer (SAP) or absorbent
gelling material (AGM)], which is often
concentrated in the crotch region. Superabsorbers
hold much more urine – weight for weight – than
fluff pulp and retain it far more tenaciously under
pressure. They are usually based on cross-linked
salts of polyacrylic acid, whose chemistry can be
varied according to the balance of properties such
as absorption capacity and absorption speed
desired. Some thermoplastic fibres are also
sometimes included in absorbent cores to reduce
core break-up and the collapse of the structure
when wet. It is increasingly common for absorbent
cores to comprise two or more layers, each
designed to perform a different function. For
example, an upper layer might comprise low-
absorbency fibres selected to receive and distribute
urine efficiently and maintain a dry layer next to
the skin, whereas lower layers provide absorption
capacity. Some disposable products have
‘breathable’ plastic backings designed to reduce
skin occlusion.
Washable absorbent cores are usually made either
from a needlefelt or knitted fabric comprising
rayon and/or polyester fibres or from terry
towelling. A variety of polymers are used for the
water proofing. In general, the thicker, stiffer
materials are more durable (the durability of the
plastic backing often determines the lifetime of
the product) but less comfortable. Topsheets are
usually made from either cotton, which is
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4 FIGURE 11 Underpads (disposable and washable) 
FIGURE 10 Disposable pouchhydrophilic and said to have good dry comfort, or
polyester, which is hydrophobic and said to have
good wet comfort.
Users of absorbent products
Continence pad users are a heterogeneous group,
ranging from young, mobile individuals (usually
with light incontinence) living independently in
the community to very disabled older people
(often with heavy incontinence) living in
residential settings. People in different user groups
may vary in their responses to the same designs; a
user of designs for moderate/heavy incontinence
may be an employed young adult and live
independently in the community or may be an
older person with multiple physical and cognitive
disabilities living in a nursing home and highly
dependent on care staff to meet their needs. It is
possible that their requirements are best met by
different designs. People with similar
characteristics may also vary in how acceptable
they find different designs and which they prefer.
The broad categories of user groups are shown in
Table 2.
Costs and provision of absorbent
products in the UK
The NHS usually provides free absorbent products
to people with incontinence in the UK. Products
are selected at different levels in the supply chain.
Until recently, the purchasing and distribution of
incontinence products were handled by separate
agencies. The NHS Purchasing and Supplies
Agency (PASA) purchased products from
manufacturers which it then advertised to NHS
Trusts in the NHS Logistics catalogue and
distributed to them using the NHS Logistics
delivery network. PASA could negotiate very large
contracts with manufacturers at favourable prices,
but purchased a limited range of products. Some
Trusts (up to two-thirds) chose to buy supplies
direct from manufacturers (usually by tender)
because they could access a wider range of
products and arrange for them to be delivered
direct to the homes of users. 
In October 2006, PASA and NHS Logistics were
merged into NHS Supply Chain, which, using
outsourcing to DHL, combines the procurement,
storage and distribution of products within the
NHS. Supply Chain incorporates a home delivery
service, and it is expected that Trusts will
increasingly use this service rather than deal direct
with manufacturers. In this way, Trusts will benefit
from Supply Chain’s considerable bulk purchasing
economies, although they will face reduced choice
in terms of the products they can offer to their
clients. PASA agrees prices and contracts with
manufacturers by auction that begins with paper
tenders and culminates with electronic bidding.
This method ensures that the NHS secures the
best possible procurement price. 
The products that PASA will consider buying are
selected on the basis of recommendations by a
panel of expert clinicians and continence advisers.
The products within each design are available in
different absorbencies and PASA categorises them
into bands according to the Rothwell method7 to
aid selection. At the local level, NHS Trusts
(usually in collaboration with local continence
services or district nurses) decide which products
to include in their formulary. Individual patients
are assessed and, if they are eligible for free NHS
supplies, they will be offered products from the
limited range provided by their Trust. Eligibility
criteria vary and the choice of designs for the
patient at this level is restricted. Many Trusts limit
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TABLE 2 Broad user-group categories 
User group Main setting
Own homes Residential settings
Children with enuresis ✕
Children with special needs ✕✕
Men with light incontinence (commonly prostate related) ✕
Women with light incontinence (commonly stress or urge related) ✕
Men with moderate/heavy incontinence (multiple causes including  ✕
neuro-disability related)
Women with moderate/heavy incontinence (multiple causes including  ✕
neuro-disability related)
Older men with moderate/heavy incontinence (commonly with complex  ✕✕
disabilities) 
Older women with moderate/heavy incontinence (commonly with complex  ✕✕
disabilities) the number of pads supplied per day in order to
contain costs. There is little evidence to determine
which designs should be purchased at the bulk-buy
level and which designs would be most cost-
effective at the individual level.
Literature review
Broadly, the literature reporting clinical trials on
absorbent products can be divided into two
groups: trials of small body-worn products for
light incontinence when used by community-
dwelling individuals (mainly women) and trials of
large body-worn products and underpads when
used by more dependent people in residential
settings such as wards for older people or nursing
homes. Both have included washable and
disposable products. 
Typically, studies have either examined a range of
products within a single product group (e.g. 12
disposable inserts for women with light
incontinence) or have made comparisons between
different product designs (e.g. body-worns versus
underpads), often using a new product against an
existing product, of undefined quality and
performance. The problem with the latter type of
study is that usually the extent to which either the
existing or the new product represents the group
of products it purports to is unknown. Results
from the former, single-group clinical trials, show
that where multiple products of nominally similar
products have been tested there have usually been
significant and substantial differences in product
performance.8,9 Generalising the results of
comparisons of one product within a design group
with a single product from another design group
is therefore meaningless and misleading. It is
perfectly possible to select (either by accident or
purposefully) a particularly ‘good’ product from
one category and a particularly ‘poor’ product
from another. A well-designed study will therefore
be seriously flawed if there is no clear process to
determine and justify the inclusion of the products
selected for testing. 
Designs for children
Most designs for light and moderate/heavy
incontinence (Table 1) are available for children,
(except for pouches and leafs which are designed
for adult men). There has been only one study of
absorbent products for children10 and this
compared diapers (six products) with (the more
expensive) pull-ups (six products) when used by
children with disabilities. Findings showed that the
different designs were similar in performance but
design preferences were influenced by specific
factors or needs, such as the use of calipers or
faecal incontinence. 
Designs for men and women with light
incontinence
The main designs of products for light
incontinence are shown in Table 1 and are mainly
gender specific, that is, the designs are specifically
for men or for women. 
Comparisons of products for light incontinence
Designs for men
There are eight product designs that are
potentially suitable for men with light
incontinence (disposable and washable pouches –
for penis only; disposable and washable leafs –
large pouches for penis and scrotum; disposable
and washable insert pads; and disposable and
washable pants with integral pad). Designs for
men have been the subject of only one study.
Fader and colleagues11 used a crossover design
and compared all six pouches with all six leafs
available in the UK with a single disposable insert
pad and washable pants with integral pad; a total
of four designs. Seventy-four men tested these
four product designs in a randomised order and
rated products using weekly product performance
questionnaires and pad leakage diaries. Findings
showed that the performance of the pouch
products (as judged by participants’ ‘overall
opinion’ scores) was significantly poorer than
those of the leaf and insert products. However,
scores for individual products within the pouch
and leaf design groups varied widely and one
particular leaf product was significantly better
than all the other products in the trial. The
washable pants with integral pad scored poorly for
leakage but overall were ‘loved or hated’ by
participants; men with very light incontinence
were the most likely to favour the pants. 
Designs for women
There are five product designs suitable for women
with light incontinence. Disposable insert pads are
the most commonly used products, but it is known
that menstrual pads are also frequently purchased
for this purpose. Washable pants with integral
pads and washable insert pads comprise a small
share of the market. Disposable pants with integral
pad (pull-ups) are available but are expensive and
seldom used for light incontinence.
Baker and Norton12 evaluated six small disposable
inserts and two menstrual pads (available in the
USA in 1991) with 65 community-dwelling women.
The products were rated using an evaluation
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menstrual pads (which were the least expensive
pads in the study) scored significantly higher than
many of the incontinence products, although
neither was the most popular pad. The authors
concluded that for economic reasons women
should try a ‘maxi’ menstrual pad first and then
move on to a higher capacity (incontinence) pad if
this is inadequate. However, products have
changed considerably since this study was carried
out and the current relative performance of
menstrual pads compared with disposable inserts
for incontinence is not known.
There have been two trials of products for women
which have compared products of a single design.
Clarke-O’Neill and colleagues9 compared the
complete range (12 products) of disposable inserts
for lightly incontinent women available in the UK
in 2000 when tested by 60 community-based
women aged 50 years or older. Products were
evaluated using a pad performance questionnaire
and a pad leakage diary. As a group, the products
performed well in terms of their ability to hold
urine without leakage, but there were significant
and substantial differences between products on
‘overall opinion’ (primary outcome variable)
scores. 
A similar study by the same research group8
compared the 10 washable pants with integral
pads available in the UK. Seventy-two community-
based women who usually used absorbent products
for light incontinence tested each product for
1 week each. Again, overall opinion scores showed
wide differences in product performance, although
leakage performance in general was found to be
poor. 
Summary of evidence for efficacy of
absorbent designs for light incontinence
● The main designs of absorbent products for
men with light incontinence have recently been
tested in a randomised cross-over trial and
there is evidence that one particular disposable
leaf design is significantly better than all
disposable pouch designs, disposable inserts
and washable pants with integral pad. However,
there has been no economic evaluation of these
designs.
● There have been no recent clinical trials
comparing the different designs of products for
women with light incontinence. 
● There are indications that menstrual pads may
perform similarly to disposable inserts and that
washable pants with integral pad may not be as
effective for leakage. 
● There are no data on the performance of
washable inserts and no data on comparative
costs of each design. 
Designs for men and women with
moderate/heavy incontinence
These designs are suitable for both men and
women (see Table 1). A large number of
comparative studies of absorbent products for
moderate/heavy incontinence have been made but
most include products that are no longer available.
Furthermore, changes in materials and design
features mean that it is impossible to generalise
any particular findings to products of today.
Brink13 identified 30 studies of absorbent products
published between 1965 and 1990. 
Comparisons between disposable body-worn
products for men and women with
moderate/heavy incontinence
Since 1990, there have been few studies
comparing different body-worn products for
moderate/heavy incontinence. In a double-blind
crossover study involving 45 heavily incontinent
older adults (38 women, seven men) Clancy and
Malone-Lee14 compared the leakage performance
of four different variants (each available in three
absorbencies) of a large, shaped, body-worn pad.
Each variant had been manufactured specifically
for the study, that is, none of the products was
available commercially. The results were complex
but, in general, the variant with two layers of fluff
pulp leaked significantly less than that with one
layer. Although adding some superabsorber to the
lower pulp layer produced a further significant
improvement, simply increasing the quantity of
superabsorber overall yielded no clear advantage.
It was also found that pads were more likely to
leak if they were not held in place by pants
(p < 0.0001) and that, if there was any leakage
from a pad, this tended to be less severe if the
supplied mesh pants were worn than if normal
pants were worn (p < 0.05). The mesh pants
probably held pads more firmly to the body.
There have been two single design group studies
of body-worn products for moderate/heavy
incontinence, both carried out in nursing
homes.15,16 A study of shaped insert pads included
228 subjects from 33 nursing/residential homes
who tested 20 ranges of insert pads (74 products
in total). A similar study of diapers involved 192
subjects from 37 nursing/residential homes who
tested 36 products. These studies showed the wide
range of product performance within single design
groups. For example, the least successful diaper
(based on ‘overall opinion’) was found to be
Health Technology Assessment 2008; Vol. 12: No. 29
7
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.unacceptable to 100% of the test subjects whereas
the most successful was unacceptable to only 6%.
Overall the diapers performed better for leakage
than the inserts.
Because clinical evaluations are expensive and
time consuming, laboratory evaluation procedures
are in widespread use. Few have been clinically
validated but there is a clinically validated
International Standard relating to the leakage
performance of disposable body-worn pads for
moderate/heavy incontinence (ISO 11948–1,
1996). It describes a simple method for measuring
the absorption capacity of pads in the laboratory
that was shown to correlate well with the leakage
performance of 18 different products evaluated in
an international multi-centre clinical study
involving 112 heavily incontinent adults.17 PASA
uses this standard (known as the Rothwell
Method7) as a basis for classifying pads by
absorbency to assist them in dealing with tenders
for national contracts.
Comparisons of washable body-worn products for
men and women with moderate/heavy
incontinence
There have been no robust clinical evaluations
comparing washable absorbent body-worn
products for moderate/heavy adult incontinence.
However, Macaulay and colleagues18 recently
carried out a pilot study of 19 products with 14
community-dwelling subjects. The products
included a mixture of washable insert, diaper and
pull-up designs and two disposable body-worn
products. Product performances varied widely: the
most popular was rated as good (for overall
opinion) by 78% of testers, whereas the least
popular scored 22%. Although most of the
washable products performed poorly for leakage,
one washable product made of cotton terry
towelling scored better than all the other washable
and disposable products.
Comparison between disposable and washable
body-worn products
Seven trials have compared disposable with
washable body-worn products for moderate/heavy
incontinence.19–24 The trials varied in size and
design from a large controlled trial with 276
subjects19 to a small trial of 11 subjects.22 In
addition, some trials have compared disposable
and washable bedpads and body-worns.25,26 No
systematic methods of product selection were used
for these studies, which limits the utility of the
results since particularly good or poor products
may have been selected to represent the
disposable or washable groups.
Skin condition was used as an outcome measure in
five of the above trials. However, only three used
an experimental design and statistical methods of
analysis.19,20,27 Two studies reported that they did
not find statistically significant differences between
the washable and disposable products in terms of
an adverse change in skin condition, but one27
reported a statistically significant improvement in
the skin condition of the disposable users as
compared with the washable users. 
Other parameters frequently investigated in these
studies were staff preference, leakage and laundry.
Overall, the disposables in the studies were
considered to have performed better than the
washable products in terms of preventing leakage
(often measured by quantity of laundry) and staff
preference.
Four studies attempted to measure costs.20,21,26,28
Of these, three used statistical methods of
analysis.20,26,28 Two studies reported no statistically
significant differences26,28 in terms of per day
product costs between disposable and washable
products. However, Brown and colleagues26
reported that the laundry costs associated with the
disposable product (i.e. for laundering soiled bed
linen and clothes) were significantly lower than
those associated with the washable product (i.e. for
laundering the products in addition to soiled bed
linen and clothes). There were no significant
differences between daily costs of the washable or
disposable products. However, statistically
significant differences were found between the
groups in terms of incontinence-related laundry,
with the disposable group producing less laundry
than the washable group. Grant20 reported that
the cost of washable products was significantly
cheaper than that of disposables, but laundry costs
were not taken into account.
In a small trial comparing two new disposable
products with a washable product that was in
established use,29 the results favoured the
disposable products. However, the washable
product was not adequately described and it is not
clear whether this product was a body-worn
product or a bedpad. Staff morale improved with
the disposable product and they reported a
decrease in unpleasantness associated with
changing pads.
Summary of evidence for efficacy of
absorbent designs for moderate/heavy
incontinence
● Research evidence indicates that disposable
insert pads leak significantly less if they are held
Introduction
8in place by mesh pants than by ordinary pants,
and using no pants at all is associated with
significantly more leakage than if either kind of
pant is worn. 
● There is evidence that disposable pads
containing superabsorber leak less than those
without.
● The leakage performance of disposable inserts
and diapers for heavy incontinence can be
predicted with reasonable precision using
international standard laboratory tests. 
● The leakage performance of disposable diapers
may be better than that of disposable inserts of
similar absorption capacity, although this has
not been demonstrated in a clinical trial.
● The literature indicates that disposable body-
worn products generally perform better than
washables in terms of skin condition and
leakage. However, it is clear that there are more
and less effective products in each category. 
Systematic reviews of literature
comparing designs for moderate/heavy
incontinence
The majority of the clinical trials comparing
different designs of absorbent products for
moderate/heavy incontinence are more than
10 years old and include products that are not
available today. Reviewers of the absorbent
product literature30–32 have also commented on
problems of weak study design, small study size
and lack of statistical power.
Shirran and Brazzelli33 carried out a Cochrane
review of four different comparisons:
(1) disposable body-worns versus washable body-
worns; (2) disposable underpads versus non-
disposable underpads; (3) one type of material
versus another; and (4) body-worns versus
underpads. The authors concluded that data from
examined studies were too few and of insufficient
quality to provide a firm basis for practice and
that there was a need for larger, well-designed
trials of products. Tentative practice
recommendations were that disposable products
may be preferable to washable products for those
with skin problems, that underpads may be
cheaper than body-worns and that disposable pads
with superabsorber appear to perform better than
those without. 
The reasons for selecting the four comparisons
made in the Cochrane review are unclear. It seems
likely that the rationale for the comparisons
chosen was that they were those most commonly
made over the last 20 years, but changes in
product use and practice mean that comparisons
of body-worn products are more clinically relevant
today (see the section ‘Which designs should be
evaluated?’, p. 10).
Methodological issues affecting
absorbent product research
Method problems affecting product evaluation
have been analysed by Fader and colleagues.34
The authors (ourselves) suggest that a simple
randomised control trial (RCT) is inappropriate
because of the difficulty in determining a ‘control’
pad. A crossover trial is therefore the most
appropriate design, particularly as incontinence is
frequently a chronic condition and use of products
does not affect the underlying symptoms.34
The problem of selecting a single product to
represent a design group (when it is known that
individual products vary considerably) may be
addressed by including several products from the
same design group rather than by simply relying
on one representative product. The need for many
secondary outcome variables to reflect the
diversity of product characteristics that influence
user preference is also discussed. For example,
invisibility under clothing may be of vital
importance to some people, whereas others are less
concerned about bulk and more concerned about
preventing leakage. We conclude that patient
‘overall opinion’ is likely to provide the most
appropriate primary outcome variable because it
synthesises the various strengths and limitations of
the product from the patient perspective.
A number of product characteristics which
contribute to patient ‘overall opinion’ are also
expected to be relevant to the development of a
health-related QoL measure for people who use
absorbent products. QoL measures are of
particular importance in clinical trials for the
comparison of treatments/products with little
apparent difference in objective clinical outcomes
in the patient’s condition but where patient
morbidity and everyday life are affected. This is
relevant for patients whose urinary or faecal
incontinence is managed by the use of absorbent
products and which are used to contain the
problem rather than improve it. Currently, there is
no validated measure for QoL for people using
absorbent products; most existing QoL
instruments measure severity of urinary
symptoms.35 Such symptoms are not expected to
change when wearing different continence
products, although patients with similar symptoms
often have different views of the ‘bothersomeness’
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associated with the effectiveness of the absorbent
products that they use. The development of a
specific QoL instrument to reflect the QoL impact
of different absorbent products would be a
valuable addition to product evaluation
methodology and would contribute to more
meaningful comparisons between studies.
Which designs should be
evaluated?
There are many designs of absorbent products and
therefore many different comparisons could be
made within the broad categories of light and
moderate/heavy incontinence. The Cochrane
review mentioned in the last section33 focused on
comparisons between bedpads and body-worns,
and washable and disposable bedpads. About
10–20 years ago it was common for incontinent
people to use bedpads alone, sometimes for both
day and night, and studies involving bedpads were
therefore of importance. Times have changed and
the use of bedpads as the primary method of
containing incontinence is not considered
optimum practice these days. Body-worn pads are
now the mainstay of management, with bedpads
being used primarily as ‘back-up’ to contain
leakage from body-worn pads. There are dignity
issues with the use of bedpads; when used on their
own bedpads require the individual to stay in one
place and be naked from the waist down, which
many regard as unacceptable. Although tentative
review findings suggest that bedpad use may be
cheaper than body-worn use, it is likely that
patient and staff acceptability will be low and it is
questionable whether there is value in attempting
to demonstrate this further.
Product designs have also already changed to
incorporate favourable features. It is hard now to
find a body-worn disposable pad without
superabsorber and virtually all products are
shaped. It is difficult to justify a study seeking to
measure the value of such features.
Of greater importance is the need to determine
which of the main body-worn designs are most
effective and most preferred by patients and
carers. The current NHS purchasing of absorbent
products is dominated by disposable insert pads
for both light and heavy incontinence; data
supplied by PASA indicate that insert pads
comprise about two-thirds of the total body-worn
market and diapers about one-quarter. Washable
absorbent products constitute less than 1% of the
market. In this way, the UK differs from other
European countries and the USA, where diaper
designs are much more popular than insert pads
for moderate/heavy incontinence.
New designs have been introduced in the last few
years which may have benefits for patients but
have yet to be tested. Both the ‘pull-up’ design
and the modified T-shaped diaper have been
designed to make application easier. Companies
are investing substantially in these designs but it is
unknown whether patients and staff prefer them
and whether they are worth their higher cost.
Although more expensive on a ‘per pad’ basis 
than diaper or insert products, these products 
may enable some patients to manage their
toileting and pads themselves and may save
nursing time.
The UK remains largely a ‘disposable’ rather than
a ‘washable’ nation, but it is possible that a shift to
washable products would be more cost-effective.
Washable products have the potential to be less
expensive to use than disposable products in the
long term,36 but their leakage performance (for
heavy incontinence particularly) has been found to
be poor. However most studies of these products
are old and technological developments have been
made which may mean that the products of today
have better performance. 
Summary
● Absorbent products are the common method of
managing urinary and faecal incontinence and
their cost to the NHS is estimated to be about
£94 million per annum. 
● Absorbent products comprise many different
designs, which may be broadly classified into
two groups: products suitable for light
incontinence or those suitable for
moderate/heavy incontinence.
● Absorbent product users are a heterogeneous
group and vary widely in terms of their ages,
abilities and needs and live both in the
community and in residential settings. 
● Absorbent products for men with light
incontinence and products for children with
disabilities have been studied recently and there
is evidence to guide product selection. 
● Systematic literature reviews indicate that there
is no firm basis for making choices between
designs of absorbent products for women with
light incontinence and for individuals with
moderate/heavy urinary and/or faecal
incontinence. Furthermore, there is no current
evidence on the cost-effectiveness of current
designs.
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changed over the last few years and new body-
worn designs have been introduced. 
● Comparisons of different body-worn designs
(both disposable and washable) for both light
and moderate/heavy incontinence are the most
clinically relevant. 
● Absorbent product evaluation is
methodologically challenging and requires
careful planning and special measures
(particularly with regard to product selection
and representation) to produce valid, reliable
and generalisable results.
● The development of a QoL instrument would
be a valuable addition to product evaluation
methodology.
● Given the substantial cost of absorbent products
to the NHS, clinical trials should incorporate an
economic component.
A project was therefore planned with the following
aims. 
Aims
The aims were to compare the performance and
cost-effectiveness of the key absorbent product
designs for the containment of urinary or urinary
and faecal incontinence for women with light
incontinence and men and women with
moderate/heavy incontinence living in the
community and in nursing homes, and to identify
aspects of absorbent product use that impact on
QoL for users and carers to form the basis for the
development of a QoL instrument.
Overall project plan
The plan for this research project comprises three
clinical trials comparing the performance of key
absorbent designs: 
● Clinical trial 1. A comparison of the
performance and cost-effectiveness of
disposable and washable designs for light
incontinence (disposable inserts, menstrual
pads, washable pants with integral pad,
washable inserts – four designs) when used by
women living in the community.
● Clinical trial 2a. A comparison of the
performance and cost-effectiveness of
disposable and washable designs for
moderate/heavy incontinence (disposable
inserts, diapers, T-shaped diapers, pull-ups and
washable diapers – five designs) when used by
men and women living in the community.
● Clinical trial 2b. A comparison of the
performance and cost-effectiveness of
disposable designs for moderate/heavy
incontinence (disposable inserts, diapers, 
T-shaped diapers, pull-ups – four designs) when
used by men and women living in nursing
homes.
Data collected during the clinical trials will be
used for the first stage in the development of a
QoL instrument for people using absorbent
products.
Health Technology Assessment 2008; Vol. 12: No. 29
11
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.Introduction
This project comprised three clinical trials of
absorbent product designs. This section gives an
overview of the research design, methods and
outcomes used in the trials. Details specific to each
clinical trial are given in the separate chapters
relating to each trial. The three clinical trials were
as follows.
1. Designs for women with light incontinence
(a) Clinical trial 1. A comparison of the
performance and cost-effectiveness of
disposable and washable designs for light
incontinence (disposable inserts, menstrual
pads, washable pants with integral pad,
washable inserts – four designs) when used
by women living in the community.
2. Designs for men and women with
moderate/heavy incontinence
(a) Clinical trial 2a. A comparison of the
performance and cost-effectiveness of
disposable and washable designs for
moderate/heavy incontinence (disposable
inserts, diapers, T-shaped diapers, pull-ups
and washable diapers – five designs) when
used by men and women living in the
community.
(b) Clinical trial 2b. A comparison of the
performance and cost-effectiveness of
disposable designs for moderate/heavy
incontinence (disposable inserts, diapers, 
T-shaped diapers, pull-ups – four designs)
when used by men and women living in
nursing homes.
3. Centres
The trials were conducted from two centres
(University College London and the University
of Southampton) who work in partnership as
the Continence and Skin Technology Group.
Design
The three clinical trials were carried out using
randomised crossover designs. A crossover design
is appropriate for testing interventions with
participants who have chronic conditions (such as
incontinence) which will not be changed by the
intervention (such as an absorbent product). A
crossover design has advantages over RCTs in that
all participants receive each of the interventions
allowing for comparison at the individual rather
than the group level. Also, as patients receive
multiple interventions, preferences may be
expressed.37 This is particularly appropriate when
there is no ‘control’ intervention, such as in these
trials, when all tested products are potential
interventions.
For crossover designs, smaller sample sizes are
needed to produce the same precision as a parallel
group design. Responses between subjects (which
may be large) in parallel group designs are
replaced by repeated responses from the same
patients (which are usually smaller) in crossover
designs and more precise results are therefore
achievable.
Absorbent product selection and
representation
Absorbent products within a design group have
been found to vary substantially in performance
(see the section ‘Literature review’ p. 6). To
overcome the potential threat to validity of
including a single product, which may not be
representative of each design under study, three
products were selected (where possible) to
represent each design group for clinical trials 1
(light, community) and 2a (moderate/heavy
community). Selection was based on data from
recent studies (where available) or from pilot data
collected before the trial began. The aim was to
include the ‘best’ of the most commonly used
products within a design group. Some design
groups, particularly newer designs, had only three
or, in one case, only two products available, in
which case all were used in the trial. The methods
used to select the products for for clinical trials 1
(light, community) and 2a (moderate/heavy,
community) are shown in Appendices 1 and 4.
For clinical trial 2b (moderate/heavy, nursing
homes), a simpler approach was used to make the
study easier for homes to administer. A single
product was selected from the three products
chosen for clinical trial 2a to represent each
design. Product selection was based on data from
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Chapter 2
Research design and methodsparticipants from clinical trial 2a (moderate/heavy,
community) who had completed the trial and on
product availability through PASA.
Randomisation
Crossover designs require participants to receive
all interventions and it is therefore the order of
testing that requires randomisation. For clinical
trials 1 and 2a, the three products selected to
represent each design were tested in random
order for 1 week each, as a 3-week block of
testing. The order of each block was also
randomised. For clinical trial 2b (moderate/heavy,
nursing homes), which had only one product to
represent each design, the order of testing each
design was randomised and each design was tested
for a 2-week period (to allow sufficient time for
staff and residents to experience each design).
Latin squares38 were used to prepare all order
sequences.
Blinding
It was not possible to blind the products. Each
design is different and most products within 
each design have some identifiable company or
product names printed on the product backing. 
Initial participant interviews
Background information
Each participant (or carer/participant in the case
of clinical trial 2b – moderate/heavy incontinence,
nursing homes) was interviewed following
recruitment and the background descriptive data
shown in Table 3 were obtained.
Participant background data were collected to
assemble individual characteristics and
incontinence-related details (e.g. age, type of
incontinence, type of absorbent products currently
used) and economic information (e.g. self or NHS
purchase of supplies, household income). It is
known that physical impairment is associated with
incontinence and the Barthel score39 (to assess
independence in activities of daily living) was used
to assess this. To measure the effect that
incontinence has on QoL, the two most commonly
used scores were used: the International
Consultation on Incontinence Questionnaire –
Urinary Incontinence (short form) (ICIQ-UI)40
and the Kings QoL score41; a generic score (SF-
12)42 was also used to enable comparisons of the
samples across other groups. Incontinence is
known to be associated with anxiety and
depression43 and the Hospital Anxiety and
Depression Scale (HADS) was therefore used.44 A
brief laundry questionnaire was used to determine
laundry habits to allow relevant calculation of
laundry burden. For the nursing home residents
(Trial 2b), who were more likely to be most at risk
of skin health problems, two scores were used to
assess pressure ulcer risk: the Braden scale,45
commonly used in the USA, and the Norton
score,46 commonly used in the UK. The
Hodkinson mental test47 score was used to assess
the extent of cognitive impairment in the nursing
home residents.
Product performance priorities and
effects of pad wearing on quality of life
Participants (and carers in trial 2b) were asked to
identify what aspects of absorbent product
Research design and methods
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TABLE 3 Background descriptive data 
Questionnaire/score Purpose: to provide  Clinical trial 
Background demographic  Descriptive data on age, gender, product use,  1, 2a and 2b (socio-economic 
socio-economic information socio-economic data data excluded from 2b)
Laundry questionnaire Information on participant laundry facilities  1 and 2a
Barthel score A measure of independence in activities of daily living score All
SF-12 A measure of general QoL  1 and 2a
Kings QoL score A measure of incontinence-specific QoL  1 and 2a
ICIQ-UI (short form) A brief measure of incontinence-specific QoL  1 and 2a
Hospital Anxiety and  An assessment of anxiety and depressive symptoms  1 and 2a
Depression Scale (HADS)
Hodkinson mental test score A (brief) assessment of cognitive function 2b only
Norton score An assessment of pressure ulcer risk (UK orientated) 2b only
Braden score An assessment of pressure ulcer risk (US orientated) 2b onlyperformance were most important to them. They
were also asked to describe how problems with
these aspects affected their QoL. For example, if
discreetness under clothes was considered
important, the effect on the participant’s QoL may
be to alter the types of clothing they might wear
or to avoid social situations where they may feel
conscious of the pad showing. These interviews
identified the most important secondary outcome
variables to utilise in the analysis of the product
performance questionnaires and also provided
data for the development of the QoL tool.
Outcome variables
Primary outcome variable
The primary function of an absorbent product is
to absorb and contain urine (and/or faeces)
without leakage. However, a design with very good
leakage performance may also be bulky,
uncomfortable or unacceptable to the individual
in some other way, and measurement of leakage
performance is not therefore the most appropriate
primary outcome variable. 
This study used the participant ‘overall opinion’ of
each absorbent design, taken at a final interview at
the end of the study after all product designs had
been tested, as the primary outcome variable
because this gives a synthesis of the individual’s
perceptions of the design. Individuals rate
products for various aspects of performance (such
as leakage, comfort or staying in place), but they
have different priorities and may weight
characteristics differently, so an aggregate score
may not give an accurate reflection of the
individual’s overall opinion of the design.
The aim was to carry out the final interview within
4 weeks of completion of the testing period. To
minimise dependence on recall, the data
collection booklets containing the participants’
product performance scores (including ‘overall
opinion’) and written comments about the
products were reviewed with the participants at
their final interviews. The products were displayed
to aid memory and participants were asked to
consider their scores and comments before
comparing the designs and giving their final
‘overall opinion’ scores. 
Overall opinion was measured on a simple rating
scale of acceptability to the individual: highly
acceptable, acceptable, unacceptable, totally
unacceptable. For analysis purposes, this scale can
be binarised to establish which designs are
unacceptable (highly acceptable + acceptable)
versus (unacceptable + totally unacceptable).
Overall opinion was also measured using a 100-mm
visual analogue scale (VAS) from ‘worst possible
design’ to ‘best possible design’ to measure
strength of preference. Participants were asked to
mark the relative positions of each design along
this scale. This method provided a single score
(out of 100) of the individual’s overall opinion of
the design. For the nursing home staff (clinical
trial 2b), a simplified 10-point measure was used
because this was found to be easier for staff to use. 
Respondents were also asked to rank the designs
to determine preferences. They were then told the
relative cost of the different designs and asked to
re-rank them.
Secondary outcome variables
Pad change/leakage diary 
During the product testing period, participants
were asked to keep a diary to record individual
pad changes. An example of how this was
recorded is shown in Table 4.
This provided the following data. 
Health Technology Assessment 2008; Vol. 12: No. 29
15
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
TABLE 4 Example of pad weight and leakage diary 
Date Unable Weight NO A LITTLE A LOT OF
to weigh (g) LEAKAGE LEAKAGE LEAKAGE
No urine leaked  Urine leaked on to  Urine leaked 
out of the pad  underwear only onto clothing or 
area other items (e.g.
cushion)
01.05.04 100 ✓Leakage performance
Leakage has been shown by pad users to be the
most important performance outcome variable.48
Leakage is dependent on urine volume (a pad with
10 ml of urine is much less likely to leak than a pad
with 100 ml of urine), and this may vary for
different designs. An individual may change their
pads more frequently or undertake efforts to
minimise their incontinence if they are concerned
that a product will leak. Differences in product
weights may also reflect differences in leakage
performance, with less urine being contained by
leaky products. Leakage performance was calculated
in two ways, using methods that have been used
successfully in previous studies8,11 – each used pad
was collected and weighed using digital scales, and
the participants (or carers in trial 2b) then rated any
leakage that occurred on a three-point scale, as
‘none’, ‘a little’ or ‘a lot’. For clinical trial 1 ‘a little’
was defined as leakage on to underwear only and ‘a
lot’ as on to underwear plus other clothing.
However, for clinical trials 2a and 2b definitions
were not given because most of the designs replaced
underwear and participants were left to make these
judgements. These diary data permit the analysis of
leakage performance in two ways: (none) versus (a
little + a lot) and (none + a little) versus (a lot).
Modelling of leakage performance as a function of
urine weight and a calculation of leakage event
frequency were also performed.
For clinical trial 2b (moderate/heavy, nursing homes),
rather than use pad change/leakage diaries, which
can be very difficult for staff to maintain, labelled
plastic bags were used to store each used pad,
which had simple tick boxes to indicate leakage
and laundry generated (if any) and to identify any
staff-observed skin problems. These pads were
weighed (as above) mainly by research staff or by
nursing home staff with training (if volunteers were
available) and the labels placed in a data book. 
Pad and laundry consumption 
The number of products used per day and the
number of laundry items (small and large)
produced from leakage were calculated using pad
change/leakage diary data. For clinical trial 2b
(moderate/heavy, nursing homes), product
consumption was calculated by regular checking of
each individual’s labelled packs and counting the
number of pads used. 
Weekly product performance questionnaire
Based on outcomes and validated questionnaires
used in previous studies8,11 of absorbent products
such as comfort when wet, comfort when dry, ease
of application and invisibility under clothes, a
questionnaire was devised for participants to
complete at the end of each week of product
testing. To add to the validity of these items, the
data obtained from the preliminary participant
interviews were used to determine and prioritise
questionnaire items. The self-report questionnaire
utilised a five-point rating scale (very good, good,
okay, poor, very poor) with the intention that
questions would be analysed by binarising in two
ways: to establish good performance (very good +
good) versus (otherwise) and poor performance
(very good + good + okay) versus (otherwise). 
For trials 2a and 2b (moderate/heavy), separate
product performance questionnaires were used for
day and for night. 
Skin health
Participants in clinical trials 1 and 2a rated their
own skin health using a rating scale ‘no skin
problems’, ‘a little or mild’ or ‘a lot or moderate/
severe’). Participants in clinical trial 2a (moderate/
heavy, community), who used much larger products
covering extensive skin areas, were also asked to
identify the location of their skin problems (groins,
buttocks, sacrum, other). If skin problems were
experienced, the participants were asked to record
what action (if any) they took to treat the problem.
For clinical trial 2b, skin problems were identified
by research staff inspecting and rating each
participant’s skin during the second week of
product testing. 
Sample size and methods of
analysis
The sample size for each module was calculated to
allow the detection, with about 90% power, of a
difference of 30% in ‘overall opinion’ scores in any
pairwise comparison of design groups, with an
overall significance level at most 5% for all such
pairwise comparisons. Using these criteria, target
participant numbers for each clinical trial were as
follows:
● clinical trial 1 (light, community): four design
comparisons, 80 participants 
● clinical trial 2a (moderate/heavy, community):
five design comparisons, 85 participants 
● clinical trial 2b (moderate/heavy, nursing
homes): four designs, 80 participants.
Most design groups were expected to perform very
similarly. To check this, comparisons would be
made on products within each design group for
leakage and overall opinion. With 80 participants
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with an overall significance level of at most 5% for
all pairwise comparisons.
Data were entered into Microsoft Excel (Version
2003), cleaned, and 10% of the data set and 100%
of the primary outcome variable data were
checked for accurate entry. Ordinal outcome
variables were analysed using cumulative logit
modelling and quantitative outcome variables were
analysed by linear modelling, allowing for
repeated observations by each subject. Bonferroni
adjustments were made in significance tests and to
confidence intervals (CIs) for multiple
comparisons between designs. R software was used
(www.r-project.org).
Economic analysis
The economic analysis adopted the perspectives of
individual participants and the health service. A
cost-effectiveness analysis was conducted based on
mean VAS scores (as a measure of product
performance) and the cost of products/designs.
VAS scores were used as the primary measure of
effectiveness because they were assigned by
participants after testing all designs, and were
therefore assumed to reflect their evaluation of
overall performance based on experience. If there
is no statistically significant difference in mean
VAS scores between designs, then a cost
minimisation approach is adopted with the less
expensive design recommended. If one design
dominates [i.e. is more effective (higher mean
VAS) and cheaper than others], it is
recommended. Where one design is more effective
and more costly than others, incremental cost-
effectiveness ratios (ICERs) are calculated to show
the cost of generating one more unit of
effectiveness (one more VAS point).
For disposable designs, costs are based on
purchase prices and mean product consumption
data reported by participants at baseline. For
washable designs, costs were calculated from
purchase prices and estimated replacement rates.
Data from manufacturers on the life of products
(number of washes) and assumptions about the
stocks of products held by users were made to
estimate replacement rates. Laundry costs of
washable designs were considered. If differential
leakage performance resulted in significant
variation in the amount of laundry generated
amongst designs, this was also included in the
analysis. Laundry costs are borne by the user,
although the NHS provides the products to most
people with moderate/heavy incontinence and
some of the women with light incontinence. In the
nursing home trial (2b), differences between
designs in the amount of time it takes to change
residents and the number of staff involved were
investigated.
Prices of products used in trials were collected
from various sources. The prices faced by women
with light incontinence in the community, many of
whom purchase their own products, were obtained
from national chain retail outlets and mail order
catalogues. The prices paid by NHS providers
were derived from the current NHS Logistics
catalogue at the time of the trial.
Environmental considerations
An important consideration in the comparison of
washable and disposable designs is the relative
environmental cost. A recent report on baby
nappies concluded that there was no significant
difference in environmental impact between three
main nappy systems (disposables, home and
commercial laundered), although the types of
impacts did vary.49 It was assumed that these
findings are generalisable to adult incontinence
products, and accordingly no allowance was made
in the cost-effectiveness calculations for
environmental factors.
Effect of costs on participant
preferences
During the final interview, after all product testing
was completed, participants were shown the
relative costs of products in different designs and
asked which they would select first, second, third
and fourth, and why. They were also asked about
their willingness-to-buy different designs from
their own perspectives (at retail/mail order prices)
and from the NHS perspective (at lower NHS bulk
buying prices, but after being reminded that the
finance is from taxpayers’ money). Changes in
respondents’ rankings of designs after costs were
disclosed were analysed. Of particular interest
were participants’ stated preferences between
disposable and washable products when potential
savings associated with washables became
apparent. The value-for-money question was
simplified in the care home trial because piloting
with care staff showed they found this line of
enquiry difficult. They were asked to focus on
differences between designs in the average 
daily (or nightly) cost of providing products to
residents.
To try to establish the extent to which participants
valued their most preferred product over their
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second choice product they would buy that instead
of their first choice. In piloting, however,
respondents found this line of questioning
difficult, so it was dropped in order to limit the
length of the interview.
Ethical arrangements
The study was reviewed by the London multi-
centre research ethics committee and complied
fully with ethical, governance and data protection
requirements and approval was obtained through
appropriate NHS research ethics committees.
Written informed consent was obtained from each
participant. In clinical trial 2b, most participants
were unable to give informed consent due to
mental impairment and a specialised consenting
procedure was devised and approved by the ethics
committee and is described in more detail in
Chapter 5. 
Withdrawal
Participants were able to withdraw from using any
particular product at any time. If withdrawal
occurred, we requested that a product
performance questionnaire was completed and a
‘reason for withdrawal from product’ form
completed. Participants were able to move on to
their next product should they wish to continue in
the study. Participants who wished to discontinue
taking part in the study could do so at any time
without giving a reason.
Confidentiality
Participants received a code number which was
used on all study documentation. The recruitment
forms containing personal details are kept in a
locked filing cabinet in a separate room from the
data. The data will be kept in a locked cabinet in a
data storage room for 15 years following study
completion.
Project supervision
The project was guided and monitored by a
steering group which comprised an independent
chairman with expertise in the urinary and faecal
incontinence field, two representatives from
Incontact (the consumer organisation for people
with bladder and bowel problems), a
representative from PASA, a representative from
the Registered Nursing Home Association, a
clinical continence service manager and other
members of the project team. 
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There are four designs of absorbent products
suitable for women with light incontinence
(Table 5). Disposable insert pads are the most
commonly used products, but it is known that
menstrual pads are also frequently purchased for
this purpose. Washable pants with integral pad
and washable insert pads comprise a small share
of the market. There have been no recent clinical
trials comparing the different designs of products
for women with light incontinence. There are
indications that menstrual pads may perform
similarly to disposable inserts12 and that washable
pants may not be as effective for preventing
leakage, although washable designs may be
cheaper on a per use basis. There are no
published data on the performance of washable
inserts and no data on comparative costs of each
design. There is therefore very little evidence on
which to base product selection decisions for NHS
purchasing and for individuals. 
Aim
The aim of the study was to compare the
performance and cost-effectiveness of absorbent
product designs for women with light urinary
incontinence living in the community. 
Design and methods
The trial was a randomised crossover clinical trial
comparing four absorbent product designs:
disposable insert (DI), menstrual pad (MP),
washable pant with integral pad (WP) and
washable insert (WI) (Figure 12). 
Recruitment of participants
The inclusion and exclusion criteria for participants
are shown in Box 1. The aim was to recruit
participants who were already using an absorbent
product suitable for light incontinence (including
MPs) and whose incontinence was consistent and
stable and occurred at least five times per week.
This was to ensure that the participants’
incontinence was not likely to change during the
period of the trial and that their frequency of
incontinence was sufficient to justify the provision
of an absorbent product from the NHS and to test
the efficacy of the products included in the trial.
Participants were recruited to the study in the
following ways:
● A press release was prepared to announce the
study and this was distributed to local and
national newspapers and magazines.
● An invitation letter was sent to purchasers of
absorbent products through Promocon (the
national information centre for continence
products) and to receivers of absorbent products
through local NHS Trust delivery services.
Study process
During the study, participants tested the four
designs (comprising 12 products, three for each
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Chapter 3
Randomised crossover trial of disposable 
and washable absorbent products for women with
light urinary incontinence (Trial 1)
TABLE 5 Classification of absorbent products for women with light incontinence 
Materials
Disposablea Washable
Design for light incontinence Disposable inserts (DIs) Washable inserts (WIs)
Menstrual pads (MPs)  Washable pants with integral pad (WPs)
a Disposable pants with integral pad (pull-ups) are available but are expensive and seldom used for light incontinence.design,) over a 12-week period (1 week for each
product). During testing, they weighed used
products and kept a pad change/leakage diary, and
completed a product performance questionnaire
at the end of each week of testing. At the end of
the testing period, a final interview was completed
to determine preferences and opinions. The study
process is shown in Figure 13.
Outcome measures
The outcome measures (see Chapter 2 for more
details) are listed below. These documents were
individualised according to the participant’s
randomisation plan, colour coded by design to
facilitate completion and assembled into a bound
booklet (case record form).
Products for women with light urinary incontinence (Trial 1)
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BOX 1 Participant inclusion and exclusion criteria
Inclusion criteria:
Adult women, over 18 years of age
Resident in community
Stable and consistent incontinence at least 5 times per
week 
Currently using absorbent products suitable for light
incontinence, e.g. small insert or MP
Able to complete self-report questionnaires
Exclusion criteria:
Acute illness
Terminal phase of illness
Outcomes during testing period
Product consumption, laundry and 
  leakage diary
Weekly product performance 
  questionnaire
Weekly skin health diary
Period 1: 3 weeks
Design 1: Product A,B,C
Interview: Participant background data and scores
Period 2: 3 weeks
Design 2: Product A,B,C
Period 3: 3 weeks
Design 3: Product A,B,C
Period 4: 3 weeks
Design 4: Product A,B,C
Final interview: Design comparisons and preferences
with and without costs
12-week 
period
FIGURE 13 Overview of study process
FIGURE 12 (a) Disposable insert (DI); (b) menstrual pad (MI);
(c) washable pant (WP) and (d) washable insert (WI)
(a)
(b)
(c)
(d)During the period of product testing, a pad
change/leakage diary (completed at each pad
change) was maintained to record:
● number of products used per day and night
(consumption)
● laundry resulting from incontinence (small and
large items) 
● leakage from product (none, a little, a lot)
● weight of used pad (g). 
At the end of each week of product testing, a
product performance questionnaire was
completed to record:
● product performance variables (e.g.
discreetness) rated as very good, good, okay,
poor, very poor
● changes in skin health problems in pad area
(none, a little or mild, a lot or moderate/severe).
At the end of the trial, a final interview was
completed to record:
● design preferences and rankings with and
without costs
● overall acceptability of design (highly
acceptable, acceptable, unacceptable, totally
unacceptable) 
● VAS (worst possible design–best possible design)
● comments about good and poor aspects of
designs 
● views about washables versus disposable designs
● views about costs and NHS provision
● willingness to buy (after prices disclosed).
Selection of absorbent products
to represent design groups
It is known that individual products within
absorbent product design groups vary widely48 and
selection of a single product to represent a given
design is unsafe. Three products were therefore
selected to represent each design with the aim of
including the ‘best’ of the most commonly used
products within a design group. Products were
selected to include (in order of priority) the
highest scoring products from previous clinical
trials, those in common use (available through
PASA and/or from major manufacturer) and from
a range of manufacturers. The method of selection
is shown in detail in Appendix 1. The full range of
DIs and WPs available in the UK have recently
been compared in separate studies and data were
used from these studies to select the three
products within the design group. Three night-
time MPs were selected from those commonly
available in chemists and supermarkets and all the
three WIs for light incontinence available on the
market were included. The size of the absorbent
area of all products was similar except for the MPs,
which were slightly smaller than the products in
the other three groups. 
Securing the product in place
The two disposable designs (DIs and MPs)
incorporated an adhesive backing to fix the
product in the pants. The WI designs were worn
with close-fitting pants and one of the products
had a Velcro patch to aid fixation in pants. The
WP designs incorporated underpants and
therefore required no additional fixings.
Study preparation and
procedures: participant
preparation and interviews
Eligibility interview
Potential participants who contacted us by
telephone, reply-paid slip, letter or email were
interviewed on the telephone. The study was
described according to the participant information
sheet and eligibility to join the study was
established. If the person was eligible and
expressed willingness to join the study, the
participant information sheet and consent form
were posted with a reply-paid envelope. 
Participant information interview
Potential participants who returned the signed
consent form were contacted and an interview was
arranged either at the research centre or in their
own home, or exceptionally, when neither was
practical, on the telephone. During this interview,
the participant background information and
scores were completed (Table 6). Participants were
also asked about the effects that incontinence pad
usage had on their QoL (see Chapter 6) and were
asked to name and rank product performance
characteristics that they considered to be of
greatest importance. 
At this interview, the self-report study
documentation and instruction booklet were
explained to the participant and the digital scales
for product weighing were demonstrated to ensure
competence.
Product testing period
Together with their box of test products,
participants were provided with an instruction
booklet, which had been piloted on volunteer
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Electronic digital scales and plastic bags were
provided for pad weighing. Participants were asked
to telephone the research centre when they received
the box to inform us when they were starting
testing and to enable us to answer any queries.
Participants tested their 12 products (four designs)
for 1 week each and completed the pad
change/leakage diary and weekly product
performance questionnaire during this 12-week
period. Participants could withdraw from testing a
product at any time, but were asked to complete
the product performance questionnaire and early
stopping form to record the reasons for stopping
using the product. The participant would then
move on to the next product. Participants were
free to withdraw from the study at any time and
without giving any reason.
Participant monitoring 
Participants were given contact numbers of their
designated research nurse and invited to
telephone the research centre if they had any
queries. In addition, the research nurses contacted
the participants regularly by fortnightly phone
calls to monitor trial progress. 
Final interview
On completion of testing, a final interview was
arranged either at the research centre or in the
participant’s home to complete the design
comparison and preferences questionnaire and to
return all questionnaires and diaries. 
At the final interview, participants were asked to
rank the individual products tested (with and
without costs) within each design group and then
rank the different designs. The different designs
were scored on a VAS and participants rated the
designs using the overall acceptability score.
Participants were also asked whether they would
recommend the designs to others.
To assess views on value for money of different
designs, participants were shown the monthly cost
of using the product they had previously identified
as the best value for money in each design.
Monthly costs were based on the assumption that
people used four products per 24 hours (the most
common rate of consumption reported by
participants at recruitment). For washables, it was
assumed that women need to hold a stock of
12 products and each product could be washed
120 times before it needed to be replaced
(manufacturers’ data and researchers’ experience).
Laundry costs of washable items were not
included, although respondents were reminded of
this when making their choice among designs. 
Participants were then asked about the
acceptability of using the designs in different
situations and the practicalities of using disposable
and washable designs. They were also asked to
comment on the relative strengths and limitations
of the designs and their views on provision of
products by the NHS.
Ethics
The study was reviewed by the London multi-
centre research ethics committee and complied
fully with ethical, governance and data protection
requirements and approval was obtained through
appropriate NHS research ethics committees.
Product preparation,
randomisation and blinding
Waist and hip measurements (for the WP design)
were used to prepare individualised boxes of
products for sending to participants. Blinding was
not practical because most products were labelled
in some way (disposable products had the name of
the product printed on their adhesive strips).
Products were therefore provided in their original
packaging complete with any instructions but,
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TABLE 6 Participant background information and scores 
Questionnaire/score Purpose: to provide
Background demographic socio-economic  Descriptive data on age, gender, product use, socio-economic data
information
Barthel score A measure of independence in activities of daily living score
SF-12 A measure of general QoL 
Kings QoL score A measure of incontinence-specific QoL 
ICIQ-UI (short form) A (brief) measure of incontinence-specific QoL 
HADS An assessment of anxiety and depressive symptoms because washing instructions varied slightly
between manufacturers, participants were provided
with generic ones used in a previous trial.8 The
washable products were washed twice to remove
any dressing and repackaged. Product packages
were marked with study labels indicating the week
number in which the product should be tested. 
The order of testing products was randomised
using Latin squares38 both for the order between
design group and within design group (i.e. the
order of the three products of the same design).
Each product was tested for 1 week and the testing
of a complete design therefore took 3 weeks. 
Analysis
Data were entered into Microsoft Excel Version
2003, cleaned and 10% of the data set and 100%
of the primary outcome variable data were
checked for accurate entry. The data were
transferred to SPSS Version 14, for further analysis.
Ordinal outcome variables were analysed using
cumulative logit modelling and quantitative
outcome variables were analysed by linear
modelling, allowing for repeated observations by
each subject. Bonferroni adjustments were made
in significance tests and to CIs for multiple
comparisons between designs. R software was used
(www.r-project.org).
Results
Participant characteristics
A total of 272 potential participants contacted the
research centre, of whom 115 were both eligible
and consented to take part in the trial. Ninety-
nine participants began testing products and 85
completed testing of all products and gave a final
interview. Four women were unable to use the WP
designs because the pants were not available in
sufficiently large sizes. Progress of participants
through the trial is shown in Figure 14. Participant
characteristics are shown in Table 7.
Generally, participants were older women (mean
age 60 years), living in their own homes with 
good mobility and independence in activities of
daily living. Twenty (23.5%) were in full- or part-
time employment or seeking work, 50 (58.8%)
were married or had a partner, about 90% had
annual household income below the national
average and the income of 40% of participants was
reported to be in the lowest quintile. Around two-
thirds of the participants bought their own
absorbent pads and the remaining one-third
obtained them from the NHS. Sixty-one (71.8%)
of the participants used products during the night
in addition to during the day. Twelve women
stated that they had experienced faecal
incontinence and seven women were carrying out
intermittent catheterisation in addition to using
absorbent products.
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47 ineligible
272 patients assessed for eligibility
14 withdrew during study:
  7 ill-health
  3 no reason given
  1 bereavement
  1 changed mind
  1 products not  suitable
  1 too much bother
16 withdrew before 
study started
225 patients sent study information
115 consented to take part
99 patients began testing
85 patients completed 
FIGURE 14 Progress of participants through the trialProducts for women with light urinary incontinence (Trial 1)
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TABLE 7 Participant characteristics (N = 85, except where missing data stated)
Participant background  % (N)
information
Age (years)  Mean 60.4  <40 40–59 60–79 80
(SD 13.9) 8.2 (7) 41.2 (35) 44.7 (38) 5.9 (5)
Type of incontinence Stress Urge Mixed Other
23.5 (20) 12.9 (11) 61.2 (52) 2.4 (2)
HADS (10 declined)  0–7 8–10 11–21
Normal Borderline Abnormal
Anxiety 53.3 (40) 22.7 (17) 24.0 (18)
Depression 68.0 (51) 16.0 (12) 16.0 (12)
ICIQ-UI score (max. 21)  Mean 12.5 (SD 3.8)
(a high score = low QoL)
SF-12: mean (SD), scale 0–100  Standardised physical component Standardised mental component
(norm = 50, best health = 100,  32.7 (14.2) 47.1 (10.4)
worst health = 0)
Kings QoL score  Mean (SD)  Mean (SD) Mean (SD) Mean (SD) 
(incontinence- specific)  all 9 domains  incontinence  social  severity 
(high score = low QoL)  impact  limitations  measures 
(Max. score all domains, 900. 
Max. each domain, 100).  473 (199.8) 69 (27.6) 30 (30.2) 73 (17.2)
Only 3 domains shown 
Barthel score  Mean 82.6 45 50–65 70–85 90
(activities of daily living) (SD 11.5) 1.2 (1) 12.9 (11) 29.4 (25) 56.5 (48)
(0 = total dependence, 
100 = independent. N.B. max. 
for this group = 90–10 points 
deducted for incontinence)
Mobility  Walk independently  Walk with aid  Uses wheelchair 
(independently) 
71.8 (61) 22.4 (19) 5.9 (5)
Intermittent catheterisation 8.2 (7)
Faecal incontinence 14.1 (12) 
Type of product used  DI MP WP Cut-up baby nappy
80.0 (68) 17.6 (15) 1.2 (1) 1.2 (1)
NHS or self-pay NHS Self-pay
36.5 (31) 63.5 (54)
Number of products used  Day Night
per day/night 3.51 (SD 1.97) 1.13 (SD 0.95)
Years using products <1: 3.5 (3)  1–5: 49.4 (42)  >5: 47.1 (40)
Incontinence laundry 44.7 (38) launder incontinence-related items separately
Socio-economic variables
Marital status Married, cohabits Single Widowed, separated, divorced 
58.8 (50) 11.8 (10) 29.4 (25)
Highest level of education Primary Secondary University Diplomas, NVQs, etc. 
8.2 (7) 70.1 (60) 10.6 (9) 10.6 (9)
Employment status Full time Part-time Homemaker Seek work Retired
8.2 (7) 10.6 (9) 10.6 (9) 4.7 (4) 48.2 (41)
Other: 17.6 (15) 
Household income (£000 pa)  <10 10–19.99 20–29.99 30–39.99 40–49.99 50
(2 missing)  43.5 (37)  31.8 (27)  14.1 (12) 3.5 (3)  2.4 (2)  2.4 (2)
Accommodation Detached Semi-detached Terraced/bungalow Flat
20.0 (17) 37.6 (32) 29.4 (25) 12.9 (11)
SD, standard deviation.Product results within design groups
The product performance questionnaires were
analysed and comparisons made between the
three different products comprising each design
group. This showed that there were no products
that were significantly worse than the two other
products in its group for leakage. The data from
the product performance questionnaires and
leakage diaries were therefore combined for all the
products within each design group. 
Frequency and severity of leakage 
A total of 8691 used products were saved and
weighed by participants and leakage severity
scores (none, a little, a lot) were recorded for 
8402 products. Pad leakage diary data were 
used to estimate the probability of the different
designs leaking for different urine masses. Table 8
shows the median urine weights in the different
designs. 
Leakage performance was modelled for each
design, based on the binarised leakage data (none)
versus (a little + a lot) and urine weights; Figure 15
shows the plots of the probabilities of no leakage
at all for increasing urine masses and Table 9
shows the proportions of the saved and weighed
pads that leaked. Urine mass was found to be a
significant variable and analysis was therefore
adjusted for this. There were significant
differences between all the designs in their ability
to prevent leakage, in the order DI better than
MP, MP better than WP and WP better than WI,
for all urine masses.
Explanation of leakage curves
Pads do not have a simple capacity below which
they are guaranteed not to leak and above which
they will definitely leak. Rather, as the volume (i.e.
mass) of urine increases, the probability of the pad
leaking increases. The leakage performance curves
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TABLE 8 Median urine mass in each design (weighed from collected pads) for 8691 total products
MP DI WP WI
Daytime 10.7 17.0 8.3 6.0
Median urine mass (g) (IQ range)  (4.3–28.0) (5.0–48.8) (3.9–23.0) (2.15–18.0)
No. of products 1835 1876 1455 1210
Night-time 12.0 17 9.0 6
Median urine mass (g) (IQ range) (4.3–28.3) (5.0–44.0) (4.0–24.2) (2.0–13.6)
No. of products  699 747 451 418
IQ, inter-quartile.
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FIGURE 15 Estimated probabilities of no leakage at different urine masses by design (with 95% CI)were constructed for each design (by combining
data from the various products of the same
design) and show how the probability of the
design not leaking changed with increasing urine
mass. In general, the more successful a design, the
higher was the performance curve on the graph:
a perfect design would have a probability of not
leaking at all of 1 (= certainty) for all urine
masses.
Intuitively, these probability curves should have a
value of 1.0 for zero urine mass – how can a pad
leak if there is no urine in it? Weighing used pads
provides an estimate only of the mass of urine in
the pad and excludes any leakage from the pad:
accordingly, the urine masses used in constructing
the curves will often have been (slight)
underestimates of the actual masses voided by the
wearer. For example, a pad may leak (and the
urine mass in the pad be recorded as zero) if the
absorbent area is out of position. One of the
effects of this is that the leakage performance
curves of products will meet the y-axis at values
<1.0, the value which would be expected
naturally. In the extreme, a pad capable of
holding no urine at all would be certain to leak
whatever quantity of urine its user voided and yet
all used pads would contain zero urine mass. It is
therefore not surprising that the leakage curves of
very poorly performing products, such as WIs,
meet the y-axis at values substantially less than 1.0.
In addition, dry masses vary (coefficient of
variation of the order of 10%) and so there will be
small errors in estimated urine masses. These
errors will be negligible for high urine masses but
more substantial for (nearly) dry pads.
Less washable products were saved and weighed,
which reflects the higher number of participants
that discontinued use of washable products. This
can be seen in the early stopping data shown in
Table 10. 
Consumption of products
Pad change diary data were used to calculate the
mean number of products used per day and night.
Table 11 shows the results [with standard deviation
(SD)] for the different design groups. Weighted
means are used because participants recorded
numbers of products used per day over variable
periods (up to 7 days).
There were no significant differences in
consumption for day or night, except that WPs
were used slightly less than WIs during the day;
this result just reached significance (estimated
difference of means 0.91, 95% CI for ratio of
means 0.82 to 0.99).
Laundry resulting from leakage
Pad change/leakage diary data were used to
calculate the mean number of items (small and
large) sent for laundering as a result of leakage
from the product. Table 12 shows the mean
number of laundry items per 24 hours by design,
including laundering the washable products
themselves. 
There were significant differences in laundry
amounts between all designs with the DI design
generating the least amount of laundry (around
half as much as MPs). The washable designs
(obviously) created more washing (around 9–10
times more than the DI). The WI design was worse
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TABLE 9 Proportions of saved and weighed pads that leaked,
for 8402 total products weighed (with leakage amount
recorded)a
% (N)
MP DI WP WI
(2459)b (2578)b (1819)b (1546)b
No leakage 74.0 84.3 62.6 46.3
(1820) (2172) (1139) (715)
A little leakage 18.3 13.2 21.2 33.3
(451) (340) (386) (514)
A lot of leakage 7.7 2.6 16.2 20.5
(188) (66) (294) (317)
a Comparisons between designs and CIs shown in forest
plots in Figures 17–22.
b No. of products.
TABLE 11 Mean number of products used day and night by
design (N = 85)
MP DI WP WI
Weighted mean number  1.77 1.71 1.64 1.79
of products used per  (0.82) (0.81) (0.86) (0.90)
day (SD)
Weighted mean number  1.15 1.12 1.10 1.13
of products used per  (0.34) (0.29) (0.26) (0.29)
night (SD)
TABLE 10 Mean number of participants who stopped testing a
design early (N = 85)
MP DI WP WI
11 5 25 34than the WP design, but this difference was small
and only just significant.
Skin health
Participants were asked to keep a weekly diary of
skin health. Table 13 shows the proportions
reporting skin health problems associated with
product use. 
The DI design was significantly better than the
two washable designs, and the MP design was
significantly better than the WP design. The two
washable designs were not significantly different
from each other.
Product performance questionnaires
Participants completed a weekly product
performance questionnaire to score the
performance of each product. Scores for the
highest priority variables (leakage, discreetness,
smell, comfort when dry, comfort when wet and
staying in place; see Chapter 6) were analysed and
those for individual products within designs are
shown in Appendix 2. There were some significant
differences between products within designs but
no product was significantly worse than the other
two products in the same group for leakage and
overall opinion. The scores for each of the three
products within a design were therefore combined
to give an average response result for each
variable and these are shown in Table 14. CIs and
comparisons between pairs of designs are shown
in the summary forest plots in Figures 17–22). 
Participants’ rating of the ability of the product to
hold urine without leaking reflected the leakage
performance from the pad leakage diary data (DI
better than MP, MP better than WP, WP better
than WI). For comfort when wet and smell there
were significant differences between all designs in
the same order as above, but no significant
differences between the two washable designs. For
comfort when dry there were no significant
differences between designs, except that the DI and
WP designs were significantly more comfortable
than the WI pads. The DI design was significantly
worse than the MP design for discreetness but
there were no significant differences between the
other designs. For staying in place, the WI pad was
significantly worse than all the other designs.
Final interview: overall opinion
and preferences
Participants were asked to rank the designs in
order of their preference (Table 15) and state 
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TABLE 12 Weighted mean number of laundry items per 24 hours by design (N = 84) 
MP DI WP WI
Weighted mean number of laundry items per  0.64 (0.99) 0.37 (0.96) 3.23 (2.39) 3.75 (2.19)
24 hours (SD)
Laundry: comparisons between designs 
Estimated ratio of means 95% CIa
MP  More laundry than: DI 1.93 1.02 to 3.66
MP  Less laundry than: WP 0.20 0.14 to 0.29
MP  Less laundry than: WI 0.17 0.11 to 0.26
DI  Less laundry than: WP 0.10 0.05 to 0.24
DI  Less laundry than: WI 0.09 0.04 to 0.21
WP  Less laundry than: WI 0.85 0.75 to 0.98
a CIs include Bonferroni adjustment for multiple comparisons.
TABLE 13 Skin health: proportions of participants reporting
skin health problems [N = 3 observations for each design
(maximum of 255 observations)]a
% (N)
MP DI WP WI
(247)b (248)b (229)b (222)b
No skin problem 84.2 88.3 78.6 73.9
(208) (219) (180) (164)
A little (mild) 13.0 9.7 14.9 20.7
(32) (24) (34) (46)
A lot (moderate/ 2.8 2.0 6.6 5.4
severe) (7) (5) (15) (12)
a CIs for comparisons between designs are shown in
Figures 17–22.
b No. of products.their overall acceptability of the different 
designs (highly acceptable, acceptable,
unacceptable, totally unacceptable) (Table 16) 
and score each design out of 100 on a VAS 
(Table 17). No night VAS scores were requested
but participants were asked if they would alter
their design ratings at night. Three people
replied that they would rate a different design as
best (DI to MP, DI to WP, MP to DI). Participants
were also asked whether they would recommend a
design for use by others.
There were significant differences between all
designs in the order DI better than MP, MP better
than WP and WP better than WI for paired
comparisons of preferences (see Figures 17–22).
Disposable designs were the most preferred and
women mainly chose the DIs first (N = 63) and
the MPs second (N = 51). Over 90% of subjects
found DIs acceptable on a binarised acceptability
scale: (highly acceptable + acceptable) versus
(unacceptable + totally unacceptable) and said
they would recommend them.
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TABLE 14 Product performance questionnaire: product responses combined to give an average response for each design (%)a,b
MP DI WP WI
Leakage (day) Very good 16 33 9 3
Good 25 32 23 10
OK 30 26 20 20
Poor 20 7 25 28
Very poor 9 3 22 40
Leakage (night) Very good 16 36 10 3
Good 23 30 22 12
OK 33 25 28 24
Poor 20 6 16 31
Very poor 8 3 24 31
Stay in place (day) Very good 18 28 26 4
Good 37 36 37 13
OK 36 31 29 22
Poor 8 5 6 34
Very poor 1 1 2 26
Smell Very good 6 20 8 2
Good 24 33 17 11
OK 46 35 34 43
Poor 17 10 29 29
Very poor 6 2 12 17
Discreet Very good 15 16 18 8
Good 32 24 34 25
OK 37 36 27 48
Poor 13 22 16 14
Very poor 2244
Dry comfort Very good 20 27 29 9
Good 38 41 32 24
OK 33 27 29 47
Poor 8 5 7 16
Very poor 2135
Wet comfort Very good 5 16 7 0
Good 25 26 14 9
OK 35 41 25 28
Poor 25 13 34 30
Very poor 10 5 21 32
Keep skin dry Very good 7 21 7 3
Good 27 34 17 7
OK 41 35 28 30
Poor 19 7 30 34
Very poor 5 3 19 26
a Shading indicates where binarisation occurs (very good + good + OK) versus (poor + very poor).
b Rounding means that numbers may not always add up to 100. Although the mean VAS score of MPs was 20
points lower than that of DIs, they were acceptable
to 80% of participants and would be
recommended by 70%. It is notable that the MP
was rarely the first choice (N = 8) and more
women chose WPs first (N = 13). Washable
products had mean VAS scores below 50 and were
acceptable to less than 50% of respondents. WIs
were rated very low, with a mean VAS of 20 and
15% acceptability and recommendation rating. 
Examination of responses about acceptability
(Table 16) shows that WPs were regarded as highly
acceptable by more participants than MPs (18.6 vs
11.8%). 
On all three criteria, both day and night, DIs were
rated most highly. The 95% CIs surrounding the
mean VAS are shown in Table 17. There is no
overlap between designs.
Acceptability in different situations
Subjects were asked about the acceptability of
different designs in different situations.
Acceptability in different situations is shown in
Figure 16. 
The results show that DIs have the highest
approval in all situations. MPs and WPs are
deemed acceptable by 87.1 and 66.7% of women,
respectively, for use at home but approval ratings
drop substantially for use in other social (out of
home) situations (MPs 46%; WPs <25%).
Explanation of forest plots
For primary and secondary outcome variables
results are calculated as proportions, such as
participants’ rating of discreetness binarised as
(very good + good + okay) versus (poor + very
poor). For example, design A may score 60% (very
good + good + okay) and 40% (poor + very
poor) and design B may score 50% (very good +
good + okay) and 50% (poor + very poor). In this
case, it appears that design A is better than design
B for discreetness. To examine whether we can be
confident that this difference between the two
designs are real, an odds ratio (OR) and CI are
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TABLE 15 Paired comparison of preferences between the
different designsa
Number preferring designb Total
DI 72 vs MP 13 85
DI 64 vs WP 17 81
DI 78 vs WI 7 85
MP 56 vs WP 25 81
MP 76 vs WI 9 85
WP 61 vs WI 20 81
a Comparisons between the designs are shown in
Figures 17–22. 
b Four women did not test the WP design because
products were not available in their sizes.
TABLE 16 Acceptability of designs for day and nighta
% (N)
MP DI WP WI
Day Night Day Night Day Night Day Night
(85) (62) (85) (62) (81) (59) (85) (62)
Highly acceptable 11.8 19.4 69.4 64.5 18.6 20.3 2.4 4.8
(10) (12) (59) (40) (15) (12) (2) (3)
Acceptable 69.4 58.1 27.1 32.3 25.9 18.6 12.9 14.5
(59) (36) (23) (20) (21) (11) (11) (9)
Unacceptable/totally 18.8 22.5 3.6 3.2 55.6 61.0 84.7 80.6
unacceptable (16) (14) (3) (2) (45) (36) (72) (50)
a Comparisons between designs and CIs are shown in Figures 17–22.
TABLE 17 Mean VAS with 95% CIs 
WI WP MP DI
Mean (95% CI)  19.9 42.7 58.3 79.3
(15.1 to 24.6) (36.1 to 49.4) (53.0 to 63.6) (75.5 to 83.1)calculated. If there is no difference between the
two results, this will give an OR of 1. Where there
are differences (as in the example of discreetness
above), the OR will be greater or less than one.
The CI is a number that spans the OR (giving a
higher and a lower limit) and shows how much
uncertainty there is about the OR.
The ORs and CIs have been calculated for
comparisons between each pair of designs and for
each variable where the results are shown as
proportions. The ORs and CIs have been stacked
one on top of each other on a forest plot showing
comparisons between each pair of designs.
The ORs and CIs are shown in relation to a
vertical line which is the centre of the forest plot.
This line gives the OR of 1 (i.e. no difference).
Each variable is named on the far left of the forest
plot and the OR and CI are written on the far
right. The scale is shown on the bottom with
numbers below 1 on the left and above 1 on the
right. 
Each OR is shown as a black box with a horizontal
line (the 95% CI) running through it. Where the
line touches or crosses the vertical line (at OR =1)
there is no significant difference between the
proportions for the two designs. Where the box
and horizontal line lie completely to one or other
side of the vertical line, one can be confident that
the proportions for each design are significantly
different.
To show readily how each pair of designs compare
with each other, the ORs are plotted so that where
a design scores better than the other design for
any variable, the OR (i.e. the black box) is on the
side of the vertical line that favours that design.
Hence the ORs shown are for the second named
design versus the first named design in the
heading. The primary outcome variables from the
final interview (overall acceptability and
preference) are shown at the bottom of each forest
plot and these reflect the overall performance of
the different designs. The other secondary
outcome variables measure different aspects of
performance and some designs may be
particularly good or bad at different variables. For
example, in the forest plot comparing the DI 
with the MP, the plot shows that the DI is better
than the MP on almost all variables (including
overall acceptability and preference), but is worse
for discreetness (the OR black box is on the
‘favours’ MP side and does not (quite) touch the
vertical line of no difference. The last line of the
forest plot shows the odds on the second named
design being preferred to the first.
There are four designs and six comparisons; each
forest plot in Figures 17–22 shows the data
obtained from:
● Leakage – pad diary: (from the pad
change/leakage diary) binarised as (none) versus
(a little + a lot).
● Leakage – participant rating: (from the final
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FIGURE 16 Acceptability of designs in different situations, for use ‘at home’ compared with ‘when out’interview) binarised as (very good + good +
OK) versus (poor + very poor) 
● Five key variables from the product performance
questionnaire: all binarised as (very good +
good + OK) versus (poor + very poor) 
● Skin health problems: (data from the
participants’ skin health diary) binarised as
(none) versus (a little + a lot).
● Every day activities: (taken from the final
interview and indicating the effect that the
design had on the users’ everyday life),
binarised as (good + none) versus (bad effect).
● Overall acceptability: (from the final interview)
and binarised as (highly acceptable +
acceptable) versus (unacceptable + totally
unacceptable), abbreviated on the forest plots as
(high/okay) versus (no).
● Preference: (from the final interview) this
indicates the odds on the second named design
being preferred to the first.
Health Technology Assessment 2008; Vol. 12: No. 29
31
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Odds ratio (95% CI)
0.29 (0.17 to 0.49) Leakage – pad diary (none vs a little/a lot)
0.27 (0.14 to 0.52) Leakage – participant rating (good/okay vs poor)
1.69 (1.01 to 2.82) Discreetness (good/okay vs poor)
0.44 (0.24 to 0.82) Smell (good/okay vs poor)
0.56 (0.18 to 1.71) Comfort when dry (good/okay vs poor)
0.40 (0.24 to 0.68) Comfort when wet (good/okay vs poor)
0.61 (0.19 to 1.92) Staying in place (good/okay vs poor)
0.70 (0.37 to 1.33) Skin health problems (none vs a little/a lot)
0.29 (0.07 to 1.11) Everyday activities (good/none vs bad effect)
0.28 (0.14 to 0.56) Overall acceptability (high/okay vs no)
0.18 (0.08 to 0.41) Preference
0.01 0.1 0.2
Favours disposable insert Favours menstrual pad
0.5 1 2 5
FIGURE 17 Forest plot: DI versus MP 
Odds ratio (95% CI)
0.14 (0.06 to 0.30) Leakage – pad diary (none vs a little/a lot)
0.12 (0.06 to 0.26) Leakage – participant rating (good/okay vs poor)
1.23 (0.65 to 2.33) Discreetness (good/okay vs poor)
0.44 (0.24 to 0.82) Smell (good/okay vs poor)
0.49 (0.19 to 1.26) Comfort when dry (good/okay vs poor)
0.18 (0.10 to 0.32) Comfort when wet (good/okay vs poor)
0.67 (0.25 to 1.80) Staying in place (good/okay vs poor)
0.48 (0.25 to 0.92) Skin health problems (none vs a little/a lot)
0.09 (0.02 to 0.32) Everyday activities (good/none vs bad effect)
0.14 (0.07 to 0.29) Overall acceptability (high/okay vs no)
0.27 (0.13 to 0.55) Preference
0.01 0.1 0.2
Favours disposable insert Favours washable pant
0.5 1 2 5
FIGURE 18 Forest plot: DI versus WPComments about designs
When ranking designs, participants were asked
about the good and poor aspects of each and
about why they thought their top and lowest
ranked products were best/worst, respectively. 
An analysis of the responses given is shown in
Table 18. Key themes were identified and the
number of times each was mentioned is 
recorded. 
Absorbency/good leakage performance/confidence
are strong points for disposable products,
especially DIs, although negative comments
relating to bulkiness were also made against DIs. 
Economic analysis
Value for money
To establish respondents’ views about the relative
value for money of each design, researchers asked
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Odds ratio (95% CI)
0.05 (0.02 to 0.12) Leakage – pad diary (none vs a little/a lot)
0.05 (0.02 to 0.12) Leakage – participant rating (good/okay vs poor)
1.36 (0.68 to 2.72) Discreetness (good/okay vs poor)
0.16 (0.08 to 0.30) Smell (good/okay vs poor)
0.23 (0.08 to 0.67) Comfort when dry (good/okay vs poor)
0.13 (0.07 to 0.25) Comfort when wet (good/okay vs poor)
0.04 (0.02 to 0.11) Staying in place (good/okay vs poor)
0.48 (0.25 to 0.92) Skin health problems (none vs a little/a lot)
0.04 (0.01 to 0.15) Everyday activities (good/none vs bad effect)
0.37 (0.20 to 0.71) Overall acceptability (high/okay vs no)
0.09 (0.03 to 0.26) Preference
0.01 0.1 0.2
Favours disposable insert Favours washable insert
0.5 1 2 5
FIGURE 19 Forest plot: DI versus WI
Odds ratio (95% CI)
0.47 (0.26 to 0.86) Leakage – pad diary (none vs a little/a lot)
0.45 (0.26 to 0.80) Leakage – participant rating (good/okay vs poor)
0.73 (0.38 to 1.41) Discreetness (good/okay vs poor)
0.42 (0.24 to 0.73) Smell (good/okay vs poor)
0.88 (0.36 to 2.15) Comfort when dry (good/okay vs poor)
0.44 (0.26 to 0.75) Comfort when wet (good/okay vs poor)
1.10 (0.44 to 2.77) Staying in place (good/okay vs poor)
0.68 (0.38 to 1.20) Skin health problems (none vs a little/a lot)
0.30 (0.13 to 0.68) Everyday activities (good/none vs bad effect)
0.50 (0.27 to 0.90) Overall acceptability (high/okay vs no)
0.45 (0.24 to 0.84) Preference
0.01 0.1 0.2
Favours disposable pad Favours washable pant
0.5 1 2 5
FIGURE 20 Forest plot: MP versus WPthem to consider the monthly cost of supplying
the products that they had previously identified as
the best value for money in each design. As most
women in the trial purchased their own products,
the retail and mail order prices prevailing at the
time (September 2004) were used. Monthly costs
were based on median reported product utilisation
at baseline (three/day, one/night). For washable
products, replacement rates were calculated from
manufacturers’ data about product life and
researchers’ experience (suggesting120 washes),
and an assumption that women would hold a stock
of 12 products. 
There was considerable variation in the costs of
products within designs, but no overlap between
designs (Table 19). The expense of laundering
washable products (which is borne by individuals)
is not included in the monthly costs and
respondents were reminded of this when asked to
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Odds ratio (95% CI)
0.17 (0.09 to 0.29) Leakage – pad diary (none vs a little/a lot)
0.20 (0.11 to 0.37) Leakage – participant rating (good/okay vs poor)
0.80 (0.41 to 1.56) Discreetness (good/okay vs poor)
0.36 (0.21 to 0.60) Smell (good/okay vs poor)
0.41 (0.19 to 1.13) Comfort when dry (good/okay vs poor)
0.33 (0.18 to 0.60) Comfort when wet (good/okay vs poor)
0.07 (0.03 to 0.15) Staying in place (good/okay vs poor)
0.53 (0.30 to 0.93) Skin health problems (none vs a little/a lot)
0.13 (0.06 to 0.31) Everyday activities (good/none vs bad effect)
0.19 (0.11 to 0.35) Overall acceptability (high/okay vs no)
0.12 (0.05 to 0.30) Preference
0.01 0.1 0.2
Favours menstrual pad Favours washable insert
0.5 1 2 5
FIGURE 21 Forest plot: MP versus WI 
Odds ratio (95% CI)
0.36 (0.21 to 0.60) Leakage – pad diary (none vs a little/a lot)
0.45 (0.26 to 0.78) Leakage – participant rating (good/okay vs poor)
1.10 (0.52 to 2.36) Discreetness (good/okay vs poor)
0.85 (0.46 to 1.58) Smell (good/okay vs poor)
0.46 (0.22 to 0.95) Comfort when dry (good/okay vs poor)
0.74 (0.45 to 1.24) Comfort when wet (good/okay vs poor)
0.06 (0.03 to 0.13) Staying in place (good/okay vs poor)
0.78 (0.42 to 1.46) Skin health problems (none vs a little/a lot)
0.45 (0.20 to 1.03) Everyday activities (good/none vs bad effect)
0.39 (0.22 to 0.67) Overall acceptability (high/okay vs no)
0.33 (0.17 to 0.65) Preference
0.01 0.1 0.2
Favours washable pant Favours washable insert
0.5 1 2 5
FIGURE 22 Forest plot: WP versus WIstate their preferences. Participants were asked, if
they were buying their own products, which
designs they would select first, second, third and
fourth, and why, and which designs they would be
willing to buy (Table 19). Of particular interest
were participants’ stated preferences between
disposable and washable products when potential
savings associated with washables became
apparent. 
When relative monthly costs were disclosed, the
main trend was for switching between disposable
designs from more expensive DIs (11 women
demoted them from top place) to less expensive
MPs (promoted to first place by six respondents).
By contrast, the switch to washable products was
small (MPs gained two top places and DIs gained
one). Willingness to buy for the two disposable
designs are similar at 80% and the clear
superiority of DIs before prices were disclosed has
been reduced (see Table 19). Less than 10% of
participants expressed a willingness to buy WIs
even though they are the cheapest design by a
large margin. 
In addition, we compared the first choice
preferences (from the ranking data) of self-payers
with NHS-funded participants (Table 20).
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TABLE 18 Summary of comments (count of key themes) on design preferences 
MP DI WP WI
Aspect N Aspect N Aspect N Aspect N
Good  Absorbency (good) 8 Absorbency (good) 34 Comfort 6 Washable 4
aspects Comfort 5 Comfort 24 Cost 2 Not  bulky/discreet  3
Not bulky/discreet 3 Disposable aspects 17 Environment 2 Comfort 4
Stay in place 2 No smell 8 Washable 3 Cost 2
Disposable aspects 4 Stay in place 7 Stay in place 3 Environment 1
Fit 2 Fit 3 Fit 2 Stay in place 1
No odour/smell 2 Not bulky 1 Not bulky 2 Absorbency (good) 1
Poor  Absorbency (poor) 2 Bulky 15 Washing drying 4 Absorbency (poor) 4
aspects  Bulky 2 Heavy when wet 2 Comfort 4 Not stay in place 7
Uncomfortable 1 Irritate skin 5 Washable 1 Irritate skin 2
Too long 1 Stay in place 1 Heavy when wet 1 Odour/smell 1
Fit (poor) 2 Absorbency 1 Noisy 1
Cost 3 Uncomfortable 1
Environment 1
Stay in place 1
Absorbency (poor) 1
Comfort 1
TABLE 19 Ranking with and without price (day) 
N Rank Willing to buy  Cost/month 
(with price only)  (range) (£)
1st 2nd 3rd 4th N Yes %
MP no price 85 9.4 (8) 60.0 (51) 23.5 (20) 7.1 (6) 83 66 79.5 9.90–16.80
With price 83a 16.9 (14) 60.2 (50) 18.1 (15) 4.8 (4)
DI no price 85 74.1 (63) 16.5 (14) 8.2 (7) 1.2 (1) 83 66 79.5 21.00–27.60
With price 83a 62.7 (52) 19.3 (16) 14.5 (12) 3.6 (3)
WP no price 81b 16.0 (13) 14.8 (12) 50.6 (41) 18.5 (15) 79 33 41.8 6.00–10.25
With price 79ab 19.0 (15) 13.9 (11) 48.1 (38) 19.0 (15)
WI no price 85 1.2 (1) 9.4 (8) 14.1 (13) 74.1 (63) 83 8 9.6 1.40–3.50
With price 83a 2.5 (2) 7.4 (6) 22.2 (18) 70.4 (57)
a Two women did not respond to the ‘with price’ question.
b Four women did not test WPs because they were not available in their sizes. Lower proportions of self-payers chose DIs and
higher proportions chose MPs as their first-choice
design, compared with NHS-funded women. This
could be because the self-payers were more price
aware and did not buy DIs before the study because
they are more expensive. Disclosing the price
causes a 13% swing away from DIs in both groups,
four (of 30) NHS-funded women alter their first
choices to MPs and WIs. Seven (of 55) self-payers
altered their first choices to MPs and WPs.
Cost-effectiveness 
A cost-effectiveness analysis was performed as the
mean VAS scores were significantly different
between designs in multivariate and paired
comparisons. To calculate the ICER the mean
monthly cost of the products in each design and
the mean of the mean product VAS scores in each
design were used. Average and incremental ratios
for the designs are shown in Table 21. The expense
of laundering washable products (which is borne by
individuals) is not included in the monthly costs.
The cheapest and least preferred product (WI) has
the lowest average cost (£0.14) per unit of
effectiveness [highest average effectiveness (7.1
VAS points) per £1 spent]. DIs [the most expensive
and most effective design (according to mean VAS
scores)] have the highest average cost (£0.32) per
unit of effectiveness [lowest average effectiveness
(3.1 VAS points) per £1 spent]. Mean VAS and
monthly costs of products were inversely related.
There is no strictly dominant design. The cost for
VAS points is shown in Figure 23.
There is more benefit for given expenditure [lower
average cost-effectiveness ratio (ACER)] with
cheaper designs. As costs go up, effectiveness goes
up also, but less than proportionately. Hence
cheaper washable products are on average better
value for money. However, more than 50% of
participants stated that WPs were unacceptable.
The proportion for WIs was above 80%. Of the
more highly rated disposable products, MPs appear
better value for money than DIs, but have a lower
acceptability rating (80 versus 95%). The ‘highly
acceptable’ ratings are 12 and 69%, respectively,
and less than half of participants would be willing
to use MPs when outside their homes.
Incremental ratios show that it costs £0.56 to gain
an extra unit of effectiveness from DIs compared
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TABLE 21 Between-design average and incremental cost-effectiveness ratios 
Design in order  Mean  Mean  Average  Average  Product pair comparisons: 
of effectiveness monthly  VAS  cost-effectiveness  effectiveness-cost  ICERa
cost (£) score ratio (ACER)  ratio (AECR)
(£) (VAS points)
DI 25.40 79.3 0.32 3.12
MP 13.70 58.3 0.24 4.26
WP 8.40 42.7 0.20 5.08
WI 2.80 19.9 0.14 7.10
a ICER refers to the incremental cost-effectiveness ratio, i.e. it is the extra cost per unit of effectiveness (VAS point); IECR is
the reciprocal of ICER, i.e. the incremental effectiveness ratio – the number of extra VAS points per £1 extra spent;
similarly, the ACER and AECR refer to the average ratios.
TABLE 20 Design preferences comparing self-payers with NHS funded women 
Without price After price disclosed
N DI WP MP WI N DI WP MP WI
NHS pay 30 25 5 0 0 30 21 5 3 1
(83%) (17%) (70%) (17%) 10% (3%)
Self-pay 55 38 8 8 1 53 31 10 11 1
(69%) (14.5%) (14.5%) (2%) (59%) (19%) (21%) (2%)
No design dominates.
WI–WP: ICER(£) 0.246,
IECR (VAS points) 4.07
WP–MP: ICER(£) 0.340,
IECR (VAS points) 2.94
MP–DI: ICER(£) 0.557,
IECR (VAS points) 1.80with MPs (or that an extra £1 spent on DIs rather
than MPs gains 1.8 extra VAS points). The
equivalent incremental ratios between WPs and
MPs are more favourable (£0.34 for an extra unit
of effectiveness and 2.9 extra VAS points for each
extra £1 spent). The best incremental ratios are
between WIs and WPs: extra VAS points cost
£0.25; an extra £1 generates 4.1 VAS points.
Comparing designs, the data show that if a woman
were to use DIs rather than MPs, she would gain
(on average) some 21 VAS points of benefit at an
extra cost of £11.70 per month. Similarly, use of
MPs instead of WPs, or WPs instead of WIs, would
give 15.6 and 22.8 extra units of effectiveness, at
extra costs of £5.30 and £5.60 per month,
respectively.
MPs seem to be a relatively inexpensive product
for the benefit gained and were deemed
acceptable by around 87% of participants for
home use and 46% for outside the home. DIs
provide improved benefit but cost almost twice as
much. They are acceptable to over 95% of women
in all situations. Spearman’s rank correlation
between four-point acceptability scale for MPs and
ICIQ summary measure of incontinence was
significant ( = –0.260, p = 0.017), showing that
women with lighter incontinence tend to be the
ones who find MPs more acceptable. Although
women who found MPs acceptable in situations
outside the home had slightly lower ICIQ
summary scores (lower incontinence) than those
who did not (11.47 versus 12.83), the difference
was not significant.
The most cost-effective option might be to allow
women to mix and match products. Women with
lighter incontinence can use the cheaper MPs or
WPs in their homes and be provided with more
expensive DIs for going out and special occasions. 
Sensitivity analysis and sources of uncertainty
The cost-effectiveness ratios are based on point
estimates of costs and effectiveness (the mean
values of products in designs). The 95% CIs
surrounding the mean design VAS and the cost
ranges do not overlap (except at the cost margins
between WP and MP). Using the extreme values of
the CIs or the cost ranges would not alter the
design ranks, although the values of the ACERs
and the ICERs would change.
There are several sources of uncertainty in the
costs that were used. First, the costs reflect the
prices of the products selected for the trial. There
was considerable variability in the prices of
selected products within designs, and the mean
price was used. There are many different products
available, so a different choice of products could
result in different mean design costs.
Second, the product prices were those of retail/mail
order outlets because many women with light
incontinence purchase their own supplies and the
NHS did not provide two of the designs tested
(MPs and WIs) at the time of the study. The prices
charged by PASA were about 50% lower than those
on the open market (52 and 45% lower for the WP
and DI products, respectively, included in the
trial). PASA offers a restricted product range, and
Products for women with light urinary incontinence (Trial 1)
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FIGURE 23 Cost for VAS pointsvariability of prices within design tends to be
lower. Use of NHS prices would affect the cost-
effectiveness ratios, but would only affect relative
values to the extent to which the NHS bulk
purchase discount varies across designs.
Third, all monthly cost estimates were based on a
consumption rate of four products per 24 hours,
which was the mean utilisation reported by
participants at baseline. This overstated the actual
consumption of products in the trial by about 25%
(see Table 11), so costs used in the cost-
effectiveness analysis were high-end estimates for
each design. This will have affected all designs
equally and will not affect relative cost-effectiveness. 
Fourth, calculation of the costs of the washables
was based on assumptions about the life (number
of washes) of products and the stocks that women
would hold. Manufacturers’ data were used on
product life (120 washes assumed) and stock levels
(minimum of 12 products) were based on daily
product use and the experience of the research
team. Varying these assumptions affects the cost-
effectiveness of washables relative to disposables.
Holding more stocks and increasing the
replacement rate increase the cost of washables,
but they still remain markedly cheaper than
disposable alternatives. When participants were
asked in the final interview how many stocks of
washables they would need to hold, the median
response was 12. 
Fifth, the cost-effectiveness calculations are based
on the purchase price of products and exclude
other costs borne by consumers, the most
important of which is the cost of laundering in the
case of washable designs. Use of disposables
involves ‘shoe leather’ costs of purchase (unless
delivered by the NHS) and also issues around
storage and disposal, but none of these are
generally considered to have a significant financial
impact for users.
Laundry costs and environmental issues
Laundry costs are of two types: those associated
with washing reusable products and laundry
generated by leakages. Women were reminded
when making their selections between designs that
the costs they were given did not include the cost
of laundering the washable products. Including
the laundry costs associated with washable
products would reduce their cost-effectiveness
relative to disposables. 
There were significant differences in laundry
generated between all designs (DI < MP < WP <
WI). These costs would be borne by the product
users. They were not estimated because they were
judged to be relatively small. Moreover, the costs
would vary, depending on the laundry
arrangements of individual women. Data collected
at baseline showed different practices regarding
whether incontinence-related items were washed
separately and regarding the use of more
expensive equipment such as tumble driers.
An important consideration in the comparison of
washable and disposable designs is the relative
environmental cost, particularly disposal (landfill)
costs of disposable designs and energy costs
associated with laundering the washables. A recent
report on baby nappies concluded that there was
no significant difference in environmental impact
between three nappy systems (disposables, home
and commercial laundered), although the types of
impacts did vary.49 It is assumed that these
findings are generalisable to adult incontinence
products and, accordingly, no allowance was made
in the cost-effectiveness calculations for
environmental factors.
Views about designs that should be
provided through the NHS
At the time of the study, only two of the designs
tested were purchased by the NHS: DIs and WPs.
PASA buys large quantities of products and uses its
market power to secure favourable contracts with
producers, which it then passes on to the Trusts
that choose to buy supplies from it. Some Trusts
buy direct from manufacturers and will also
negotiate more favourable terms than retail or
mail order rates, but these are unlikely to match
those of PASA.
Respondents were asked to compare DIs and WPs
at the NHS prices (including delivery), converted
to an annual cost of supplying one woman with
light incontinence, and to identify the best and
worst value-for-money design. They were also
asked whether they thought the NHS should
purchase each, giving reasons. The annual cost of
DIs is 3–4 times higher than that of WPs.
Respondents were reminded that NHS
expenditure comes from taxpayers. The responses
are shown in Table 22. Significantly more people
thought that the NHS should buy DIs than WPs
(2, p = 0.02).
Compared with rankings that participants made
for personal purchases, DIs were ranked first by
similar numbers of women when they were asked
to compare them with WPs in the context of NHS
provision (52 versus 49) (Tables 19 and 22). In the
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were ranked best for NHS purchasing by a larger
number of women (15 versus 34). There was
higher support for the NHS purchasing WPs than
willingness-to-pay at the personal level (65%
versus 42%). Stated reasons showed that lower cost
was an important factor for ranking WPs highest,
although some people felt that the relatively poor
performance of this design rendered the products
to be poor value.
Participants were asked whether they thought DIs,
compared with WPs, were worth the extra cost to
the taxpayer. Of 72 responses made, 50 (69.4%)
said they were, citing superior reliability,
convenience, comfort and hygiene (in that order).
Attitudes towards washable and disposable
products
At the final interview, participants were asked an
open question as to whether they favoured
washable or disposable products, and why. The
results are shown in Table 23. The majority
favoured disposables (N = 53, 62.4%), which were
overwhelmingly preferred for convenience aspects.
A substantial minority (N = 23, 27.1%) favoured
washables, largely for cost and environmental
reasons, and eight participants (9.4%) did not feel
strongly either way. 
Practical aspects of washables and disposables
Respondents were asked for their views about the
practical aspects of using each type of product and
the extent to which these constituted a problem
(four-point scale). The results are presented in
Table 24. Practical issues associated with use of
washables constitute greater problems in the
opinions of participants, in particular dealing with
wet washable products when out. When asked how
they would feel if WPs were the only incontinence
products supplied by the NHS, 13 (15.5% of
respondents) said it would not worry them, six
(7.1%) said they would be pleased and 54 (64.3%)
said they would be concerned. 
Provision of products 
The final section of the questionnaire asked
respondents about provision of their products.
People who received NHS products and those who
did not were treated separately. The NHS
Products for women with light urinary incontinence (Trial 1)
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TABLE 22 Ranking of designs provided by NHS only 
Design Annual cost (£) Day rank NHS should buy
1st 2nd Total n Yes vs no
DI 145–166 49 33 82 79 64
(57.6%) (38.8%) (81.0%)
WP 40–60 34 50 84 79 51
(40.0%) (58.8%) (64.6%)
Total 83 83
(97.6%) (97.6%)
Missing 2 2
(2.4%) (2.4%)
TABLE 23 Views on washable and disposable products, daytime 
Favour disposables  62.3% (53)
Favour washables  27.0% (23)
No strong feeling either way  9.4% (8) (1 missing)
Reasons for favouring disposablesa N Reasons for favouring washablesa N
Easy to use/convenience 38 Economical/costs 15
Being disposable/not carrying wet pads/pants 12 Environment 10
Hygienic 10 Convenient 3
Lack of washing 5 Comfort 2
No need to change clothes when changing pad 3 No need to obtain pads 1
Feminine (pants) 1
a Participants could give more than one response.provided products to 31 women, of whom six also
self-paid for additional products. There were 54
women who bought all their own products. 
Self-payers
Women without NHS provision (N = 54) were
asked about their purchasing behaviour, whether
they had requested NHS supplies and whether
they would like to purchase supplies direct from
NHS. Responses are shown in Table 25. Most
women buy their products locally and regularly
use the same brand. A few may shop for bargains
or be influenced by availability. Most would 
like to cut the cost of supplies by buying through
the NHS.
Approximately one-third of women had been
refused NHS supplies although many of these had
been offered other treatments. About one-quarter
did not feel that their problem was severe enough
to warrant NHS supplies. A further 20% did not
realise that the NHS provided supplies for women
with light incontinence.
Several of the 60 women who fully or partly
provided their own products reported that the
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TABLE 24 Practical aspects 
Feature (N = 85) % (N)
No problem Small problem Big problem Insurmountable 
problem
Dealing with washable products before washing  41.2 (35)  31.8 (27) 24.7 (21) 2.4 (2)
(e.g. rinsing out, nappy bucket)
Washing washables 45.9 (39) 30.6 (26) 22.4 (19) 1.2 (1)
Drying washables (1 missing) 42.4 (36) 21.2 (18) 30.6 (26) 4.7 (4)
Dealing with wet washable products when out 15.3 (13) 24.7 (21) 42.4 (36) 17.6 (15)
Disposal of used disposable products 80.0 (68) 16.5 (14) 3.5 (3) 0
Storage of disposable products 78.8 (67) 18.8 (16) 2.4 (2) 0
Obtaining supplies of disposable products 89.4 (76) 8.2 (7) 2.4 (2) 0
TABLE 25 Self-payers’ purchasing behaviours: questions to self-payers about buying behaviours (N = 54) (plus 2 NHS/self-pay mix
who additionally answered these questions): % (N)
Where do you usually buy  Mail order Local store Varies according to special offers Other
your supplies? 7.1 (4) 78.6 (44) 7.1 (4) 7.1 (4)
Did you realise that the NHS  Yes No
can buy products at about half  32.7 (18) 67.2 (37)
the price that individuals pay 
as they buy in bulk?
(1 missing)
If you could buy your supplies  Yes, would buy from NHS No, would continue to buy from local shop 
through the NHS at a lower  or mail order
price, would you?  94.5 (52) 5.5 (3)
(1 missing)
Have you ever asked your  Yes Refused  No Did not realise 
GP or continence adviser if  33.9 (19), of whom: products 66.1 (37), of whom: could get
the NHS could provide  15.8 (3) 32.4 (12)
pads to you? 18.9 (7) 
no reason
Refused Products  Currently  Problem  not  Thought  NHS Too 
products but  given but  under  severe  products  embarrassed
offered  unsuitable assessment enough/never  were not nice 
treatment occurred  to 
instead me
57.9 (11) 21.1 (4) 5.3 (1) 37.8 (14) 2.7 (1) 8.1 (3)trial had made them more aware of the range of
products on offer. Five had sought to change the
brand of product they used and 13 stated that
they had started to use WPs provided by the trial
in at least some situations. Two participants had
sought NHS assessments to see if they could get
their products funded.
Women in receipt of NHS supplies
Women receiving NHS supplies (N = 31) were
asked about choices offered to them and
satisfaction with the products they receive.
Responses are summarised in Table 26. 
Restricted choice is shown, with two-thirds of
women given no choice of products and some
dissatisfaction with both the quality and quantity
of products received. Five women reported that
they continued to use the WPs provided during
the study in conjunction with the NHS products
they received, because they had liked the fit and
comfort of the pants.
NHS versus self-pay participants
The NHS and self-paying participants were
compared and no significant differences were
found between them on a range of background
variables including incontinence (ICIQ and
Kings), income, age and employment status.
However, self-payers had significantly better SF-12
physical functioning (p = 0.048), were more likely
to walk independently (p = 0.044), and tended to
be less dependent, according to the Barthel score
(p = 0.067).
Previous product use
Thirteen of the participants were using MPs before
the study, one used WP and the remainder were
using DIs (N = 71). The effect of previous product
use on the overall acceptability scores was
examined, but this was not found to be significant. 
Discussion
This clinical trial has shown that there are
substantial differences between the different
designs of absorbent products available to women
with light incontinence. For the primary outcome
variables of overall acceptability, and for mean
VAS, preference and leakage performance, DI
pads are better than MPs, which are better than
WPs, which are better than WIs. 
The superior leakage performance of DIs is
evident at both low and high urine masses and it
is notable that the washable designs performed
relatively poorly in this respect. The leakage graph
shows that even at very low urine masses, washable
designs are likely to leak, indicating that the
ability of the washable materials to allow fast
penetration or ‘strike through’ of urine is poor –
leakage probably occurs because some urine
simply runs off the interface material rather than
because absorption capacity has been exceeded. A
similar problem with increased risk of leakage at
very low urine masses is evident with the
disposable MPs, although this effect is less
pronounced; it is probably because MPs are not
designed to receive urine at high flow rates and
the construction and materials differ from those of
DI pads.
The median mass of urine was significantly
different between the four designs, with the DI
design measuring more than the MP design,
which measured more than the WP design, which
measured more than the WI design. The DI
design median was around twice as much as the
WI design. There are four possible explanations
for this finding. First, the urine masses may have
been less for the non-DI designs because more
urine leaked from them; second, the women using
the more leaky designs may have taken action to
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TABLE 26 NHS receivers’ purchasing behaviour: women receiving NHS products about service (N = 31) (includes 6 who receive NHS
and top up themselves): % (N)
Who makes decision about your  Continence adviser Joint decision between self and continence adviser
incontinence supplies? 71.0 (22) 29.0 (9)
How much product choice are  No choice Between designs Between different products  Design and 
you offered? within a design product
67.7 (21) 16.1 (5) 12.9 (4) 3.2 (1)
How satisfied are you with the  Very satisfied Quite satisfied Not satisfied
quality of the product you receive? 41.9 (13) 48.4 (15) 9.7 (3)
How satisfied are you with the  Very satisfied Quite satisfied Not satisfied
quantity of the product you receive? 46.7 (14) 26.7 (8) 26.7 (8)
(1 missing)limit their incontinence, such as increasing
toileting; third, women may have avoided using
these products in challenging situations (such as
going out; see Figure 16, p. 30) where toilet
accessibility may have been unpredictable and
incontinence more likely; or fourthly, the women
changed their pads more frequently. The last
explanation was not borne out by consumption
data, which showed that there were no significant
differences between products, except for the WI
design, which was used significantly less. 
This indicates that the use of less effective
products is not associated with greater
consumption of products, but rather that it may
result in activities to mitigate incontinence and
avoidance of certain situations. The consumption
of products used during the study was less than
was reported by participants at the beginning (by
around one product per day). We do not know
why this is, but it is possible that participants
believed that the study would in some way be
connected to future provision of their products
(although they were assured of the study’s
independence) and therefore gave generous
estimations of their product consumption. Cost
estimates used for the economic analysis were
related to baseline consumption reports and
therefore overestimated actual mean costs. 
Overall, the DI had very high levels of
acceptability in all situations, with very few women
(N = 4) finding it an unacceptable option for
going out, the most demanding of the activities.
Discreetness and price are the main drawbacks of
DIs, although discreetness was only significantly
worse than for the MP. The main improvement
that women suggested for DIs was a reduction in
bulk. DIs are rated 36% more effective than MPs
(mean VAS 79.3 versus 58.3), but are almost twice
as expensive. The most common type of DI
provided by the NHS was used. Smaller, more
discreet, less absorbent and cheaper DIs are
available. If their performance were still better
than that of the other three designs, then this
would reduce costs; however, their comparative
performance is unknown.
The MP performed significantly worse than the DI
pad for overall acceptability, preference, leakage,
smell and comfort when wet. The MP was
substantially cheaper than the DI and had a high
level of acceptability (69%), although few women
chose it as their first choice (N = 8 before price).
Thirty-nine women stated that they would not find
the MP acceptable for ‘going out’, indicating that
for most women full-time use of MPs is likely to be
detrimental to QoL. The MP was praised for its
discreetness, but higher absorbency was
considered a necessary improvement, without
additional bulk. MPs are rated 37% more effective
that WPs (mean VAS 58.3 versus 42.7) and are
56% more expensive before laundry costs are
taken into account. Although costs of provision
may be borne by the NHS, laundry costs are the
responsibility of the user. 
The WP performed significantly worse than the
MP for overall acceptability, preference, leakage,
smell, comfort when wet and effect on everyday
activities, but the differences were smaller than
between the DI pad and the MP. The WPs were
cheaper to use than MPs even when laundry costs
are taken into account. More women chose the
WPs as their first-choice design (N = 13) (despite
their poorer leakage performance) than MPs, but
the majority of women did not support the use of
washable designs in general and reported high
levels of practical problems associated with their
use. However, a substantial minority of 23 women
(27%) favoured washables and would be likely to
choose washable products if their leakage
performance were improved. 
WIs performed worse than WPs for overall
opinion, preference, leakage, comfort when dry
and staying in place. Most women experienced
difficulty with keeping the WI in place even
though they were worn with close-fitting pants (as
recommended by manufacturers). Special pants
are available with a pouch for a WI and use of
these may improve performance, although this
would increase cost. 
Overall, the washable products performed much
less well than the disposable products, particularly
for leakage, but also for smell and comfort when
wet, both of which were significantly worse for the
washables than the disposables, but not
significantly different between the two washables.
The constituents of disposable pads, particularly
superabsorbent gel and hydrophobic covering
materials, are likely to be better at retaining odour
(preventing smell) and reducing wet-back (i.e.
retaining urine in the absorbent core) and there is
much scope for improvements in the materials
and construction of washable products. 
There have been indications from previous studies
of larger products for heavy incontinence that
washables may be worse for skin health than
disposables.27 This was not demonstrated
unequivocally in this trial, but it must be
acknowledged that the participants had light
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significantly better than the two washable designs
for skin health, the MP design was only
significantly better than the WI design (not the
WP design). It is plausible that it is not the
washable materials per se that affect skin health,
but their poor leakage performance and inability
to retain urine in the absorbent core (poor wet-
back), which may lead to wetter skin and
impairment of skin health. Wet skin is more easily
abraded than dry skin and is more susceptible to
irritation.50
Most of the women in this trial paid for their own
absorbent products and some were unaware that
they may be provided by the NHS or had been
denied provision. The incontinence levels of self-
paying women were similar to those obtaining free
NHS products and the provision of these products
by the NHS is inequitable. Where NHS products
are provided, most women reported that they had
little or no choice. 
At the time of the trial, the NHS was offering only
DIs and (to a lesser extent) WPs. Yet provision of
DI pads (the design mainly provided by the NHS)
is likely to be neither the most cost-effective nor
the optimum strategy from the women’s
perspective. The cost-effectiveness analysis 
showed no dominant design. DIs are the most
expensive and perform the best but at almost
twice the cost of the MPs, which are the second
most effective. A significant minority of women
prefer washable products or MPs, both of which
are cheaper. 
Savings could be made if the NHS offered the full
range of designs, gave women greater choice and
allowed them to ‘mix and match’ the products
they used according to their daily activities or
circumstances. One possibility might be to provide
women with direct payments or vouchers for
absorbent product purchases. Women would use
their vouchers on products that suit their
preferences, for example to purchase WPs or MPs
for use around the home and DIs for going out. A
fixed-value voucher would provide an incentive for
women to choose the combination of products that
was most cost-effective for them.
The NHS does not currently offer MPs, yet this
trial shows that women with light incontinence
find them acceptable in certain situations. The
retail prices of MPs are lower than those of DIs,
and the NHS could use its considerable influence
in the market to negotiate favourable contracts
with product manufacturers and achieve further
savings. Self-paying women might be offered the
opportunity to purchase their incontinence
supplies through the NHS. As NHS prices are
typically half those of retail or mail order outlets,
they would be able to reap significant personal
financial benefits.
Limitations
Product development means that the
characteristics and availability of individual
products change over time and the products used
in this study are likely to be superseded. However,
the main designs are much more stable and the
results should therefore outlive those of the
individual products. 
The sample of women living in the community
with light incontinence was intended to represent
the ‘heavier’ end of light incontinence, because
women with very infrequent incontinence would
be less likely to represent those who received
products from the NHS and would be less able to
evaluate leakage performance, which was an
important outcome. However, it was also intended
to include those who paid for products themselves
and those who received them from the NHS.
Compared with a similar study which evaluated
only DI brands9 and which included only older
women (mean age 71 years) who received their
products from the NHS, our sample was somewhat
younger (mean age 60 years) and slightly less
incontinent (median urine mass 17 g compared
with 22 g). It is therefore possible that our results
would have shown even greater favouring of the
DI pads (which performed substantially better for
leakage at higher volumes than the other designs)
for an ‘NHS supplied’ population. 
Further limitations applying to the study more
generally are discussed in Chapter 7.
Conclusions
This trial demonstrated that DI pads were better
than the other designs for most aspects of
performance (including leakage), and were the
most acceptable and preferred design, but were
the most expensive. The washable designs had
relatively poor leakage performance and low
acceptability compared with disposable designs
(particularly WIs). Not all women chose the DI as
their first choice and the alternative, cheaper,
washable and disposable designs were preferred by
nearly one-quarter of women and more would find
them acceptable in certain situations. Cost-
effective management may be achieved by offering
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combinations (within a limited budget) to suit
their own circumstances. 
Implications for healthcare
There is evidence that:
● For women with light incontinence, DIs are
better than all other designs and for most
circumstances.
● The WPs with integral pad and the MP are the
preferred choice for a substantial minority of
women and allowing choice from the full range
of designs is likely to be economical for the
NHS.
● The two washable designs (WPs and WIs) had
poor leakage performance compared with the
disposable designs and the use of washables
incurred more practical problems than the use
of disposables. Restricting the range of available
products to washable designs alone is therefore
not recommended.
● The cheaper washable designs and MP designs
are likely to be more acceptable under some
circumstances than others (e.g. staying at
home); allowing women to choose combinations
of designs (e.g. WPs within the home, DIs for
going out) within a limited budget is likely to be
economical for the NHS.
● The NHS provision of absorbent products to
women with light incontinence is inequitable
and guidelines are needed to determine the
rationale and criteria for provision. 
● An NHS ‘shop’ (virtual or otherwise) whereby
NHS vouchers (or individuals’ money) could be
used to purchase combinations of product
designs, at cheaper prices (using the buying
power of the NHS), would be welcomed by
users.
Research recommendations
● Translational research to pilot the feasibility of
provision of a range of designs and enabling
women to chose combinations of designs within
a limited budget.
● Development of washable designs (in particular
WPs with integral pad) to improve leakage
performance. 
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There are four designs of disposable and washable
body-worn absorbent products suitable for people
with moderate/heavy incontinence (inserts,
diapers, T-shaped diapers and pull-ups) (Table 27).
Products are not gender-specific. Although
increasing numbers of washable products are
becoming available, disposable designs dominate
the market and washable designs are not
commonly used; none are bought by PASA.
Insert pads are the simplest, cheapest (on a per
product basis) and most commonly used of the
disposable designs in the UK, although the use of
diaper designs, particularly for more heavily
incontinent individuals, is increasing. Both of
these designs have been available for many years;
however, in the last few years, two new designs
have become available (T-shaped diapers and pull-
ups), which are intended to be easier for the carer
or individual to apply, but their effectiveness is not
known.
Selection of designs for individuals in the UK is
based on little evidence. There have been no
direct comparisons made of the different
disposable body-worn designs and most clinical
trials that have focused on comparisons of
disposable and washable designs are more than
10 years old and were carried out in hospital or
nursing home settings rather than in primary care
settings. 
There are indications from trials of products from
a single design15,16 that insert pads may be less
effective than diapers, but this has not been tested
in a clinical trial. There are also indications that
designs vary in how long they take to apply and
remove; however, this has not been demonstrated
clinically.51
In a small pilot study (N = 14) comparing a range
of washable designs for heavy incontinence,18 there
were indications that diaper-style washable designs
perform better than other washable designs
(particularly inserts) and may perform favourably
when compared with disposable designs, but this
has not been tested in a clinical trial.
Aims
The aim of the study was to compare the
performance and cost-effectiveness of disposable
and washable absorbent product designs for
women and men with moderate/heavy urinary or
urinary and faecal incontinence living in
community settings.
Design and methods
The trial was a randomised crossover clinical trial
comparing four disposable absorbent product
designs (insert, diaper, T-shaped diaper, 
pull-up) and one washable product design 
(Figures 24 and 25).
Recruitment of participants
The inclusion and exclusion criteria for
participants are shown in Box 2. The aim was to
recruit participants who were already using an
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Chapter 4
Randomised crossover trial of disposable and 
washable absorbent products for women and men
with moderate/heavy urinary or urinary and faecal
incontinence living in community settings (Trial 2a)
TABLE 27 Pad design categories
Designs for moderate/heavy urinary and/or faecal
incontinence
Disposable Washable
Inserts Inserts 
Diapers Diapers
T-shaped diapers T-shaped diapers
Pull-ups Pull-upsabsorbent product suitable for moderate to heavy
incontinence and who had consistent and stable
incontinence. This was to ensure that the
participants’ incontinence was not likely to change
during the period of the trial. Designs for
moderate to heavy incontinence are not gender-
specific (unlike designs for light incontinence) and
both men and women were therefore recruited.
Participants were recruited to the study in the
following ways:
1. A press release was prepared to announce the
study and this was distributed to local and
national newspapers and magazines.
2. An invitation letter was sent to purchasers of
absorbent products through Promocon (the
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FIGURE 24 (a) Insert; (b) diaper; (c) T-shaped diaper and (d) pull-up
(a) (b)
(c) (d)
FIGURE 25 Washable diapers (these products are less homogeneous in design than the disposable product designs so pictures of all
three variants are shown: (a) terry-towelling sewn into a diaper shape and (b) a simple square of terry-towelling folded into a diaper are
shown without plastic pants; (c) contains integral plastic backing.
(a) (b) (c)national information centre for continence
products) and to receivers of absorbent
products through local NHS Trust delivery
services in London and Southampton.
3. Advertisements were placed in the Incontact’s
quarterly magazine and Internet message board
asking people who were interested in testing
products to contact us for further information.
4. People who had taken part in previous studies
were sent letters containing study information
and were asked to respond if they were
interested in taking part.
Study process
During the study, participants tested the five
designs (four disposable, one washable),
comprising 14 products (three for each design,
except two for the T-shaped diaper) each tested for
1 week (overall test period 14 weeks). During
testing they weighed used pads and kept a pad
change/leakage diary and completed a product
performance questionnaire at the end of each
week of testing. At the end of the testing period, a
final interview was completed to determine
preferences and opinions. The study process is
shown in Figure 26.
Outcome measures
The outcome measures (see Chapter 2 for more
details) are listed below. All participants were
given two booklets (case record forms) for day and
night products. These contained the product
performance questionnaires and pad
change/leakage diaries that would be needed for
the study.
Participants were each provided with a set of digital
scales in order to weigh each used pad, record
whether the product had leaked urine (none, a
little, a lot) and whether leakage had resulted in
incontinence laundry items. They also recorded
the number of each product used day and night.
In summary, a pad change/leakage diary was used
to record: 
● weight of pad (g) 
● leakage from product (none, a little, a lot) 
● laundry resulting from incontinence (small and
large items)
● number of products used per day and night.
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BOX 2 Inclusion and exclusion criteria
Inclusion criteria:
Adult women and men
Resident in the community
Incontinence status consistent and stable
Currently using absorbent products for moderate/heavy 
urinary and/or faecal incontinence
Willing to test washable and disposable absorbent 
products
Able to complete self-report questionnaires
Exclusion criteria:
Acute illness
Terminal phase of illness
Outcomes during testing period
Product consumption, laundry and 
  leakage diary
Weekly product performance 
  questionnaire
Weekly skin health observation
Design 1: 2 weeks
Interview: Participant background data and scores
Design 2: 3 weeks
Design 3: 3 weeks
Design 4: 3 weeks
Design 5: 3 weeks
Final interview: Design comparisons and preferences
with and without costs
14-week 
test 
period
FIGURE 26 Overview of study processAt the end of each period of product testing
(1 week), a product performance questionnaire
was completed to record:
● product performance variables (e.g.
discreetness) rated as very good, good, okay,
poor, very poor
● changes in skin health problems in pad area
(none, a little or mild, a lot or moderate/severe).
At the end of the trial, a detailed final interview
was completed to record:
● design preferences and rankings (with and
without costs) 
● overall acceptability of design (highly
acceptable, acceptable, unacceptable, totally
unacceptable)
● VAS (worst possible design–best possible design)
● willingness to buy (after prices disclosed)
● comments about good and poor aspects of
designs
● views about washable versus disposable designs.
Selection of absorbent products
to represent design groups
It is known that individual products within
absorbent product design groups vary widely48 and
selection of a single product to represent a given
design is unsafe. Three disposable products were
therefore selected to represent each disposable
design group (the exception was for the T-shaped
diaper because only two products were available at
the time). The aim was to include products with
the most commonly used absorbent capacities
(according to data provided by PASA) and from a
wide range of manufacturers. Candidate products
for the insert, diaper and pull-up designs were
tested in a pilot study (see Appendix 4) and results
were used to inform selection of the three
products for the clinical trial. Products had an
approximate maximum absorbency (Rothwell
score7) of 1900 ml  20% for daytime use and
2400 ml  20% for night-time use. The aim was to
compare designs with similar absorbent capacities
in order to minimise the confounding effect of
absorbent capacity, which may override the effect
of design. For the inserts, the most commonly
purchased stretch pants were provided for all
three products. The three washable products
chosen for the study were all diaper style and were
the best performing products from a previous
study.18 Two of the products were made out of
traditional terry towelling (Figure 25a and b), of
which one (a) was sewn into a diaper shape, but
also required pins to hold the pad in place and
the other (b) was a simple square which required
folding and pinning in place (as with a
conventional baby’s nappy). Both of these
products were provided with separate plastic pants
of the type used in a previous study.18 The third
washable diaper (Figure 25c) was different from the
others. It was made from a needle-felt with a
woven interface and had an integral waterproof
backing with Velcro patches to hold the pad in
place. The two terry-towelling products performed
better in the published pilot study but the third
product was included because it was more typical
of washable products that are most commonly
considered by purchasers. All of the washable
products had optional booster pads, which
participants could use to increase the absorbency.
Because of the differences between this product
and the terry-towelling products, it was decided a
priori not to combine the results for this product
with those for the other two in the analysis, but to
present these results separately. 
Study preparation and 
procedures
Waist and hip measurements were used to order
appropriately sized products for each participant.
Blinding was not practical because each design
had a different appearance. Products were
therefore provided in their original packaging
complete with any instructions but, because
washing instructions varied slightly between
manufacturers, for simplicity participants were
provided with one generic set of instructions (used
in a previous trial8) that covered all the
manufacturers’ guidelines. The washable products
were washed twice to remove any dressing and
repackaged. Product packages were marked with
study labels indicating that they were day or night
products. The labels were colour coded to
correspond with the labels on the front of the
booklets, and the product performance
questionnaire and pad change/leakage diaries
were also colour coded. This was designed to
simplify the testing procedure. 
The order of testing for all products was
randomised using Latin squares38 for the order of
both between-design groups and within-design
groups (i.e. the order of the three products of the
same design). Each product was tested for 1 week
and the testing of a complete design therefore
took 3 weeks. However, because this method
would require large numbers of each washable
product to be supplied (to ensure adequate
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participants were asked to test the washable
products in daily rotation, according to the order
of testing allocated (e.g. 1, 2, 3 or 2, 3, 1).
Products were randomised for both day and night
use, therefore participants tested different designs
during the day and night. This was done to help
the participants to consider the different designs
separately for day and night.
Participant preparation and interviews
Eligibility interview
Potential participants who contacted us by
telephone, reply-paid slip, letter or email were
interviewed on the telephone. The study was
described according to the participant information
sheet and eligibility to join the study was
established. If the person was eligible and
expressed willingness to join the study, the
participant information sheet and consent form
were posted with a reply-paid envelope. 
Participant information interview
Potential participants who returned the signed
consent form were contacted and an interview was
arranged either at the research centre or in their
own home, or exceptionally, when neither was
practical, on the telephone. During this interview,
the participant background information
questionnaires and scores were completed
(Table 28). Participants were also asked about the
effects that incontinence pad usage had on their
QoL and were asked to name and rank product
performance characteristics that they considered
to be of greatest importance (see Chapter 6). 
At this interview, the self-report study
documentation and instruction booklet were
explained to the participant and the digital scales
for product weighing were demonstrated to ensure
competence.
Product testing period
Together with their box of test products,
participants were provided with the instruction
booklet, which had been piloted on volunteer
participants for clarity and comprehension.
Electronic digital scales and plastic bags were
provided for pad weighing. Participants were
asked to telephone the research centre when 
they received the box to notify us when they were
starting testing and to enable any queries to be
answered.
Participants tested their 14 products (five designs)
for 1 week each and completed the pad
change/leakage diary and product performance
questionnaire during this 14-week period. A 
1-week testing period for each product has 
been shown to be sufficient for community
participants to form an opinion about the
products and for sufficient products to be collected
to record pad leakage data.34 Participants could
withdraw from testing a product at any time, 
but were asked to complete the product
performance questionnaire and early stopping
form to record the reasons for stopping using the
product. The participant would then move on to
the next product. Participants were free to
withdraw from the study at any time and without
giving any reason.
Participant monitoring 
Participants were given contact numbers of their
designated research nurse and invited to
telephone the research centre if they had any
queries. In addition, the participants were
telephoned at the start of the study and
fortnightly during the data collection period 
to check that they understood the procedure and
to address any problems, and they were
encouraged to call the research staff if they had
any queries.
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TABLE 28 Background descriptive data
Questionnaire/score Purpose: to provide
Background demographic and socio-economic  Descriptive data on age, gender, product use, socio-economic 
information data
Barthel score A measure of independence in activities of daily living score
SF-12 A measure of general QoL 
Kings QoL score A measure of incontinence-specific QoL 
ICIQ-UI (short form) A brief measure of incontinence-specific QoL 
HADS An assessment of anxiety and depressive symptoms Final interview
On completion of testing, a final interview was
arranged either at the research centre or in the
participant’s home (or exceptionally by telephone)
to complete the design comparison and
preferences questionnaire and to return all
questionnaires and diaries. 
At the final interview, participants were asked to
rank the individual products tested within each
design group and then rank the different designs
(with and without costs). The different designs
were scored on a VAS and participants rated the
designs using the overall acceptability score.
Participants were also asked whether they would
recommend the designs to others. To assess views
on value for money of different designs,
participants were shown the monthly cost of using
the product they had previously identified as the
best value for money in each design. Monthly
costs were based on the assumption that people
used four products per 24 hours (the most
common rate of consumption reported by
participants at recruitment). For the washables, it
was assumed that a stock of 12 products would be
needed and each product could be washed 120
times before it needed to be replaced
(manufacturers’ data and researchers’ experience).
Laundry costs of washable items were not
included, although respondents were reminded of
this when making their choice among designs. 
Participants were then asked questions about the
different situations in which they would consider
using the designs and the practicalities of using
disposable and washable designs. Participants were
also asked to comment on the relative strengths
and limitations of the designs.
Ethics
The study was reviewed by the London multi-
centre research ethics committee and complied
fully with ethical, governance and data protection
requirements and approval was obtained through
appropriate NHS research ethics committees.
Analysis
Data were entered into Microsoft Excel Version
2003, cleaned and 10% of the data set and 100% of
the primary outcome variable data were checked
for accurate entry. The data were transferred to
SPSS Version 14, for further analysis. 
Ordinal outcome variables were analysed using
cumulative logit modelling, and quantitative
outcome variables were analysed by linear
modelling, allowing for repeated observations by
each subject. Bonferroni adjustments were made
in significance tests and to CIs for multiple
comparisons between designs. R software was used
(www.r-project.org).
Results
Participant characteristics
A total of 286 potential participants contacted the
research centre, of whom 184 met the inclusion
criteria, and 134 consented to take part in the
trial. A total of 117 participants began testing
products and 85 completed the study and gave a
final interview. Progress of participants through
the trial is shown in Figure 27. 
Participant characteristics are shown in Table 29.
The mean age of participants was 53 years and 49
were men (57.6%). Most participants were living in
their own homes with good mobility and
independence in activities of daily living. Thirty-
six (42.3%) were in full- or part-time employment
or seeking work. Forty-two were married or had a
partner. More than three-quarters usually used
insert or diaper designs and most received their
products entirely or mainly by the NHS. All but
one used products during both the night and the
day. Reasons for incontinence were varied, with
nearly 30% of participants reporting that they did
not know why they were incontinent. Nine carried
out intermittent catheterisation and 23 said they
had faecal incontinence in addition to urinary
incontinence. 
Data completion
This study proved rather demanding for
participants and, although full completion of the
questionnaires was encouraged during the testing
period by keeping regular contact, some
participants were unable to provide full data. The
final interview was also rather lengthy and it was
therefore agreed to carry out a shortened version
with some participants which focused on the
primary outcome variables. This means that for
some final interview questions the number of
responses does not equal 85. The number of
responses is indicated in each final interview table.
Product results within design groups
The product performance questionnaires were
analysed and comparisons made between the three
(or two) different products comprising each design
group. This showed that two of the disposable
night products (one pull-up and one insert) were
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102 ineligible
286 people assessed for eligibility
14 too much work
  8 illness
  9 did not return calls
  1 products not suitable
17 withdrew before 
starting study
184 consent forms sent out
134 consent forms returned
117 began testing
85 completed
FIGURE 27 Progress of participants through the trial
TABLE 29 Participant characteristics (N = 85, except where missing data stated)
Participant background  % (N)
information
Age (years):  Mean 52.8 39 40–59 60–79 80
(SD 15.5) 20.0 (17) 50.6 (43) 23.5 (20) 5.9 (5)
Gender Male Female
57.6 (49) 42.3 (36)
Cause of incontinence Overactive bladder Neurological (MS/CVA) Post-surgery/illness/treatment
22.4 (19) 10.6 (9) 9.4 (8)
Accident/injury/back injury Unknown cause Other 
11.8 (10) 28.2 (24) 17.6 (15)
HADS (15 declined):  0–7 8–10 11–21
Normal Borderline Abnormal
Anxiety 61.4 (43) 20.0 (14) 18.6 (13)
Depression 70.0 (49) 12.9 (9) 17.1 (12)
ICIQ score (max. score 21)  Mean 14.2 (SD 3.4)
(high score = low QoL) 
SF-12: mean (SD), scale 0–100  Standardised physical component Standardised mental component
(norm = 50, best health = 100,  40.0 (14.0) 46.5 (11.4)
worst health = 0)
Kings QoL score  Mean (SD)  Mean (SD)  Mean (SD)  Mean (SD) 
(incontinence-specific)  all 9 domains incontinence  social  severity 
(high score = low QoL)  impact limitations measures
(Max. score all domains, 900.  396.8 (193.7) 56.1 (31.0) 34.8 (28.5) 64.2 (16.4)
Max. each domain, 100) 
Key domains shown
Barthel score (activities of  Mean 82.6 45 50–65 70–85 90
daily living) (0 = total dependence,  (SD 11.5) 5.9 (5) 15.3 (13) 31.8 (27) 47.1 (40)
100 = independent. N.B. max. for 
this group = 90–10 points 
deducted for incontinence)
continuedeach significantly worse than the other two
products in their group for leakage. Each product
that came in different sizes (and therefore different
absorbencies) was tested for differences in leakage
performance (using pad leakage diary data), but
no significant differences were found. The data
from the product performance questionnaires and
pad change/leakage diaries were therefore
combined for the products within each design
group. In order not to bias the results unfavourably
for night pull-up and insert designs, the two
significantly different products were excluded when
combining the data from variables that may be
related to leakage, namely leakage, laundry and
consumption variables and variables that may be
related to leakage in the product performance
questionnaire (i.e. variables related to leakage:
leakage, wet comfort, smell). 
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TABLE 29 Participant characteristics (N = 85, except where missing data stated) (cont’d)
Participant background  % (N)
information
Mobility Walk independently  Walk with aid  Uses wheelchair (independently) 
70.5 (60) 15.3 (13) 14.1 (12)
Intermittent catheterisation 10.6 (9)
Faecal incontinence 27.0 (23)
Design of product used before  Insert pads Pull-ups Diaper T-shaped
study: day (1 missing data) 45.2 (38) 9.5 (8) 41.7 (35) 3.6 (3)
Design of product used before  Insert pads Pull-ups Diaper T-shaped Washable
study: night (1 missing data) 39.3 (33) 7.1 (6) 46.4 (39) 2.4 (2) 4.8 (4)
Who provides your pads?  NHS Self-pay Both
63.5 (54) 17.6 (15) 18.8 (16)
Number of products used per day/night Day Night
Mean 3.4 (SD 1.3) Mean 1.9 (SD 1.0)
Years using products (10 missing data) <1 1–5 >5
0.0 (0) 30.7 (23) 69.3 (52)
Incontinence laundry  56.8 (46) Launder incontinence-related items separately
(4 missing data)
Socio-economic variables
Marital status Married, cohabits Single Widowed, separated, divorced
49.4 (42)  10.6 (9)  40.0 (34)
Highest level of education Primary Secondary University Postgraduate College/ Other
diplomas/NVQs
2.4 (2) 50.6 (43) 20.0 (17) 7.0 (6) 15.3 (13) 4.7 (4)
Employment status Full time Part-time  Homemaker
(29) (4) (4)
Seek work Retired Student Other 
(3) (28) (4) (13)
Household income (£000 pa)  <10 10–19.99 20–29.99 30–39.99 40–49.99 50
44.7 (38) 25.9 (22) 12.9 (11) 5.9 (5) 3.5 (3) 7.1 (6)
Accommodation Detached Semi-detached Terraced/bungalow Flat/maisonette
28.2 (24) 25.9 (22)  23.5 (20)  22.4 (19)
CVA, cerebrovascular accident; MS, multiple sclerosis.To simplify analysis and to reduce the number of
multiple comparisons, the four disposable designs
were compared with each other (six comparisons)
and the washable design (which comprised diaper-
style products) was compared only with the
disposable diaper design.
As both men and women were recruited to the
study, outcome measures were tested for
dependence on gender. Unexpectedly, this was
significant for most variables and we therefore
made comparisons between designs using
combined data and with data separated for men
and women. 
Frequency and severity of leakage 
Pad leakage diary data were used to estimate the
probability of the different designs leaking for
different urine masses. Table 30 shows the median
urine masses in the different designs. 
The urine weights varied between designs with
inserts containing the least urine and washables
containing the most urine for day and night
(gender was a significant variable and results are
shown by gender in Appendix 5). Leakage
performance was therefore modelled for each
design, based on the binarised leakage data (none)
versus (a little + a lot) and urine weights.
Figures 28 and 29 show the probability of there
being no leakage for day and night at different
urine masses by design (with 95% CIs). 
Explanation of leakage curves
Pads do not have a simple capacity below which
they are guaranteed not to leak and above which
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TABLE 30 Median urine mass in each design (weighed from collected pads) 
Insert Diaper Pull-up T-shaped Washable  diaper
Daytime 234.0 294.5 257.0 298.0 414.0
Median urine mass (g)  (128.5–366.5) (189.0–446.3) (147.3–388.0) (171.3–462.8) (268.5–632.0)
(IQ range)
No. of products  1943 2196 2066 1426 819
Night-time 271.5 363.0 319.0 345.0  511.5 
Median urine mass (g)  (149.0–412.0) (208.0–562.0) (191.0–503.5) (202.8–537.0) (291.3–763.5)
(IQ range)
No. of products  1032 1545 1012 956 666
IQ, inter-quartile.
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FIGURE 28 Estimated probabilities of no leakage at different urine masses with 95% CIs (day) they will definitely leak. Rather, as the volume (i.e.
mass) of urine increases, the probability of the pad
leaking increases. The leakage performance curves
were constructed for each design (by combining
data from the various products of the same
design) and show how the probability of the
design not leaking changed with increasing urine
mass. In general, the more successful a design, the
higher was the performance curve on the graph:
a perfect design would have a probability of not
leaking at all of 1 ( = certainty) for all urine
masses.
Intuitively, these probability curves should have a
value of 1.0 for zero urine mass – how can a pad
leak if there is no urine in it? Weighing used pads
provides an estimate only of the mass of urine in
the pad and excludes any leakage from the pad:
accordingly, the urine masses used in constructing
the curves will often have been (slight)
underestimates of the actual masses voided by the
wearer. For example, a pad may leak (and the
urine mass in the pad be recorded as zero) if the
absorbent area is out of position. One of the
effects of this is that the leakage performance
curves of products will meet the y-axis at values
<1.0, the value which would be expected
naturally. In the extreme, a pad capable of
holding no urine at all would be certain to leak
whatever quantity of urine its user voided and yet
all used pads would contain zero urine mass. 
In addition, dry masses vary (coefficient of
variation of the order of 10%) and so there will be
small errors in estimated urine masses. These
errors will be negligible for high urine masses but
more substantial for (nearly) dry pads.
Tables 31 and 32 show the proportions of the saved
and weighed pads that leaked. Gender was found
to be significant for comparisons of the designs
and the data for men and women are shown
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FIGURE 29 Estimated probabilities of no leakage at different urine masses with 95% CIs (night)
TABLE 31 Leakage performance of daytime designs (total number of products saved = 8450)
Leakage % (N = number of products)
Insert Diaper Pull-up T-shapeda Washablea
None 59.9 (1163) 70.7 (1553) 72.6 (1500) 76.6 (1092) 80.1 (656)
A little  25.3 (492) 20.1 (460) 18.7 (387) 17.5 (250) 15.7 (129)
A lot  14.8 (288) 8.3 (183) 8.6 (179) 5.9 (84) 4.2 (34)
a Data combined for two products only; see the section ‘Selection of absorbent products to represent design groups’ (p. 48).separately in Appendix 6. Leakage performance
(at specified urine weights) was compared using the
binarised data: (no leak) versus (a little + a lot). 
The leakage results in the forest plots
(Figures 31–44 with ORs and 95% CIs) show
comparisons of leakage performance between
designs for the median urine weight (280 g for
daytime and 330 g for night-time) for (no leak)
versus (a little + a lot). Results showed that during
the daytime, the inserts were worse for leakage
than the other three disposable designs (p < 0.01)
and the diaper was worse than the T-shaped diaper
(p = 0.009). The washable/diaper comparison
showed no significant difference in leakage. 
At night, the insert was significantly worse than the
diaper and the pull-up design (p < 0.005). The
diaper, T-shaped and pull-up were not significantly
different from each other. The washable/diaper
comparison showed that the washable was better
than the diaper for leakage (p = 0.0003). 
The urine weights and leakage performance were
also examined by gender. Mean urine weights
showed that the men’s pads contained
substantially more urine than the women’s pads:
mean daytime urine mass 375.4 g for men and
215.3 g for women (difference 148.7 g, 95% CI
79.8 to 217.7) mean night-time urine mass 453.4 g
for men and 290.9 g for women (difference
148.5 g, 95% CI 63.2 to 233.9). Leakage
performance scores by gender (Appendix 7)
showed that during the daytime men’s pads leaked
around 10% more than women’s pads for inserts
and diapers and around 20% more for pull-ups.
During the night-time the difference was greater
and was more than 20% for inserts, diapers and
pull-ups. Differences were less for the T-shaped
and much less for the washables. The leakage
probability curves (Appendix 6) show that at
median urine weights the leakage performance for
the pull-up design was relatively better for women
than for men. The insert was worst for leakage for
both men and women but was particularly poor
for men at night.
It should be noted that the differences in the
numbers of pads saved and weighed results from
the availability of only two (rather than three) 
T-shaped diapers, the exclusion of one of the
washable products (for day and night), and the
exclusion of one of the inserts and one of the pull-
ups for night. Overall fewer pads were saved and
weighed for the washable design because more
participants (nearly half during the day and one-
third at night) stopped testing the products
prematurely (Table 33).
Consumption of products
Pad change/leakage diary data were used to
calculate the mean number of products used per
day and night. Table 34 shows the results for the
different designs. Weighted means are used
because participants recorded numbers of products
used per day over variable periods (up to 7 days). 
Significantly more inserts were used during both
the daytime and night-time (except compared with
diapers in the daytime) compared with the other
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TABLE 32 Leakage performance of night-time designs (total number of products saved = 5211)
Leakage % (N = number of products)
Inserta Diaper Pull-upa T-shapedb Washableb
None 55.5 (573) 60.7 (938) 65.3 (661) 64.4 (616) 85.4 (569)
A little  27.9 (288) 27.6 (426) 21.8 (221) 23.4 (224) 11.4 (76)
A lot  16.6 (171) 11.7 (181) 12.9 (130) 12.1 (116) 3.1 (21)
a Data combined for two products only; see the section ‘Product results within design groups’ (p. 50).
b Data combined for two products only; see the section ‘Selection of absorbent products to represent design groups’ (p. 48).
TABLE 33 Early stopping data (N = 85 participants)
Insert Diaper Pull-up T-shaped Washable  diaper
Mean number of participants: day 29 27 25 31 47
Mean number of participants: night 24 28 26 27 39disposable designs and washables were used
significantly less than diapers, both day and night.
However, the differences were small (about one-
quarter of a pad for disposables per day and less
at night). Overall, men used more products than
women for all designs during the daytime and
similar numbers during the night. The
substantially higher urine masses measured in the
men’s pads could not therefore be explained by
less consumption (i.e. less changing of pads) 
(see Appendix 8).
Laundry resulting from leakage
Pad change/leakage diary data were used to
calculate the mean number of items (small and
large) sent for laundering as a result of leakage
from the product [none or number of items (if
any)]. Table 35 shows the proportions for each
design. The washable product is included as an
item of laundry.
Laundry results showed that inserts produced
nearly twice as many laundry items as the other
three disposable designs for both day and 
night. There were no significant differences
between the other disposable designs. When
compared with the disposable diaper (and
including the washable in the number of items),
the washable design produced around twice as
many laundry items.
Skin health
Participants were asked to complete a skin health
diary every week to record the location, severity
and duration of any skin health problems. The site
with the maximum severity (i.e. the worst skin
problem) was used to make comparisons between
designs. Tables 36 and 37 show the proportions of
participants with and without skin health problems
for the day and night, respectively. 
When worn during the daytime there was a
significant difference between the inserts and the
T-shaped design, (no skin problem) versus (any
skin problem), with more skin problems recorded
with the T-shaped product. These tended to be
related to the waist-band (see ‘Skin health’, p. 77).
When worn during the night-time, there were no
significant differences between any of the designs.
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TABLE 34 Consumption of day and night products (N = 85 participants)
Weighted mean number of products used per day (SD)
Insert Diaper Pull-up T-shaped Washable
Daytime  2.77 (1.16) 2.70 (1.03) 2.52 (0.92) 2.54 (0.92) 2.01 (0.83)
Night-time 1.68 (0.79) 1.51 (0.56) 1.49 (0.55) 1.50 (0.62) 1.21 (0.41)
Consumption: comparisons between designs 
Estimate of ratio of means 95% CIa
Daytime
Insert  used more than T-shaped 1.12 1.04 to 1.20
Insert  used more than Pull-up 1.10 1.02 to 1.20
Pull-up  not different to T-shaped 1.01 0.95 to 1.08
Diaper  not different to Insert 1.06 0.97 to 1.15
Diaper  not different to T-shaped 1.06 1.00 to 1.12
Diaper  not different to Pull-up 1.04 0.97 to 1.12
Diaper  used more than Washable 1.36 1.24 to 1.50
Night-time
Insert  used more than T-shaped 1.14 1.04 to 1.26
Insert  used more than Diaper 1.12 1.01 to 1.24
Insert  used more than Pull-up 1.15 1.05 to 1.26
Diaper  not different to T-shaped 1.02 0.95 to 1.09
Diaper  not different to Pull-up 1.02 0.97 to 1.09
T-shaped  not different to Pull-up 1.01 0.94 to 1.08
Diaper  used more than Washable 1.23 1.14 to 1.32
a CIs include Bonferroni adjustment for multiple comparisons except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).Product performance questionnaires
Participants completed a weekly product
performance questionnaire to score the
performance of each product. Scores for the
highest priority variables (leakage, discreetness,
smell, comfort when dry and wet, fit and staying 
in place; see Chapter 6) were analysed and those
for individual products within designs are shown
in Appendix 9. The scores for each of the three
(or two) products within a design were combined to
give an average response result for each variable. 
Results presented in Tables 38 and 39 and in the
forest plots (in Figures 31–44) are for men and
women combined. Most variables analysed from
the product performance questionnaire were
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TABLE 35 Laundry day and night
Weighted mean no. of laundry items (SD)
Disposable Disposable Disposable Disposable  Washable
insert diaper pull-up T-shaped
Daytime 1.34 (1.72) 0.78 (0.98) 0.80 (1.06) 0.66 (0.89) 2.52 (1.46)
Night-time 1.16 (1.54) 0.78 (0.78) 0.72 (0.99) 0.73 (0.94) 1.57 (0.94)
Laundry: comparisons between designs 
Estimate of ratio of means 95% CIa
Daytime
Insert produced more laundry than  T-shaped 2.30 1.36 to 4.05
Insert produced more laundry than Diaper 1.87 1.18 to 2.95
Insert produced more laundry than Pull-up 1.76 1.07 to 2.90
Diaper  not different to T-shaped 1.25 0.80 to 1.97
Pull-up  not different to T-shaped 1.33 0.84 to 2.11
Pull-up  not different to Diaper 1.06 0.70 to 1.60
Washable produced more laundry than Diaper 3.73 2.70 to 5.13
Night-time
Insert produced more laundry than T-shaped 1.79 1.01 to 3.19
Insert produced more laundry than Diaper 1.63 1.03 to 2.57
Insert produced more laundry than Pull-up 1.77 1.12 to 2.80
Diaper  not different to T-shaped 1.01 0.68 to 1.79
Pull-up  not different to T-shaped 1.01 0.61 to 1.67
Diaper  not different to Pull-up 1.09 0.71 to 1.69
Washable produced more laundry than Diaper 2.10 1.56 to 2.84
a CIs include Bonferroni adjustment for multiple comparisons, except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).
TABLE 36 Skin health problems: daya
Skin problem % (N)
Disposable Disposable  Disposable Disposableb Washableb
insert diaper pull-up T-shaped
(N = 185) (N = 186) (N = 189) (N = 124) (N = 124)
None 81.6 (151) 74.7 (139) 75.7 (143) 66.9 (83) 71.8 (89)
A little (mild) 10.8 (20) 14.5 (27) 13.2 (25) 13.7 (17) 13.7 (17)
A lot (moderate/severe) 7.6 (14) 10.7 (20) 11.1 (21) 19.4 (24) 14.5 (18)
N, number of weekly observations.
a Comparisons between designs and 95% CIs are shown in forest plots in Figures 31–44.
b Two products only; see the section ‘Selection of absorbent products to represent design groups’ (p. 48).significant for gender and results for men and
women are presented separately in Appendix 10.
Combining results for men and women has
reduced the differences for some variables.
The product performance questionnaire results
showed that:
● There were no significant differences between
the diaper and T-shaped diaper for both day
and night (including ease of putting on)
[significance is defined as p  0.05; forest plots
(Figures 31–34) show ORs and 95% CIs for each
variable]. 
● The T-shaped was significantly better than the
insert for leakage and smell (daytime), but
otherwise was not better than other disposable
designs on other variables. 
● The diaper was significantly better than the
insert for leakage, staying in place and smell
(daytime), but for no other designs or variables. 
● The insert was significantly better for
discreetness compared with the T-shaped diaper
and diaper, but for no other designs or
variables. 
● The pull-up was significantly better for staying
in place than the T-shaped (day), insert (day
and night); better for fit compared with the 
T-shaped (day and night), the diaper (day and
night) and the insert (day and night); better for
smell compared with the diaper and insert
(night); better for discreetness compared with
the T-shaped and the diaper; better for comfort
when dry compared with the T-shaped (day),
the diaper (night) and the insert (day); better
than the insert for comfort when wet (day); and
easier to put on compared with the diaper and
T-shaped diaper (night).
● The diaper was significantly better than the
washable for all variables during the day, except
for comfort when dry (not quite significant) and
leakage. During the night, the diaper was
significantly better only for ease of putting on
and comfort when dry. The washable was
significantly better for leakage.
Examination of the results by gender
(Appendix 10) shows that the main differences
[20% or more for (very good, good, okay) versus
(otherwise)] were in the higher ratings of leakage
performance given to the pull-ups by women
compared with men; the better ratings given by
men for diapers for discreetness and fit; the worse
ratings given by men for inserts for staying in
place; the worse ratings given by women for the
T-shaped for discreetness and fit; and the better
ratings given by men for washables for most
variables, particularly at night. 
Faecal incontinence
The participant background information showed
that 27% (23) of participants reported that they
had both urinary and faecal incontinence before
starting the study. During the final interview,
participants were asked to rate the acceptability of
the different designs for ability to hold faeces
without leakage; between 15 and 17 participants
responded to this question for the different
designs (see below) and the results are shown in
Table 40.
The data obtained from the final interview
indicated that fewer participants were faecally
incontinent than originally stated in the
participant background information. This may be
because the participants did not experience any
faecal leakage during the period of the study, or
did not experience any that they felt was serious
enough to have an impact on the product or
design being tested.
The small number of participants reporting on the
performance of the designs for faecal incontinence
means that no firm conclusions could be drawn.
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TABLE 37 Skin health problems: nighta
Skin problem % (N)
Disposable Disposable Disposable Disposableb Washableb
insert diaper pull-up T-shaped
(N = 188) (N = 186) (N = 186) (N = 124) (N = 123)
None 75.5 (142) 71.5 (133) 80.0 (145) 74.2 (92) 75.6 (93)
A little (mild) 11.2 (21) 12.4 (23) 11.8 (22) 12.9 (16) 18.7 (23)
A lot (moderate/severe) 13.3 (25) 16.1 (30) 10.2 (19) 12.9 (16) 5.7 (7)
N, number of weekly observations.
a Comparisons between designs and 95% CIs are shown in forest plots in Figures 31–44.
b Two products only; see the section ‘Selection of absorbent products to represent design groups’ (p. 48).Health Technology Assessment 2008; Vol. 12: No. 29
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TABLE 38 Product performance questionnaire: mean results for each design (%): daya,b
Insert Diaper Pull-up T-shaped  Washable
diaper
Leakage (urine) Very good 9.0 20.5 23.1 28.2 25.2
Good 27.4 26.7 35.9 34.8 33.9
OK 27.9 30.8 21.5 23.0 23.5
Poor 23.7 15.9 15.4 11.9 10.4
Very poor 12.1 6.2 4.1 2.2 7.0
Leakage (faeces) Very good 3.0 26.2 24.3 19.4 34.8
Good 27.3 33.3 35.1 45.2 21.7
OK 57.6 28.6 24.3 22.6 13.0
Poor 9.1 4.8 16.2 9.7 8.7
Very poor 3.0 7.1 0.0 3.2 21.7
Stay in place Very good 7.7 17.0 44.3 27.9 12.8
Good 25.8 35.5 32.8 25.0 29.1
OK 37.6 35.5 16.4 27.9 31.6
Poor 18.6 10.0 7.0 15.4 15.4
Very poor 10.3 2.5 1.0 3.7 11.1
Fit Very good 8.2 17.5 31.8 20.7 9.2
Good 26.7 26.5 36.8 31.1 30.0
OK 39.5 31.5 22.4 23.7 21.7
Poor 20.5 20.0 9.0 18.5 16.7
Very poor 5.1 4.5 0.0 5.9 22.5
Smell Very good 9.3 10.7 16.2 16.4 6.1
Good 26.9 31.0 32.3 32.1 27.2
OK 42.5 50.8 39.0 44.8 37.7
Poor 17.1 5.6 11.6 6.0 16.7
Very poor 4.2 2.0 1.0 1.0 12.3
Discreet Very good 13.3 15.0 33.5 22.2 1.7
Good 41.0 32.0 41.5 31.9 5.1
OK 40.0 33.0 22.0 28.9 17.8
Poor 5.1 16.5 3.0 11.1 32.2
Very poor 1.0 3.5 0.0 5.9 43.2
Dry comfort Very good 15.5 19.8 44.0 25.2 22.7
Good 38.1 40.1 39.0 37.8 31.1
OK 33.0 33.5 16.5 25.2 34.5
Poor 11.9 5.6 1.0 8.2 5.9
Very poor 1.6 1.0 0.0 3.7 5.9
Wet comfort Very good 8.3 7.1 14.9 14.9 7.0
Good 25.9 28.1 36.4 35.8 13.2
OK 37.3 45.9 39.0 35.1 45.6
Poor 20.2 14.3 9.2 12.7 17.5
Very poor 8.3 4.6 1.0 1.5 16.7
Ease on (standing) Very good 14.4 10.1 42.8 27.9 5.8
Good 36.4 33.2 37.8 25.7 12.4
OK 39.0 38.7 10.5 27.2 35.5
Poor 10.3 12.6 8.0 16.2 19.8
Very poor 0.0 5.5 1.0 2.9 26.5
a Shading indicates where binarisation occurs (very good + good + OK) versus (poor + very poor).
b For all variables, two products were combined for the T-shaped and washable designs; see the section ‘Selection of
absorbent products to represent design groups’ (p. 48).Final interview: overall opinion
and preferences
Participants were asked to rank the designs in
order of their preference. Participants then
marked their opinion of the design on a VAS and
stated their overall acceptability of the different
designs (highly acceptable, acceptable,
unacceptable, totally unacceptable). Participants
were also asked whether they would recommend a
design for use by others. This process was
repeated for nighttime products. Table 41 shows
paired comparisons of preferences between
designs and Table 42 shows the acceptability
ratings of the designs, both for day and night 
use.
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TABLE 39 Product performance questionnaire: mean results for each design (%): nighta,b
Insert Diaper Pull-up T-shaped  Washable
diaper
Leakagec (urine) Very good 12.1 9.8 29.6 19.4 36.7
Good 29.0 34.5 27.4 24.0 30.3
OK 25.0 33.0 20.7 27.1 21.1
Poor 16.9 17.5 11.9 19.4 5.5
Very poor 16.9 5.2 10.4 10.1 6.4
Leakagec (faeces) Very good 9.5 15.8 30.8 13.0 22.2
Good 19.1 52.6 34.6 39.1 44.4
OK 42.9 21.1 23.1 30.4 27.8
Poor 9.5 10.5 7.7 8.7 5.6
Very poor 19.1 0.0 3.9 8.7 0.0
Stay in place Very good 8.1 12.3 34.0 20.0 16.1
Good 29.3 43.1 40.0 23.9 35.7
OK 29.3 26.7 17.0 36.9 25.9
Poor 23.7 11.8 7.5 16.2 10.7
Very poor 9.6 6.1 1.5 3.1 11.6
Fit Very good 11.1 11.3 27.0 22.3 13.3
Good 33.8 37.6 45.0 19.2 26.6
OK 30.8 27.8 21.5 40.8 29.2
Poor 19.7 17.5 5.5 14.6 13.3
Very poor 4.6 5.7 1.0 3.1 17.7
Smellc Very good 7.9 8.3 19.6 12.4 8.3
Good 33.3 30.1 36.1 25.6 25.7
OK 42.1 40.4 36.8 49.6 36.7
Poor 15.1 17.6 7.5 11.6 19.3
Very poor 1.6 3.6 0.0 1.0 10.1
Dry comfort Very good 17.7 14.8 42.8 22.3 26.8
Good 39.9 42.4 39.8 35.4 36.6
OK 36.4 34.7 16.4 35.4 20.5
Poor 4.6 5.1 1.0 5.4 6.3
Very poor 1.5 3.1 0.0 1.5 9.8
Wet comfortc Very good 6.4 6.6 17.8 10.7 12.7
Good 35.2 29.6 40.7 32.3 16.4
OK 42.4 40.3 31.1 40.0 41.8
Poor 9.6 16.3 8.9 14.6 16.4
Very poor 6.4 7.1 1.5 2.3 12.7
Ease on  Very good 14.6 8.7 50.3 26.7 6.2
Good 39.4 34.9 36.3 26.7 19.5
OK 35.9 39.5 11.0 31.3 35.4
Poor 11.6 12.3 2.0 13.0 16.8
Very poor 1.0 4.6 1.0 2.3 22.1
a Shading indicates where binarisation occurs (very good + good + OK) versus (poor + very poor).
b For all variables only two products were combined for the T-shaped and washable designs; see the section ‘Selection of
absorbent products to represent design groups’ (p. 48).
c For these variables only two products were combined for the insert and pull-up designs; see the section ‘Product results
within design groups’ (p. 50).For the daytime, in paired comparisons of
preferences the pull-up was significantly preferred
to the insert only. For the diaper/washable
comparison, the diaper was significantly preferred
to the washable.
During the night-time, in paired comparisons of
preferences the insert was significantly worse than
the pull-up and the T-shaped, and the T-shaped
was significantly worse than the diaper. The
preferences by gender can be seen in Appendix 12.
Scores for acceptability were binarised both as
(highly acceptable) versus (other scores) and
(highly acceptable/acceptable) versus (other
scores). For the daytime, the pull-up was
significantly better than the insert on both
measures and better than the T-shaped for (highly
acceptable + acceptable) versus (other). For the
diaper/washable comparison, the washable was
significantly worse for both measures. 
Health Technology Assessment 2008; Vol. 12: No. 29
61
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
TABLE 40 Acceptability of different designs for ability to hold
faeces without leakage 
Design % unacceptable 
(N)
Day
T-shaped (N = 16) 25.0  (4)
Washable (N = 16) 25.0  (4)
Diaper (N = 16) 18.75 (3)
Insert (N = 17) 35.3  (6)
Pull-up (N = 16) 12.5  (2)
Night 
T-shaped (N = 15) 26.7  (4)
Washable (N = 15) 20.0  (3)
Diaper (N = 15) 13.3  (2)
Insert (N = 15) 26.7  (4)
Pull-up (N = 15) 26.7  (4)
TABLE 41 Preference for different designs
Number preferring design 
Day (N = 85) Night (N = 85)
Diaper 52 vs Insert 33 Diaper 53 vs Insert 32
Pull-up 69 vs Insert 16 Pull-up 66 vs Insert 19
Pull-up 45 vs Diaper 40 Pull-up 40 vs Diaper 45
Pull-up 50 vs T-shaped 35 Pull-up 50 vs T-shaped 35
T-shaped 33 vs Diaper 52 T-shaped 27 vs Diaper 58
T-shaped 53 vs Insert 32 T-shaped 56 vs Insert 29
Diaper 74 vs Washable 11a Diaper 49 vs Washable 36a
Preferences: comparisons between designs 
Estimated odds on 95% CIb
Daytime
Pull-up  preferred to Insert 4.31 2.07 to 8.97
T-shaped  not different to Diaper 0.63 0.35 to 1.14
T-shaped  not different to Pull-up 0.70 0.39 to 1.25
T-shaped  not different to Insert 1.66 0.92 to 1.14
Diaper  not different to Insert 1.58 0.88 to 2.83
Diaper  not different to Pull-up 0.89 0.50 to 1.58
Diaper  preferred to Washable 6.73 3.57 to 12.67
Night-time
Pull-up  preferred to Insert 3.47 1.75 to 6.91
T-shaped  preferred to Insert 1.93 1.06 to 3.53
Diaper  preferred to T-shaped 2.15 1.16 to 3.97
T-shaped  not different to Pull-up 0.70 0.39 to 1.25
Diaper  not different to Inserts 1.66 0.92 to 2.99
Diaper  not different to Pull-up 1.13 0.63 to 1.99
Diaper  not different to Washable 0.73 0.48 to 1.13
a To reduce the number of comparisons, the washable design is only compared with the diaper design of the disposables.
b CIs include Bonferroni adjustment for multiple comparisons except for diaper compared with Washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).For the night-time, the pull-up and the diaper
were significantly better than the insert for both
measures and the diaper was significantly better
than the T-shaped on both measures. The
washable was significantly worse than the diaper
for (highly acceptable + acceptable) versus 
(other scores), but scores were very divided for 
the washable, with nearly half (42.4%) of
participants rating the washable as highly
acceptable and nearly half (42.4%) rating it as
unacceptable. The acceptability scores by gender
can be seen in Appendix 12. VAS scores are
shown in Table 43.
VAS scores reflected the preference and
acceptability scores. The VAS scores by gender can
be seen in Appendix 13.
Preferences and overall acceptability 
by gender
Examination of preference results by gender
(Appendix 11) showed that there were important
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TABLE 42 Acceptability of designs for day and night (N = 85)
Acceptability % (N)
Insert Diaper Pull-up T-shaped Washable
Day Night Day Night Day Night Day Night Day Night
Highly  acceptable 20.0 11.8  35.3 32.9  41.2 31.8  24.7 15.3  4.7  42.4 
(17) (10) (30) (28) (35) (27) (21) (13) (4) (36)
Acceptable 36.5  29.4 37.7  43.5 44.7 35.3 41.2  42.4 29.4  15.3
(31) (25) (32) (37) (38) (30) (35) (36) (25) (13)
Unacceptable/ 43.5 58.8  27.0 23.6  14.0 32.9  34.0 42.3  65.9 42.3
totally unacceptable (37) (50) (23) (20) (12) (28) (29) (36) (56) (36)
TABLE 43 Mean VAS scores (day and night) (N = 85)
Mean (SD)
Insert Diaper Pull-up T-shaped Washable
Day 48.5 (32.1) 66.3 (27.3) 72.7 (23.9) 60.1 (27.6) 33.7 (31.0)
Night 43.1 (32.7) 64.5 (26.9) 62.2 (29.8) 53.9 (26.3) 53.2 (40.6)
VAS scores: comparisons between designs 
Estimated difference of means 95% CIa
Daytime
Pull-up  scored higher than Insert 24.13 15.20 to 33.06
Diaper  scored higher than Insert 17.81 3.58 to 32.05
Pull-up  scored higher than T-shaped 12.52 1.11 to 23.93
T-shaped  not different to Insert 11.61 –1.73 to 24.96
Diaper  not different to Insert 1.58 0.88 to 2.83
Diaper  not different to Pull-up –6.32 –18.63 to 5.10
Diaper  scored higher than Washable 32.66 26.53 to 38.78
Night-time
Pull-up  scored higher than Insert 19.11 9.69 to 28.53
Diaper  scored higher than Insert 21.40 6.76 to 36.04
Diaper  scored higher than T-shaped 10.56 –1.36 to 19.77
T-shaped  not different to Pull-up –8.27  –19.57 to 3.03
T-shaped  not different to Inserts 10.84 –1.58 to 23.25
Diaper  not different to Pull-up 2.29 –10.59 to 15.18
Diaper  scored higher than Washable 11.32 3.75 to 18.89 
a CIs include Bonferroni adjustment for multiple comparisons except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).differences between designs dependent on gender;
however there were relatively small numbers in
each group (49 men and 36 women) and some of
the results were not significant (NS). Results
showed that women preferred pull-ups to diapers
(29 versus 7; p < 0.05 both day- and night-time),
and inserts to diapers (25 versus 11; NS daytime
and 22 versus 14; NS night-time), whereas men
preferred diapers to pull-ups (33 versus 16; NS
daytime and 38 versus 11; p < 0.05 night-time)
and diapers to inserts (41 versus 8; p < 0.05
daytime and 39 versus 10; p < 0.05 night-time).
Both women and men preferred the diaper to the
washable during the daytime, but during the
night-time, although the diaper was significantly
better than the washable for women this was not
significant for men and more men preferred the
washable to the diaper (29 versus 20). Both
women and men significantly preferred pull-ups to
inserts both day and night.
Acceptability scores for men and women reflected
their preferences (Appendix 13). Nearly two-thirds
of men scored inserts as unacceptable during the
day, and this rose to three-quarters at night,
compared with 17 and 33% of women,
respectively. Very few women (5–8%) found pull-
ups unacceptable either day or night, but 20 and
51% of men found them unacceptable for day and
night, respectively. Nearly half of women (44%)
found diapers unacceptable during the day and
more than one-third at night compared with 14%
for men both day and night. Washables were
unacceptable for almost all women during the
daytime (except 4/36) compared with half of men
and were unacceptable for three-quarters of
women at night, but for less than 20% of men. 
Overall for both men and women pull-ups were
better than inserts (p < 0.05), and for women both
pull-ups and inserts (NS) were better than diapers
(p < 0.05), whereas for men diapers were better
than both pull-ups (NS) and inserts (p < 0.05).
Acceptability of designs for different
situations
In order to consider acceptability in more detail,
participants were asked in which situations they
would find the different designs acceptable. The
results are shown in Figure 30.
The most challenging situation for a product is
going out of the home; the washables were the
least acceptable product, with only 7% of
participants finding them acceptable. The pull-ups
were the most acceptable product, with 63% of
participants finding them acceptable. When at
home, all the designs were scored relatively well
for acceptability (47–64%). 
Explanation of forest plots
For primary and secondary outcome variables,
results are calculated as proportions, such as
participants’ rating of discreetness binarised as
(very good + good + okay) versus (poor + very
poor). For example, design A may score 60% (very
good + good + okay) and 40% (poor + very
poor) and design B may score 50% (very good +
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FIGURE 30 Acceptability of designs in different situations good + okay) and 50% (poor + very poor). In this
case, it appears that design A is better than design
B for discreetness. To examine whether we can be
confident that this difference between the two
designs is real, an OR and CI are calculated. If
there is no difference between the two results, this
will give an OR of 1. Where there are differences
(as in the example of discreetness above), the OR
will be greater or less than one. The CI is a
number that spans the OR (giving a higher and
lower limit) and shows how much uncertainty
there is about the OR.
The ORs and CIs have been calculated for
comparisons between each pair of designs and for
each variable where the results are shown as
proportions. The ORs and CIs have been stacked
on top of each other on a forest plot showing
comparisons between each pair of designs.
The ORs and CIs are shown in relation to a
vertical line which is the centre of the forest plot.
This line gives the OR of 1 (i.e. no difference).
Each variable is named on the far left of the forest
plot and the OR and CI are written on the far
right. The scale is shown on the bottom with
numbers below 1 on the left and above 1 on the
right. 
Each OR is shown as a black box with a horizontal
line (the 95% CI) running through it. Where the
line touches or crosses the vertical line (at OR = 1)
there is no significant difference between the
proportions for the two designs. Where the box
and horizontal line lie completely to one or other
side of the vertical line, one can be confident that
the proportions for each design are significantly
different.
To show readily how each pair of designs compare
with each other, the ORs are plotted so that where
a design scores better than the other design for
any variable, the OR (i.e. the black box) is on the
side of the vertical line that favours that design.
Hence the ORs shown are for the second named
design versus the first named design in the
heading. The primary outcome variables from the
final interview (overall acceptability and
preference) are shown at the bottom of each forest
plot and these reflect the overall performance of
the different designs. The last line of the forest
plot shows the odds on the second named design
being preferred to the first.
There are 12 comparisons (day and night)
between the four disposable designs. In addition,
the washable design is only shown compared with
the diaper (day and night) giving a total of 14
forest plots.
Each forest plot in Figures 31–44 shows the data
obtained from:
● Leakage – diary: (from the pad change/leakage
diary) binarised as (none) versus (a little + a lot).
● Leakage – rating: (the participants’ rating from
the final interview) binarised as (very good +
good + OK) versus (poor + very poor). 
● Seven key variables from the product
performance questionnaire: all binarised as
(very good + good + OK) versus (poor + very
poor). 
● Skin health problems: (data from the
participants’ skin health diary) binarised as
(none) versus (a little + a lot).
● Overall acceptability: taken from the final
interview, and binarised as (highly acceptable +
acceptable) versus (unacceptable + totally
unacceptable) abbreviated on the forest plots as
(high/OK vs no).
● Overall acceptability: taken from the final
interview, and binarised as (highly acceptable)
versus (OK + unacceptable) abbreviated on the
forest plots as (high vs OK/no).
● Preference men: this shows the odds on the
second named design being preferred to the
first by a man.
● Preference women: this shows the odds on the
second named design being preferred to the
first by a women.
Comments about designs
When ranking designs, participants were asked
about the good and poor aspects of each and
about why they thought their top and lowest
ranked products were best and worst, respectively.
An analysis of the responses given is shown in
Appendix 14 by gender. Key themes were
identified and the number of times each was
mentioned is recorded. 
Comfort, discreetness and appearance (‘like
normal pants’) were strong points for pull-ups,
although some described them as ‘feminine’ and
this was unfavourable for men. Some people
found them difficult to change, especially when
out or when wearing trousers; others found them
easy. Comments were made by men that there was
insufficient padding or that the padding was in
the wrong place for them.
Diaper comments indicated good absorbency, but
bulkiness and sweatiness were negative points.
Comments on T-shaped diapers also indicated
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Odds ratio (95% CI)
0.23 (0.13 to 0.41)
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0.58 (0.24 to 1.38)
0.95 (0.41 to 2.20)
0.26 (0.07 to 0.98)
3.24 (1.05 to 9.96)
0.84 (0.33 to 2.19)
0.41 (0.17 to 0.97)
2.12 (0.54 to 2.17)
2.16 (1.18 to 3.97)
0.67 (0.26 to 1.76) Overall acceptability (high/okay vs no)
0.01 0.1 0.2
Favours T-shaped Favours insert
0.5 1 2 5 10
0.76 (0.26 to 2.22)
0.23 (0.09 to 0.60)
1.77 (0.71 to 4.42) Preference women
Leakage – diary (none vs a little/a lot)
Leakage – rating (good/okay vs poor)
Staying in place (good/okay vs poor)
Fit (good/okay vs poor)
Smell (good/okay vs poor)
Discreetness (good/okay vs poor)
Comfort when dry (good/okay vs poor)
Comfort when wet (good/okay vs poor)
Ease on (good/okay vs poor)
Skin health problems (none vs a little/a lot)
Overall acceptability (high vs okay/no)
Preference men
FIGURE 31 Forest plot: T-shaped vs insert (day)
Odds ratio (95% CI)
0.50 (0.23 to 1.09)
0.77 (0.36 to 1.63)
0.48 (0.21 to 1.09)
0.69 (0.28 to 1.67)
0.68 (0.26 to 1.72)
0.86 (0.16 to 4.47)
1.09 (0.45 to 2.68)
1.34 (0.44 to 4.07)
1.11 (0.61 to 2.02)
0.51 (0.21 to 1.25)
0.74 (0.20 to 2.70)
Overall acceptability (high/okay vs no)
0.01 0.1 0.2
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0.5 1 2 5 10
0.26 (0.10 to 0.65)
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Staying in place (good/okay vs poor)
Fit (good/okay vs poor)
Smell (good/okay vs poor)
Comfort when dry (good/okay vs poor)
Comfort when wet (good/okay vs poor)
Ease on (good/okay vs poor)
Skin health problems (none vs a little/a lot)
Overall acceptability (high vs okay/no)
Preference men
FIGURE 32 Forest plot: T-shaped vs insert (night)Products for women and men living in community settings (Trial 2a)
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Odds ratio (95% CI)
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0.70 (0.27 to 1.81)
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1.72 (0.79 to 3.76)
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Smell (good/okay vs poor)
Discreetness (good/okay vs poor)
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Comfort when wet (good/okay vs poor)
Ease on (good/okay vs poor)
Skin health problems (none vs a little/a lot)
Overall acceptability (high vs okay/no)
Preference men
FIGURE 33 Forest plot: T-shaped vs diaper (day)
Odds ratio (95% CI)
1.00 (0.57 to 1.75)
1.37 (0.69 to 2.72)
1.08 (0.50 to 2.34)
0.72 (0.32 to 1.64)
1.93 (0.70 to 5.30)
1.08 (0.43 to 2.68)
0.85 (0.20 to 3.61)
1.49 (0.67 to 3.32)
0.89 (0.54 to 1.47)
2.39 (1.07 to 5.35)
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2.77 (1.18 to 6.50)
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Leakage – diary (none vs a little/a lot)
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Staying in place (good/okay vs poor)
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Smell (good/okay vs poor)
Ease on (good/okay vs poor)
Comfort when dry (good/okay vs poor)
Comfort when wet (good/okay vs poor)
Skin health problems (none vs a little/a lot)
Overall acceptability (high vs okay/no)
Preference men
FIGURE 34 Forest plot: T-shaped vs diaper (night)Health Technology Assessment 2008; Vol. 12: No. 29
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Odds ratio (95% CI)
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FIGURE 35 Forest plot: pull-up vs T-shaped (day)
Odds ratio (95% CI)
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0.13 (0.01 to 1.21)
0.55 (0.19 to 1.63)
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1.45 (0.67 to 3.12)
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Smell (good/okay vs poor)
Comfort when dry (good/okay vs poor)
Comfort when wet (good/okay vs poor)
Ease on (good/okay vs poor)
Skin health problems (none vs a little/a lot)
Overall acceptability (high vs okay/no)
Preference men
FIGURE 36 Forest plot: pull-up vs T-shaped (night)Products for women and men living in community settings (Trial 2a)
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Odds ratio (95% CI)
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FIGURE 37 Forest plot: pull-up vs insert (day)
Odds ratio (95% CI)
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Overall acceptability (high vs okay/no)
Preference men
FIGURE 38 Forest plot: pull-up vs insert (night)Health Technology Assessment 2008; Vol. 12: No. 29
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Odds ratio (95% CI)
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FIGURE 39 Forest plot: pull-up vs diaper (day)
Odds ratio (95% CI)
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Odds ratio (95% CI)
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FIGURE 41 Forest plot: diaper vs insert (day)
Odds ratio (95% CI)
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Odds ratio (95% CI)
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FIGURE 43 Forest plot: diaper vs washable (day)
Odds ratio (95% CI)
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FIGURE 44 Forest plot: diaper vs washable (night)good absorbency, but some people experienced
problems with the waistband and men in
particular made comments about insufficient
padding at the sides. 
The main positive comments for inserts concerned
ease of putting on and discreetness. Negative
aspects included poor absorbency and difficulty
staying in place. The washables attracted positive
comments about absorbency and low leakage from
men in particular, but were criticised for bulkiness
and difficulties with putting them on, problems
with laundry and, for women in particular, their
‘babylike’ appearance.
Economic analysis
Relative value for money
To establish respondents’ views about the relative
value for money of each design, researchers asked
them to consider the monthly cost of supplying
the products that they had previously identified as
the best value for money in each design. Retail
and mail order prices prevailing at the time of the
trial (April 2005) were used. Allowance was
included for net pants worn with inserts and plastic
pants for two of the washable products that did
not have integral waterproof covering. Monthly
costs were based on median reported product
utilisation at baseline (three/day, one/night). For
washable products, replacement rates were based
on manufacturers’ data about product life (270
washes for washable products, 30 washes for
plastic pants), and assumptions about stocks of
products that participants would hold (12
washable products and 12 pants for day use, 
six washable products and six pants for night use). 
There was considerable variation in the prices of
products within designs both day and night
(Tables 44 and 45). Washables were much cheaper
than disposables. Of the disposable designs,
inserts and diapers were cheaper than T-shaped
and pull-ups. In the day, the mean cost of the
insert products that were tested was below that of
the diapers, but the night diapers were cheaper
than the inserts. The expense of laundering
washable products (which is borne by individuals)
is not included in the monthly costs, and
respondents were reminded of this when asked to
state their preferences.
Participants were asked if they were buying their
own products, which designs they would select
first, second, third, etc., and why, and which
designs they would be willing to buy (Table 44). Of
particular interest were participants’ stated
preferences between the disposable and washable
designs when potential savings associated with
washables became apparent.
Some switching of stated day preferences
occurred into cheaper designs (washables and
inserts) and away from the more expensive ones
(pull-ups and T-shaped) once the relative prices
were disclosed. For night products, where the
washables were already more popular, and 
T-shaped less so, the switching was less
pronounced, although there was a large swing
away from pull-ups. The willingness to buy
exceeded 50% only for diapers (both day and
night) and for washables (night) (Table 44). This
might be because most participants in this trial
were not used to purchasing their supplies.
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TABLE 44 Ranking with and without price (day) (no price N = 85; with price N =74)
Rank Willing to buy  Cost/month
(with price only)  (range) (£)
1st 2nd 3rd 4th 5th Yes No DK/
missinga
Insert no price 10.6 (9)0 21.2 (18) 14.1 (12) 23.5 (20) 30.6 (26) 29 39 6 28.50–59.00
With price 14.9 (11) 28.4 (21) 10.8 (8)0 14.9 (11) 31.1 (23)
Diaper no price 29.4 (25) 22.4 (19) 25.9 (22) 20.0 (17) 2.4 (2) 37 31 6 42.00–65.50
With price 32.4 (24) 12.2 (9)0 27.0 (20) 24.3 (18) 4.1 (3)
Pull-up no price 37.6 (32) 21.2 (18) 22.4 (19) 15.3 (13) 3.5 (3) 32 36 6 74.00–88.00
With price 32.4 (24) 20.3 (15) 21.6 (16) 18.9 (14) 6.8 (5)
T-shaped no price 18.8 (16) 27.1 (23) 18.8 (16) 29.4 (25) 5.9 (5) 29 40 6 58.00–93.00
With price 12.2 (9)0 31.1 (23) 23.0 (17) 24.3 (18) 9.5 (7)
Washables no price 3.5 (3) 8.2 (7) 18.8 (16) 11.8 (10) 57.6 (49) 28 42 4 7.33–10.00
With price 8.1 (6) 8.1 (6) 17.6 (13) 17.6 (13) 48.6 (36)
a DK/missing: ‘don’t know’ response or data missing.Cost–effectiveness
To calculate the cost-effectiveness ratios, the mean
monthly cost of the products in each design and
the mean of the mean product VAS scores in each
design were used. Design level average ratios are
shown in Table 46. Washables had the lowest cost
per unit of effectiveness (VAS point) in the day
(£0.27) and night (£0.11). The T-shaped had the
highest ACER in the day (£1.25) and the insert
had the highest ACER at night (£0.52). 
In the day analysis, there was no significant
difference in the mean VAS between diapers and
pull-ups (p = 0.178) or between diapers and 
T-shaped (p = 0.085). There were significant
differences between all the other designs. With the
exception of the T-shaped design, more highly
priced products have higher effectiveness. The 
T-shaped products, however, cost more than
diapers and have lower mean VAS scores. 
The ICERs derived from Table 46 show that
compared with diapers, the extra monthly cost 
of pull-ups per VAS point gained is £5.00 
(without any significant increase in 
acceptability). It costs £2.34 for each extra VAS
point gained if inserts rather than washables are
purchased, and £0.19 for an extra VAS point if
money is spent on diapers rather than inserts.
Although inserts are significantly more 
acceptable than washables, diapers have
significantly higher acceptability ratings than 
both those designs. The evidence points to
diapers as the most cost-effective option for day
use. However, this analysis has not taken the 
effect of gender into account and women
preferred inserts during the day (25 versus 11)
and their VAS scores are accordingly higher for
inserts (Appendix 11). Inserts may therefore be
the most cost-effective option for day use for
women.
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TABLE 45 Ranking with and without price (night) (no price N = 85; with price N =75)
Rank Willing to buy  Cost/month
(with price only)  (range) (£)
1st 2nd 3rd 4th 5th Yes No DK/
missinga
Insert no price 10.6 (9)0 17.6 (15) 11.8 (10) 20.0 (17) 40.0 (34) 25 45 5 14.30–28.40
With price 14.7 (11) 16.0 (12) 16.0 (12) 14.7 (11) 38.7 (29)
Diaper no price 17.6 (15) 32.9 (28) 28.2 (24) 15.3 (13) 5.9 (5) 39 32 4 12.33–16.20
With price 16.0 (12) 38.7 (29) 26.7 (20) 16.0 (12) 2.7 (2)
Pull-up no price 27.1 (23) 16.5 (14) 27.1 (23) 21.2 (18) 8.2 (7) 29 39 7 24.50–27.50
With price 21.3 (16) 20.0 (15) 17.3 (13) 29.3 (22) 12.0 (9)0
T-shaped no price 9.4 (8) 18.8 (16) 28.2 (24)  37.6 (32) 5.9 (5) 25 46 4 19.30–31.00
With price 10.7 (8)0 10.7 (8)0 36.0 (27) 34.7 (26)  8.0 (6)
Washables no price 35.3 (30) 14.1 (12) 4.7 (4) 5.9 (5) 40.0 (34) 40 33 2 2.45–7.60
With price 37.3 (28) 14.7 (11) 4.0 (3) 5.3 (4) 38.7 (29)
a DK/missing: ‘don’t know’ response or data missing.
TABLE 46 Cost-effectiveness of designs 
Day Night
Design Mean  of  Mean ACER Design Mean  Mean ACER
monthly VAS  monthly  VAS
cost (£) of  score Cost  VAS  cost (£)  score Cost  VAS 
products per  points (1/night    per points 
in design  VAS  per £ 30) VAS  per £
(3/day   point point
30) (£) (£)
Pull-ups 78.70 72.66 1.08 0.92 Diapers 14.80 64.47 0.23 4.36
Diapers 47.10 66.34 0.71 1.41 Pull-ups 25.50 62.18 0.41 2.43
T-shaped 75.50 60.14 1.25 0.80 T-shaped 25.15 53.91 0.47 2.14
Inserts 43.70 48.53 0.90 1.11 Washables 6.00 53.15 0.11 8.86
Washables 9.00 33.68 0.27 3.74 Inserts 22.60 43.07 0.52 1.91In the night analysis, washables are cheaper than
the other three disposable designs but were
significantly less acceptable (highly acceptable +
acceptable) versus (unacceptable + totally
unacceptable) than the diaper design (with which
it was compared). Diapers are cheaper than the
other three disposable designs. They are rated
significantly better than washables, T-shaped and
inserts but their mean VAS score was not
significantly different from that of pull-ups. 
Compared with washables, the extra monthly cost
of diapers and pull-ups per VAS point gained is
£0.78 and £2.16, respectively. There was no
difference in the acceptability of washables and
pull-ups. However, washables were ranked best for
night use by more people (almost all men) than
both pull-ups and diapers (30 versus 23 and 15).
Over one-third of the sample therefore preferred
the cheapest product. For the rest who preferred a
disposable design and find washables
unacceptable, diapers are the most cost-effective
option. However, as in the daytime, women
preferred inserts to diapers (22 versus 14) and
their mean VAS scores for inserts were higher 
than those for diapers. Inserts may therefore 
be the most cost-effective option for night use 
for women.
Sensitivity analysis and sources of uncertainty
The cost-effectiveness ratios are based on point
estimates of costs and effectiveness (as represented
by VAS mean scores). There is less variation in
design mean VAS scores at night than in the day.
Washables and inserts have significantly lower
mean VAS scores than the other three designs in
the day.
There are several sources of uncertainty in the cost
estimates. First, the costs reflected the prices of
products selected for the trial. There was
considerable variability in prices of included
products within designs, and the mean price was
used (Tables 44 and 45). There are many different
products available (especially in the diaper and
the insert categories), so a different choice of
product may have resulted in different mean
design costs. As products may vary in
characteristics and performance, and respondents
were asked to evaluate the products that they had
tested, it was decided that they should be
presented with the associated relative prices. Two
of the night insert products that were used in the
trial were at the top of the price range, resulting
in the mean design cost above that of the diapers
group. A different choice of products could have
reversed that ordering.
Second, the product prices used were those of
retail/mail order outlets. A few people purchased
some or all of their own products. Although all of
the disposable products were purchased through
PASA, at the time of the study, the NHS did not
provide four of the night products tested (two
diapers, one T-shaped, one pull-up) and five of
the day products (one insert, one diaper, one 
T-shaped, two pull-ups) as standard. The PASA
bulk purchase discount on the products that it
supplied relative to the retail/mail order price, 
was about 50% (range 33–67%). PASA prices vary
less within the diaper and insert designs than is
the case in the retail/mail order market. Use of
NHS prices would have affected the values of the
cost-effectiveness ratios, but not the relative values
unless the bulk purchase discount secured by
PASA varied between designs. The washable
products were purchased directly (with discount
for bulk purchase) from the suppliers and none
were supplied through PASA or by the NHS at the
time of the study.
Third, all monthly cost estimates are based on a
consumption rate of three products per day and
one per night (median consumption reported by
participants at baseline). This resulted in a slight
underestimate of the actual mean product
consumption per 24 hours recorded during
testing.
Fourth, the trial found that the utilisation of
products varied significantly across designs:
participants made fewer changes of washables 
and more changes of inserts. Adjustment for this
would alter the relative costs of the designs
slightly.
Fifth, calculation of the monthly costs of the
washables was based on assumptions about the life
(number of washes) of products and the stocks that
participants would hold. Varying these
assumptions affects the cost-effectiveness of
washables relative to disposables. Holding more
stocks and increasing the replacement rate
increases the costs of washables. Even when
pessimistic assumptions about stocks and product
life were used, washables remained substantially
cheaper than disposable products.
Similarly, varying the assumptions about the
replacement rate of the stretch mesh pants used
with inserts and the plastic pants for washable
products would affect the costs of these designs,
but only marginally, as the prices of these items
are very low relative to that of the products that
they support.
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on the purchase price of products and exclude the
costs borne by consumers, the most important of
which is the cost of laundry in the case of the
washables. Use of disposables involves ‘shoe
leather’ costs of purchase (except where products
are delivered by the NHS) and also issues around
storage and disposal, but these are generally
considered to have minimal financial impact for
users. 
Laundry and environmental costs
Laundry costs are of two types: those associated
with washing reusable products and laundry
generated by leakages. Participants were reminded
when making their selections between designs that
the costs they were given did not include the cost
of laundering the washable products. Including
the laundry costs associated with washables would
reduce their cost-effectiveness relative to
disposables. Inserts generated significantly more
laundry items than the other designs in the day
and the night, and washables created significantly
less leakage-generated laundry at night (but
significantly more laundry overall) than the other
designs, but the monetary values of these
differences were not estimated. 
An important consideration in the comparison of
washable and disposable designs is the relative
environmental cost, particularly disposal (landfill)
costs of disposable designs and energy costs
associated with laundering the washables. A recent
report on baby nappies concluded that there was
no significant difference in environmental impact
between three nappy systems (disposables, home
and commercial laundered), although the types of
impacts did vary.49 It is assumed that these findings
are generalisable to adult incontinence products
and, accordingly, no allowance was made in the
cost-effectiveness calculations for environmental
factors.
Attitudes towards washable and
disposable products
At the final interview, participants were asked an
open question as to whether they favoured
washable or disposable products, and why. The
results are shown in Tables 47 and 48. Less than
10% favoured washables for the daytime, but this
proportion rose to more than one-third for night-
time; both environmental and absorbency reasons
were the most common given. 
Participants were asked how they would feel if
washables were the only products supplied by the
NHS and nearly two-thirds (60.7%) said that they
would be concerned. 
Practical aspects of washables and disposables
Respondents were asked for their views about the
practical aspects of using each type of product and
the extent to which these constituted a problem
(four-point scale). The results are presented in
Tables 49 and 50. Practical issues associated with
the use of washables constitute bigger problems in
the opinions of participants, in particular dealing
with wet washable products when out.
Discussion
This study is the first community-based trial of
body-worn absorbent products for men and
women with moderate/heavy urinary (or urinary
and faecal) incontinence.
The main findings were that for day and night use
the pull-up was significantly better than the insert
for most variables, including overall acceptability
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TABLE 47 Views on washable and disposable products (day): N = 65a
Favour disposables  78.5% (51)
Favour washables  9.2% (6)
No strong feeling either way  12.3% (8)
Reasons for favouring disposablesb N Reasons for favouring washablesb N
Easy to use/practical/convenient 30 Economical/cheaper 3
Being disposable/no laundry 16 Environment 3
Less bulk/more discreet 9 Wash with normal laundry 1
No smell 2 Convenient 1
Familiarity 1
Hygiene 2
a See the section ‘Data completion’, p. 50.
b Participants could give more than one response.and preference. The diaper was significantly better
than the insert for leakage for day and night but
was only significantly more acceptable at night. The
washable was significantly better than the diaper for
leakage for both day and night but was significantly
worse for most other variables, including overall
acceptability and preference in the daytime. 
Inserts
When compared with the other disposable
designs, inserts were significantly leakier than the
other disposable designs and produced around
twice as much laundry during the daytime. They
were particularly poor for staying in place, which
may account in part for their poor leakage
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TABLE 48 Views on washable and disposable products (night): N = 67a
Favour disposables  61.2% (41)
Favour washables  35.8% (24)
No strong feeling either way  3.0% (2)
Reasons for favouring disposablesb N Reasons for favouring washablesb N
Easy to use/practical/convenient 27 Economical/cheaper 6
Being disposable/no laundry 11 Environment 9
Less bulk/more discreet 2 Don’t move at night 1
Environment 1 Reliable/confidence/good absorbency 10
Reliable 1 No changes needed at night 3
Less space needed 2
a See the section ‘Data completion’, p. 50.
b Participants could give more than one response.
TABLE 49 Practical aspects (day) 
Feature %  (N)
No Small Big  Insurmountable  Totala
problem problem problem problem
Big outlay to purchase stock of  28.1 (18) 32.8 (21) 31.3 (20) 7.8 (5) 100.0 (64)
washable products at outset
Dealing with washable products before  25.4 (16) 28.6 (18) 31.7 (20) 14.3 (9) 100.0 (63)
washing (e.g. rinsing out, nappy bucket)
Washing washables 33.8 (22) 24.6 (16) 33.8 (22) 7.7 (5) 100.0 (65)
Drying washables 29.2 (19) 30.8 (20) 30.8 (20) 9.2 (6) 100.0 (65)
Dealing with wet washable products  6.3 (4) 27.0 (17) 42.9 (27) 23.8 (15) 100.0 (63)
when out
Disposal of used disposable products 64.6 (42) 24.6 (16) 10.8 (7) 0.0 (0) 100.0 (65)
Storage of disposable products 55.4 (38) 35.4 (23) 9.2 (6) 0.0 (0) 100.0 (64)
Obtaining supplies of disposable products 59.4 (38) 29.7 (19) 9.4 (6) 1.6 (1) 100.0 (64)
a See the section ‘Data completion’, p. 50.
TABLE 50 Practical aspects (night) 
Feature %  (N)
No Small Big  Insurmountable  Totala
problem problem problem problem
Dealing with wet washable products  30.8 (20) 30.8 (20) 30.8 (20) 7.7 (5) 100.0 (65)
at night
Dealing with wet disposable products  64.1 (41) 25.0 (16) 9.4 (6) 1.6 (1) 100.0 (64)
at night 
Big outlay to purchase stock of washable  30.0 (18) 36.7 (22) 31.7 (19) 1.7 (1) 100.0 (60)
products at outset
a See the section ‘Data completion’, p. 50.performance. The main positive point for inserts
was their discreetness. Despite poor leakage
performance, there were indications that women
preferred inserts to diapers (see below). 
Pull-ups
Pull-ups scored significantly better than other
designs on many performance variables (but not
leakage, or overall acceptability except compared
with inserts), particularly during the day and
particularly for staying in place, fit, comfort when
dry and discreetness. They were easier to put on
than the two diaper-style designs (but not the
insert) at night, but not during the day when there
would be a need to remove clothing in the toilet
with the pull-up. Comments indicated that
changing pull-ups when out, and particularly
when wearing trousers, was a problem. However,
there were gender differences (see below).
Diapers and T-shaped diapers
The diaper was the most cost-effective design for
the day and for the night (for those who did not
find the washable acceptable), but was more likely
to be preferred by men than women (see below).
The diaper had no particular strong points apart
from its superiority over inserts for leakage and
overall acceptability (at night). The diaper was not
significantly different to the T-shaped diaper for
most variables but was scored significantly better
for overall opinion than the T-shaped diaper at
night. The T-shaped diaper was not found to be
significantly easier to put on than the diaper for
day or night.
Washables
The washables had very good leakage
performance, particularly for large urine volumes,
both day and night, but scored poorly for most
other variables, particularly discreetness and ease
of putting on. Most participants found dealing
with washables more problematic than dealing
with disposables, particularly when outside the
home. Less than 10% considered them acceptable
for going out, although rather more (nearly half)
considered them acceptable for staying at home.
During the night-time, opinions about the
washables were much divided, with nearly half
(42%) of participants (almost all men) scoring
them as highly acceptable and the same
proportion scoring them as unacceptable. This
may have reflected its very good leakage
performance (one participant commented “bomb-
proof for leakage”), but also its poor, baby-like
appearance and bulk, which many found
unacceptable. The clear plastic pants and white
terry-towelling absorbent closely resemble babies’
nappies, yet terry-towelling can be dyed or printed
and there is considerable scope for improving the
appearance of plastic pants. It is notable that the
third washable product (see Appendix 9) was very
much worse for leakage than the two terry-
towelling products and there may be considerable
variability in the performance of washables in
general. 
Faecal incontinence
Less than one-third of participants stated that they
had faecal incontinence at the beginning of the
study and fewer responded to the final interview
question about the performance of the designs for
faecal incontinence. No firm conclusions could
therefore be drawn and further evaluation of
designs for the management of faecal
incontinence is needed.
Skin health
No evidence was found of greater skin problems
when using washable products; however,
randomisation of day and night designs meant
that most subjects did not test washable products
continuously. As this is also likely to be the
situation in practice (e.g. washables may be worn
only during the night, with disposables used in the
daytime), the study findings may be generally
applicable. 
The finding that skin problems were more
frequent with the T-shaped diaper may be
explained by the waist-band, which was considered
to be a source of irritation by some participants.
The T-shaped diapers used in the study were the
first of their kind to be available on the market
and discussions with one of the manufacturers
indicate that initially there were problems with the
waist-band, which has since been modified.
Absorbency levels
All the designs tested in this study were available
in a range of absorbencies and the most
commonly used absorbency levels (according to
PASA data) were selected for inclusion in this
study. The main difference in leakage
performance results related to the poor
performance of the insert design relative to the
other designs; it is therefore possible that the
inserts would score better if more absorbent (and
more expensive) inserts were used.
Gender differences
Important differences were found between men
and women in the severity of their incontinence,
in the performance of the different designs and in
the preferences that men and women held for
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explore these differences, but the division of the
sample into the two smaller gender groups
reduces the power of the study and interpretation
must therefore be cautious.
Severity of urinary incontinence and
leakage: gender differences
The men in the study were more severely
incontinent of urine than the women. The average
urine mass in the men’s pads was around two-thirds
greater than that in the women’s pads. Pad
consumption data showed that men used similar
numbers of pads (possibly more during the
daytime) to women and this finding could not
therefore be explained by men changing their 
pads less frequently. In general, the leakage
performance of the pads was around 10% worse for
men than women during the day and around 20%
worse during the night (less differences for T-
shaped and washables). This may in part be
explained by the larger urine masses in the men’s
pads (leakage performance declines with increased
urine mass), but also by anatomical differences.
Women have a fixed urethra and urine loss occurs
from a predictable position. For men, the
orientation of the penis may vary considerably,
particularly at night when lying on the side. It is
therefore more difficult for pads to be leak-free 
for men.
Leakage performance of different
designs: gender differences
Leakage performance also differed for men and
women between the different pad designs. The
leakage performance tables and probability 
curves by gender (see Appendix 6) indicate that
the pull-ups performed better for women than for
men (around 20% difference) and this was
supported by similar differences in the rating of
leakage performance by men and women.
Comments were made by men (none by women)
that the absorbent padding in the pull-ups was 
not in the right place for them and this may be a
possible explanation and should be investigated
further. Inserts performed badly for leakage for
both men and women but the leakage probability
curves indicated that inserts performed relatively
worse for men than for women at night. For
example, the probability of inserts leaking at 
night with 250 g of urine is around 0.72 for
women but is only around 0.52 for men (see
Appendix 6). Inserts were commonly rated as
being poor for staying in place (particularly by
men) and this problem, combined with 
anatomical issues described above, may explain
this finding.
Overall acceptability and preferences:
gender differences
Preferences indicated by men and women are
generally supported by performance findings, but
there are some notable differences. Both men and
women preferred pull-ups to inserts (better
leakage performance and better for most other
variables) for both day- and night-time. Women
significantly preferred pull-ups (best leakage
performance for women, high scores for most
variables) to the two diaper designs, but men
preferred diapers to the pull-up and T-shaped
designs. This is probably because for men, unlike
for women, the pull-ups are not better for leakage
(and may be worse) and have an important
disadvantage, in requiring trousers to be removed
for changing pads. In addition, some men felt the
pull-ups to be feminine (“like frilly girls’ knickers”,
commented one participant). It is not clear why
men significantly preferred the diaper to the 
T-shaped diaper. The T-shaped diaper was at least
as good for leakage performance as the diaper
(and may be better), but the T-shaped design was
not found to be easier to be put on than the
conventional diaper and participants made
negative comments about the waist-band and the
lack of padding at the sides, which may have
influenced their choices.
Perhaps more surprising is the indication that
women prefer inserts over diapers, given the
significantly worse leakage performance for
inserts. Women’s preferences favouring the insert
(25 versus 11 for daytime; 22 versus 14 for night-
time) were not significant, but are in the opposite
direction to men’s preferences. In general, women
scored the diaper lower than men for key variables
such as discreetness and ease of putting on and
made more negative comments about the
appearance of the diaper. 
The washables were disliked during the daytime by
both men and women (despite their superior
leakage performance), but many more men found
them acceptable or highly acceptable for night-
time use (40/49) use than women (9/36). This may
reflect the general acceptance by men of diaper-
style designs and the general dislike of diaper-
style products by women.
For women, inserts and pull-ups may be
considered essentially quite feminine designs,
inserts being simply (very) large versions of
familiar menstrual pads. For men, absorbent pads
are not familiar products and they are faced with a
choice between rather female-orientated products
(inserts and pull-ups) or rather babyish ones
Products for women and men living in community settings (Trial 2a)
78(diapers). There is no male-specific product. It is
probably not surprising that they opt for the most
effective designs for leakage or those which they
perceive have the least number of drawbacks
(washables and diapers). 
Cost-effective provision of products
Where people find cheaper alternatives acceptable
for some situations (if not all situations), it should
be possible to allow a sufficiently flexible choice of
products such that potential savings could be
realised. If the NHS offers the whole range of
designs (i.e. includes washables) and gives greater
choice through direct payments or vouchers, then
clients are given an incentive to ‘mix and match’
designs in a way that will make the best use of the
funds they have. For example, they might
economise at night by buying washables and use
the savings to buy pull-ups for special occasions
while making diapers (or inserts) the mainstay of
their daily incontinence management.
Limitations
Product development means that the
characteristics and availability of individual
products change over time and the products used
in this study are likely to be superseded. However,
the main designs are much more stable and the
results should therefore outlive those of the
individual products. Market changes, however,
mean that absolute and relative prices can alter.
For example, a greater demand for pull-ups by
NHS Trusts (in response to client preferences)
could enable competitive manufacturers to exploit
further economies of scale in production and offer
more favourable purchasing terms for PASA.
It is difficult to know how well the sample
represented men and women using absorbent
pads for moderate/heavy incontinence living in
the community. There are no published data on
the characteristics of this population. Considerable
background data were collected on the sample
which should enable future comparisons to be
made. The inclusion of the criterion that
participants were able to complete self-report
questionnaires meant that individuals with
cognitive impairment were not included in the
study. It would not therefore be possible to
generalise these results to the population of pad
users with dementia, many of whom would also be
looked after by carers.
The findings of substantial differences in the
degree of incontinence and the preferences for
different designs between men and women were
important, but the subsequent need to analyse
data in gender groups reduced the sample sizes
for each group, with a consequent loss of power.
This meant that some differences between designs
(particularly in the smaller group of women) did
not reach significance, and it was more difficult to
reach firm conclusions. Future studies should
therefore be powered to allow for analysis by
gender group. 
Further limitations applying to the study more
generally are discussed in Chapter 7.
Conclusions
In this study, we found significant differences
between the performance, overall acceptability
and cost-effectiveness of the different absorbent
designs for men and women with moderate/heavy
incontinence. Important and unexpected
differences were found between men and women
for most variables and the overall conclusions (in
this paragraph) should be considered alongside
those by gender (in the following paragraph). 
The pull-up was better than the insert (but not the
diaper) for the daytime and the pull-up and
diaper were better than the insert at night.
However, the pull-up was expensive and the
diaper was the most cost-effective design for the
day. For the night, the washables were the most
cost-effective design, but for those who found
them unacceptable the diaper was the most cost-
effective choice. The inserts were worse than all
the other designs for leakage performance for
both day and night. 
Gender differences were found for most variables
(including leakage performance), but few firm
conclusions could be drawn because of small
numbers in each group. The men were more
severely incontinent than the women and
generally experienced more leakage (around 20%
at night). The men did not prefer pull-ups but
significantly preferred diapers to inserts and
diapers were the most cost-effective product for
men for the day. For the night the washable was
the most cost-effective product for men, but nearly
half found them unacceptable and for them the
diaper was the most cost-effective product. The
pull-up was significantly preferred by women to all
the other designs, both day and night, but is
relatively expensive. Despite inserts having worse
leakage performance than diapers, women
generally preferred inserts (although this was not
significant), and the insert may be the more cost-
effective choice. The washable was unacceptable to
most women for day or night. 
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There is evidence that:
● The performance of, and preferences for,
different designs are different for men and
women and this implies that a range of 
options may be needed to ensure adequate
provision.
● Incontinence severity varies widely, but men
(who use absorbents for moderate/heavy
incontinence) are generally more severely
incontinent than women and may need more
products or more absorbent ones.
● Diapers are the most cost-effective disposable
design, for men. However, gender differences
indicate that inserts may be cost-effective for
women. For women, pull-ups are strongly
preferred, have better performance (than
inserts) but are more expensive. Bulk 
contracts would reduce the price of pull-ups
and make them more affordable for the 
NHS.
● Provision of the terry-towelling washable diaper
is likely to be economical for the NHS when
used at night. However, most women (and some
men) strongly dislike them. Restricting the
range of available products to washable designs
alone is therefore not recommended. 
● Allowing men and women to choose
combinations of designs (washable and
disposables) for day and night and for different
circumstances (e.g. for women, inserts at home
and pull-ups when out) within a limited budget
is likely to be economical for the NHS.
● An NHS ‘shop’ (virtual or otherwise) whereby
NHS vouchers could be used to purchase
combinations of product designs, at cheaper
prices (using the buying power of the NHS),
would be welcomed by users.
Recommendations for research
● Translational research to pilot the feasibility of
provision of a range of designs and enabling
men and women to choose combinations of
designs within a limited budget.
● Development of more effective and aesthetically
acceptable washable products, particularly for
night-time use and for women.
● Development of more effective and acceptable
disposable designs specifically for men.
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Around two-thirds of people in nursing homes and
one-quarter of those in residential homes
experience urinary and/or faecal incontinence and
body-worn absorbent pads are the most common
method of management.52 Although there are four
main designs of body-worn pads available in
disposable and washable variants (inserts, diapers,
T-shaped diapers and pull-ups) (Table 51),
disposable products dominate and washables are
more seldom used in homes. Insert pads are the
simplest, cheapest (on a per product basis) and
most commonly used of the disposable designs in
the UK, although diaper designs are also
frequently used. In the last few years, two new
designs have become available (T-shaped diapers
and pull-ups) which are intended to be easier for
the carer or individual to apply, but their
effectiveness is not known.
Selection of designs for individuals in nursing and
residential homes in the UK is based on little
evidence. There have been no direct comparisons
made of the different disposable body-worn
designs and most clinical trials have focused on
comparisons of disposable and washable designs,
but they are more than 10 years old. There are
indications from trials of products of a single
design15,16 that insert pads may be less effective
than diapers, but this has not been tested directly
in a clinical trial. There are also indications that
designs vary in how long they take to apply and
remove; however, this has not been demonstrated
clinically.51
Several studies have shown that incontinence is a
costly aspect of care in nursing homes,52 including
laundry, disposal and staff changing costs in
addition to the purchase price of the products.
The choice of containment method is likely to
affect significantly the overall expenditure,53 but it
is not known which designs of product are most
cost-effective.
Aims
The aim of the study was to compare the
performance and cost-effectiveness of disposable
absorbent product designs for women and men
with moderate/heavy urinary/faecal incontinence. 
A washable design was not included in this trial.
The costs and preparation needed to introduce
washable products into nursing homes are very
substantial and there is a lack of clinical data on
washable designs to inform selection from the
many designs available. Preliminary enquires with
nursing home staff also indicated that testing of
washable products would pose laundry difficulties
and staff would be reluctant to test them. 
Design and methods
The trial was a randomised crossover clinical trial
comparing four disposable absorbent product
designs (insert, diaper, T-shaped diaper, pull-up)
when used in nursing homes (Figure 45, p. 82).
Recruitment of participants
Nursing homes in the north London and
Southampton areas were contacted to inform them
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Chapter 5
Randomised crossover trial of disposable 
absorbent products for women and men with
moderate/heavy urinary or urinary and faecal
incontinence living in nursing homes (Trial 2b)
TABLE 51 Classification of products for moderate/heavy
incontinence 
Disposable Washable
Inserts Inserts 
Diapers Diapers
T-shaped diapers T-shaped diapers
Pull-ups Pull-upsabout the study and to invite them to take part. In
total 31 nursing homes were approached: 7 in
north London and 24 in Southampton and the
surrounding area. The aim was to recruit a total of
80 resident participants from a minimum of 10
homes to minimise potential bias from the group
effects of single homes. The inclusion and
exclusion criteria for participants are shown in
Box 3.
Consenting procedure
Eligible residents were introduced to the
researcher by the nursing home staff; the
researchers explained the purpose of the research
to the resident and, when necessary, read the
participant information sheet to the resident and
discussed it with them. If the researcher felt that
the resident understood the research and would be
able to make an informed decision, they were
given 24 hours to consider whether they wished to
take part. During this time they were encouraged
to discuss their decision with relatives and nursing
home staff if they wished. The researcher revisited
the resident the next day, checked that they still
understood the study and answered any questions.
If the resident was willing to proceed, they signed
a consent form.
If, following the meeting, the researcher felt that
the resident was unable to give their own consent
due to mental impairment, relatives were
contacted by post or in person and provided with
study information and asked to consider if the
resident would have wanted to take part in the
study had she or he been able to decide for
themselves. Residents were included in the trial if
the relatives believed that the resident would have
wanted to take part and were excluded if
objections were raised by either the relatives or the
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82
FIGURE 45 (a) Insert; (b) diaper; (c) T-shaped and (d) pull-up 
(a) (b)
(c) (d)
BOX 3 Inclusion and exclusion criteria
Inclusion criteria:
Adult women and men
Resident in nursing homes
Currently using absorbent products for moderate/heavy 
urinary or urinary and faecal incontinence
Exclusion criteria:
Acute illness
Terminal phase of illness
Urethral or supra-pubic cathetercare staff. The consenting procedure was reviewed
by the ethics committee and is shown in
Appendix 15. 
During the study period, staff were able to
discontinue the use of any product if it was
deemed unsatisfactory for the participant in any
way or the participant showed, in words or actions,
that they did not wish to participate.
Outcome measures
The outcome measures (see Chapter 2 for more
details) are listed below. Carers and (where
possible) participants completed a product
performance questionnaire at the end of each
product testing period and a final interview at the
end of the study. A primary carer was allocated for
each resident together with a backup carer to cover
staff holidays and sickness. We recognised from
the consenting data (see above) that few residents
would be able to provide complete responses to
the product performance questionnaires or final
interviews themselves and therefore aimed to
obtain primary data from the nominated care
staff, who were asked to take residents’ opinions
and preferences into account where available. Due
to staff absence, some carers completed product
performance questionnaires/final interviews for
more than one subject; however, they were always
encouraged to give resident-specific responses. For
the final interview, the researchers prompted each
carer to focus on the named participant to ensure
that responses reflected the performance of the
designs for the specific resident. Residents who
were able to give their own opinions completed a
separate shortened final interview.
Pad leakage and laundry
During the period of product testing, care staff
were asked to save as many used pads as possible
in individual plastic bags and complete a label
(stuck to each bag) which recorded the
participant’s initials, the date, where the pad was
worn (in bed or out of bed), whether the product
had leaked urine (none, a little, a lot) and whether
leakage had resulted in incontinence laundry
items. Used products were then weighed daily by a
researcher (or trained staff member) using digital
scales, the urine mass was recorded on the label
and the label was removed from the bag and stuck
into a data entry book. If there were faeces in the
pad, staff were instructed to dispose of the pad,
but still to complete the label giving details of
urine leakage and additionally to complete a card
to report details of any faecal leakage.
Product pad change labels were used to record: 
● laundry resulting from incontinence (small and
large items) 
● leakage from pad (none, a little, a lot)
● weight of used pad (g). 
A baseline data questionnaire (completed by
researchers) was completed through interviews
with carers and residents.
At the end of each period of product testing
(2 weeks), a product performance questionnaire
was completed to record:
● product performance variables (e.g.
discreetness) on a five-point scale (very good,
good, okay, poor, very poor).
● numbers of staff usually required to carry out
product change (none, one, two). 
During the second week of each product testing,
skin health was observed in the buttock, groin and
sacral areas and the maximum severity of any skin
problem was recorded: 
● skin health (none, mild or a little,
moderate/severe or a lot).
At the end of the trial, a final interview was
completed to record:
● Design preferences and rankings.
● Acceptability of design (highly acceptable,
acceptable, unacceptable, totally unacceptable),
with and without costs; and whether the carer
would recommend to other care staff. 
● Score on a VAS (worst possible design–best
possible design). A simplified 10-point measure
was used in this module because piloting
showed that this was easier for staff to use than
the VAS used in trial 2a.
● Comments about good and poor aspects of
designs.
Selection of absorbent products
to represent design groups
A single product was selected to represent each of
the four design groups (insert, pull-up, diaper, 
T-shaped diaper) for day and another for night
use (a total of eight products). The products were
selected from interim data available from the
similar clinical trial of absorbent products which
was being undertaken with community-dwelling
individuals (see Chapter 4). This community trial
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group, which had been preselected from a pilot
study. They had similar absorbencies to those most
commonly purchased by the NHS (see Chapter 2)
and, in order to avoid the confounding effects of
different absorbencies, had similar absorbencies to
each other (1900 ml ± 20% for daytime use and
2400 ml ± 20% for night-time use7). A single
product was selected to represent each design
because preliminary discussions with nursing
homes indicated that the additional time and
complexity of testing three products to represent
one design was excessive for nursing home staff.
Study preparation and procedures
Product preparation, randomisation
and blinding
Waist and hip measurements were used to order
appropriately sized products for each participant.
Blinding was not practical because each design
had a different appearance. Products were
therefore provided in their original packaging
complete with any manufacturers’ instructions.
Packs of products were marked with study labels
indicating whether they were day or night
products. At the beginning of each 2-week testing
period, the new, labelled test products were placed
in the residents’ bathrooms, together with the
labelled plastic bags for product saving, and the
previous products were removed.
Products were cluster randomised to each nursing
home using Latin squares.38 Randomisation of the
order of products for each individual was thought
likely to cause confusion and error and
participants within each home therefore used the
same design of products at the same time.
Staff meetings
Care staff meetings were held at each nursing
home to discuss the study with the carers and to
seek their cooperation. The product designs were
shown and demonstrated to staff to ensure that all
carers were familiar with them. The completion of
the pad labels at each pad change was also
demonstrated. At these meetings, we also asked
carers to prioritise the pad performance variables
they considered to be of greatest importance
(using a list; see Chapter 6) and these variables
were selected for analysis from the product
performance questionnaire. 
Baseline data
Research staff collected baseline information
(demographic data and descriptive scores; see
Chapter 2) from participants and care staff using
questionnaires.
Product testing period
Each design was tested for a 2-week period; the
total test period was therefore 8 weeks. Although a
1-week testing period was used for each product in
the community trials (with three products
representing each design), a longer period was
considered necessary for the homes to ensure that,
given different shift patterns, leave and days off,
staff had sufficient time to experience pad
performance with included residents. The homes
were visited daily for pad weighing and to discuss
trial progress with staff. Product consumption was
measured by counting the numbers of products
used during the test period. During the second
week of testing, skin health was observed and
recorded by the researcher. At the end of each 
2-week period, the care staff (both day and night)
and participants (where possible) were asked to
complete product performance questionnaires. 
Final interview
On completion of the 8-week testing period, a
final interview was arranged with the carers 
(and participants), who were asked to indicate
their preferences by ranking the designs. The
different designs were scored on a 10-point VAS
and were rated using the overall acceptability
score. An overview of the study process is shown 
in Figure 46.
Pad change timing exercise
The two newer designs (pull-up and T-shaped) 
were both engineered to be easier to put on than
the conventional designs (insert and diaper) and
they might therefore be expected to save on time
taken for pad changes. In addition to the clinical
trial, we therefore carried out a small pad-change
timing study which aimed to compare the length
of time designs took for pad changing. Our
hypothesis was that the pull-up design would be
faster than the insert design and that the 
T-shaped diaper design would be faster than the
diaper design. 
Design and methods
Crossover design: for each participant the four
pad changes (with the four different designs) were
carried out consecutively, in random order by the
same pair of carers (or individual carer) according
to Latin squares.
Sample
Residents who had taken part in the clinical trial
(from three homes)and were able to give their own
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the exercise. Staff member volunteers who had
taken part in the clinical trial, regularly cared for
the resident and were willing to take part in the
exercise were recruited with the resident. The
number of staff used to undertake the pad change
was the usual number required by the resident
(either one or two).
Before commencing the timing exercise, the
volunteer staff member(s) carried out a practice
run-through using the researcher as a model. This
was to ensure that the staff members were familiar
with the designs, particularly those not in regular
use (pull-ups and T-shaped). 
Procedure
The pad change was timed in four stages. 
● Stage 1 – the time taken to remove the
resident’s underclothes and the absorbent
product currently worn. This was measured
once, at the beginning of the exercise.
● Stage 2 – the time taken to apply the pad. 
This was measured once for each design (i.e.
four times). The timing started with the
resident in the same position (sitting in a 
chair) and the pad was placed in the same
location next to the resident. The finishing 
time was measured when the resident had 
been re-seated.
● Stage 3 – the time taken to remove the tested
design and re-seat the resident. This was
measured once for each design (i.e. four times).
● Stage 4 – the time taken to replace the residents
clothing and re-seat them. This was measured
once, at the end of the exercise.
Stages 1 and 4 were measured only once in order
to minimise the effort required for the resident
and staff member. These measures were used to
provide estimates of the total time taken to change
the residents’ pad. 
Outcomes
Time in seconds measured by stopwatch by the
observing researcher for stages 2 and 3 (added
together) of the pad change.
Ethics
The study was reviewed by the London multi-
centre research ethics committee and complied
fully with ethical, governance and data protection
requirements and approval was obtained through
appropriate NHS research ethics committees.
Analysis
Data were entered into Microsoft Excel (Version
2003), cleaned and 10% of the data set and 
100% of the primary outcome variable data were
checked for accurate entry. Ordinal outcome
variables were analysed using cumulative logit
modelling, and quantitative outcome variables
were analysed by linear modelling, allowing for
repeated observations by each subject. Bonferroni
adjustments were made in significance tests and
to CIs for multiple comparisons between designs.
R software was used (www.r-project.org).
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Outcomes during testing period
Product consumption, laundry and 
  leakage diary
2-weekly product performance 
  questionnaire
2-weekly skin health observation
Design 1: 2 weeks
Interview: Outcome –  participant background data and scores
Design 2: 2 weeks
Design 3: 2 weeks
Design 4: 2 weeks
Final interview: Outcomes – design preferences,
acceptability scores, VAS scores and comments
8-week 
test 
period
FIGURE 46 Overview of study process and outcomes Results
Participant characteristics
A total of 149 potential participants were eligible
from the 10 nursing homes. Consent (or
agreement from a relative or third party) was
obtained from 120 participants; 113 began testing
products and 100 completed testing of all designs.
Progress of participants through the trial is shown
in Figure 47 and participant characteristics are
shown in Table 52. Most of the 100 participants
were female (73%) and the mean age was
81.9 years (range 42–105 years). Most required a
high level of care; 70% were wheelchair, chair or
bed bound, 89% were totally dependent on care
staff for their continence needs and 90% had
medium or high dependency according to the
Barthel index. Half of the participants scored zero
on the Hodkinson mental test score. Most (75%)
participants were using disposable inserts before
the study and the rest used diapers. None were
using T-shaped products and one resident was
using a pull-up at night. 
Staff characteristics
Ninety-six care staff (68 day staff and 28 night
staff) completed the fortnightly product
performance questionnaires and the final
interviews. The staff characteristics are shown in
Table 53. Most staff were female (81%) and the
mean age was 39 years (range 19–66 years). Most
staff were care assistants and were in full-time
employment. More than 95% had been in post for
more than 6 months and 50% had been in post for
3 years. Over 40% of staff were in their first
caring job and 57% had a formal qualification,
such as NVQ, which was relevant to care of older
people. Two-thirds had been on a short course
about care of older people.
Nursing home characteristics
Ten nursing homes were recruited, three in the
London area and seven in the Southampton area.
The homes varied in size: the three London
homes had beds for between 52 and 62 residents,
whereas the Southampton homes were generally
smaller and varied from 24 to 55 beds. The home
manager was asked to describe the category of
resident that the home was registered to care for;
the results are shown in Table 54. All the homes
provided nursing care but may additionally
provide care for terminally ill or physically
disabled people. Some homes had a dedicated
unit to care for individuals who are elderly
mentally ill (including Alzheimer’s disease and
dementia); these homes have registration for
elderly mentally infirm (EMI). The characteristics
of the homes are shown in Table 55.
Comparisons of different designs
Leakage performance 
The leakage performance of the different designs
was calculated using data from the pad change
labels, which were completed at each pad change.
Leakage was recorded as none, a little, a lot.
Tables 56 and 57 show the proportions of saved
and weighed pads that leaked. 
The median urine masses were calculated for each
design and are shown in Table 58.
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437 total number of beds in nursing homes
3 relatives withdrew agreement during test period, 
(2 changed mind, 1 concerned about rash)
2 withdrew during study 
8 died during study
6 died before testing started
1 moved home
149 residents identified as meeting inclusion criteria
Consent/relative agreement obtained from 120
113 started testing
100 completed testing
FIGURE 47 Progress of participants through the trial The daytime insert design contained less urine
than the other three designs and night-time
designs overall contained more urine than
daytime designs. The urine weights varied
between designs and leakage performance was
therefore compared at specified urine weights
using the binarised data: (no leak) versus (a little
+ a lot). 
The urine weights were also examined by gender.
Mean urine weights showed that the men’s pads
contained significantly more urine than the
women’s pads: mean daytime urine mass 214.4 g
for men and 162.4 g for women (difference 53.6 g,
95% CI 30.0 to 77.3); the difference was not
significant for night-time: 256.0 g for men and
176.9 g for women (difference 35.6, 95% CI –15.9
to 87.2).
The leakage results in the forest plots
(Figures 50–61) show comparisons of leakage
performance between designs for the median
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TABLE 52 Participant characteristics: (N = 100, except where missing data stated)
Participant background  % (N)
information
Age (years):  Mean 81.9 <70 70–79 80–84 85–89 90–94 95–99 100
(SD 13.3) 13.0 (13) 20.0 (20) 15.0 (15) 20.0 (20.0) 18.0 (18) 12 (12.0) 2.0 (2)
Gender: Male Female
27.0 (27) 73.0 (73)
Diagnosis related to  CVA (stroke) Alzheimer’s/dementia Parkinson’s disease
incontinence: 21.0 (21) 29.0 (29) 7.0 (7)
CVA and dementia CVA and Parkinson’s Parkinson’s and dementia Other (and unknown)
8.0 (8) 1.0 (1) 2.0 (2) 32.0 (32)
Body build Underweight Normal Overweight 
20.0 (20) 66.0 (66) 14.0 (14)
Mobility Independent Uses  aid Wheelchair/chairbound Bedbound
7.0 (7) 19.0 (19) 57.0 (57) 17.0 (17)
Norton score 14 or below (at greatest risk) 15–17 (not at risk but observe) 18–20 (minimal risk)
(pressure ulcer risk) 94.0 (94) 6.0 (6) 0.0 (())
Braden score – pressure  Mean 14.6  6–10 (very high) 11–15 (high) 16–19 (medium)  20–23 (low) 
Ulcer risk assessment (SD 3.5) 14.0 (14) 44.0 (44) 33.0 (33) 9.0 (9)
(level of risk)
Barthel score (activities of  Mean 19.8 0–20 25–40 45–60
daily living) (3 missing) (SD 18.3) 61.9 (60) 21.6 (21) 16.5 (16)
(0 = total dependence, 
100 = independent, 
N.B. maximum for this 
group = 90–10 points 
deducted for incontinence)
Hodkinson mental test  Unable to answer 0 1–6 7–10
(7–10 = not impaired,  4.4 (4) 56.0 (51) 31.9 (29) 12.1 (11)
0–6 abnormal, 
(5 missing data))
Faecal incontinence  No Yes – small amounts Yes – larger amounts
22.0 (22) 12.0 (12) 66.0 (66)
Design of product used before  Insert Diaper Pull-up
study day (1 missing data) 76.7 (76) 23.2 (23) 0.0 (0)
Design of product used before  Insert Diaper Pull-up
study night (2 missing data) 69.4 (68) 29.6 (29) 1.0 (1)
Number of products used  Day Night
per day/night Mean 3.26 (SD 0.909)  Mean 2.37 (SD 0.993) 
CVA, cerebrovascular accident.urine weight (150 g for daytime and 180 g for
night-time). The results showed that during the
daytime, at the median urine mass (150 g) the
insert design was significantly worse than the 
T-shaped design. During the night-time, the insert
and the pull-up designs were significantly worse
than the diaper design and the pull-up design was
also significantly worse than the T-shaped design
at the median urine mass (180 g). However, where
differences between designs were found they were
not large (typically around 10%). 
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TABLE 53 Characteristics of care staff [N = 96: 68 (70.8%) day; 28 (29.2) night]
N %
Gender Male 15 15.6
Female 81 84.4
Position (1 missing) Registered nurse 6 6.3
Care assistant 84 87.5
Adaptation nurse 5 5.2
First job as a carer Yes 42 43.8
Length of time in current position (4 missing) <6 months 3 3.1
6 months–2 years 41 42.7
3–5 years 26 27.1
6–10 years 16 16.7
>10 years 6 6.3
Formal training in older people care  NVQ or equivalent 55 57.3
Short course 64 66.7
Age (years) (7 declined to answer) Mean 39.24 (SD 10.93) 
Median 37 (range 19–66)
TABLE 54 Home registration categories
Type of home No. of 
homes
Elderly, disabled, terminally ill 3
Elderly and terminally ill 1
Elderly mentally infirm (EMI) 1
Physical disability and elderly 3
Continuing care, palliative care, dementia,  1
frail elderly
Nursing care 1
TABLE 55 Nursing home characteristics
Median number of beds (range) 46.5 (24–62)
Ownership of home Independent Small chain five Large  chain  six
424
Type of building Conversion Purpose-built
55
Pads supplied by Continence  Home given money  Purchase from  Mixture (some 
service from the continence  own budget provided by 
service to purchase  continence service, 
pads buy the rest)
3 214
Pad assessments performed by Continence adviser RNs or matron Continence adviser and 
RNs/matron
145
Do you have any choice about the  Yes No
designs/absorbency that you have? 6 4
RN, Registered Nurse.Based on the binarised leakage data, (none) versus
(a little + a lot), and urine weights, the leakage
performance was modelled for each design and
Figures 48 and 49, show the probability of there
being no leakage for day and night at the different
urine weights for each of the four designs.
Explanation of leakage curves
Pads do not have a simple capacity below which
they are guaranteed not to leak and above which
they will definitely leak. Rather, as the volume (i.e.
mass) of urine increases, the probability of the pad
leaking increases. The leakage performance curves
were constructed for each design (by combining
data from the various products of the same design)
and show how the probability of the design not
leaking changed with increasing urine mass. In
general, the more successful a design, the higher
was the performance curve on the graph: a perfect
design would have a probability of not leaking at
all of 1 (= certainty) for all urine masses.
Intuitively, these probability curves should have a
value of 1.0 for zero urine mass – how can a pad
leak if there is no urine in it? Weighing used 
pads provides an estimate only of the mass of
urine in the pad and excludes any leakage from
the pad: accordingly, the urine masses used in
constructing the curves will often have been
(slight) underestimates of the actual masses voided
by the wearer. For example, a pad may leak (and
the urine mass in the pad be recorded as zero) if
the absorbent area is out of position. One of the
effects of this is that the leakage performance
curves of products will meet the y-axis at values
less 1.0, the value which would be expected
naturally. In the extreme, a pad capable of
holding no urine at all would be certain to leak
whatever quantity of urine its user voided and yet
all used pads would contain zero urine mass. 
In addition, dry masses vary (coefficient of
variation of the order of 10%) and so there will be
Health Technology Assessment 2008; Vol. 12: No. 29
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TABLE 56 Leakage performance of daytime designs (number of participants = 100, total number of products saved = 5798)
% (N)
Insert Diaper Pull-up T-shaped
No leakage 69.7 (992) 68.8 (1082) 72.2 (958) 74.9 (1105)
A little  16.2 (231) 18.3 (288) 14.5 (192) 11.9 (175)
A lot  14.1 (201) 12.9 (202) 13.3 (177) 13.2 (195)
TABLE 57 Leakage performance of night-time designs (number of participants = 100, total number of products saved = 4646)
% (N)
Insert Diaper Pull-up T-shaped
No leakage 66.1 (771) 70.9 (904) 63.3 (655) 68.6 (802)
A little  18.6 (217) 14.6 (186) 18.6 (192) 16.4 (192)
A lot  15.3 (178) 14.6 (186) 18.2 (188) 15.0 (175)
TABLE 58 Median urine mass in each design 
Insert Diaper Pull-up T-shaped
Daytime
Median urine mass (g) (IQ range) 133.0  153.0 147.0 147.0
(73.0–220.0) (81.0–261.0) (84.0–244.0) (86.0–240.5)
No. of products  1424 1572 1327 1475
Night-time
Median urine mass (g) (IQ range) 174.0 183.0 168.0 205.0
(95.25–310.5) (100.0–314.25) (91.0–281.0) (112.0–327.0)
No. of products  1166 1276 1035 1169Products for women and men living in nursing homes (Trial 2b)
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FIGURE 49 Estimated probabilities of no leakage for different urine masses by design (night) small errors in estimated urine masses. These
errors will be negligible for high urine masses but
more substantial for (nearly) dry pads.
Consumption of products
Estimates were made of the mean numbers of
products used per day and per night and results
for each design are shown in Tables 59 and 60. 
During the daytime, significantly more pull-up
designs were used than the other designs. During
the night-time, significantly less pull-up designs
were used than the other designs and the insert
design was used significantly more than other
designs. Overall during the daytime a mean of 2.59
products were used, which is less than was reported
by staff at the beginning of the study (mean = 3.26),
and results for the daytime were similar to the
night-time. Night-time products are often applied
during the afternoon and evening, in preparation
for the night, and this may explain why differences
in day- and night-time use were not greater. The
overall night-time mean was 2.35, which was very
similar to that reported by staff (2.37). 
Laundry resulting from leakage
Staff were asked to record (on the pad change
label) whether there was any laundry generated at
a pad change (yes/no). If there was, they were
asked to record the type of laundry, namely how
many small and how many large items. However,
staff did not usually manage to record this level of
detail and so the type of laundry was not analysed.
Tables 61 and 62 show the proportions of recorded
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TABLE 59 Consumption: mean number of daytime designs used (N = 100 participants) 
Insert Diaper Pull-up T-shaped
Weighted mean number of products  2.5 (0.69) 2.5 (0.76) 3.0 (0.92) 2.4 (0.78)
used per day (SD)
Consumption: comparisons between designs 
Estimated difference 95% CIa
Insert  not significantly different to Diaper 0.03 –0.19 to 0.25
Insert  used significantly less than Pull-up –0.40 –0.62 to –0.18
Insert  not significantly different to T-shaped 0.18 –0.09 to 0.45
Diaper  used significantly less than Pull-up –0.43 –0.72 to –0.14
Diaper  not significantly different to T-shaped 0.15 –0.13 to 0.43
Pull-up  used significantly more than T-shaped 0.58 0.31 to 0.86
a CIs include Bonferroni adjustment for multiple comparisons except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).
TABLE 60 Consumption: mean number of night-time products used (N = 100 participants) 
Insert Diaper Pull-up T-shaped
Weighted mean number of products  2.8 (1.13) 2.4 (1.14) 2.1 (0.79) 2.5 (1.15)
used per night (SD)
Consumption: comparisons between designs 
Estimated difference 95% CIa
Insert  not different to Diaper 0.16 –0.01 to 0.33
Insert  used more than Pull-up 0.58 0.35 to 0.82
Insert  used more than T-shaped 0.19 0.04 to 0.34
Diaper  used more than Pull-up 0.42 0.17 to 0.67
Diaper  not different to T-shaped 0.02 –0.14 to 0.19
Pull-up  used less than T-shaped –0.40 –0.65 to –0.14
a CIs include Bonferroni adjustment for multiple comparisons except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).pad changes which resulted in incontinence
laundry. There were no significant differences
between designs.
Laundry results showed no differences between
the designs in the amount of laundry produced
during the day. During the night, the diaper
produced significantly less laundry than the pull-
up, and the diaper and T-shaped diaper produced
less laundry than the insert [but these difference
was small (<5%)].
Skin health
Skin health observations on five sites within the
pad area were made weekly (right and left groins
and buttocks and sacrum). The site with the
maximum severity (i.e. the worst skin problem)
was used to make comparisons between designs.
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TABLE 61 Laundry (day): number of pad changing episodes (N) resulting in clothing/bedding being sent to laundry as a result of
incontinence
% (N)
Insert Diaper Pull-up T-shaped
No incontinence laundry 80.2 (1230) 80.0 (1356) 79.6 (1166) 82.3 (1341)
Incontinence laundry 19.8 (304) 20.0 (339) 20.4 (298) 17.7 (289)
Laundry: comparisons between designs 
Estimated ORa 95% CIb
Insert  not different to T-shaped 0.83 0.65 to 1.07
Insert  not different to Diaper 0.91 0.70 to 1.19
Insert  not different to Pull-up 1.05 0.82 to 1.35
Diaper  not different to T-shaped 0.91 0.68 to 1.22
Pull-up  not different to T-shaped  0.79 0.60 to 1.05
Diaper  not different to Pull-up 1.15 0.89 to 1.49
a ORs are for no laundry.
b CIs include Bonferroni adjustment for multiple comparisons, except for diaper compared with washables (single
comparison made).To assist the reader, comparisons between designs have been described as ‘not different’ if they are not
significant (p > 0.05).
TABLE 62 Laundry (night): number of pad changing episodes (N) resulting in clothing/bedding being sent to laundry as a result of
incontinence
% (N)
Insert Diaper Pull-up T-shaped
No incontinence laundry 74.7 (930) 80.4 (1180) 74.5 (847) 78.9 (1013)
Incontinence laundry 25.3 (315) 19.6 (287) 25.5 (290) 21.1 (271)
Laundry: comparisons between designs 
Estimated ORa 95% CIb
Insert  more laundry than T-shaped 0.75 0.58 to 0.98
Insert  more laundry than Diaper 0.69 0.53 to 0.91
Insert  not different to Pull-up 1.02 0.74 to 1.42
Diaper  not different to T-shaped 0.91 0.68 to 1.22
Pull-up  not different to T-shaped  0.79 0.60 to 1.05
Pull-up  more laundry than Diaper 1.47 1.10 to 1.97
a ORs are for no laundry.
b CIs include Bonferroni adjustment for multiple comparisons, except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05). Table 63 shows the proportions of participants with
and without skin health problems. 
There were no significant differences between
designs when the data were binarised, (no skin
problem) versus (otherwise). The T-shaped design
had the most moderate to severe skin problems.
Examination of the researchers’ records of the
nature of the skin problems showed that irritation
in the area of the waist-belt was a common source
of this problem.
Product performance questionnaires
Product performance questionnaires were
completed at the end of testing each design (after
2 weeks). Results were analysed for high-priority
variables and the scores are displayed in Tables 64
and 65. Comparisons between each pair of designs
are shown, with these data binarised, (very good,
good, okay) versus (poor, very poor), in the forest
plots in Figures 50–61. 
Faecal incontinence
Data from the participant background information
showed that 66.0% (66) of participants experienced
large amounts of faecal incontinence; this is
consistent with the pad leakage diary data shown
in Table 66. Data were collected via cards, which
were completed by staff when a pad containing
faeces was disposed of. A total of 644 cards were
collected (around 10 per subject). This relatively
small number of pads per design (around 160)
means that it is hard to draw any firm conclusions
regarding leakage performance.
The main differences between designs concerned
the following variables: leakage, discreetness and
ease of putting on. 
● The diaper design performed significantly
better than the insert for leakage (significance is
defined as p  0.05; forest plots (Figures 50–61)
show ORs and 95% CIs for each variable). 
● The insert design was better than the diaper for
discreetness and ease of putting on (standing).
The pull-up design was significantly better than
the insert on most variables during the daytime
but not discreetness or ease of putting on
(standing). 
● The pull-up was significantly more difficult to
put on in the lying position than the insert
during the night. 
● There were no significant differences between
the T-shaped diaper and the diaper, except that
the diaper was easier to put on in a standing
position in the day. 
Final interview: overall opinion
and preferences
Preferences
Carers and participants (where possible) were
asked to rank the designs in order of their
preference and were asked why they chose the
designs as best or worst and to identify the good
and poor aspects of each design. Final interview
data were not available for one resident for the
day and two for the night.
Table 67 shows the paired comparisons of carer
preferences and Table 68 shows the rankings of the
designs. Appendix 16 shows the first-choice
preferences for those participants (N = 14) who
could express an opinion. More participants chose
the pull-up design than other designs (6/14), but
the data were too few to analyse statistically.
Appendix 17 shows the paired comparisons for
the different designs by gender.
In the daytime, paired comparisons show that 
the pull-up was significantly better than the T-
shaped diaper (p < 0.0005), insert (p < 0.0005)
and diaper (p < 0.006). There were no significant
differences between the T-shaped, insert and
diaper designs. 
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TABLE 63 Skin health: proportions of participants with observed skin health problems (N = 100)a
% (N)
Insert Diaper Pull-up T-shaped
No skin problem 27.3 (27) 33.0 (33) 30.6 (30) 25.7 (26)
A little (mild) 39.4 (39) 29.0 (29) 40.8 (40) 34.0 (34)
A lot (moderate/severe) 33.3 (33) 38.0 (38) 28.6 (28) 40.0 (40)
(1 missing) (2 missing)
a Comparisons between designs and 95% CIs are shown in Figures 50–61. In the night-time, paired comparisons show that
the insert was significantly worse than the diaper
(p < 0.0005), pull-up (p < 0.0005) and T-shaped
designs (p < 0.0005). There were no significant
differences between the diaper, pull-up and 
T-shaped designs.
During the daytime, the best design (most
frequently rated first) was the pull-up, followed by
the diaper and then the insert. The T-shaped
diaper was the design that was most frequently
rated worst.
During the night-time the diaper was most
frequently rated first and the insert was most
frequently rated worst. Although the pull-up was
in second place with more top rankings than the
T-shaped diaper, on mean ranks it was in third
place. 
Each design was also rated by carers on a VAS
scale of 0 (worst possible design) to 10 (best
possible design). VAS scores are shown in Tables 69
and 70. These results reflect preferences, with
pull-ups being significantly better than T-shaped
diapers, inserts and diapers (p < 0.001). There
were no significant differences between the T-
shaped, diaper and insert designs. For the night-
time, inserts were significantly worse than the
other three designs (p < 0.0005). There were no
significant differences between the T-shaped,
diaper and pull-up designs. 
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TABLE 64 Product performance questionnaire: design responses (%): daya
Insert Diaper Pull-up T-shaped
Leakage (urine) Very good 18.4 17.4 24.2 16.5
Good 18.4 39.8 44.4 36.1
OK 24.1 23.5 14.1 27.8
Poor 24.1 7.1 10.1 14.4
Very poor 14.9 12.2 7.0 5.2
Leakage (faeces) Very good 10.6 16.5 17.0 14.3
Good 22.4 35.1 43.6 33.0
OK 32.9 30.9 22.3 34.1
Poor 23.5 13.4 13.8 14.3
Very poor 10.6 4.1 3.2 4.4
Staying in place Very good 14.8 25.0 30.3 10.1
Good 20.5 34.0 44.4 32.3
OK 43.2 30.0 17.2 38.4
Poor 15.9 11.0 4.0 18.2
Very poor 5.7 0.0 4.0 1.0
Fit Very good 16.3 17.4 21.0 10.1
Good 19.8 29.6 46.0 30.3
OK 38.4 28.6 23.0 29.3
Poor 17.4 23.5 9.0 24.2
Very poor 8.1 1.0 1.0 6.1
Smell Very good 10.3 11.0 20.2 6.2
Good 21.8 38.0 46.5 45.4
OK 40.2 38.0 27.3 36.1
Poor 23.0 12.0 6.1 10.3
Very poor 4.6 1.0 0.0 2.1
Discreetness Very good 16.3 5.1 22.2 8.2
Good 25.6 27.3 46.5 32.7
OK 53.5 43.4 27.3 45.9
Poor 2.3 21.2 4.0 12.2
Very poor 2.3 3.0 0.0 1.0
Ease on (standing) Very good 29.3 10.6 18.8 10.1
Good 29.3 27.1 42.5 16.5
OK 33.3 34.1 25.0 26.6
Poor 5.3 22.4 11.3 32.9
Very poor 2.7 5.9 2.5 13.9
a Shading indicates where binarisation occurs (very good + good + OK) versus (poor + very poor).Acceptability
Finally, care staff were asked to consider how
acceptable each design was for the resident
(Table 71).
The results for overall acceptability were binarised
both as (highly acceptable) versus (otherwise) and
(highly acceptable + acceptable) versus
(otherwise). Both levels of comparisons are shown
in the forest plots in Figures 50–61. 
For the daytime, the pull-up was significantly better
than the insert and the T-shaped diaper on both
levels of comparisons and the diaper for (highly
acceptable) versus (otherwise), but not quite for
(highly acceptable + acceptable) versus (otherwise). 
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TABLE 66 Leakage of faeces from pads, day and night
combined (N = 66 participants/644 pads) 
Design % of pads not leaking 
at all
Insert 56.9
Diaper 64.8
Pull-up 50.0
T-shaped 71.3
TABLE 67 Paired comparisons of preferences between the
different designsa
Number preferring design 
Day (N = 99) Night (N = 98)
Pull-up 65 vs Insert 34 Pull-up 72 vs Insert 26
Pull-up 66 vs Diaper 33 Pull-up 40 vs Diaper 58
Pull-up 66 vs T-shaped 33 Pull-up 47 vs T-shaped 51
T-shaped 49 vs Insert 50 T-shaped 68 vs Insert 30
T-shaped 48 vs Diaper 51 T-shaped 41 vs Diaper 57
Diaper 52 vs Insert 47 Diaper 73 vs Insert 25
a Comparisons between designs showing the odds on
preferring a design with 95% CIs are shown in
Figures 50–61 (1 missing data).
TABLE 65 Product performance questionnaire: design responses (%): nighta
Insert Diaper Pull-up T-shaped
Leakage (urine) Very good 14.0 20.8 23.2 22.6
Good 28.0 34.9 29.3 38.7
OK 20.0 21.9 16.2 21.5
Poor 24.0 10.4 26.3 12.9
Very poor 14.0 12.5 5.1 4.3
Leakage (faeces) Very good 14.9 23.1 16.0 20.5
Good 26.6 42.9 36.2 35.2
OK 36.2 20.9 31.9 28.4
Poor 13.8 6.6 13.8 15.9
Very poor 8.5 6.6 2.1 0.0
Staying in place Very good 7.2 23.2 35.7 22.6
Good 42.3 33.3 29.6 36.6
OK 40.2 31.3 24.5 28.0
Poor 9.3 9.1 7.1 8.6
Very poor 1.0 3.0 3.1 4.3
Fit Very good 11.1 19.2 28.3 12.0
Good 29.3 38.4 35.4 47.8
OK 41.4 19.2 24.2 26.1
Poor 15.2 15.2 10.1 10.9
Very poor 3.0 8.1 2.0 3.3
Smell Very good 2.0 7.1 16.3 15.1
Good 40.4 35.4 32.7 36.6
OK 36.4 42.4 40.8 37.6
Poor 12.1 8.1 8.2 9.7
Very poor 9.1 7.1 2.0 1.1
Ease on (lying) Very good 25.3 17.7 5.2 15.6
Good 33.3 43.8 27.1 36.7
OK 26.3 29.2 34.4 31.1
Poor 10.1 8.3 27.1 15.6
Very poor 5.1 1.0 6.3 1.1
a Shading indicates where binarisation occurs (very good + good + OK) versus (poor + very poor).Products for women and men living in nursing homes (Trial 2b)
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TABLE 68 Design rankings 
Design % (N)
DAY (N = 99)a NIGHT (N = 98)b
1st 2nd 3rd 4th 1st 2nd 3rd 4th
T-shaped 15.2 (15) 28.3 (28) 24.2 (24) 32.3 (32) 20.4 (20) 37.8 (37) 29.6 (29) 12.2 (12)
Diaper 22.2 (22) 19.2 (19) 36.4 (36) 22.2 (22) 39.8 (39) 29.6 (29) 11.2 (11) 19.4 (19)
Insert 18.2 (18) 27.3 (27) 25.3 (25) 29.3 (29) 6.1 (6) 19.4 (19) 25.2 (25) 49.0 (48)
Pull-up 44.4 (44) 25.3 (25) 14.1 (14) 16.2 (16) 33.7 (33) 13.3 (13) 33.7 (33) 19.4 (19)
a 1 missing data.
b 2 missing data.
TABLE 69 Mean VAS with SD (day) (N = 99, 1 missing data)
% (N)
Insert Diaper Pull-up T-shaped
VAS: mean (SD) 5.0 (3.0) 5.1 (2.8) 6.8 (3.0) 4.9 (3.0)
VAS: comparisons between designs (men and women combined)
Estimated difference 95% CIa
Pull-up  better than Insert 1.80 0.75 to 2.84
Pull-up  better than Diaper 1.62 0.34 to 2.91
Pull-up  better than T-shaped 1.91 0.66 to 3.16
Diaper  not different to Insert 0.17 –0.98 to 1.32
Diaper  not different to T-shaped 0.28 –0.78 to 1.34
Insert  not different to T-shaped 0.11 –1.15 to 1.37
a CIs include Bonferroni adjustment for multiple comparisons except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).
TABLE 70 Mean VAS with SD (night) (N = 98, 2 missing data)
% (N)
Insert Diaper Pull-up T-shaped
VAS: mean (SD) 4.3 (2.5) 6.6 (2.8) 6.2 (2.5) 6.3 (2.6)
VAS: comparisons between designs (men and women combined)
Estimated difference 95% CIa
Insert  worse than Pull-up –1.90 –2.87 to –0.92
Insert  worse than Diaper –2.30 –3.40 to –1.19
Insert  worse than T-shaped –1.99 –2.98 to –1.00
Diaper  not different to Pull-up 0.40 –0.81 to 1.61
Diaper  not different to T-shaped 0.31 –0.65 to 1.26
Pull-up  not different to T-shaped –0.09 –1.11 to 0.93
a CIs include Bonferroni adjustment for multiple comparisons except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).During the night-time, the inserts were
significantly worse than diapers, pull-ups and 
T-shaped diapers at both levels of binarisation. 
The results of these overall opinion and
preference measures provide consistent evidence
that pull-ups were significantly better than the
other designs in the day and there were no
significant differences between the other designs.
During the night, inserts were significantly worse
than the other designs and there were no
significant differences between the other designs. 
Gender differences in final interview
scores
As gender differences were significant in the results
of the community trial of the same disposable
products, we analysed the final interview
preference, VAS and overall acceptability data by
gender. Results are shown in Appendix 17. These
results show that although there was a strong and
significant preference for pull-ups over the other
three designs during the daytime for women, this
was not the case for men, and there are indications
that diapers may be better. However, the small
number of men in this sample (27) means that no
firm conclusions can be drawn. For men during
the daytime, diapers were preferred over pull-ups
(16 versus 11), over T-shaped diapers (18 versus 9)
and over inserts (19 versus 8), but none of these
findings reached significance. At night, the
evidence favouring diapers for men was stronger.
Men significantly preferred diapers over pull-ups
(21 versus 6; p = 0.04) and over inserts (23 versus
4; p = 0.007). Diapers were also preferred over 
T-shaped diapers (20 versus 7), but not
significantly so. 
Overall acceptability for daytime (highly acceptable)
versus (otherwise) shows that outcome was
significantly dependent on gender. Diapers were
recorded as being highly acceptable for 41.7%
(11/27) of men compared to 6.9% (5/72) of
women. During the night-time, the diapers were
recorded as being highly acceptable for 70.4%
(19/27) of men compared with 35.6% (25/71) of
women. The VAS results indicate similarly different
results for men and women. However, we did not
statistically analyse these scores between men and
women because of the small number of men.
The forest plots (Figures 50–61) show the paired
comparisons of ORs for key product performance
and overall opinion variables.
Explanation of forest plots
For primary and secondary outcome variables,
results are calculated as proportions, such as
participants’ rating of discreetness binarised as
(very good + good + okay) versus (poor + very
poor). For example, design A may score 60% (very
good + good + okay) and 40% (poor + very
poor) and design B may score 50% (very good +
good + okay) and 50% (poor + very poor). In this
case, it appears that design A is better than design
B for discreetness. To examine whether we can be
confident that this difference between the two
designs is real an OR and CI are calculated. If
there is no difference between the two results, this
will give an OR of 1. Where there are differences
(as in the example of discreetness above), the OR
will be greater or less than one. The CI is a
number that spans the OR (giving a higher and
lower limit) and shows how much uncertainty
there is about the OR.
The ORs and CIs have been calculated for
comparisons between each pair of designs and for
each variable where the results are shown as
proportions. The ORs and CIs have been stacked
on top of each other on a forest plot showing
comparisons between each pair of designs.
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TABLE 71 Acceptability of designs for day and night (Day: N = 99, 1 missing data; Night: N = 98, 2 missing data)a
% (N)
Insert Diaper Pull-up T-shaped
Day Night Day Night Day Night Day Night
(N = 98) (N = 98) (N = 99) (N = 98) (N = 99) (N = 97) (N = 99) (N = 98)
Highly acceptable 15.3 (15) 6.1 (6) 16.2 (16) 44.9 (44) 45.5 (45) 27.8 (27) 11.1 (12) 28.6 (28)
Acceptable 44.9 (44) 50.0 (49) 47.5 (47) 30.6 (30) 35.4 (35) 52.6 (51) 50.5 (50) 51.0 (50)
Unacceptable/totally 39.8 (39) 43.8 (43) 36.4 (36) 24.5 (24) 19.2 (19) 19.6 (19) 37.4 (37) 20.4 (20)
unacceptable
a Comparison between designs and 95% CIs are shown in the forest plots in Figures 50–61.The ORs and CIs are shown in relation to a
vertical line which is the centre of the forest plot.
This line gives the OR of 1 (i.e. no difference).
Each variable is named on the far left of the forest
plot and the OR and CI are written on the far
right. The scale is shown on the bottom with
numbers below 1 on the left and above 1 on the
right. 
Each OR is shown as a black box with a horizontal
line (the 95% CI) running through it. Where the
line touches or crosses the vertical line (at OR = 1)
there is no significant difference between the
proportions for the two designs. Where the box
and horizontal line lie completely to one or other
side of the vertical line, one can be confident that
the proportions for each design are significantly
different.
To show readily how each pair of designs compare
with each other, the ORs are plotted so that where
a design scores better than the other design for
any variable the OR (i.e. the black box) is on the
side of the vertical line that favours that design.
Hence the ORs shown are for the second named
design versus the first named design in the
heading. The primary outcome variables from the
final interview (overall acceptability and
preference) are shown at the bottom of each forest
plot and these reflect the overall performance of
the different designs. The last line of the forest
plot shows the odds on the second named design
being preferred to the first.
For example, in the forest plot comparing the
pull-up with the insert for the daytime, the plot
shows that the pull-up is better than the insert on
almost all variables (including overall acceptability
and preference).
There are 12 comparisons (day and night)
between the four disposable designs. giving a total
of 12 forest plots.
Each forest plot in Figures 50–61 shows the data
obtained from:
● Leakage – diary: (from the pad change/leakage
diary) binarised as (none) versus (a little + a
lot).
● Leakage – rating: (the participants’ rating from
the final interview) binarised as (very good +
good + OK) versus (poor + very poor). 
● Seven key variables from the product
performance questionnaire: all binarised as
(very good + good + OK) versus (poor + very
poor). 
● Skin health problems: (data from the
participants’ skin health diary) binarised as
(none) versus (a little + a lot).
● Overall acceptability: taken from the final
interview, and binarised as (highly acceptable +
acceptable) versus (unacceptable + totally
unacceptable). Abbreviated on the forest plots
as (high/OK vs no).
● Overall acceptability: taken from the final
interview, and binarised as (highly acceptable)
versus (Okay + unacceptable). Abbreviated on
the forest plots as (high vs OK/no).
● Preference men: this shows the odds on the
second named design being preferred to the
first by a man.
● Preference women: this shows the odds on the
second named design being preferred to the
first by a women.
Comments
At the final interview, an open request was made
for carers to comment on good and poor, best and
worst features of the design. These comments are
summarised in Appendix 19 and in particular
highlight some of the strengths of pull-ups for
women, such as their dignified/pant-like/good
appearance. For men it is notable that there are
comparatively few negative comments about
diapers either for day or for night. 
Views on washables
Although washable designs had not been tested in
the care homes, staff were asked how they would
feel if washable products were provided for the
residents to use. Responses are shown in Table 72.
Reports on number of staff needed to change
residents
Care staff were also asked about the number of
staff they thought would be required to change the
resident usually and for each of the designs in the
day (standing up and lying down) and at night
(lying only). Responses are given in Appendix 20
and show no differences between designs.
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TABLE 72 Staff views about using washable products 
Response % (n)
Day Night 
(N = 89) (N = 69)
It wouldn’t worry me 19.1 (17) 24.6 (17)
I would be pleased 1.1 (1) 4.3 (3)
I would be concerneda 68.5 (61) 62.3 (43)
I don’t know 11.2 (10) 8.7 (6)
a Main reasons given were cross-infection and smell.In most homes, staff commented that for safety
reasons policy required them to have two carers
assisting in pad changing for all residents who
needed assistance to stand or used a standing
hoist. Therefore, even if it were possible to change
some pad designs with fewer staff than others, it
would make little difference to the number of staff
required in practice.
Pad change timing exercise
Results
Twelve women residents from three different
homes volunteered for the pad-changing exercise.
Two were unable to stand and therefore always
had their pads changed in a lying position,
whereas the other 10 residents were able to stand.
To reduce variation, we excluded the two residents
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Odds ratio (95% CI)
0.80 (0.61 to 1.06) Leakage – diary (none vs a little/a lot)
0.38 (0.18 to 0.84) Leakage – rating (good/okay vs poor)
0.43 (0.19 to 0.98) Leakage – faeces (good/okay vs poor)
0.45 (0.14 to 1.43) Staying in place (good/okay vs poor)
1.04 (0.41 to 2.63) Fit (good/okay vs poor)
0.41 (0.15 to 1.08) Smell (good/okay vs poor)
6.49 (1.56 to 26.92) Discreetness (good/okay vs poor)
4.55 (1.31 to 15.73) Ease on standing (good/okay vs poor)
0.76 (0.37 to 1.56) Skin health problems (none vs a little/a lot)
0.86 (0.36 to 2.06) Overall acceptability (high/okay vs no)
0.93 (0.34 to 2.58) Overall acceptability (high vs okay/no)
0.90 (0.53 to 1.54) Preference (D vs I)
0.01 0.1 0.2
Favours diaper Favours insert
0.5 1 2 5 10
FIGURE 50 Forest plot: diaper vs insert (day)
Odds ratio (95% CI)
0.70 (0.54 to 0.91) Leakage – diary (none vs a little/a lot)
0.48 (0.23 to 1.02) Leakage – rating (good/okay vs poor)
0.53 (0.21 to 1.35) Leakage – faeces (good/okay vs poor)
1.17 (0.38 to 3.60) Staying in place (good/okay vs poor)
1.36 (0.55 to 3.38) Fit (good/okay vs poor)
0.66 (0.31 to 1.44) Smell (good/okay vs poor)
0.59 (0.21 to 1.63) Ease on lying (good/okay vs poor)
0.57 (0.27 to 1.20) Skin health problems (none vs a little/a lot)
0.41 (0.17 to 1.01) Overall acceptability (high/okay vs no)
0.08 (0.02 to 0.30) Overall acceptability (high vs okay/no)
0.34 (0.19 to 0.63) Preference (D vs I)
0.01 0.1 0.2
Favours diaper Favours insert
0.5 1 2 5 10
FIGURE 51 Forest plot: diaper vs insert (night)who were unable to stand and 10 residents
completed the exercise. Eight of these 
10 residents required two members of staff to
change their pads and two of these also required a
standing hoist; two of the residents could be
changed by one carer. Ten staff members were
recruited to take part in the exercise. Staff worked
in pairs or individually (depending on residents’
needs), with the same staff changing all four
designs for a given resident. The results of the 
pad timing exercise are shown in Table 73 and
Figure 62.
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Odds ratio (95% CI)
0.70 (0.54 to 0.90) Leakage – diary (none vs a little/a lot)
0.39 (0.15 to 1.00) Leakage – rating (good/okay vs poor)
0.47 (0.19 to 1.15) Leakage – faeces (good/okay vs poor)
0.87 (0.34 to 2.23) Staying in place (good/okay vs poor)
1.29 (0.51 to 3.26) Fit (good/okay vs poor)
0.39 (0.15 to 0.99) Smell (good/okay vs poor)
3.12 (0.61 to 15.95) Discreetness (good/okay vs poor)
10.00 (2.98 to 34.67) Ease on standing (good/okay vs poor)
1.06 (0.49 to 2.28) Skin health problems (none vs a little/a lot)
1.11 (0.44 to 2.79) Overall acceptability (high/okay vs no)
1.31 (0.40 to 4.32) Overall acceptability (high vs okay/no)
1.02 (0.60 to 1.73) Preference (T vs I)
0.01 0.1 0.2
Favours T-shaped Favours insert
0.5 1 2 5 10
FIGURE 52 Forest plot: T-shaped vs insert (day)
Odds ratio (95% CI)
0.88 (0.68 to 1.15) Leakage – diary (none vs a little/a lot)
0.31 (0.13 to 0.73) Leakage – rating (good/okay vs poor)
0.60 (0.25 to 1.44) Leakage – faeces (good/okay vs poor)
1.23 (0.43 to 3.50) Staying in place (good/okay vs poor)
0.73 (0.27 to 2.02) Fit (good/okay vs poor)
0.40 (0.13 to 1.25) Smell (good/okay vs poor)
1.11 (0.45 to 2.79) Ease on lying (good/okay vs poor)
0.50 (0.24 to 1.05) Skin health problems (none vs a little/a lot)
0.33 (0.13 to 0.80) Overall acceptability (high/okay vs no)
0.16 (0.04 to 0.63) Overall acceptability (high vs okay/no)
0.44 (0.25 to 0.79) Preference (T vs I)
0.01 0.1 0.2
Favours T-shaped Favours insert
0.5 1 2 5 10
FIGURE 53 Forest plot: T-shaped vs insert (night)Pad change times varied considerably between
residents according to their different disabilities,
but the timings of the repeated pad changes using
the different designs in a randomised order showed
that there were significant differences between
designs. Contrary to expectations, the T-shaped
design took significantly longer to change than the
diaper design. Both the diaper and T-shaped
designs took significantly longer than the pull-up
and insert designs (around 15–25 seconds more).
However, there were no significant differences
between the pull-up and insert designs. These data
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Odds ratio (95% CI)
0.85 (0.64 to 1.15) Leakage – diary (none vs a little/a lot)
0.33 (0.16 to 0.71) Leakage – rating (good/okay vs poor)
0.42 (0.19 to 0.92) Leakage – faeces (good/okay vs poor)
0.32 (0.11 to 0.94) Staying in place (good/okay vs poor)
0.33 (0.13 to 0.81) Fit (good/okay vs poor)
0.17 (0.05 to 0.58) Smell (good/okay vs poor)
0.87 (0.12 to 6.07) Discreetness (good/okay vs poor)
1.82 (0.49 to 6.82) Ease on standing (good/okay vs poor)
0.86 (0.43 to 1.70) Skin health problems (none vs a little/a lot)
0.36 (0.17 to 0.77) Overall acceptability (high/okay vs no)
0.22 (0.08 to 0.58) Overall acceptability (high vs okay/no)
0.52 (0.30 to 0.91) Preference (PU vs I)
0.01 0.1 0.2
Favours pull-up Favours insert
0.5 1 2 5 10
FIGURE 54 Forest plot: pull-up vs insert (day)
Odds ratio (95% CI)
1.21 (0.82 to 1.81) Leakage – diary (none vs a little/a lot)
0.77 (0.38 to 1.55) Leakage – rating (good/okay vs poor)
0.69 (0.28 to 1.72) Leakage – faeces (good/okay vs poor)
0.95 (0.30 to 3.04) Staying in place (good/okay vs poor)
0.62 (0.23 to 1.67) Fit (good/okay vs poor)
0.47 (0.17 to 1.28) Smell (good/okay vs poor)
2.76 (1.13 to 6.76) Ease on lying (good/okay vs poor)
0.57 (0.28 to 1.18) Skin health problems (none vs a little/a lot)
0.31 (0.13 to 0.73) Overall acceptability (high/okay vs no)
0.17 (0.05 to 0.63) Overall acceptability (high vs okay/no)
0.36 (0.20 to 0.66) Preference (PU vs I)
0.01 0.1 0.2
Favours pull-up Favours insert
0.5 1 2 5 10
FIGURE 55 Forest plot: pull-up vs insert (night)support the findings from the product performance
questionnaires, which also showed that the pull-up
and insert designs were significantly easier to
change in the standing position than the diaper
and T-shaped diaper designs. Although pull-ups
were found to be as quick and easy to put on as
inserts, they may be more time consuming to
change in practice. When a pull-up is changed,
clothing (e.g. trousers, tights) must be removed
completely and reapplied, whereas with the other
designs clothing need only be pulled down. The
data showed that pull-ups were the most successful
design for women, and although there were more
comments regarding difficulties with changing or
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Odds ratio (95% CI)
0.94 (0.69 to 1.28) Leakage – diary (none vs a little/a lot)
0.87 (0.44 to 1.73) Leakage – rating (good/okay vs poor)
0.97 (0.41 to 2.32) Leakage – faeces (good/okay vs poor)
0.71 (0.18 to 2.79) Staying in place (good/okay vs poor)
0.34 (0.11 to 1.03) Fit (good/okay vs poor)
0.43 (0.10 to 1.81) Smell (good/okay vs poor)
0.13 (0.03 to 0.54) Discreetness (good/okay vs poor)
0.40 (0.14 to 1.18) Ease on standing (good/okay vs poor)
1.13 (0.55 to 2.32) Skin health problems (none vs a little/a lot)
0.42 (0.16 to 1.09) Overall acceptability (high/okay vs no)
0.23 (0.09 to 0.61) Overall acceptability (high vs okay/no)
0.50 (0.28 to 0.88) Preference (PU vs D)
0.01 0.1 0.2
Favours pull-up Favours diaper
0.5 1 2 5 10
FIGURE 56 Forest plot: pull-up vs diaper (day)
Odds ratio (95% CI)
1.73 (1.18 to 2.52) Leakage – diary (none vs a little/a lot)
1.60 (0.76 to 3.39) Leakage – rating (good/okay vs poor)
1.32 (0.54 to 3.18) Leakage – faeces (good/okay vs poor)
0.81 (0.27 to 2.44) Staying in place (good/okay vs poor)
0.45 (0.17 to 1.21) Fit (good/okay vs poor)
0.71 (0.25 to 2.03) Smell (good/okay vs poor)
4.71 (1.60 to 13.19) Ease on lying (good/okay vs poor)
1.00 (0.50 to 2.00) Skin health problems (none vs a little/a lot)
0.75 (0.27 to 2.12) Overall acceptability (high/okay vs no)
2.13 (0.86 to 5.26) Overall acceptability (high vs okay/no)
1.45 (0.84 to 2.49) Preference (PU vs D)
0.01 0.1 0.2
Favours pull-up Favours diaper
0.5 1 2 5 10
FIGURE 57 Forest plot: pull-up vs diaper (night)application compared with inserts, this did not
affect their overall popularity.
It was speculated that because the pull-up and
insert designs were both significantly easier and
significantly quicker to change in the standing
position than the two diaper designs, the pull-up
and insert designs may be preferred by staff for
daytime use. The residents were therefore
categorised as being ‘able to stand’ or ‘unable to
stand’ and examined their first-choice daytime
design when binarised as (pull-ups + inserts) and
(diaper + T-shaped). The results are shown in
Table 74.
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Odds ratio (95% CI)
0.87 (0.64 to 1.18) Leakage – diary (none vs a little/a lot)
1.01 (0.42 to 2.44) Leakage – rating (good/okay vs poor)
1.09 (0.42 to 2.83) Leakage – faeces (good/okay vs poor)
1.93 (0.68 to 5.45) Staying in place (good/okay vs poor)
1.34 (0.65 to 2.79) Fit (good/okay vs poor)
1.05 (0.41 to 2.66) Smell (good/okay vs poor)
0.48 (0.21 to 1.09) Discreetness (good/okay vs poor)
2.24 (1.09 to 4.58) Ease on standing (good/okay vs poor)
1.40 (0.69 to 2.86) Skin health problems (none vs a little/a lot)
1.04 (0.50 to 2.19) Overall acceptability (high/okay vs no)
1.40 (0.45 to 4.37) Overall acceptability (high vs okay/no)
1.06 (0.63 to 1.81) Preference (T vs D)
0.01 0.1 0.2
Favours T-shaped Favours diaper
0.5 1 2 5 10
FIGURE 58 Forest plot: T-shaped vs diaper (day)
Odds ratio (95% CI)
1.25 (0.95 to 1.64) Leakage – diary (none vs a little/a lot)
1.54 (0.64 to 3.71) Leakage – rating (good/okay vs poor)
1.13 (0.39 to 3.31) Leakage – faeces (good/okay vs poor)
1.06 (0.33 to 3.37) Staying in place (good/okay vs poor)
0.54 (0.23 to 1.28) Fit (good/okay vs poor)
0.60 (0.18 to 2.08) Smell (good/okay vs poor)
1.71 (0.61 to 4.76) Ease on lying (good/okay vs poor)
0.88 (0.47 to 1.67) Skin health problems (none vs a little/a lot)
0.79 (0.36 to 1.76) Overall acceptability (high/okay vs no)
2.04 (1.03 to 4.01) Overall acceptability (high vs okay/no)
1.39 (0.81 to 2.39) Preference (T vs D)
0.01 0.1 0.2
Favours T-shaped Favours diaper
0.5 1 2 5 10
FIGURE 59 Forest plot: T-shaped vs diaper (night)The odds on preferring pull-up/insert for those
able to stand is estimated to be 2.9 times higher
than that for those unable to stand. The 95% CI
for this OR is 1.2 to 7.0, which indicates that the 
pull-up/insert designs are likely to be preferable
for those who can stand.
Economic analysis
Cost data 
The prices and costs used in both the value-for-
money questions and the cost-effectiveness
analysis were those derived for Trial 2a, since the
same products were used in both trials. The base
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Odds ratio (95% CI)
1.22 (0.89 to 1.68) Leakage – diary (none vs a little/a lot)
0.86 (0.33 to 2.24) Leakage – rating (good/okay vs poor)
1.12 (0.43 to 2.90) Leakage – faeces (good/okay vs poor)
0.37 (0.12 to 1.13) Staying in place (good/okay vs poor)
0.26 (0.09 to 0.74) Fit (good/okay vs poor)
0.45 (0.12 to 1.63) Smell (good/okay vs poor)
0.28 (0.06 to 1.25) Discreetness (good/okay vs poor)
0.18 (0.06 to 0.55) Ease on standing (good/okay vs poor)
0.81 (0.40 to 1.63) Skin health problems (none vs a little/a lot)
0.40 (0.15 to 1.02) Overall acceptability (high/okay vs no)
0.17 (0.06 to 0.43) Overall acceptability (high vs okay/no)
0.50 (0.28 to 0.88) Preference (PU vs T)
0.01 0.1 0.2
Favours pull-up Favours T-shaped
0.5 1 2 5 10
FIGURE 60 Forest plot: pull-up vs T-shaped (day)
Odds ratio (95% CI)
1.38 (1.02 to 1.87) Leakage – diary (none vs a little/a lot)
2.47 (1.01 to 6.05) Leakage – rating (good/okay vs poor)
1.16 (0.43 to 3.13) Leakage – faeces (good/okay vs poor)
0.77 (0.25 to 2.36) Staying in place (good/okay vs poor)
0.84 (0.30 to 2.36) Fit (good/okay vs poor)
0.86 (0.24 to 3.09) Smell (good/okay vs poor)
2.48 (1.01 to 6.09) Ease on lying (good/okay vs poor)
1.14 (0.63 to 2.06) Skin health problems (none vs a little/a lot)
0.95 (0.37 to 2.46) Overall acceptability (high/okay vs no)
1.04 (0.40 to 2.71) Overall acceptability (high vs okay/no)
1.09 (0.64 to 1.85) Preference (PU vs T)
0.01 0.1 0.2
Favours pull-up Favours T-shaped
0.5 1 2 5 10
FIGURE 61 Forest plot: pull-up vs T-shaped (night)Health Technology Assessment 2008; Vol. 12: No. 29
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FIGURE 62 Pad change times for 10 residents (N = 10 for each design)
TABLE 73 Mean pad change times for different designs (N = 10)
Insert Diaper Pull-up T-shaped
Time (s) 35.2 53.2 37.9 62.0
(SD) (6.9) (15.1) (12.1) (15.5)
Pad change time: comparisons between designs 
Estimated difference 95% CIa
Insert  not different to Pull-up –2.71 –13.58 to 8.16
Insert  faster than Diaper –18.01 –28.18 to –7.84
Insert  faster than T-shaped –26.81 –37.70 to –15.92
Pull-up  faster than Diaper –15.30 –24.63 to –5.97
Pull-up  faster than T-shaped –24.10 –36.99 to –11.21
Diaper  faster than T-shaped –8.80 –16.91 to –0.69
a CIs include Bonferroni adjustment for multiple comparisons, except for diaper compared with washables (single
comparison made). To assist the reader, comparisons between designs have been described as ‘not different’ if they are
not significant (p > 0.05).
TABLE 74 First-choice design and ability to stand (N = 99)
First-choice daytime design
Pull-up/insert Diaper/T-shaped
Able to stand: % (N) 70.5 (48)  29.5 (20)
Unable to stand: % (N) 45.2 (14) 54.8 (17)cost metric was taken to be the monthly cost (day
and night) of supplying one resident assuming a
utilisation rate of three products per day and one
product per night. This utilisation rate was
derived from previous studies by the research team
but was subsequently found to understate the
median use among the sample which was 3 + 2
(day and night). Prices charged by NHS Logistics
at the start of the module trial (April 2005),
including VAT, were used since this was the most
usual source of supply for care homes at that time.
Estimates for two of the products which were not
supplied by the NHS at the time were based on
the differential between the NHS price and the
open market price for other products. Where
prices differed for different sizes of any product,
the mean price of all sizes was used.
Relative value for money 
In piloting the final interview, care staff were given
the monthly costs per resident for each design and
asked to rank them on value for money. This was
intended to investigate whether they would revise
their preferences when the relative cost of designs
was disclosed. However, care staff found this line
of questioning difficult and it was dropped. Staff
were instead asked to consider the differences in
the costs between designs. The differences used
reflected the approximate cost relativities between
designs (£15, £10, £5 for the day and £6, £4, €2
for the night). 
To probe strengths of preferences for designs, care
staff were given cost differences between designs
and asked if they still thought their preferred
design was best if it cost the NHS the extra
amounts. This exercise was conducted for day and
night products. Care staff were asked to consider
only designs that they had deemed to be
acceptable and then to compare (as appropriate)
their first and second choices, second and third
choices and third and fourth choices. The results
are shown in Appendix 21. Staff found these
questions difficult to answer (not surprisingly) for
third and fourth choices and only their views
about the first and second preferences are reported. 
These results show that preferences for pull-ups in
the day appear to be strong and almost all care
staff who had ranked pull-ups best and who
answered the question felt that they were worth an
extra £15 per month of cost to the NHS compared
with their second-choice design. Preferences for
other first-choice products were less strong. At
night, strengths of preference were higher for
pull-ups and T-shaped than for diapers, even
though they were the overall favourite design. In
general, strengths of preference reflected overall
design rankings for both day and night. 
Cost-effectiveness
Mean VAS scores were used to calculate ACERs,
which show the cost per unit of effectiveness for
any design (lower values mean benefit is produced
at lower cost).
In the day, there was no significant difference in
the mean VAS between T-shaped, diapers and
inserts, but the mean VAS for pull-ups was
significantly higher than for the other three
designs. 
At night, there was no significant difference in the
mean VAS between T-shaped, diapers and pull-
ups, but the mean VAS for inserts was significantly
lower than for the other three designs. The cost-
effectiveness data are shown in Table 75.
Pull-ups were the most expensive day design. If
pull-ups were provided rather than the other three
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TABLE 75 Cost-effectiveness of designs 
Day Night
Design Mean  Mean ACER Design Mean  Mean ACER
monthly VAS  monthly  VAS
cost (£)  score Cost  VAS  cost (£)  score Cost  VAS 
(3/day   per VAS  points  (1/night   per VAS  points 
30) point (£) per £ 30) point (£) per £
Pull-ups 46.50 6.77 6.87 0.15 Diapers 9.00 6.62a 1.36 0.73
Diapers 21.00 5.14a 4.08 0.24 T-shaped 10.00 6.32a 1.58 0.63
T-shaped 25.00 4.86a 5.14 0.19 Pull-ups 15.50 6.22a 2.49 0.40
Inserts 21.00 4.97a 4.23 0.24 Inserts 9.00 4.33 2.08 0.48
a No significant difference.designs, the mean VAS would be about 1.8 points
(18 percentage points) higher at a cost of £21–25
extra per resident per month. This is equivalent to
8 percentage points extra effectiveness per extra
pound spent.
Diapers dominate the night designs. Although
there were no significant differences in the mean
VAS of diapers, T-shaped and pull-ups, diapers
were the cheapest of the three. Compared with
inserts that had a significantly lower mean VAS,
there was no extra cost per VAS point if diapers
were used, £0.50/month if T-shaped diapers were
used and £3.42/month for pull-ups. Inserts had
significantly worse mean VAS than the other three
designs, and had the second highest cost per unit
of effectiveness (after pull-ups).
Sensitivity analysis and sources of uncertainty
Only one product per design was tested and the
cost-effectiveness ratios are based on point
estimates of monthly costs and effectiveness (as
represented by VAS means). Effectiveness was
rated by care staff on behalf of residents, so the
assessments reflect staff perspectives of what would
be best for residents. 
Pull-ups are significantly more effective than the
other three designs in the day, but are more than
twice as expensive as diapers and inserts (the
cheapest of the designs). Inserts are significantly
less effective than the other three designs at night.
There are several sources of uncertainty in the cost
estimates. First, the prices used were those
prevailing at the time of the trial for the products
tested and absolute and relative prices could have
altered subsequently. Choice of different products
within designs could also have affected relative
prices. 
Second, the monthly cost estimates are based on
observation at baseline that suggested a
consumption rate of three products per day and
one per night. This was an underestimate of actual
night consumption and will have affected the
ACERs and ICERs but not the relativities or the
outcome that favours diapers.
Third, no allowance is included for differences in
laundry between designs. No significant
differences were observed in the day, but at night
the pull-ups and inserts generated significantly
more laundry from leakage than the other two
designs.
Fourth, the daily consumption of pull-ups was
significantly higher than for the other designs.
This would add to the cost disadvantage of pull-
ups, but has not been quantified and included. It
is not clear why consumption of pull-ups was
higher than the other designs in the day but not
at night. This may reflect staff preference for 
pull-ups during the day and the finding that they
are easy to put on during the day but not at night.
Fifth, there were no reported differences between
the designs in the numbers of staff needed to
change the designs. No allowance has therefore
been included for different numbers of staff. For
resident and staff safety reasons, it is likely to be
increasingly common that homes have a policy of
requiring two staff to be present to change
residents who are not independent for pad
changing and staff numbers are not therefore
likely to be affected by pad design. In the pad
change experiment, pull-ups and inserts took the
shortest time (significantly shorter than diapers
and T-shaped), but this only covered standing
changes and the time saved was only around
15–30 seconds per pad change. In addition, these
savings may not apply to night changes when
residents would be lying in bed. 
Discussion
Inserts
In this study, we aimed to compare designs of
products that had similar absorbent capacities in
order to minimise the confounding effect of
absorption capacity, which may override the effect
of design. However, previous studies had shown
that for similar absorption capacities the insert
design was significantly less effective at preventing
leakage than the diaper design.7 The findings
from the pad change/leakage diary data from this
study showed that there was little difference in
leakage performance between the designs; at the
median urine weight the insert design was the
worst during the daytime but only significantly so
when compared with the T-shaped diaper. At
night-time, the leakage performance of the insert
was also worst (and very similar to the pull-up) but
only significantly worse than the diaper.
However, carers in this study perceived the leakage
performance of the inserts to be significantly
worse than all three other designs during the day
and both diaper-style designs during the night. It
is notable that the median urine masses for the
insert pads were substantially less than for the
other designs, particularly the diaper styles, which
may indicate increased changing/consumption of
pads, and pad consumption data showed that
Health Technology Assessment 2008; Vol. 12: No. 29
107
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.Products for women and men living in nursing homes (Trial 2b)
108
significantly more insert pads were used at night
than the other three designs. There are several
possible explanations for increased consumption;
it may indicate that staff took action to prevent
leakage, either by changing the pads more often,
or by using two pads at the same time at night, or
by using some of the more absorbent night insert
pads during the day to prevent daytime leakage,
or that pads were used for other purposes such as
to protect the bed while washing the resident.
However, increased consumption may also indicate
the popularity of a design. For example, the pull-
up was the most popular daytime design and pad
consumption data show that it was used
significantly more than the other three designs.
Overall, the combined evidence indicates that the
leakage performance of the insert design was
worse than that of the other designs for both day-
and night-time use.
Although there is evidence that the insert design is
worse than the other three designs for leakage
prevention, it does have important advantages in
the daytime over the two diaper-style designs in
being significantly easier and quicker to put on in
a standing position. It is also more discreet under
clothes (although not significantly so compared
with the T-shaped diaper) and probably for these
reasons it has better acceptability for daytime use
than would be expected from its poor rating of
leakage. 
For night-time use, the advantages of the insert
design are removed. It is not easier to put on in a
lying position than the diaper designs and
discreetness (a strength of inserts) is not a key
variable at night. The poor leakage performance
of the insert design dominates and is evident in
that only six carers chose it for participants as
their first-choice design; nearly half found it to be
unacceptable at night and all three alternative
designs were preferred to the insert by two-thirds
to three-quarters of carers. The insert was the least
successful product for night-time use.
Pull-ups
The pull-up design was the most successful design
for daytime use, being preferred over all other
designs by around two-thirds of carers and was the
first choice for nearly half. The pull-up design has
the advantages of the insert design, being easy
and quick to put on in a standing position and
discreet, but is better than the insert at daytime
leakage, staying in place, fit and smell prevention.
During the night-time, the pull-up design was less
successful, particularly for leakage, but also for
ease of putting on in a lying position, for which it
was significantly worse than all three alternative
designs. The pull-up was used significantly less
than the other designs during the night, possibly
because it was difficult to change. However,
despite its shortcomings, the pull-up was
surprisingly popular, with a low proportion of
carers finding it unacceptable for participants 
and it being significantly preferred to inserts (but
not to any other design). The considerable
enthusiasm shown by staff and residents for 
pull-ups during the daytime appears to have
carried over to the night, despite the pull-up’s
disadvantages.
Diaper and T-shaped diaper
In the daytime, the diaper and the T-shaped
diaper performed similarly to each other, the only
significant difference being that the T-shaped
diaper, contrary to expectations, was significantly
worse than the diaper for ease of putting on in a
standing position and for speed of pad changing.
However, the T-shaped diaper was an unfamiliar
product and this may have resulted in slower pad
change times than would occur if the design was
used regularly. Compared with the insert, both the
diaper and the T-shaped diaper were significantly
better for leakage during the daytime. However,
both the diaper and the T-shaped diaper were
rated as significantly worse than the insert and the
pull-up for ease of putting on in a standing
position and the diaper was also significantly
worse for discreetness. Both the diaper and the 
T-shaped diaper were significantly worse for
preference and overall acceptability than the 
pull-up.
During the night-time, the T-shaped diaper and
the diaper performed similarly, although the
diaper was significantly more acceptable at the
level of (highly acceptable) versus (acceptable +
unacceptable). The diaper was the most popular
first-choice design for night-time use (41/98)
whereas the T-shaped diaper was first choice 
for 19. 
Faecal incontinence 
Around two-thirds of the participants had faecal
incontinence. Product performance questionnaire
responses indicated that inserts may be least
effective for containing faecal leakage (during the
day). This was not strongly supported by the pad
change/leakage diary data, but there were
insufficient data to draw firm conclusions. Further
investigation comparing the performance of
designs for the management of faecal
incontinence is needed. Gender and standing ability
The significant effects of ability to stand and
gender on preferences demonstrate that different
designs are likely to be more or less suitable for
residents with different characteristics.
Carers had a strong preference for pull-ups for
women participants, particularly during the day,
and if they were able to stand for pad changes.
Pull-ups have the advantage of being easy to put
on in a standing position, performed more
effectively for leakage than inserts and are liked
for their dignified pant-like appearance. Although
the inserts are as easy to put on, it seems that 
pull-ups are a substantial improvement and this
was first choice for more than half of women
(39/73), whereas only 14/73 chose inserts. Diaper
style designs are much less popular choices than
the pull-ups for women (7/73 chose diaper, 12/73
chose T-shaped diaper).
For women who are unable to stand for pad
changing, and for all women during the night-
time, the pull-up was still a popular choice 
(30/73 carers chose it as first choice for night),
although it may be difficult to put on for some
women and is less effective for leakage during the
night than during the day. In these circumstances,
a diaper-style product is likely to be better. Inserts
were least preferred for women during the night
(6/71) and for women who are unable to stand
(2/22).
For men who are unable to stand and for men at
night, diapers and T-shaped diapers (but in
particular diapers) were overwhelmingly the most
popular choice, with inserts not selected for any
men at night and pull-ups the first choice for only
two men. Diapers were also preferred during the
day for men who could stand, but less strongly so
(9/18). Comments from men and their carers
indicated that although easy to put on, pull-ups
require trousers to be removed (whereas inserts
and diapers do not), and this is a disadvantage 
for men. 
Inserts versus diapers
Inserts and diapers are currently the most
commonly used designs in the UK and both are
cheaper than the newer T-shaped diaper and 
pull-up designs. For women, inserts are a better
choice than diapers during the day; although they
are significantly worse for leakage, they are easier
to put on than diapers and, for most women
where a pull-up was preferred, the insert was the
second choice. However, for women who cannot
stand for pad changing, or for use during the
night-time, a diaper is likely to be preferable and
is better for leakage performance.
For men, diapers are the preferred choice for most
circumstances. No carer chose an insert for a man
as a first choice for use during the night and only
4/27 chose an insert as first choice during the day. 
How effective are the new pull-up and
T-shaped designs?
This study shows that the pull-up design is an
important advance in continence management
and is the first-choice design for most women in
nursing homes. Pull-ups are significantly better
than insert pads on most key variables during the
daytime and are appreciated for their dignified
and pant-like appearance. However, at night they
are more difficult to put on than other designs for
both men and women and are generally less
popular for men because of the need to remove
trousers when changing. 
The T-shaped diaper was not found to offer
significant advantages over the traditional diaper
on any key variables for day or night. Although it
was designed to be easier and quicker to apply,
particularly in the standing position, this was not
found to be the case. On the contrary, the 
T-shaped design was found to be significantly
more difficult to apply than all other designs and
took significantly longer to change. The T-shaped
diaper would have been an unfamiliar design to
nursing home staff and this may have contributed
to the poorer ratings. However, staff training was
given to all nursing homes and the staff tested the
designs for a 2-week period, which should have
enabled them to gain sufficient experience of
using the designs. The traditional diaper was
generally preferred for men (15/27 chose it as
their first choice) compared with the T-shaped
diaper (3/27) but there are indications that for
women the T-shaped design may be preferable
(12/72 chose it as their first choice compared with
7/72 for the traditional diaper); this may be
because it had higher scores for discreetness
(although this was not a significant finding).
Limitations
Carrying out research in nursing homes is
challenging. We used several strategies to
minimise carer burden and the burden on the
home (e.g. all visits at times suited to staff) and to
maximise data reliability (pad weighing and skin
inspections carried out by researchers, supervision
of product performance questionnaire
completion). However, staff changes/absences and
availability meant that it was difficult to ensure
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questionnaires for an individual resident and it
was frequently necessary for staff to act for each
other and completion of more than one
questionnaire by a staff member was common. To
minimise replication of responses, questionnaire
completion was supervised by researchers and staff
were always encouraged to consider the individual
resident when providing their responses.
In this study, only one product was used (rather
than two or three) to represent each design group.
This decision was made for practical reasons
following consultation with nursing homes.
Nursing home staff felt that it was important to
limit the time of the study to a manageable period
and 12 weeks was considered too long. There were
also concerns that staff may be confused by
multiple products and this would threaten the
reliability of the data recorded. Selection of only
one product does, however, threaten the validity of
the study because the selected products may not
adequately represent each of their design groups.
The products were selected from interim data
available from the similar clinical trial of
absorbent products which was being undertaken
with community-dwelling individuals (see
Chapter 4). This community trial included three
products (or two) to represent each design group,
which had been preselected from a pilot study.
They had similar absorbencies to those most
commonly purchased by the NHS (see Chapter 2)
and, in order to avoid the confounding effects of
different absorbencies, had similar absorbencies to
each other (1900 ml ± 20% for daytime use and
2400 ml ± 20% for night-time use7). In the
community study, results for each of the three
products (or two) within each design group were
compared and if any products were significantly
worse than the other products within their design
group for leakage performance variables or for
overall opinion then these results were excluded
from the analysis. Two night-time products were
excluded (see the section ‘Design results’, p. 50)
for these reasons, but neither of these were
products that were tested in this nursing home
trial. We can therefore be reasonably confident
that the products used in this trial represented
their design groups within their absorbency range.
Participants were recruited from 10 nursing homes
in the London and Southampton areas. These
homes varied in size, category of registration and
ownership, but how well do they represent nursing
home residents (who wear absorbent pads for
incontinence) more generally? Comparisons with
(the limited) participant data from the two most
recent studies of nursing home residents, which
tested (1) disposable insert pads15 and 
(2) disposable diapers,16 showed that the average
age of participants in our study (around 82 years)
is similar; Norton scores were slightly lower in our
study (6% were scored as being at low risk in our
study compared with 10%16 and 15%15) and
Hodkinson mental test scores were very similar
(around 50% scored zero). However, although in
our study the median urine weights for day and
night were very similar to those in the study
testing disposable insert pads (150 g day and
180 g night), they were lower than those in the
study testing disposable diapers (which reported
medians of 210 g for day and 280 g for night). 
A possible explanation for this discrepancy may be
that the trial of disposable diapers included all
diapers on the market, including many with very
high absorbencies (and therefore high Rothwell
scores), whereas in our trial we used diapers with
similar absorbencies to the other designs included
in the study, and representing the level of
absorbency typically purchased by the NHS (with
more moderate Rothwell scores). Use of products
with very high absorbencies may have resulted in
staff changing the products less frequently, with
consequently higher urine masses. It seems
unlikely that the participants in our study (or in
the study of disposable inserts15) were less
incontinent than those in the study of disposable
diapers.16
Product development means that the
characteristics and availability of individual
products change over time and the products used
in this study are likely to be superseded. However,
the main designs are much more stable and the
results should therefore outlive those of the
individual products. Market changes, however,
mean that absolute and relative prices can alter.
For example, a greater demand for pull-ups by
NHS Trusts (in response to client preferences)
could enable competitive manufacturers to exploit
further economies of scale in production and offer
more favourable purchasing terms for PASA.
Further limitations applying to the study more
generally are discussed in Chapter 7.
Conclusions
This study showed that the main differences
between the different designs of absorbent
products concerned the ease with which they were
applied, leakage performance and preferences for
different designs, which were dependent on
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Pull-ups and inserts were easier and quicker to
apply in the standing position than the diaper
style designs. Considerable enthusiasm was shown
by staff and residents for pull-ups, which
represented the best design for women during the
daytime, particularly those who could stand, but
are the most expensive. The insert would be a
cheaper alternative and is still easy to apply, but a
more absorbent product may be needed. At night
the diaper was the most cost-effective option for
both men and women and was the most cost-
effective product for men during the day. The 
T-shaped diaper was not better than the traditional
diaper overall, nor for ease of application.
Implications for healthcare
There is evidence that:
● A range of designs is required to meet the
needs of carers and residents in nursing homes. 
● Characteristics of residents, particularly ability
to stand and gender, are likely to aid selection
of the most appropriate design.
● The pull-up and insert designs are easiest and
quickest to apply in the standing position.
● Pull-ups are the best design for women during
the daytime but are relatively expensive. Bulk
contract to reduce pull-up price and enable
provision would increase satisfaction.
● For women, the insert would be a cheaper
alternative than pull-ups and is still easy to
apply, but a more absorbent product may be
needed.
● The diaper is the most cost-effective design for
men both day and night, and for women at
night.
● Individual preferences vary and, where possible,
residents should be consulted about product
choice. 
● Most care staff would be concerned about
introducing washable designs and there is
evidence (see Chapter 4) that if able to choose
for themselves most women (and some men)
would not find them acceptable. Restricting the
range of available products to washable designs
alone is therefore not recommended.
Recommendation for research
● Clinical trial of absorbent product designs for
community-dwelling carer-dependent men and
women with moderate/heavy incontinence. 
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Very little is known about users’ perceptions and
satisfaction with pads or the impact on their lives
and the Third International Conference on
Incontinence in 2004 recommended the
development of a QoL instrument for users of
continence products.32 The results of an
investigation into the effects of pad wearing on
QoL are presented. 
Background summary
Living with urinary incontinence has multiple
implications for individuals, including a well-
recognised, negative impact on QoL.54–56 People
with urinary incontinence have higher levels of
depression and anxiety, feel more stigmatised and
have poorer life satisfaction compared with people
who are continent.57,58 Most treatments for urinary
incontinence are directed towards improving
symptoms and correspondingly most existing
health-related QoL measures, including both
generic and incontinence condition-specific
instruments, are designed for use in trials where
some change in patient symptoms is expected.59
However, the principal aim of using absorbent
pads is to contain incontinence and, therefore,
changes in the design or other characteristics of
the pad are not expected to influence
incontinence symptoms directly. Consequently,
existing QoL tools are unlikely to be sufficiently
sensitive for use with pad users. However, users’
perspectives on pad-related factors are critically
important to aid product selection by individuals
and healthcare providers and to enhance product
evaluation methodology and inform new product
development. There is a need to be able to
determine the balance between beneficial effects
of pad use and less desirable side-effects, for both
individuals and different population groups (e.g.
light or heavy incontinence; physical disabilities;
workplace or home settings). 
The aim was to gain a better insight into how pad
users’ everyday lives may be affected by the
management of incontinence with absorbent
products and to look beyond measures of pad
performance alone, towards impact on overall
QoL. QoL is a complex concept which
encompasses “those attributes valued by patients,
including their resultant comfort or sense of well-
being; the extent to which they are able to
maintain reasonable physical, emotional and
intellectual function; the degree to which they
retain their ability to participate in valued
activities within the family, in the workplace and in
the community”.60 An acknowledgement of this
multi-dimensional nature of QoL helps to
emphasise the importance of considering
individuals’ needs and experiences of pad use in
relation to their own circumstances. 
Aims
The aims were:
● to examine how absorbent pad use impacts on
the lives of women and men with urinary
incontinence 
● to determine key domains for inclusion in the
development of QoL measure for people using
absorbent products
● to identify the pad characteristics which impact
most strongly on users and should influence
new product design and evaluations.
Design
The study design comprised two stages and data
were collected as part of the two community-based
clinical trials: for women with light incontinence
(Chapter 3) and for men and women with
moderate/heavy incontinence (Chapter 4). Data
were also collected from nursing home care staff as
part of the third clinical trial; findings are not
described here and are described in Chapter 5.
Stage 1: determining important pad
characteristics 
An initial ‘bank’ of pad characteristics, considered
most important by users, was derived from a critical
review of published literature and subsequently
refined through focus group discussion with pad
users. Electronic databases were systematically
searched for published papers examining the use
of absorbent products, using the keywords
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Chapter 6
Absorbent products for incontinence: first stage in 
the development of a quality of life instrumentcontinence, incontinence, absorbent products,
pads, evaluation and QoL. The only restriction
was that papers were published in English. 
Focus groups offer the advantage of group
dynamics to stimulate discussion,61 but travel to a
central location for group activity can be difficult
for many in this population, which includes a high
proportion of people with physical disability
arising from disease, injury or advanced age.
However, as the continence user group (Incontact)
were holding their annual conference, it was
possible to incorporate the focus group and invite
(pad-using) volunteers who were attending the
conference. The participants were asked to
describe ‘the ways in which wearing an absorbent
pad affected their lifestyle and QoL’. The
discussion was recorded and supplemented by
written notes made concurrently by one of the two
researchers facilitating the focus group. The
researchers independently reviewed the recording
transcript and written notes to identify relevant
issues and then agreed on emerging categories.
Categories were compared with issues identified
from the literature review and formulated into a
series of pad-related characteristics, which
provided the basis for the subsequent ranking
exercise in Stage 2.
Stage 2: Face-to-face interviews and ranking
exercise
Face-to-face interviews were conducted with a large
sample of women and men using pads for urinary
incontinence, to examine the impact of pad use on
their daily lives. Interview subjects were women
with light incontinence and women and men with
moderate/heavy incontinence recruited to the
main clinical trials of product designs. 
Interviews took place at the participant’s home or
the research centre. All interviews were conducted
by one of two researchers who had both received
prior training in the process. Interviewees were
asked about the impact of absorbent product use
on their daily lives and what would make life
better. All participants were encouraged to give
examples of how pad use and specific pad
characteristics affected their lives, in order to help
them think about their pad-related QoL and not
simply incontinence-related QoL or satisfaction
(or not) with pad performance. Lastly, they were
asked to use a five-point Likert scale (where 1
represented very important and 5 not important)
to rank (1) the importance of individual pad
characteristics to them and (2) the five most
important pad characteristics for day use and for
night use. 
Analysis of interview data
Interviewers aimed to promote rigour and
minimise potential misperceptions by checking the
accuracy of their understanding through
supplementary questioning as the interview
proceeded.62 Interviews were recorded and
verbatim transcripts imported into Hyper-
Research software (ResearchWare, USA,
Version 2.6) and subjected to rigorous content
analysis.63 Codes were assigned to lines, sentences
or paragraphs and passages of text with similar
codes were grouped into categories. Some sections
of transcripts were given more than one code.
Categories were gradually refined through
repetitive comparison of data and examination of
additional written notes. Categories were grouped
into emergent themes independently by two
researchers and outcomes, then reviewed and
agreed together. 
Results
Stage 1
The range of identified literature on absorbent
pad use and/or product evaluation was identified
(see Chapter 1). The main function of absorbent
pads is to absorb urine without leakage and,
unsurprisingly, ‘absorbency’ was the most
frequently cited pad performance item in the
literature. Most questionnaires used a large
number of secondary outcome variables which
included practical issues related to application,
comfort and ease of use. These variables formed
the initial bank of pad performance
characteristics, which were subsequently further
refined through focus group activity. Fifteen
volunteers took part in the focus group and
discussions contributed to the final formulation of
the set of pad characteristics used later in the
ranking exercise. 
Stage 2 – interviews
The two community-based clinical trials
(Chapters 3 and 4) were held consecutively,
beginning with designs for women with light
incontinence, followed by the clinical trial of
designs for men and women with moderate/heavy
incontinence. Participant characteristics for both
trials are shown in Tables 7 (p. 24) and 29 (p. 51).
Interviews were held at the beginning of the two
trials and, for health or personal reasons, some
participants did not go on to take part in the
product-testing phase. All women from the clinical
trial of products for light incontinence
participated (N = 85), including 14 women who
withdrew from the study (for health or personal
Absorbent products for incontinence: first stage in the development of a quality of life instrument
114reasons) before product testing began. All
participants from the clinical trial of products for
moderate/heavy incontinence took part in the
ranking exercise (N = 85) with 29 (19 men and 10
women) taking part in the QoL interviews. Despite
their apparent diversity, these 29 participants did
not reveal any important differences or add any
new themes to the data and data are therefore
presented together. 
Analysis of interviews
Content analysis of interview transcripts resulted
in the identification of a single superordinate
theme described as ‘Containing the problem’
(Figure 63). This theme encompassed critical
practical issues impacting on the confidence, felt
by interviewees, relating to the effective
containment of their incontinence. Although the
reliability of the pad to ‘hold urine’ was their
predominant concern, they were also extremely
anxious about ‘hiding the problem’ from others
and about ‘ease of use’, particularly in changing
and disposing of used pads. Two associated
subordinate themes were ‘physical impact’ and
‘psychological impact and social functioning’.
These themes were closely inter-related (Figure 63)
and issues to do with containment of urine,
discreetness and physical comfort exerted a strong
influence on psychological impact and social
functioning.
Containing the problem
Women and men acknowledged that wearing a
pad would not prevent or improve their
continence symptoms, but they needed to be
confident that the pad would hold urine effectively
and would not be visible to others. Yet this
confidence was often fragile and could easily be
damaged. Many were constantly anxious about
leakage and visibility of the pad. Several described
feelings of panic if the pad slipped out of position.
Three-quarters of interviewees (94/124) expressed
a general sense of anxiety, with 52/124 raising
specific concerns about pad visibility:
“It’s vital to be able to carry on with everyday life.
Knowing that the pad will hold urine gives you
security so allows you to do things. If the pad leaks
then you stop doing things. It’s easy to lose
confidence in yourself and stop doing everyday
activities.” [076]
Pad discreetness and containment of smell
(odour) were identified by all women and men as
crucial aspects of ‘hiding the problem’. Pad size
was recognised as part of a dynamic relationship
between effective absorbency whilst maintaining
discreetness:
“Discreetness of a pad means a huge amount. 
You don’t want people to see it; you’d be really
embarrassed if people knew you had a bladder
problem. I prefer to use thin pads and change
regularly, which is a bit inconvenient but better than
wearing a pad that was bulky and could be seen ….”
[379]
“You cover up and wear baggy clothes so no one can
see the pad. You don’t want them to hear it either.
You would get embarrassed if someone saw the pad.
It’s my age, I’m young and don’t want it seen. It
makes life worse because I’m young.” [581] 
‘Ease of use’ was influenced by pad size and the
convenience with which pads could be hidden
discreetly in a handbag, or a rucksack (often used
by men). The length of time required to change
the pad was an important issue for some women
and men managing busy lives:
“Being young and wanting to get on means that your
time is really precious. You have constraints and you
are expected to be speedy. You have a role to fulfil as
a mum or a young person so speed of putting on a
pad is relevant.” [147]
“For longer trips out with work it’s essential to change
easily if out in the afternoon, say. I would at least
need one change to be sure of no leaks.” [172]
For some people with limited dexterity, some
packs of pads could be difficult to open and some
pads were awkward to put on. If pads were easy 
to change this aided coping with incontinence 
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FIGURE 63 Themes from interview data, illustrating inter-
relationshipsand helped to promote a greater degree of
independence.
Physical impact
The key domains within this sub-theme related to
issues of ‘general comfort’, ‘skin health’ and
‘sleep’. Interviewees commented that some pads
were more comfortable than others but most were
uncomfortable when wet. Dry comfort was closely
related to pad size and fit, with poorly fitting pads
known to cause discomfort and chafing at the top
of legs:
“A comfortable pad gives you more confidence to go
out, it makes you feel like you are wearing normal
underwear, gives you more security.” [34]
Pads also needed to stay securely in place while
the wearer was moving about or they could lead to
itching and soreness. Wet pads were uncomfortable
because they could become more bulky and heavy
and made the individual more conscious of having
to wear a pad. They made the skin feel wet,
causing worries about developing skin rashes and
they could change shape or become lumpy and
rub against the skin. Consequently, wearers tried
to change them as soon as possible, but this meant
having to have spares with them at all times.
Wearing a pad at night presented particular
difficulties for some and often resulted in poor
sleep and tiredness during the day. Wet pads were
often worn for longer at night and were not only
uncomfortable but added to increased risks of skin
irritation: 
“I have a routine of using creams and wash much
more regularly. Soreness makes you very
uncomfortable and makes you aware the pad is there,
making you feel even more unhappy or low.” [222]
“Halfway through the night the last thing you need is
to have problems removing a pad. Some pads can
break up, which is frustrating and makes you annoyed.
You end up being shattered in the day.” [210]
Psychological impact and social
functioning
These issues were initially considered as two
distinct sub-themes but were later placed together
because the major psychological impact was
around concerns that other people would become
aware of their incontinence problem. This
influenced their personal perception of themselves
(‘self-perception’), their ‘personal relationships’
and their personal ‘coping strategies’ in familiar
and unfamiliar situations. All the women and men
interviewed spoke extensively of the psychological
impact of their continence problems and reliance
on absorbent pads on their everyday lives. The
effectiveness and discreetness of the pad were
critical issues which affected how they felt about
themselves and how they might be seen (and
judged) by others. They talked about their desire
for normality, and this was often eroded by the
need for pads, which eroded their feelings of
femininity or masculinity and the efforts required
in hiding their problems. They spoke of feeling
self-conscious and being forced to select clothing
which would hide the pad and any possible damp
patches. This often limited their choice of ‘nice
clothes’ and of tight-fitting fashions:
“I don’t wear tight clothes in case the outline of the
pad can be seen. It would be embarrassing. I have
different clothes for different occasions but all tend to
be baggy and they are chosen for the incontinence
problem.” [243]
Effective containment of smell from a wet pad,
when being worn or carried prior to disposal, was
a constant source of concern. When they talked
about the risk of urine smells, interviewees used
language which demonstrated high levels of real
and potential emotional distress. They used words
such as ‘devastated’, ‘mortified’, ‘horrendous’,
‘embarrassed’ and ‘ashamed’ to describe their
feelings and fears. They worried about their
proximity to other people, whether family or close
friends would tell them if there was a urine smell
and about giving offence to others: 
“I’m terrified the pad will smell. If I was out with
friends I would have to leave. I couldn’t be next to
them in case they could smell me and I would be
utterly mortified.” [324]
Some (less than 20%) talked about open
relationships with partners and/or families, and
sometimes with close friends, where they felt
comfortable that their continence problems were
known. However, this could still cause difficulties
and embarrassment, and these issues could
become more acute when with friends who didn’t
know. Pads were considered ‘unsexy’ and could
interfere with sexual relationships, even with
supportive partners:
“Sometimes it affects being with friends because you
just don’t trust the pad and don’t want to leave a wet
patch on their seat, so you tend to leave early so it
spoils the time with them and they often don’t
understand why you are leaving earlier than you
should.” [324]
“Nappies and plastic pants perform the best at night
but I look and feel totally ridiculous in them and my
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[479]
“My partner hates waking up in a wet bed; she
complains about me if I smell in the morning.” [172]
The possibility of the pad leaking prevented some
women and men from applying for jobs and of the
25% who did go out to work most expressed
concerns about the need for confidence in their
pads: 
“If the pad didn’t hold urine then I wouldn’t be able
to go to work … as it is I feel constantly anxious
wondering if the pad can last long enough to get
through a morning’s work ….” [158]
Many women and men appeared to exist in a state
of ongoing tension, with their need for social
activities compromised by their concerns over pad
performance and sense of security. Over two-thirds
(86/124) of interviewees identified anxieties over
social interactions, ranging from theatre trips,
visiting friends to simply going shopping.
Problems were less demanding at home or in a
known environment but became increasingly
dominant as the environment became less familiar
and less ‘safe’. 
For all men and women in this study, it was
important for them to be able to control their
situation and to minimise pad-related anxieties.
They did this by planning ahead for high-risk
situations where potential leakage might occur,
through their choice of clothing, knowing how
long a pad could last before changing, carrying
spare supplies of pads, pants, wipes and carrier
bags or nappy sacks with them, avoidance of
cheaper pads which could give off smells and
often through simply avoiding certain situations or
going to unfamiliar places:
“You prepare yourself before going to see friends,
wash before going and carry wipes in bag. You tend to
go over the top with padding when you are going out
but then you worry about discreetness ….” [204]
Travelling and particularly staying away overnight
presented major concerns about coping in an
‘unsafe environment’. If interviewees did not know
when or where the next accessible toilet might be
found, they often felt very anxious, fearing leaks
and lack of opportunity to change. Staying in
hotels raised concerns over leakages in bed and
poor facilities for pad disposal: 
“You can’t stay away from home because you are
always too fearful that it will leak in someone else’s
bed or at a hotel so I tend to avoid these
circumstances.” [216]
Ability to cope with their situations varied
considerably, for both those with light and those
with moderate/heavy incontinence. Although for
most their urinary incontinence was contained
through their use of absorbent pads, it was clear
that pad use brought with it other effects which
severely affected their overall QoL.
Pad characteristic ranking exercise
Tables 76 and 77 summarise the pad characteristics
ranked in the top five for day- or night-time use
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TABLE 76 Summary of pad characteristics ranked in top five (women with light incontinence) 
Top 5 characteristics (day) % women (n = 99)  Top 5 characteristics (night) % women (n = 81)
To hold urine 83.8 To hold urine 93.8
To contain smell 75.8 To stay in place 77.8
To stay in place  54.5 To contain smell  54.3
Discreetness 41.4 Comfortable when wet  54.3
Comfort when wet 40.4 To keep skin dry 48.1
TABLE 77 Summary of pad characteristics ranked in top five (moderate/heavy incontinence) 
Top 5 characteristics (day) % of men and women  Top 5 characteristics (night) % men and women 
(n = 67)  (n = 67)
To hold urine 92.5 To hold urine 95.5
To contain smell 56.7 To stay in place 68.7
To stay in place  50.1 Comfortable when wet 53.7
Discreetness 46.3 Fit 43.3
Fit 43.3 To keep skin dry 37.3
Comfort when wet 35.8 To contain smell 34.3for the women with light incontinence and the men
and women with moderate/heavy incontinence. 
Although some characteristics were more closely
associated than others (e.g. ‘comfort’ or ‘ability to
stay in place’), there was clear consensus on the
top five ranking characteristics, with minor
differences between day- and night-time use.
There was also strong consistency between the two
participant groups, with the main difference being
the inclusion of ‘fit of pad’ in the moderate/heavy
incontinence group. This is likely to be because
products in this group are much larger and
enclose the body, whereas ‘fit’ is likely to be less of
an issue for most absorbents for light
incontinence. The ability to hold urine without
leaking was the most important feature for day
and night. Ability to stay in place was particularly
important at night and slightly less so during the
day in both groups. Notably, the ability to contain
smell was ranked second only to holding urine for
daytime use but was also identified as important at
night. Comfort when wet was important at all
times but was ranked third for night-time use in
both participant groups. Interviewees explained
that they were likely to be in a wet pad for longer
periods at night than during the day, when they
would aim to change the pad as soon as it became
wet. Discreetness of the pad was a particular issue
for day use, with interviewees expressing
considerable anxiety over whether others could
see they were wearing a pad. Although there was
strong agreement on the five major pad
characteristics, it is important to recognise that for
some individuals other characteristics featured
highly. For example, ease of opening the pack and
putting on the pad were ranked top by some
women with dexterity and mobility difficulties. 
Discussion
The ranking exercise on pad characteristics
demonstrated a clear consensus on the most
critical features of pad performance for women
with light incontinence and men and women with
moderate/heavy incontinence, but although these
priorities provide some insights which may help
guide product choice and new product designs,
they focus almost exclusively on practical aspects
of pad use. The focus group discussion and
individual interviews showed that measures of pad
performance alone are too insensitive to explain
the impact of pad use on daily life or to be used to
assess influence on QoL. This was demonstrated
by the close inter-relationship between domains
within the superordinate theme ‘containing the
problem’, and the two sub-themes (‘physical
impact’ and ‘psychological impact and social
functioning’). Even when urine leakage was
successfully contained, concerns over issues such
as comfort, skin health and the need to hide the
problem of urinary incontinence from others
generated anxieties for users and demanded
complex personal coping strategies. Although
fears about urine leakage and exposure of
continence problems to others are common to
most people with incontinence symptoms,64–66
there were clearly a range of issues which were
specifically related to pad use. These included
precautions needed to contain urine effectively
whilst hiding pad bulkiness, containing urine
smell, disposing of used pads and planning ahead
to facilitate pad changes when engaging in
personal and social interactions. For most
interviewees, this meant restrictions in the choices
of clothing, often with an accompanying
detrimental impact on self-image and confidence.
It also resulted in extensive and time-consuming
washing regimes, frequent use of wipes and
complex planning to ensure containment of
possible smells from wet pads prior to their
disposal. The constant requirement for thinking
ahead and being prepared to deal with wet pads
were continual reminders of incontinence and
women often felt they were unable to maintain the
levels of normality and femininity that they wished
for. Pad performance was an important factor in
the level of self-confidence which could be
maintained, but factors influencing overall QoL
went beyond pad performance alone, impacting
on psychological and social functioning across the
spectrum of personal relationships, working lives
and wider social interfaces. 
This study makes an important new addition to a
previously, poorly, researched aspect of living with
incontinence. The consistencies of findings
suggest that the findings could be potentially
generalisable to a wider population of women and
men using these products. The study has
identified key domains which should be included
in the development of a QoL instrument for pad
users. By encompassing both positive and negative
aspects of pad use, this should enable the final
QoL measure to establish the ‘net gain’ to be
achieved by different absorbent products. This
model has not been applied to incontinence-
specific QoL tools to date, which have focused on
the effects of urinary symptoms alone. 
Limitations and next steps
The current study was limited to women using
products for light incontinence and women and
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incontinence. It is acknowledged that there may
be different issues and priorities for lightly
incontinent men. The next step will be to compare
data from different population groups to develop
a QoL questionnaire, based on the identified
domains. This draft QoL measure will be
subjected to a cycle of field testing, refinement
and psychometric analysis to determine its value
in clinical practice and as a research and
development tool. 
Conclusions
The study provides important new insights into
critical issues affecting women’s and men’s
experiences of containing incontinence with
absorbent pads. The findings support the need for
the development of a QoL outcome measure for
pad users and key domains for inclusion have
been identified. A more sensitive, patient-oriented
QoL instrument would contribute to improved
continence care and user satisfaction, through
more informed choices on appropriate products
for particular users and their circumstances. Such
a measure would also provide a broader
perspective on product use to inform new product
development and effective product evaluation
methodologies. 
The next stage will involve the development of
questionnaire items such as ‘How much does
wearing this pad affect your clothing choices?’ and
‘How much does this pad seem like your normal
underwear?’ Further stages will involve processes
of validation and reliability testing to produce a
quality of life tool suitable for research and clinical
purposes.
Implications for clinical practice
Users, purchasers and carers need
comprehensive, evidence-based guidance to
help inform their choice of products from the
wide and constantly changing range available on
the market. This study has shown that the
impact of living with absorbent pads goes
beyond pad performance characteristics alone
and users could benefit from advice, not only on
the range of pads available, but also on
strategies to reduce associated anxieties and
practical aspects of coping. Continence
assessments should include recognition of
lifestyle issues that may influence advice on
most suitable products for individuals. For those
users who buy their own pads and are unknown
to continence services (two-thirds in this study),
there is a need to find other ways of
offering/disseminating appropriate advice. This
may include stronger working relationships with
manufacturers and suppliers. In summary, the
practical outcomes of this work include
identifying and understanding issues for people
managing incontinence with absorbent pads, the
initial stages of development of a QoL tool that
can be applied to a treatment (or treatments)
where no change in symptoms is expected and
identification of QoL issues that should be used
to inform new/improved continence product
development and evaluation. 
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his study comprised three clinical trials of
washable and disposable designs of body-worn
absorbent pads and the first stage of the
development of QoL tool for people with
incontinence who use absorbent pad management.
Each chapter has its own discussion, study
limitations and conclusions section, but issues that
apply more generally or cut across the trials are
discussed here.
Study limitations
Participant drop-out during trials and
analysis 
In all three trials, participants dropped out of the
study during the course of the study and progress
and attrition of subjects are shown within each
module. Ill-health was a common reason, as was
‘too much bother/effort’, particularly for
participants in the community with
moderate/heavy incontinence who tested products
for the longest period (14 weeks). Future trials
should aim for a shorter testing period (if
possible) to avoid this problem. 
For data analysis, the usual practice in a parallel
group randomised controlled trial would be to
carry out an intention-to-treat analysis to include
data from all participants who started the study.
This would usually require imputing data obtained
at baseline (or at the last recorded time before
drop-out) to the final outcomes. The main reason
for this is because participant drop-out may well
relate to the intervention (such as lack of efficacy
or side-effects) and participants who drop out may
therefore be expected to have worse outcomes
than those who do not; it would therefore be
important to include them in the analysis to avoid
bias.
In our trials data from participants who did not
complete testing of all designs were not included
in the analysis. We encouraged participants to test
all designs and gave them the opportunity to
cease testing any particular design (however short
the test period) and move on to the next design.
Probably as a result of these efforts, very few
participants dropped out for product/design-
related reasons and it is not obvious how removal
of these participants from the analysis could bias
the results. Inclusion of these participants presents
problems for the analysis in two ways. First, it is
not possible to impute data from designs that a
participant has tested to designs that they have
not tested. Crossover design analysis requires data
from each participant from all test periods (i.e.
from all designs) and participants who only
provide partial data weaken the power of the
study. New recruits are therefore needed until the
target number for each trial is reached, with each
participant providing data from all test periods
(designs). Second, most participants who dropped
out did not provide any data on the designs
because they did not return their data collection
booklets, or those that they did return were
unusable. It was anticipated that it would not be
possible to use data from participants who did not
complete the study and so there was over-
recruitment to ensure that there were sufficient
participants to meet the target numbers with data
in all testing periods. 
Final interview and recall bias
The length of product testing (12 weeks or more
for participants in the community) meant that by
the time participants had their final interview
(usually within 4 weeks after testing), many weeks
would have passed since the participant tested
products at the beginning of the study. There was
therefore potential for recall bias. To minimise
dependence on recall, the data collection booklets
containing the participants’ product performance
scores (including ‘overall opinion’) and written
comments about the products were reviewed with
the participants at their final interviews. The
products were displayed to aid memory and
participants were asked to consider their scores
and comments before comparing the designs and
giving their final ‘overall opinion’ scores and
preferences. In practice, we did not find that
participants had many problems with recall and
most had formed firm opinions about the designs
and their preferences.
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Chapter 7
Discussion, conclusions, implications for healthcare 
and recommendations for future researchOutcome measures
There is no single tool for evaluating the
performance of absorbent products. Tools were
constructed based on outcomes and validated
questionnaires used in previous studies8,11 of
absorbent products and, to add to the validity of
these items, the data obtained from the
preliminary participant interviews were used to
determine and prioritise questionnaire items.
However, it is recognised that assessment of
product performance would be enhanced with a
tool to measure the impact that product
performance has on QoL and part of this study
was designed to begin the process of producing
such a tool. The interviews with participants to
establish their priorities and to identify the impact
that absorbent pads have on their QoL showed
strong consistency between participants in the
community-based trials, with similar issues being
raised and similar priorities being rated highly for
women with light incontinence and men and
women with moderate/heavy incontinence. It may
therefore be possible to develop a single tool that
can be used for participants with different levels of
incontinence and this will improve measurement
of product performance in future clinical trials. 
Leakage performance data for all trials were
obtained by saving and weighing used pads and
recording leakage severity. In the nursing homes,
research staff (and sometimes trained volunteer
staff) carried out the weighing to improve
reliability and reduce the burden on care staff.
However, these data are demanding for
community participants because the process needs
to be done frequently, is not very pleasant to carry
out and can be impossible to achieve in certain
circumstances (e.g. when out of the house).
Because collecting pads is difficult for most people
to achieve continuously, we did not require
participants to collect all pads, but asked them to
collect as many as possible. Where patients tested
products for shorter periods (because they
stopped testing products early), fewer data were
collected and therefore there were fewer data for
less popular products such as washables. The
leakage performance data were used to construct
leakage performance curves, and accuracy
increases with number of products. It is therefore
likely that these curves are less reliable where
fewer products were used, but it should be noted
that the smallest number of products collected
from a single design exceeded 600 and a
minimum of 300 products were required for the
modelling. Bias may have occurred if participants
saved and weighed more pads that did (or did
not) leak from one particular design than another,
when they had a particularly small or large urine
mass, but this would have required systematic
effort on behalf of participants and is not a likely
scenario. The volume of urine in the pad will
generally have been somewhat underestimated
because some urine will have been lost through
leakage or (less so) through evaporation, and this
is likely to have affected the poorer performing
designs (for leakage) more than the better designs. 
Discussion
Provision of absorbent products in 
the UK
In the UK, current absorbent product practice
focuses on the provision of disposable body-worn
products, with the insert design predominating
(for both light and moderate/heavy incontinence),
but with a growing provision of diapers (mainly for
heavier incontinence). There is no clear evidence
to inform assessment for individual needs.
Washables represent a very small share of the
market and, where these are provided, they are
usually for light incontinence. However, a small
minority of nursing homes have changed their
absorbent pad management mostly or entirely to
washables. Interest in the provision of washables is
generally increasing for cost reasons and also
because they are perceived as more environmentally
friendly, although this may not be the case.49
Disposable designs for moderate/heavy
incontinence: comparisons between
community and nursing home results
Two of the trials (Chapters 4 and 5) included
disposable designs for moderate/heavy
incontinence and showed similar findings. The
nursing home trial included more women than
men (71 versus 29) and participants had limited
or no mobility and had physical and mental
disabilities; analysed results were the responses of
carers (who were predominantly women). The
community trial included more men than women
(49 versus 36) and participants were mainly
mobile and independent, and gave their own
responses. Results from both trials showed that the
leakage performance of the inserts was worse than
that of the other designs for both day and night
(although this was shown more in carer responses
in the nursing home trial than in pad leakage
data) and pull-ups were significantly better than
inserts for the daytime. Gender was significant for
most variables in the community trial and in the
final interview data for the nursing home trial.
Further analysis by gender showed similar findings
in both trials. The pull-ups were found to be
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than the other designs for preference and
acceptability for women for the daytime. There
were indications from both trials that for men
diapers were preferred to other disposable 
designs during the daytime and that they were
significantly preferred to other disposable 
designs at night. The surprising indication from
the community trial that women preferred inserts
over diapers for day (but less strongly for night) 
is not apparent in the nursing home results, but
inserts did better for preference during the
daytime than might be expected from their poor
leakage results (33 diapers versus 39 inserts). 
This may be a reflection of the advantage of
inserts being found to be easier to put on in the
standing position (during the day) than the
diaper. During the night (when this advantage was
lost), diapers were significantly preferred to
inserts. 
These combined findings show that pull-ups are
the design of first choice for women in the
community and in nursing homes, during the
daytime, but they are relatively expensive. The
cheaper alternative for women would be the
insert or diaper. There are indications that the
insert would be a better second choice than the
diaper (discreet, easier to change by carer and
preferred by community women generally), but
they leak more, and more products may be
needed (in the community), or inserts with 
higher absorbency may be required to improve
leakage performance, which would increase cost.
For the night-time, pull-ups are still the first
choice for women in the community, with
indications that the insert is still preferable to 
the diaper as a second choice, although the 
same issues with increased leakage and cost 
will apply. The diaper design is the most cost-
effective for women for night-time use in 
nursing homes, but it should be borne in mind
that some women may prefer inserts (and dislike
diapers) and where possible residents should be
consulted regarding their choices. 
For men in the community and in nursing homes,
the most cost-effective design is the diaper for
both day- and night-time. There are indications
that carers and men prefer the diaper to the pull-
up, particularly at night. The insert is significantly
and substantially worse than the diaper for men
for day and night (and may perform worse for
men than women). Men had substantially higher
urine losses than women and may need products
with higher absorbency (or better products; see
below) to reduce leakage. 
Improvements still needed for
disposables
Although the pull-up appears to be a considerable
advance for disposable designs, its performance
and appeal are better for women. For men there is
no such comparable product. Although the diaper
was the preferred design for men, it has
limitations (e.g. sweatiness) and a baby-like
appearance; a more masculine product, designed
with the male anatomy in mind, is needed.
Improvements still needed for
washables
The findings from this study indicate that
washables have more potential than is reflected by
current practice, but that there is a need for more
product development to improve their function
(particularly for women with light incontinence)
and aesthetics (particularly for moderate/heavy
incontinence, and particularly for women).
Increase in washable product use is likely to be
limited until improvements are made.
Washables in nursing homes
Washables were not tested in nursing homes, but
findings from the community-based trials are
useful to consider in the context of nursing
homes. These showed that very few women found
the washable products (in their current form) to be
acceptable and opinions were strongly divided
among men. It is therefore difficult to justify
ethically the general introduction of washables for
moderate/heavy incontinence to nursing homes
until products have improved and until there is
evidence that more people (particularly women)
find them acceptable.
Washable–disposable combinations
Even with better performance and aesthetics,
washables are more problematic to deal with than
disposables, particularly outside the home, where
managing wet products is a difficult problem.
Combinations of disposables and washables are
likely to be a better option, with washables
playing a greater part while at home, and at night
(particularly for heavy incontinence) when
discreetness is less of an issue and bulkier
products can be used. This approach would also
reduce the laundry burden of washables, which
would be considerable and probably intolerable
for many (particularly with heavy incontinence), 
if washables were used all the time. 
Offering variety and choices
NHS rhetoric is that it wants to be a consumer-
driven service, so in the context of continence
supplies people with the capacity to choose for
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voucher and allowed to select the combination of
products that is most efficient for them. This
would enable users to choose combinations of
designs (both cheaper and more expensive,
disposable and washable) for their different
circumstances (home and when out, holidays and
‘best’). The provision of an NHS ‘shop’ to buy
supplementary products at cheaper prices (due to
the buying power of the NHS) would also reduce
costs to users. The incontinence product market is
large and competitive and manufacturers will have
the incentive to develop products to meet
consumers’ tastes and preferences at realistic
prices.
NHS provision
The NHS Supply Chain expects to purchase for an
increasing proportion of the total adult
incontinence market in the next few years. There
is a tension between reducing product choice in
order to maximise bulk purchasing discounts and
the need to increase the product range to meet
the diverse preferences of NHS consumers.
Analysis of the product portfolio offered by NHS
Logistics in the last 2 years shows that it has
reduced the number of manufacturers with which
it contracts. The range of inserts on offer has been
reduced, but the number of T-shaped products (a
relatively new line) has increased. The number of
diaper products has not altered. Prices have risen
across the board due to increases in the cost of
basic inputs, but technological advances mean that
there is excess capacity in the industry. As a result,
the potential to sell to the large NHS market is
likely to keep manufacturers keen to compete for a
hefty share of it by a combination of price and
non-price means. 
Quality of life
Interviews with participants for the first stage in
the development of a QoL tool for assessing the
performance of absorbent products show that
absorbent pad management is fraught with
anxieties and practical problems, but the provision
of effective products can do much to alleviate this
burden. Further development of this tool is
needed to permit better evaluation of products in
the future. 
Conclusions
This study showed that there were significant and
substantial differences between the designs of
absorbent products and for moderate/heavy
incontinence some designs are better for
men/women than others. There was considerable
individual variability in preferences, and cost-
effective management may best be achieved by
allowing users to choose combinations of designs
for different circumstances within a budget.
Implications for healthcare
There is evidence that:
1. A range of disposable and washable designs
need to be provided to meet cost-effectively the
needs of men and women with incontinence.
2. Men may require more, or more absorbent,
products than women.
3. Although some users prefer washables, current
products have important limitations and
restricting the range of available products to
washable designs alone is not recommended.
4. Allowing men and women to choose
combinations of designs for day and night and
for different circumstances, within a limited
budget, is likely to be economical for the NHS.
Recommendations for research
1. Translational research: to pilot the feasibility of
providing choice and combinations of designs
to users.
2. Development of more effective washables for
women with light incontinence and more
effective and appealing (particularly to women)
washables for moderate/heavy incontinence.
3. Development of specifically male disposable
products for moderate/heavy incontinence.
4. Further development of a tool to measure QoL
for users of absorbent products.
5. Clinical trial of designs for community-dwelling
carer-dependent men and women with
moderate/heavy incontinence.
Discussion, conclusions, implications for healthcare and recommendations for future research
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he aim was to select three products that were
similar to each other within each design group.
The four designs are: menstrual pads (MPs),
disposable inserts (DIs), washable pants with
integral pants (WPs) and washable inserts (WIs). 
Previous data from the Continence Product
Evaluation (CPE) network studies on the DIs and
WPs were available to help make a selection of
three products to represent the design in module
product selections.
Selection of disposable inserts
The data from a previous CPE network study11
provided evidence on which to base our product
selection. The most successful pads in this study
(based on overall opinion scores) were:
● Indas Indasec Grande 
● Ontex Euron Micro Extra Plus
● SCA Tena Comfort Mini Extra
● Contisure Premium Micro Plus
● Prevail Extra Plus
● Anamini Extra
● Tender Light Extra.
The following products were rejected:
Contisure Premium Micro Plus, sold by Shiloh but
made by Ontex, is identical to the Microflex
Super; Prevail Extra Plus had variable scores, was
either loved or hated, and it was much smaller
than others; Anamini Extra – ID Medica were
taken over by Ontex and it is the same product as
the Microflex Super sold under another name;
Tender Light Extra (Tanner Brothers), which were
much larger and more rectangular than the others.
Selected products
● Indas Indasec Grande
● Ontex Euron Micro Extra Plus 
● SCA Tena Lady Extra (now called Tena Comfort
Mini Extra). 
Selection of menstrual pads
There were no recent evaluations on which to base
the selection of these products. We therefore
searched the market for any suitable products.
MPs can be categorised into two main types, thick
and thin.
It was decided that the newer thin pads may be
less acceptable than thicker products.The thicker
products are shown in the table below; we selected
night-time products of a similar size and these are
shaded in the table. 
Selected products
● Always Maxi Night
● Kotex Maxi Night Time
● Boots Body-Shaped Night-time Pads.
Selection of washable pants with
integral pad
There are data from a recent study carried out by
the CPE Network.8 In this study, the full range of
WPs available on the UK market were tested. This
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Appendix 1
Trial 1: method of product selection
Name Wings Manufacturer Place bought Price (£) Quantity  Night-time
in pack
Pennywise No SCA Co-Op 0.99 10 Yes
Always Maxi No P&G Co-Op  1.89 10/12 Yes
Safeway 1.41
Always Maxi Long Plus No P&G Boots 1.89  14 No
Bodyform Classic Yes SCA Co-Op Pharmacy 1.78 14 No
Kotex Maxi No Kimberly Clark Safeway  1.49 10 Yes
Boots No ? Boots 0.99 12 Yes
Always Maxi Long No P&G Boots 1.59 14 Nostudy provides the most up-to-date evidence-based
product performance data available. The best
performing pants with integral pad were identified
from this study:
● Ganmill Duofem Elite
● Robinsons Activ Pants
● Kylie Super Pants
● Kylie Extra Pants
● Kylie Standard Pants.
We established that the size of the garment did
not make a difference to the size of the absorbent
pad, that is, the pad was the same size regardless
of whether the pant was small, medium, large or
extra large.
However, for one brand (Kylie), the style of the
pant (e.g. high leg or full pant) does make a
difference to the size of the pad; therefore, it was
decided that unlike in the CPE network study, only
one style would be offered to participants. This
was thought to be acceptable to participants, as
75% had chosen the full pant in the previous
study.
There has also been a change to the design of the
Kylie range since the previous study. When all
three types of Kylie pants were examined (Extra,
Super and Standard) it was noted that all of the
absorbent pads were thinner (and therefore
presumably had less absorbent capacity) than the
ones tested previously. In order to choose ‘best’
pants, it was judged that the Kylie Extra pant (the
most absorbent) should be selected.
Selected products
● Kylie Extra Pants
● Robinsons Activ Pants
● Ganmill Duofem Elite.
Selection of washable insert
There are no previous evaluations on which to
base the selection of WI products. We therefore
searched the market for any suitable products and
asked Promocon to advise us on the washable
inserts (for light incontinence) of which they were
aware. The search found the following products
that were suitable for light incontinence:
● PHP Multi Use Mini Pads 
● Milton Stay Dry Contenta Repeat Liners 
● Martex (EMS Medical) Micro Liner. 
As only three products were suitable, all three were
used in the pilot study; the products were of
similar size and design.
Appendix 1
132In all tables below, an X indicates that a product was significantly worse (very good + good + OK) vs
(poor + very poor) than another product(s) (initial(s) shown in brackets).
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Appendix 2
Trial 1: product performance questionnaires
(results for each product in a design)
Menstrual pads
Boots Kotex Always
Leakage Very  good 18 13 16
(day) Good 28 21 25
OK 23 34 34
Poor 24 20 16
Very poor 6 12 10
Leakage Very  good 19 14 15
(night) Good 22 21 25
OK 31 32 34
Poor 19 23 19
Very poor 9 9 7
Stay in  Very good 24 11 19
place (day) Good 32 40 39
OK 33 39 36
Poor 10 11 5
Very poor 1 0 1
Smell Very good 8 4 8
Good 25 25 22
OK 49 44 46
Poor 15 20 16
Very poor 2 7 7
Discreet Very good 14 12 19
Good 29 34 34
OK 40 35 35
Poor 14 16 9
Very poor 2 2 2
Menstrual pads
Boots Kotex Always
Dry Very  good 23 14 22
comfort Good 31 42 40
OK 56 34 29
Poor 10 8 6
Very poor 1 1 2
Wet Very  good 5 5 7
comfort Good 29 21 25
OK 31 39 35
Poor 25 24 25
Very poor 11 10 8
Keep skin  Very good 11 6 6
dry Good 29 24 27
OK 36 42 45
Poor 20 23 15
Very poor 4 6 7
Overall Very  good 19 18 16
opinion Good 27 19 27
(day) OK 20 32 34
Poor 22 19 13
Very poor 12 12 9
Overall Very  good 13 20 22
opinion Good 41 25 26
(night) OK 14 27 40
Poor 19 X (A) 17  7
Very poor 13 12 5Appendix 2
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Disposable inserts
Tena Indasec Euron
Leakage Very  good 33 37 28
(day) Good 35 30 29
OK 24 25 29
Poor 6 4 11
Very poor 2 5 2
Leakage Very  good 35 43 30
(night) Good 32 25 33
OK 24 26 25
Poor 5 5 9
Very poor 3 2 3
Stay in  Very good 33 29 21
place  (day) Good 38 38 27
OK 21 27 44
Poor 4 5 7
Very poor 0 1 1
Smell Very good 21 24 15
Good 44 27 28
OK 27 35 44
Poor 7 12 11 
Very poor 1 2 2
Discreet Very good 22 13 14
Good 27 27 16
OK 36 36 35
Poor 13 21 31 X (T)
Very poor 1 2 4
Dry Very  good 33 28 18
comfort Good 42 41 40
OK 21 27 33
Poor 4 4 7
Very poor 0 0 2
Wet Very  good 15 16 15
comfort Good 27 28 21
OK 43 41 39
Poor 10 12 18
Very poor 5 2 7
Keep skin  Very good 22 24 18
dry Good 38 35 28
OK 29 35 41
Poor 7 6 8
Very poor 4 0 5
Overall Very  good 44 41 26
opinion Good 35  28 33
(day) OK 15 21 26
Poor 5 8 11 X (T)
Very poor 1 1 5
Overall Very  good 48 52 37
opinion Good 35 24 28
(night) OK 8 19 23
Poor 5 3 8
Very poor 3 2 5
Washable pants with 
integral pad
Robinsons Kylie Duofem
Leakage Very  good 15 8 7
(day) Good 21 25 23
OK 12 26 21
Poor 27 24 25
Very poor 25 18 23
Leakage Very  good 11 6 13
(night) Good 23 22 21
OK 28 33 23
Poor 17 12 19
Very poor 21 27 25
Stay in  Very good 34 21 23
place (day) Good 36  30 44
OK 23 43 23
Poor 5 6 9
Very poor 3 0 3
Smell Very good 11 5 8
Good 14 14 24 
OK 31 38 31
Poor 26 31 31
Very poor 18 12 6
Discreet Very good 22 11 20
Good 42 20 41 
OK 20 39 23
Poor 16 18 X (R&D) 15
Very poor 0 13 1
Dry Very  good 38 21 27
comfort Good 31 25 41 
OK 25 35 26
Poor 5 13 X (R&D) 4
Very poor 1 6 2
Wet Very  good 6 6 8
comfort Good 16 10 16
OK 22 30 23
Poor 40 30 32
Very poor 16 25 22
Keep skin  Very good 9 5 8
dry Good 19 14 18
OK 29 31 24
Poor 25 35 30
Very poor 19 16 21
Overall Very  good 19 9 15
opinion Good 17 20 20
(day) OK 23 20 25
Poor 21 33 25
Very poor 20 19 16
Overall Very  good 21 13 14
opinion Good 23  10 25
(night) OK 15 29 24
Poor 21 23 22
Very poor 21 25 16Health Technology Assessment 2008; Vol. 12: No. 29
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Washable inserts
Martex Contenta PHP
Leakage Very  good 1 0 6
(day) Good 11 12 8
OK 16 23 20
Poor 30 23 28
Very poor 41 42 37
Leakage Very  good 0 0 8
(night) Good 13 11 12
OK 23 32 19
Poor 32 24 35
Very poor 32 34 27
Stay in  Very good 1 3 8
place (day) Good 10 9 19
OK 20 20 27
Poor 38 X  31 X  31
(PHP) (PHP)
Very poor 31 36 14
Smell Very good 2 2 1
Good 8 13 11
OK 43 43 42
Poor 28 33 26
Very poor 18 10 20
Discreet Very good 10 10 7
Good 25 15 33 
OK 52 48 43
Poor 10 23 X (M) 12
Very poor 4 5 5
Dry Very  good 8 8 10
comfort Good 23 20 29
OK 44 49 48
Poor 17 20 12
Very poor 8 3 2
Wet Very  good 0 0 1
comfort Good 12 7 7
OK 24 36 27
Poor 25 34 32
Very poor 39 23 32
Keep skin  Very good 2 2 4
dry Good 8 7 5
OK 23 36 33
Poor 36 34 33
Very poor 30 21 27
Overall Very  good 2 0 6
opinion Good 8 11 12
(day) OK 23 18 13
Poor 29 34 35
Very poor 37 36 35
Overall Very  good 6 2 10
opinion Good 8 10 10
(night) OK 30 24 23
Poor 30 37 31
Very poor 26 27 27R
eusable products incur two additional costs on
the users: first, costs arise from laundering the
washable products themselves; and second, users
report higher leakage from reusable products,
requiring the laundering of additional pieces of
clothing. 
The modal usage rate reported at baseline (four
products per 24 hours) suggests that 28 WPs or
WIs would be laundered per week. The mean dry
weight of WIs is 20 g. WPs are made in a variety of
sizes with mean dry weights ranging from 40 to
80 g. For the purpose of this costing exercise, a
dry weight of 60 g is used for WPs. The dry weight
of laundry generated per week is therefore 560 g
for WIs and 1680 g for WPs. 
Excess laundry generated by washable products
compared with disposables is equivalent to 5.6
small items for WPs and 14 small items for WIs
(larger items reported by participants were
weighted 2). Assuming that small items weigh
50 g, the weekly laundry caused by leaks for WPs
and WIs is 280 g and 700 g, respectively.
The total extra weekly laundry associated with WPs
and WIs is therefore 1960 and 1260 g, respectively.
The load of absorbent materials recommended for
domestic washing machines is 7 lb (3100 g). This
means that at the end of 1 week, use of WIs and
WPs rather than disposable products would create
40 and 54% of a full washing machine load,
respectively.
The cost of running a washing machine varies with
the make and age of the machine, the
temperature, detergents used and wash
programme chosen. It has been estimated that the
cost of detergent and electricity for a middle-
range machine and programme is £0.30.
Depreciation and maintenance would be a further
£0.10 per week (assuming incontinence products
were 10% of all washing and a 10-year machine
life). The cost of one machine load per week is
therefore about £0.40 or £1.60 per month.
(www.wen.org.uk/nappies/cost_comparison,
accessed 6 October 2006). 
The costs of tumble drying are not included as
most women (80%) reported that they did not use
this method and because tumble drying is not
advised for products with plastic backings.
These calculations are a maximum estimate. If
incontinence-related laundry was washed
separately from other laundry, the washing
machine would not be full and a cheaper economy
programme could be used. If incontinence items
were washed with others, the cost of the full load
would be shared. It is possible that women would
not want to wash all incontinence items together
just once a week as this would entail storing used
products (which could cause odour) and also
holding stocks of at least 32 products. In fact,
most women reported that they washed
incontinence-related items with other pieces of
laundry, which could be done at small additional
cost (unless every load is full), or by hand. In
addition, the estimates are based on use of four
products per 24 hours, whereas the actual use was
three. 
Conclusion
There are many elements of uncertainty in the
estimation of the extra laundry costs associated
with using reusable products. For the purposes of
the cost-effectiveness analysis, we used a relatively
high estimate of £0.25 per week or £1 per month. 
Health Technology Assessment 2008; Vol. 12: No. 29
137
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Appendix 3
Trial 1: calculation of the extra laundry costs 
associated with reusable productsT
he five main designs of absorbent products
included in the study are as follows:
● disposable inserts 
● disposable diapers
● disposable pull-ups
● disposable T-shaped diapers 
● washable body-worn (various designs). 
Selection of disposable products
Information from PASA (data supplied June 2006)
shows that inserts are the most commonly
purchased design, followed by diapers. There is
much less purchasing of pull-ups and T-shaped
products, which are more recent designs. PASA
data show that the most commonly purchased
inserts are in bands I10 and I11 (14 million and
10 million p.a.). The most commonly purchased
diaper is in band D15 (7 million p.a.). 
The aim of selecting products for inclusion in the
study was to match closely the absorbent capacity,
as measured by Rothwell score,17 of products from
each of the design groups. This would therefore
test the effect of design on product performance
(rather than absorbency). The aim was also to
reflect clinical practice by including products with
Rothwell scores most commonly purchased. 
We were unable to match products across the
disposable design groups with Rothwell scores
within I10 (1250–1499 g) or I11 (1500–1799),
which are the most commonly purchased insert
pads, because there were very few products in the
other design groups with similar scores. We were
better able to match products with Rothwell scores
within D15 (1700–2099 g), which represents the
most commonly purchased diaper, with three of
the four different disposable design groups having
some products within this band, although overall
there were too few products available in all design
groups for selection for the study. By expanding
this band to encompass the range 1520–2280 g
and aiming for a mean Rothwell score of 1900 g,
we were able to identify sufficient products in
three of the four design groups (the T-shaped
designs are only available with higher Rothwell
scores). 
It is common for products of a higher absorbent
capacity to be applied for night-time use. Insert
products within band I13 (2100–2499 g) are
frequently purchased (7.5 million p.a.) and this
level of absorbency is commonly found in diapers,
both the new T-shaped products and the pull-ups.
By aiming for a mean Rothwell score of 2400 g
(±20%, i.e. 1920–2880 g) for night-time use, we
were able to match products from all four
disposable designs. 
Some products have different absorbencies for
different sizes. In this case, we attempted to match
the medium-sized product because we anticipated
that the majority (around two-thirds) of recruited
subjects would be medium sized. 
To select products for inclusion in the study, a
pilot study was carried out of the shortlist of
products identified as above.
Pilot study
Six products were selected from each insert and
diaper design based on matching the Rothwell
capacity of the products: daytime products
1900 ml; night-time products 2400 ml ± 20%.
There is a much more limited range of products
for pull-ups (n = 6) and all products were
therefore piloted. T-shaped products were not
piloted because there were only two available.
Pilot methods
● demographic information
● product performance questionnaire (weekly
product test questionnaires)
● pad leakage diary.
Sample
Ten subjects tested six products from each design
group (30 subjects total).
Analysis
Analysis of the results to select products for
inclusion in the study was made and the following
selection criteria were then applied (in order of
priority):
● Rothwell score within specified range.
● One-third or more of pilot subjects found the
product poor or very poor (product rejected).
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Appendix 4
Trial 2a: pilot study and product selection● Of the remaining products in the group, those
with the highest overall opinion scores were
selected. 
● In the event of products scoring similarly,
products were selected to ensure a range of
prices and inclusion of as many companies as
possible.
Products selected for main study
Inserts
● daytime products: target Rothwell score 1900
(±20%), range 1520–2280 g
● night-time products: target Rothwell score 2400
(±20%), range 1920–2880 g.
Daytime
Night-time
Diapers
Daytime
Night-time
Pull-ups
Daytime
Night-time
T-shaped diapers
Day- and night-time
Selection of washable products
Washable body-worn designs for moderate/heavy
incontinence are rarely purchased by the NHS and
there are few research data to guide product
selection for the study. The ISO standard
(Rothwell score) has not been validated on
reusable products. A pilot study of all 20 available
body-worn products in the UK was published in
200418 and this indicated relatively poor
performance (particularly in the daytime)
compared with disposable products. No design
appeared to be superior to others; however,
designs made from terry-towelling material were
the most successful. The three best performing
products (based on overall opinion) that were still
on the market and represented different designs
of products were selected for inclusion in the
study. These products comprised two terry-
towelling products and one other. It was thought
that the terry-towelling products may perform
similarly and it was decided that study findings for
the non-terry-towelling product (the Martex)
would be analysed separately. 
The washable products selected were:
● Paddy-T (terry-towelling)
● Bullen nappy (terry-towelling)
● Martex Unisex Brief 1000.
Both the terry-towelling products can be made to
different sizes to order. Two sizes of the Paddy-T
and the Bullen nappy were commissioned to
match the medium and large sizes available in
disposable products (70–100 and 105–120 cm).
The Martex product has four sizes which
encompass the same size range.
Manufacturer Product name
Abena Abriwing
SCA Tena Flex Super
(Extra for daytime in nursing
homes)
Manufacturer Product name
Paperpak Attends Supera
Hartmann Molicare mobilea
SCA Tena Pants Super
a Two products were tested during both day- and 
night-time.
Manufacturer Product name
Paperpak Attends Supera
Hartmann Molicare mobilea
Abena Abriflex Extra
a Two products were tested during both day- and 
night-time.
Manufacturer Product name
Shiloh Contifit 
Abena Abri-form plus
Vernagroup Karocare Brief
Manufacturer Product name
Ontex Euron form Ultra
Tyco Lille Supreme fit Regular Plus
Paperpak Attends Slip Extra
Manufacturer Product name
Paperpak Attends contour Super Plus
SCA Tena Comfort Super
Shiloh Contisure Super
Manufacturer Product name
Paperpak Attends contour Super
Abena Abri-san Super 
Hartmann Moliform Plus
Appendix 4
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Appendix 5
Trial 2a: median urine mass in each design, 
combined and by gender
Insert Diaper Pull-up T-shaped Washable 
diaper
Daytime: men and women combined 234.0 294.5 257.0 298.0 414.0
Median urine mass (g)  (128.5–366.5) (189.0–46.3) (147.3–388.0) (171.3–462.8) (268.5–632.0)
(IQ range)
Men 284.0 347.0 303.0 355.0  431.0 
Median urine mass (g) (190.0–415.0) (238.0–491.0) (199.0–445.0) (226.0–543.0) (282.0–662.0)
(IQ range) N = 1245 N = 1525 N = 1286 N = 969 N = 659
Women 147.0 203.0 176.0 186.0  311.0 
Median urine mass (g) (87.3–253.8) (112.0–290.0) (98.0–284.3) (90.0–296.0) (181.0–525.0)
(IQ range) N = 698 N = 671 N = 780 N = 457 N = 160
Number of products 1943 2196 2066 1426 819
Night-time: men and women combined 271.5 363.0 319.0 345.0 511.5 
Median urine mass (g)  (149.0–412.0) (208.0–562.0) (191.0–503.5) (202.8–537.0) (291.3–763.5)
(IQ range)
Men 320.0 442.5 385.0 396.5  545.0 
Median urine mass (g) (189.5–473.0) (286.3–623.0) (234.8–581.3) (264.5–590.3) (326.8–818.3)
(IQ range) N = 587 N = 966 N = 580 N = 576 N = 518
Women 209.0 253.0 250.5 269.5  443.0 
Median urine mass (g) (110.0–347.0) (105.0–391.0) (122.8–402.3) (163.8–395.8) (194.0–590.3)
(IQ range) N = 445 N = 579 N = 432 N = 380 N = 148
Number of products 1032 1545 1012 956 666Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 6
Trial 2a: estimated probabilities of no leakage 
at different urine masses, by gender
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Night: women
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Appendix 7
Trial 2a: leakage performance of designs, by gender
Number of products saved % (N) Daytime (number of subjects N = 85)
Insert Diaper Pull-up T-shaped Washable 
diaper
No leakage 59.9 (1163) 70.7 (1553) 72.6 (1500) 76.6 (1092) 80.1 (656)
Men 56.2 (700) 68.1 (1038) 64.9 (834) 75.1 (728) 79.4 (523)
Women 66.3 (463) 76.8 (515) 85.4 (666) 79.7 (364) 83.1 (133)
A little  25.3 (492) 20.1 (460) 18.7 (387) 17.5 (250) 15.7 (129)
Men 26.7 (332) 22.2 (339) 23.1 (297) 18.3 (177) 17.2 (113)
Women 22.9 (160) 18.0 (121) 11.5 (90) 16.0 (73) 10.0 (16)
A lot  14.8 (288) 8.3 (183) 8.6 (179) 5.9 (84) 4.2 (34)
Men 17.1 (213) 9.7 (148) 12.1 (155) 6.6 (64) 3.5 (23)
Women 10.7 (75) 5.2 (35) 3.1 (24) 4.4 (20) 6.9 (11)
Number of products saved % (N) Night-time (number of subjects N = 85)
Insert Diaper Pull-up T-shaped Washable 
diaper
No leakage 55.5 (573) 60.7 (938) 65.3 (661) 64.4 (616) 85.4 (569)
Men 45.7 (268) 53.1 (513) 55.3 (321) 58.9 (339) 84.2 (436)
Women 68.5 (305) 73.4 (425) 78.7 (340) 72.9 (277) 89.9 (133)
A little  27.9 (288) 27.6 (426) 21.8 (221) 23.4 (224) 11.4 (76)
Men 30.5 (179) 32.3 (312) 25.7 (149) 26.2 (151) 12.6 (65)
Women 24.5 (109) 19.7 (114) 16.7 (72) 19.2 (73) 7.4 (11)
A lot  16.6 (171) 11.7 (181) 12.9 (130) 12.1 (116) 3.1 (21)
Men 23.9 (140) 14.6 (141) 19.0 (110) 14.9 (86) 3.3 (17)
Women 7.0 (31) 6.9 (40) 4.6 (20) 7.9 (30) 2.7 (4)Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 8
Trial 2a: consumption by gender – weighted mean 
number of products used per day/night (SD)
Daytime (N = 85 participants)
Insert Diaper Pull-up T-shaped Washable 
diaper
All participants  2.77 (1.16) 2.70 (1.03) 2.52 (0.92) 2.54 (0.92) 2.01 (0.83)
Men 3.05 (1.21) 2.94 (1.06) 2.75 (0.99) 2.69 (0.97) 2.03 (0.85)
Women 2.36 (0.95) 2.25 (0.77) 2.19 (0.71) 2.26 (0.75) 1.95 (0.75)
Night-time (N = 85 participants)
Insert Diaper Pull-up T-shaped  Washable 
diaper
All participants 1.66 (0.77) 1.51 (0.56) 1.50 (0.55) 1.50 (0.62) 1.21 (0.41)
Men 1.58 (0.66) 1.50 (0.49) 1.50 (0.49) 1.49 (0.51 1.15 (0.34)
Women 1.78 (0.90) 1.53 (0.66) 1.49 (0.63) 1.53 (0.78) 1.36 (0.53)In all tables below, an X indicates that a product was significantly worse (very good + good + OK) vs
(poor + very poor) than the numbered product(s).
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Appendix 9
Trial 2a: product performance questionnaires 
(results for each product in a design)
T-shaped (day) Tena Flex  Abri Wing 
Super (10) (11)
Leakage Very  good 33.9 24.2
Good 33.9 37.9
OK 20.0 22.7
Poor 10.8 12.1
Very poor 1.5 3.0
Stay in  Very good 28.8 28.8
place Good 19.7 31.8
OK 30.3 22.7
Poor 16.7 13.6
Very poor 4.6 3.0
Smell Very good 17.2 16.7
Good 39.1 27.3
OK 39.1 47.0
Poor 4.7 7.6
Very poor 0.0 1.5
Discreet Very good 26.2 19.7
Good 35.4 30.3
OK 26.2 28.8
Poor 6.2 15.2
Very poor 6.2 6.1
Dry Very  good 26.2 25.8
comfort Good 41.5 36.4
OK 20.0 25.8
Poor 9.2 7.6
Very poor 3.1 4.6
Wet Very  good 20.0 10.8
comfort Good 43.1 30.8
OK 27.7 38.5 X (10)
Poor 7.7 18.5
Very poor 1.6 1.5
Keep skin  Very good 20.3 15.2
dry Good 43.8 30.3
OK 29.7 40.9
Poor 6.3 13.6
Very poor 0.0 0.0
Overall Very  good 23.3 22.2
opinion Good 37.0 29.2
(day) OK 21.9 22.2
Poor 17.8 23.6
Very poor 0.0 2.8
T-shaped (night) Abri Wing  Tena Flex 
(24) Super (25)
Leakage Very  good 16.4 23.4
Good 23.0 26.6
OK 32.8 23.4
Poor 19.7 17.2
Very poor 8.2 9.4
Stay in  Very good 21.0 20.3
place Good 25.8 23.4
OK 40.3 34.4
Poor 9.7 18.8
Very poor 3.2 3.1
Smell Very good 9.7 15.6
Good 27.4 25.0
OK 48.4 51.6
Poor 12.9 7.8
Very poor 1.6 0.0
Discreet Very good 12.9 24.6
Good 35.5 29.2
OK 35.5 35.4
Poor 12.9 9.2
Very poor 3.2 1.5
Dry Very  good 24.2 21.9
comfort Good 33.9 39.1
OK 35.5 34.4
Poor 4.8 3.1
Very poor 1.6 1.6
Wet Very  good 8.1 14.0
comfort Good 30.7 35.9
OK 41.9 35.9
Poor 16.1 12.5
Very poor 3.2 1.6
Keep skin  Very good 8.1 12.7
dry Good 29.0 31.8
OK 43.6 46.0
Poor 19.3 7.9
Very poor 0.0 1.6
Overall Very  good 20.0 20.6
opinion Good 21.4 24.7
(night) OK 34.3 30.1
Poor 14.3 16.4
Very poor 10.0 8.2Appendix 9
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Washables (day) Martex Brief 1000a Bullen Nappy  Paddy T 
(12) (terry-towelling) (terry-towelling) 
(13) (14)
Leakage Very  good 2.6 30.9 21.1
Good 15.8 23.6 43.9
OK 26.3 X (13 and 14) 25.4 19.3
Poor 26.3g 10.9 10.5
Very poor 29.0 9.1 5.2
Stay in place  Very good 26.3 10.7 15.5
Good 29.0 26.8 32.8
OK 42.1g) 28.6 X (12 and 14) 32.8 
Poor 0.0 17.9 12.1
Very poor 2.6 16.1 6.9
Smell Very good 7.9 7.3 5.4
Good 18.4 23.6 32.1
OK 57.9 40.0 33.9
Poor 10.5 14.6 17.9
Very poor 5.3 14.6 10.7
Discreet Very good 0.0 1.8 1.7
Good 10.8 5.3 5.1
OK 35.1 15.8 19.0
Poor 27.0 28.1 36.2
Very poor 27.0 49.1 37.9
Dry comfort Very good 21.1 26.3 20.3
Good 18.4 31.6 32.2
OK 34.2 X (13) 28.1 37.3
Poor 18.4 8.8 3.4
Very poor 7.9 5.3 6.8
Wet comfort Very good 2.6 9.3 5.3
Good 10.5 13.0 14.0
OK 42.1 40.7 47.4
Poor 31.6 13.0 22.8
Very poor 13.2 24.1 10.5
Keep skin dry Very good 2.6 7.4 1.8
Good 18.4 13.0 25.0
OK 31.6 38.9 39.3
Poor 31.6 20.4 21.4
Very poor 15.8 20.4 12.5
Overall opinion (day) Very good 0.0 11.9 11.9
Good 19.1 16.4 22.4
OK 14.3 X (14) 19.4 23.4
Poor 26.2 16.4 16.4
Very poor 40.5 35.8 25.4
a We excluded the Martex product from any of the combined analyses (shaded) because it was not similar to the two 
terry-towelling products.Health Technology Assessment 2008; Vol. 12: No. 29
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Washables (night) Bullen Nappy Paddy T Martex Brief 
(terry-towelling) (terry-towelling)  1000a
(26) (27) (28)
Leakage Very  good 34.0 41.5 3.0
Good 34.0 22.6 3.0
OK 18.9 24.5 12.1 (X 26 and 27)
Poor 7.6 3.8 33.3
Very poor 5.7 7.6 48.5
Stay in place  Very good 14.8 18.2 29.4
Good 37.0 34.6 26.5
OK 20.4 29.1 29.4
Poor 14.8 7.3 8.8
Very poor 13.0 10.9 5.9
Smell Very good 11.3 5.6 6.1
Good 24.5 27.8 6.1
OK 35.9 37.0 60.6
Poor 15.1 22.2 21.2
Very poor 13.2 7.4 6.1
Discreet Very good 3.9 0.0 0.0
Good 0.0 14.8 11.8
OK 23.1 24.1 38.2
Poor 34.6 27.8 29.4
Very poor 38.5 33.3 20.6
Dry comfort Very good 27.8 27.3 20.6
Good 37.0 36.4 20.6
OK 18.5 20.0 26.5 X (26 and 27)
Poor 5.6 7.3 23.5
Very poor 11.1 9.1 8.8
Wet comfort Very good 15.1 11.1 6.1
Good 17.0 16.7 6.1
OK 37.7 42.6 36.4 X (26 and 27)
Poor 15.1 18.5 21.2
Very poor 15.1 11.1 30.3
Keep skin dry Very good 7.7 7.7 3.0
Good 21.2 21.2 15.2
OK 25.0 34.6 21.2 X (27)
Poor 32.7 25.0 33.3
Very poor 13.5 11.5 27.3
Overall opinion  Very good 25.8 25.0 0.0
(night) Good 25.8 26.7 8.1
OK 9.7 16.7 8.1 X (26 and 27)
Poor 9.7 10.0 32.4
Very poor 29.0 21.7 51.4
a We excluded the Martex product from any of the combined analyses (shaded) because it was not similar to the two 
terry-towelling products.Appendix 9
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Diaper (day) Lille Kendall Supreme  Euron Form  Attends Slip 
Fit Regular Plus  Ultra  Extra 
(4) (5) (6)
Leakage Very  good 13.6 16.4 32.8
Good 30.3 24.6 26.6
OK 34.9 27.9 X (6) 26.6
Poor 15.2 21.3 10.9
Very poor 6.1 9.8 3.1
Stay in place  Very good 11.9 18.8 21.5
Good 34.3 42.2 32.3
OK 37.3 28.1 35.4
Poor 13.4 7.8 9.2
Very poor 3.0 3.1 1.5
Smell Very good 7.6 11.1 14.1
Good 33.3 19.1 42.2
OK 50.0 61.9 37.5
Poor 7.6 3.2 6.3
Very poor 1.6 4.8 0.0
Discreet Very good 11.9 15.6 18.5
Good 28.4 37.5 32.3
OK 35.8 28.1 33.9
Poor 20.9 12.5 13.9
Very poor 3.0 6.3 1.5
Dry comfort Very good 16.7 18.8 25.4
Good 37.9 45.3 39.7
OK 40.9 28.1 27.0
Poor 3.1 6.2 7.9
Very poor 1.5 1.6 0.0
Wet comfort Very good 4.6 9.5 7.9
Good 22.7 23.8 39.7
OK 56.1 38.1 39.7
Poor 13.6 19.1 11.1
Very poor 3.0 9.6 1.2
Keep skin dry Very good 3.1 6.4 11.1
Good 34.4 25.4 38.1
OK 37.5 38.1 (X 6) 39.7 
Poor 20.3 23.8 11.1
Very poor 4.7 6.4 0.0
Overall opinion (day) Very good 8.2 14.3 25.4
Good 26.0 25.7 36.6
OK 38.4 31.4 X (6) 19.7
Poor 15.1 17.1 12.7
Very poor 12.3 11.4 5.6Health Technology Assessment 2008; Vol. 12: No. 29
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Diaper (night) Shiloh Contifit  Karocare  Abri-Form Plus
(18) All-in-One Brief  (20)
(19)
Leakage Very  good 4.8 11.1 13.9
Good 38.7 25.4 40.0
OK 33.9 42.9 23.1
Poor 16.1 15.9 18.5
Very poor 6.5 4.8 4.6
Stay in place  Very good 4.3 9.5 13.9
Good 49.2 46.0 35.4
OK 22.2 27.0 27.7
Poor 7.9 12.7 15.4
Very poor 6.4 4.8 7.7
Smell Very good 6.5 9.7 9.1
Good 32.3 29.0 30.3
OK 46.8 38.7 34.9
Poor 9.7 19.4 22.7
Very poor 4.8 3.2 3.0
Discreet Very good 7.9 14.3 15.4
Good 41.3 28.6 36.9
OK 33.3 42.9 26.2
Poor 12.7 11.1 15.4
Very poor 4.8 3.2 6.2
Dry comfort Very good 14.1 15.9 15.4
Good 45.3 33.3 49.2
OK 31.3 41.3 29.2
Poor 4.7 7.9 3.1
Very poor 4.7 1.6 3.1
Wet comfort Very good 3.2 7.9 9.1
Good 27.0 34.9 27.3
OK 49.2 31.8 37.9
Poor 11.1 19.1 19.7
Very poor 9.5 6.4 6.1
Keep skin dry Very good 3.2 4.8 10.6
Good 35.5 31.8 34.9
OK 35.5 34.9 30.3
Poor 17.7 22.2 16.7
Very poor 8.1 6.3 7.6
Overall opinion  Very good 5.6 8.6 11.0
(night) Good 38.0 28.6 30.1
OK 32.4 32.9 31.5
Poor 15.5 22.9 19.2
Very poor 8.5 7.1 8.2Appendix 9
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Inserts (day) Abri-San Super  Moliform Plus  Attends Contour 
(1) (2) Super (3)
Leakage Very  good 9.1 5.0 13.3
Good 21.2 25.0 35.0
OK 30.3 33.3 20.0
Poor 28.8 23.3 20.0
Very poor 10.6 13.3 11.7
Stay in place  Very good 6.2 7.9 9.7
Good 26.2 23.8 27.4
OK 35.4 42.9 35.5
Poor 21.5 15.9 17.7
Very poor 10.8 9.5 9.7
Smell Very good 9.1 4.8 14.8
Good 24.2 27.4 31.2
OK 42.4 43.5 39.3
Poor 22.7 17.7 9.8
Very poor 1.5 6.5 4.9
Discreet Very good 10.6 14.3 16.1
Good 42.4 41.3 38.7
OK 40.9 36.5 41.9
Poor 4.5 7.9 3.2
Very poor 1.5 0.0 0.0
Dry comfort Very good 15.2 14.5 17.7
Good 34.9 40.3 40.3
OK 31.8 30.7 33.9
Poor 16.7 11.3 8.1
Very poor 1.6 3.2 0.0
Wet comfort Very good 7.6 6.5 11.5
Good 25.8 24.2 29.5
OK 36.4 41.9 32.8
Poor 21.2 19.4 19.7
Very poor 9.1 8.1 6.6
Keep skin dry Very good 14.1 4.8 14.8
Good 21.9 29.0 34.4
OK 42.2 40.3 36.1
Poor 18.8 24.2 13.1
Very poor 3.1 1.6 1.6
Overall opinion (day) Very good 8.2 4.4 7.5
Good 21.9 24.6 28.4
OK 31.5 26.1 25.4
Poor 23.3 23.2 23.9
Very poor 15.1 21.7 14.9Health Technology Assessment 2008; Vol. 12: No. 29
155
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Inserts (night) Tena Comfort  Attends Contour  Contisure Premium 
Super (15) Super Plus (16) Extraa (17)
Leakage Very  good 14.5 9.7 4.6
Good 24.2 33.9 24.6
OK 25.8 24.2 16.9 X (15 and 16)
Poor 16.1 17.7 30.8
Very poor 19.4 14.5 23.1
Stay in place  Very good 10.8 9.5 4.6
Good 30.8 25.4 33.3
OK 24.6 34.9 27.3
Poor 29.2 17.5 25.8
Very poor 4.6 12.7 9.0
Smell Very good 7.8 8.1 6.1
Good 32.8 33.9 31.8
OK 40.6 43.6 34.9 X (16)
Poor 18.8 11.3 22.7
Very poor 0.0 3.2 4.6
Discreet Very good 10.8 14.3 7.6
Good 35.4 38.1 48.5
OK 43.1 39.7 37.9
Poor 10.8 7.9 6.1
Very poor 0.0 0.0 0.0
Dry comfort Very good 18.5 20.6 15.2
Good 385 41.3 40.9
OK 38.5 30.2 37.9
Poor 3.1 6.4 4.6
Very poor 1.5 1.6 1.5
Wet comfort Very good 6.4 6.5 3.0
Good 36.5 33.9 24.2
OK 38.1 46.8 40.9 X (16)
Poor 11.1 8.1 21.2
Very poor 7.9 4.8 10.6
Keep skin dry Very good 9.5 9.7 6.4
Good 28.6 30.7 27.0
OK 41.3 43.6 36.5 X (16)
Poor 17.5 12.9 27.0
Very poor 3.2 3.2 3.2
Overall opinion  Very good 12.9 11.4 6.9
(night) Good 27.1 31.4 21.9
OK 25.7 20.0 17.8 X (15 and 16)
Poor 15.7 20.0 31.5
Very poor 18.6 17.1 21.9
a Contisure Super (a more absorbent product) should have been tested. Product therefore excluded from analysis for
leakage-related variables (shaded). Appendix 9
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Pull-ups (day) Attends  Molicare Mobile  Abri-Flex Extra 
Pull-on Super (7) (8) (9)
Leakage Very  good 25.8 22.6 22.2
Good 39.4 30.7 38.1
OK 22.7 19.4 19.1
Poor 10.6 19.4 17.5
Very poor 1.5 8.1 3.2
Stay in place  Very good 44.1 41.5 50.0
Good 33.8 30.8 28.1
OK 13.2 20.0 15.6
Poor 8.8 6.2 6.3
Very poor 0.0 1.5 0.0
Smell Very good 20.9 12.5 15.9
Good 28.4 39.1 31.8
OK 40.3 34.4 38.1
Poor 10.5 12.5 12.7
Very poor 0.0 1.6 1.6
Discreet Very good 29.9 36.9 35.9
Good 40.3 40.0 42.2
OK 25.4 21.5 18.8
Poor 4.5 1.5 3.1
Very poor 0.0 0.0 0.0
Dry comfort Very good 50.0 43.1 41.3
Good 35.3 40.0 42.9
OK 14.7 16.9 14.3
Poor 0.0 0.0 1.6
Very poor 0.0 0.0 0.0
Wet comfort Very good 16.2 14.8 14.5
Good 39.7 34.4 37.1
OK 33.8 39.3 40.3
Poor 8.8 11.5 8.1
Very poor 1.5 0.0 0.0
Keep skin dry Very good 22.4 15.6 15.9
Good 40.3 37.5 39.7
OK 35.8 39.7 30.2 X (7)
Poor 0.0 7.8 14.3
Very poor 1.5 0.0 0.0
Overall opinion  Very good 34.7 27.9 29.4
(day) Good 36.1 33.8 36.8
OK 19.4 13.2 X (7 and 9) 22.1
Poor 9.7 20.6 10.3
Very poor 0.0 4.4 1.5Health Technology Assessment 2008; Vol. 12: No. 29
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Pull-ups (night) Attends Pull-on  Molicare Mobilea Tena Pants Super 
(21) (22) (23)
Leakage Very  good 29.4 15.6 31.3
Good 25.0 18.8 31.3
OK 25.0 28.1 X (21 and 23) 15.6
Poor 11.8 25.0 10.9
Very poor 8.8 12.5 10.9
Stay in place  Very good 38.2 31.2 35.4
Good 32.4 41.3 46.2
OK 23.5 14.3 10.8
Poor 5.9 11.1 6.2
Very poor 0.0 3.2 1.5
Smell Very good 22.1 14.1 17.5
Good 30.9 28.1 42.9
OK 42.7 39.1 X (21) 30.2
Poor 4.4 17.2 9.5
Very poor 0.0 1.6 0.0
Discreet Very good 29.4 23.4 30.8
Good 42.7 56.3 44.6
OK 26.5 20.3 24.6
Poor 1.5 0.0 0.0
Very poor 0.0 0.0 0.0
Dry comfort Very good 50.0 40.6 40.0
Good 33.8 37.5 49.2
OK 16.1 20.3 9.2
Poor 0.0 1.6 1.5
Very poor 0.0 0.0 0.0
Wet comfort Very good 22.1 14.1 14.1
Good 36.8 21.9 46.9
OK 30.9 46.9 29.7
Poor 8.9 15.6 7.8
Very poor 1.5 1.6 1.6
Keep skin dry Very good 27.3 14.1 29.2
Good 36.4 28.1 35.4
OK 33.3 40.6 X (21) 26.2
Poor 1.5 14.1 9.2
Very poor 1.5 3.1 0.0
Overall opinion  Very good 31.1 22.2 26.1
(night) Good 28.4 29.2 35.6
OK 17.6 13.9 X (23) 15.1
Poor 16.2 22.2 15.1
Very poor 6.8 12.5 8.2
a Product therefore excluded from analysis for leakage-related variables (shaded). Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 10
Trial 2a: design performance by gender (%)
Very good Good OK Poor Very poor
Women: day
Ease on T-shaped 19.2 11.5 38.5 23.1 7.7
Washable 2.3 7.0 14.0 23.3 53.5
Diaper 10.8 23.0 29.7 21.6 14.9
Insert 25.0 40.8 28.9 5.3 0.0
Pull-up 50.0 32.5 12.5 5.0 0.0
Fit T-shaped 11.8 19.6 21.6 31.4 15.7
Washable 0.0 7.1 19.0 21.4 52.4
Diaper 13.3 18.7 29.3 26.7 12.0
Insert 13.2 35.5 38.2 10.5 2.6
Pull-up 36.3 35.0 22.5 6.3 0.0
Comfort dry T-shaped 19.6 27.5 31.4 13.7 7.8
Washable 10.0 10.0 60.0 7.5 12.5
Diaper 13.7 32.9 38.4 12.3 2.7
Insert 23.7 36.8 28.9 10.5 0.0
Pull-up 56.3 30.0 12.5 1.3 0.0
In place T-shaped 23.1 17.3 30.8 21.2 7.7
Washable 7.9 5.3 42.1 18.4 26.3
Diaper 10.7 33.3 40.0 9.3 6.7
Insert 14.7 33.3 41.3 5.3 5.3
Pull-up 60.0 31.3 7.5 1.3 0.0
Discreet T-shaped 17.6 23.5 25.5 17.6 15.7
Washable 0.0 4.9 9.8 14.6 70.7
Diaper 5.3 24.0 29.3 32.0 9.3
Insert 17.1 46.1 28.9 7.9 0.0
Pull-up 41.3 32.5 20.0 6.3 0.0
Urine T-shaped 23.5 31.4 29.4 11.8 3.9
Washable 15.8 21.1 39.5 10.5 13.2
Diaper 22.5 33.8 23.9 15.5 4.2
Insert 15.8 32.9 21.1 22.4 7.9
Pull-up 35.9 41.0 15.4 7.7 0.0
Faeces T-shaped 20.0 40.0 20.0 10.0 10.0
Washable 28.6 0.0 28.6 14.3 28.6
Diaper 30.8 7.7 30.8 15.4 15.4
Insert 8.3 33.3 50.0 0.0 8.3
Pull-up 40.0 20.0 20.0 20.0 0.0
Comfort wet T-shaped 9.8 31.4 41.2 13.7 3.9
Washable 5.3 5.3 28.9 36.8 23.7
Diaper 8.5 31.0 42.3 14.1 4.2
Insert 10.5 26.3 36.8 22.4 3.9
Pull-up 22.1 40.3 35.1 2.6 0.0
Urine smell T-shaped 17.6 29.4 39.2 11.8 2.0
Washable 7.9 10.5 28.9 28.9 23.7
Diaper 13.9 27.8 45.8 8.3 4.2
Insert 13.2 25.0 47.4 9.2 5.3
Pull-up 26.6 30.4 31.6 11.4 0.0
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Very good Good OK Poor Very poor
Skin dry T-shaped 18.0 32.0 34.0 16.0 0.0
Washable 2.7 10.8 24.3 35.1 27.0
Diaper 8.7 39.1 27.5 18.8 5.8
Insert 14.9 27.0 44.6 10.8 2.7
Pull-up 26.9 39.7 24.4 9.0 0.0
Ease off T-shaped 20.0 24.0 34.0 18.0 4.0
Washable 10.8 13.5 27.0 18.9 29.7
Diaper 13.0 31.9 26.1 26.1 2.9
Insert 29.7 40.5 25.7 4.1 0.0
Pull-up 47.4 25.6 20.5 5.1 1.3
Women: night
Ease on T-shaped 19.2 23.1 36.5 15.4 5.8
Washable 0.0 9.3 16.3 25.6 48.8
Diaper 8.6 23.5 30.9 25.9 11.1
Insert 19.5 41.5 29.3 8.5 1.2
Pull-up 50.0 32.1 16.7 0.0 1.2
Fit T-shaped 21.6 19.6 33.3 19.6 5.9
Washable 7.0 4.7 25.6 18.6 44.2
Diaper 8.8 35.0 21.3 22.5 12.5
Insert 11.0 41.5 34.1 9.8 3.7
Pull-up 33.3 47.6 14.3 3.6 1.2
Comfort dry T-shaped 21.6 27.5 37.3 9.8 3.9
Washable 17.1 17.1 29.3 12.2 24.4
Diaper 13.4 34.1 34.1 11.0 7.3
Insert 17.1 43.9 36.6 2.4 0.0
Pull-up 54.8 31.0 13.1 1.2 0.0
In place T-shaped 17.3 21.2 36.5 23.1 1.9
Washable 2.4 22.0 31.7 17.1 26.8
Diaper 7.5 37.5 25.0 16.3 13.8
Insert 8.5 31.7 37.8 18.3 3.7
Pull-up 46.4 39.3 11.9 2.4 0.0
Discreet T-shaped 15.4 26.9 32.7 19.2 5.8
Washable 0.0 2.5 7.5 25.0 65.0
Diaper 8.6 19.8 38.3 22.2 11.1
Insert 11.0 36.6 42.7 9.8 0.0
Pull-up 34.5 42.9 21.4 1.2 0.0
Urine T-shaped 19.6 27.5 25.5 19.6 7.8
Washable 26.3 15.8 28.9 13.2 15.8
Diaper 11.4 41.8 30.4 15.2 1.3
Insert 13.6 39.5 18.5 22.2 6.2
Pull-up 38.1 26.2 22.6 9.5 3.6
Faeces T-shaped 11.1 33.3 11.1 22.2 22.2
Washable 33.3 0.0 50.0 16.7 0.0
Diaper 8.3 41.7 33.3 16.7 0.0
Insert 0.0 16.7 41.7 16.7 25.0
Pull-up 25.0 25.0 31.3 12.5 6.3
Comfort wet T-shaped 7.8 39.2 31.4 19.6 2.0
Washable 10.3 2.6 35.9 25.6 25.6
Diaper 7.4 27.2 38.3 18.5 8.6
Insert 8.5 31.7 42.7 13.4 3.7
Pull-up 22.9 36.1 36.1 4.8 0.0
Urine smell T-shaped 13.7 31.4 39.2 13.7 2.0
Washable 7.7 7.7 30.8 33.3 20.5
Diaper 7.5 38.8 30.0 16.3 7.5
Insert 9.8 35.4 40.2 13.4 1.2
Pull-up 25.0 42.9 23.8 8.3 0.0
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Very good Good OK Poor Very poor
Skin dry T-shaped 10.0 36.0 38.0 16.0 0.0
Washable 10.5 13.2 10.5 44.7 21.1
Diaper 8.9 32.9 29.1 16.5 12.7
Insert 11.3 32.5 38.8 15.0 2.5
Pull-up 31.7 35.4 25.6 7.3 0.0
Ease off T-shaped 20.0 40.0 32.0 8.0 0.0
Washable 13.5 16.2 13.5 29.7 27.0
Diaper 15.2 31.6 31.6 16.5 5.1
Insert 29.1 39.2 27.8 3.8 0.0
Pull-up 47.6 25.6 23.2 2.4 1.2
Men: day
Ease on T-shaped 33.3 34.5 20.2 11.9 0.0
Washable 7.7 15.4 47.4 17.9 11.5
Diaper 9.6 39.2 44.0 7.2 0.0
Insert 7.6 33.6 45.4 13.4 0.0
Pull-up 38.0 41.3 9.1 9.9 1.7
Fit T-shaped 26.2 38.1 25.0 10.7 0.0
Washable 14.1 42.3 23.1 14.1 6.4
Diaper 20.0 31.2 32.8 16.0 0.0
Insert 5.0 21.0 40.3 26.9 6.7
Pull-up 28.9 38.0 22.3 10.7 0.0
Comfort dry T-shaped 28.6 44.0 21.4 4.8 1.2
Washable 29.1 41.8 21.5 5.1 2.5
Diaper 23.4 44.4 30.6 1.6 0.0
Insert 10.2 39.0 35.6 12.7 2.5
Pull-up 35.8 45.0 19.2 0.0 0.0
In place T-shaped 31.0 29.8 26.2 11.9 1.2
Washable 15.2 40.5 26.6 13.9 3.8
Diaper 20.8 36.8 32.0 10.4 0.0
Insert 3.4 21.0 35.3 26.9 13.4
Pull-up 33.9 32.2 22.3 10.7 0.8
Discreet T-shaped 25.0 36.9 31.0 7.1 0.0
Washable 2.6 5.2 22.1 41.6 28.6
Diaper 20.8 36.8 35.2 7.2 0.0
Insert 10.9 37.8 47.1 3.4 0.8
Pull-up 28.3 47.5 23.3 0.8 0.0
Urine T-shaped 31.0 36.9 19.0 11.9 1.2
Washable 29.9 40.3 15.6 10.4 3.9
Diaper 19.4 22.6 34.7 16.1 7.3
Insert 4.4 23.7 32.5 24.6 14.9
Pull-up 14.5 32.5 25.6 20.5 6.8
Faeces T-shaped 19.0 47.6 23.8 9.5 0.0
Washable 37.5 31.3 6.3 6.3 18.8
Diaper 24.1 44.8 27.6 0.0 3.4
Insert 0.0 23.8 61.9 14.3 0.0
Pull-up 13.6 45.5 27.3 13.6 0.0
Comfort wet T-shaped 18.1 38.6 31.3 12.0 0.0
Washable 7.9 17.1 53.9 7.9 13.2
Diaper 6.4 26.4 48.0 14.4 4.8
Insert 6.8 25.6 37.6 18.8 11.1
Pull-up 10.2 33.9 41.5 13.6 0.8
Urine smell T-shaped 15.7 33.7 48.2 2.4 0.0
Washable 5.3 35.5 42.1 10.5 6.6
Diaper 8.8 32.8 53.6 4.0 0.8
Insert 6.8 28.2 39.3 22.2 3.4
Pull-up 9.2 33.6 43.7 11.8 1.7
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Very good Good OK Poor Very poor
Skin dry T-shaped 17.5 40.0 36.3 6.3 0.0
Washable 5.5 23.3 46.6 13.7 11.0
Diaper 5.8 28.9 44.6 18.2 2.5
Insert 8.8 29.2 36.3 23.9 1.8
Pull-up 12.1 38.8 42.2 6.0 0.9
Ease off T-shaped 43.2 39.5 14.8 2.5 0.0
Washable 14.3 40.3 31.2 9.1 5.2
Diaper 17.2 42.6 37.7 2.5 0.0
Insert 13.9 46.1 38.3 1.7 0.0
Pull-up 41.5 39.0 17.8 1.7 0.0
Men: night
Ease on T-shaped 31.6 29.1 27.8 11.4 0.0
Washable 10.0 25.7 47.1 11.4 5.7
Diaper 8.8 43.0 45.6 2.6 0.0
Insert 7.8 37.9 40.5 13.8 0.0
Pull-up 50.4 39.3 6.8 3.4 0.0
Fit T-shaped 22.8 19.0 45.6 11.4 1.3
Washable 17.1 40.0 31.4 10.0 1.4
Diaper 13.2 39.5 32.5 14.0 0.9
Insert 11.2 28.4 28.4 26.7 5.2
Pull-up 22.4 43.1 26.7 6.9 0.9
Comfort dry T-shaped 22.8 40.5 34.2 2.5 0.0
Washable 32.4 47.9 15.5 2.8 1.4
Diaper 15.8 48.2 35.1 0.9 0.0
Insert 18.1 37.1 36.2 6.0 2.6
Pull-up 34.2 46.2 18.8 0.9 0.0
In place T-shaped 21.8 25.6 37.2 11.5 3.8
Washable 23.9 43.7 22.5 7.0 2.8
Diaper 15.7 47.0 27.8 8.7 0.9
Insert 7.8 27.6 23.3 27.6 13.8
Pull-up 25.0 40.5 20.7 11.2 2.6
Discreet T-shaped 20.3 34.2 40.5 5.1 0.0
Washable 2.9 10.1 34.8 34.8 17.4
Diaper 14.9 45.6 33.3 6.1 0.0
Insert 10.3 42.2 40.5 6.9 0.0
Pull-up 22.2 49.6 28.2 0.0 0.0
Urine T-shaped 19.2 21.8 28.2 19.2 11.5
Washable 42.3 38.0 16.9 1.4 1.4
Diaper 8.7 29.6 34.8 19.1 7.8
Insert 6.3 18.8 25.0 20.5 29.5
Pull-up 15.5 23.3 24.1 20.7 16.4
Faeces T-shaped 14.3 42.9 42.9 0.0 0.0
Washable 16.7 66.7 16.7 0.0 0.0
Diaper 19.2 57.7 15.4 7.7 0.0
Insert 13.0 30.4 30.4 13.0 13.0
Pull-up 26.1 47.8 21.7 4.3 0.0
Comfort wet T-shaped 12.7 27.8 45.6 11.4 2.5
Washable 14.1 23.9 45.1 11.3 5.6
Diaper 6.1 31.3 41.7 14.8 6.1
Insert 2.7 30.1 41.6 14.2 11.5
Pull-up 12.0 33.3 36.8 15.4 2.6
Urine smell T-shaped 11.5 21.8 56.4 10.3 0.0
Washable 8.6 35.7 40.0 11.4 4.3
Diaper 8.8 23.9 47.8 18.6 0.9
Insert 5.3 30.1 38.9 22.1 3.5
Pull-up 12.3 26.3 47.4 13.2 0.9
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Very good Good OK Poor Very poor
Skin dry T-shaped 10.7 26.7 49.3 12.0 1.3
Washable 6.1 25.8 40.9 19.7 7.6
Diaper 4.5 34.8 36.6 20.5 3.6
Insert 6.5 25.9 41.7 22.2 3.7
Pull-up 17.7 31.9 38.9 8.8 2.7
Ease off T-shaped 33.3 34.7 32.0 0.0 0.0
Washable 19.7 36.4 36.4 6.1 1.5
Diaper 12.6 40.5 41.4 5.4 0.0
Insert 18.8 52.7 27.7 0.9 0.0
Pull-up 40.2 45.5 12.5 1.8 0.0Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 11
Trial 2a: preference for designs, by gender
Number preferring design (daytime)
Men (N = 49) Women (N = 36)
Diaper 41 vs Insert 8 Diaper 11 vs Insert 25
Pull-up 42 vs Insert 7 Pull-up 27 vs Insert 9
Pull-up 16 vs Diaper 33 Pull-up 29 vs Diaper 7
Pull-up 21 vs T-shaped 28 Pull-up 29 vs T-shaped 7
T-shaped 18 vs Diaper 31 T-shaped 15 vs Diaper 21
T-shaped 40 vs Insert 9 T-shaped 13 vs Insert 23
Diaper 41 vs Washable 8 Diaper 33 vs Washable 3
Number preferring design (night-time) 
Men (N = 49) Women (N = 36)
Diaper 39 vs Insert 10 Diaper 14 vs Insert 22
Pull-up 39 vs Insert 10 Pull-up 27 vs Insert 9
Pull-up 11 vs Diaper 38 Pull-up 29 vs Diaper 7
Pull-up 20 vs T-shaped 29 Pull-up 30 vs T-shaped 6
T-shaped13 vs Diaper 36 T-shaped 14 vs Diaper 22
T-shaped 39 vs Insert 10 T-shaped 17 vs Insert 19
Diaper 20 vs Washable 29 Diaper 29 vs Washable 7Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 12
Trial 2a: acceptability of designs for day and night, 
by gender
N = 85 % (N)
Men = 49
Insert Diaper Pull-up T-shaped Washable Women = 36
Day Night Day Night Day Night Day Night Day Night
Highly  20.0  11.8 35.3 32.9  41.2 31.8  24.7 15.3  4.7  42.4 
acceptable (17) (10) (30) (28) (35) (27) (21) (13) (4) (36)
Men 6.0 2.0  46.9 46.9  24.5 12.2  30.6 20.4  6.1  63.3 
(3) (1) (23) (23) (12) (6) (15) (10) (3) (31)
Women 38.9  25.0 19.4 13.9  63.9 58.3  16.7  8.3  2.8  13.9 
(14) (9) (7) (5) (23) (21) (6) (3) (1) (5)
Acceptable 36.5  29.4 37.7 43.5  44.7 35.3  41.2 42.4  29.4 15.3 
(31) (25) (32) (37) (38) (30) (35) (36) (25) (13)
Men 30.6  20.4 38.8 38.8  55.1 36.7  53.1 40.8  44.9 18.4 
(15) (10) (19) (19) (27) (18) (26) (20) (22) (9)
Women 44.4  41.7 36.1 50.0  30.6 33.3  25.0 44.4  8.3  11.1 
(16) (15) (13) (18) (11) (12) (9) (16) (3) (4)
Unacceptable/ 43.5  58.8 27.0 23.6  14.0 32.9  34.0 42.3  65.9 42.3 
totally unacceptable (37) (50) (23) (20) (12) (28) (29) (36) (56) (36)
Men 63.3  77.6 14.3 14.3  20.4 51.0  16.3 38.8  49.0 18.3 
(31) (38) (7) (7) (10) (25) (8) (19) (24) (9)
Women 16.7  33.4 44.5 36.1  5.6  8.4  58.3 47.2  88.8 75.0 
(6) (12) (16) (13) (2) (3) (21) (17) (32) (27)Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 13
Trial 2a: mean VAS scores (SD), by gender
Insert Diaper Pull-up T-shaped Washable
Day
Men and women combined  48.5 (32.1) 66.3 (27.3) 72.7 (23.9) 60.1 (27.6) 33.7 (31.0)
Men 34.6 (31.5) 76.4 (23.5) 65.9 (25.3) 68.1 (24.7) 43.0 (31.6)
Women 67.5 (21.7) 52.6 (26.4) 81.8 (18.5) 49.3 (27.9) 20.9 (25.6)
Night
Men and women combined 43.1 (32.7) 64.5 (26.9) 62.2 (29.8) 53.9 (26.3) 53.2 (40.6)
Men 30.3 (30.0) 72.4 (25.6) 49.9 (29.2) 58.4 (25.6) 71.4 (35.4)
Women 60.5 (28.1) 53.6 (25.1) 78.9 (21.5) 47.8 (26.5) 28.3 (33.8)Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 14
Trial 2a: comments by gender
Design Women (N = 36) Men (N = 49)
Good N Poor N Good  N Poor N
Day
T-shaped Absorbent 12 Difficult to put on 13 Easy on/off/toilet 15 Problems with  14
tabs/belt
Easy to use 5 Problems with  10 Comfortable 11 Not enough  6
tabs/Velcro padding at sides
Reliable/secure  5 Leaks 7 Easy to change 11 Leaks 5
confidence
Uncomfortable 5 Absorbent 7 Sag/not secure  3
when wet
Poor fit 3 Secure/confidence 3
Bulky 3
Washable Absorbent/no leaks 4 Bulky 18 Absorbency/no  17 Bulky 32
leaks
Comfortable/ 4 Difficulty on/off 14 Good for  7 Difficulty  16
kind to skin environment changing/on
Problems 9 Cost  savings 5 Laundry 5
laundering
Poor appearance/ 7
disgusting/
child-like
Diaper Absorbent/no leaks 20 Bulky 18 Absorbency/no  21 Can be bulky 8
leaks
Secure/confident 4 Difficult to put  7 Low/reasonable  7 Difficult to put on 8
on/change leakage
Stayed in place 3 Problems with  7 Easy to change 11 Problems with tabs 7
tabs not sticking
Sweaty 3 Sweaty/hot 5
Leaks 3 Leaks 4
Uncomfortable 3 Uncomfortable 3
Insert Easy to change/ 17 Leaks  15 Easy on/change/ 13 Does not stay  22
put on to use in place
Absorbent/ 8 Moves/does not  11 Discreet/not bulky 6 Leakage 17
holds urine/ stay in place
no leaks
Discreet 6 Problems with  3 Absorbent 4 Problems with  7
pants pants/having to 
wear stretch 
pants
Comfortable 5 Bulky 3 Comfortable 3 Not good for men 4
Fit/size 4
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Design Women (N = 36) Men (N = 49)
Good N Poor N Good  N Poor N
Pull-up Comfortable/soft  19 Difficult to change  15 Comfortable 14 Difficult to change  19
when out  when out
(especially 
removing 
trousers)
Easy use/on/off/ 14 Leak/low  5 Looks like ‘normal’  13 Leaks 14
change absorbency underwear
Absorbent/no leaks 11 Easy to put on/off/ 12 Not enough  12
change padding/in wrong
place for men
Like normal pants 13 Discreet/not bulky 8
Discreet 7 Stays in place 5
Night
T-shaped Absorbent/no leaks 12 Leaks 12 Easy to change/ 15 Problems with  14
put on tabs/waist-band
Easy to use 4 Problems with  8 Absorbent 6 Leaks 12
tabs/waist-band
Secure/confidence 4 Difficult to put on 6 Comfortable 5 No padding at sides 8
No padding at sides 4
Washable Absorbent/no leaks 9 Difficult to put on 12 Absorbency/no  24 Bulky 12
leaks
Comfortable/soft 6 Laundry 10 Comfortable 18 Laundry 12
Baby-like/won’t  5 Slept through  6 Difficult to put on 9
wear nappy/ night/good sleep
disliked 
appearance
Diaper Absorbent/no leaks 14 Difficult to put  8 Absorbent/no leaks 15 Difficult to put  7
on/change on/go to toilet
Easy to use/on/off/  4 Leak 6 Stays in place 9 Leak 6
change
Problems with tabs 5 Fit 7 Problems with tabs 6
Too big/bulky 5 Comfortable 5 Sweaty/hot/clammy 6
No side padding 3
Insert Easy/quick to  9 Leak/not absorbent 17 Easy on/off/change 10 Leak 23
change
Discreet/not bulky 5 Does not stay in  10 Discreet/not bulky 4 Does not stay in  18
place place
Comfortable 4 Comfortable 3 No padding at sides 3
Pull-up Ease on/off/ 15 Leak 12 Comfortable 13 Leak/not absorbent  26
change/use toilet enough
Comfortable/soft 14 Difficult on/off/ 5 Easy on/off/change 11 Padding in wrong  8
change place
Looks good/like  10 Discreet 5 Difficult changing  5
underwear/
feminine
Stays in place 6 Looked good/ 4
‘normal’
Absorbent 5 Stayed in place 4Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 15
Trial 2b: consenting procedure for nursing home 
residents
Interview with eligible resident 
Patient information sheet provided
Informed consent possible
Comprehension unsatisfactory
No objections raised by 
relative/friend/guardian
(senior nursing staff)
Objections raised by 
relative/friend/guardian
(senior nursing staff)
Resident recruited Resident non-recruited
Informed consent
not possible
Comprehension satisfactory 
Written informed consent given 
Resident recruited
Named 
relative/friend/guardian 
unavailable
Consultation
with senior
nursing staff
a Comprehension question:
  Can you tell me a little bit about the research project I was talking to you about a couple of days ago?
Named  
relative/friend/guardian 
available
Letter and information 
sheet sent to 
relative/friend/guardian
(senior nursing staff)
Comprehension 
satisfactory, 
consent declined
Follow-up interview with comprehension questiona 
at least 24 hours laterResident initials: 
Resident consenting procedure
Date Sign
1. Staff have identified resident as appropriate and asked permission 
for researcher to discuss the study with them  …………………………
2. Resident does not meet inclusion/exclusion criteria NOT RECRUITED
…………………………
3. Resident interviewed, study discussed and resident information sheet given …………………………
4. (a) Resident apparently able to give informed consent and interested in 
taking part …………………………
(b) Resident apparently able to give informed consent but not interested  NOT RECRUITED
in taking part …………………………
(c) Resident unable to give informed consent (go to point 7) …………………………
5. Follow-up interview carried out …………………………
6. (a) Resident recalls study and gives informed consent RECRUITED
…………………………
(b) Resident recalls study and does not consent  NOT RECRUITED 
…………………………
(c) Resident does not recall study and re-consents  RECRUITED 
…………………………
(d) Resident does not recall study and consent doubtful …………………………
7. Discuss resident with nursing home staff regarding possible participation 
in the study and resident’s likely responses …………………………
8. Problems raised by staff NOT RECRUITED
…………………………
9. Letter sent to relative/friend/guardian OR …………………………
No relative/friend or guardian …………………………
10. (a) Relative/friend/guardian suggests inclusion RECRUITED
(b) Relative/friend/guardian suggests exclusion NOT RECRUITED
(c) Relative/friend/guardian requests further discussion …………………………
Further discussion with relative/friend/guardian RECRUITED
NOT RECRUITED
If no relative/friend or guardian then staff views will be carefully considered before deciding whether
resident should be included 
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Appendix 16
Trial 2b: resident first-choice preference
N = 14 % (N)
Disposable insert Disposable diaper Disposable pull-up Disposable 
T-shaped
First-choice preference 3164Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 17
Trial 2b: mean VAS scores (SD), by gender
Insert Diaper Pull-up T-shaped
Day
Men (N = 27) 4.6 (3.1) 6.2 (3.4) 5.9. (2.7) 4.7 (3.0)
Women (N = 72) 5.1 (2.9) 4.8 (2.4) 7.1 (3.0) 4.9 (3.0)
(1 missing data)
Night
Men (N = 27) 3.7 (2.8) 7.7 (2.6) 5.7 (2.0) 6.3 (3.1)
Women (N = 71) 4.5 (2.4) 6.2 (2.8) 6.4 (2.7) 6.3 (2.4)
(2 missing data)Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 18
Trial 2b: paired comparisons of preferences between 
the different designs, by gender
Number preferring design (daytime)
Men (N = 27) Women (N = 72, 1 missing data)
Pull-up 14 vs Insert 13 Pull-up 51 vs Insert 21
Pull-up 11 vs Diaper 16 Pull-up 55 vs Diaper 17
Pull-up 17 vs T-shaped 10 Pull-up 49 vs T-shaped 23
T-shaped 16 vs Insert 11 T-shaped 33 vs Insert 39
T-shaped 9 vs Diaper 18 T-shaped 39 vs Diaper 33
Diaper 19 vs Insert 8 Diaper 33 vs Insert 39
Number preferring design (night-time) 
Men (N = 27) Women (N = 71, 2 missing data)
Pull-up 20 vs Insert 7 Pull-up 52 vs Insert 19
Pull-up 6 vs Diaper 21 Pull-up 34 vs Diaper 37
Pull-up 10 vs T-shaped 17 Pull-up 37 vs T-shaped 34
T-shaped 20 vs Insert 7 T-shaped 48 vs Insert 23
T-shaped 7 vs Diaper 20 T-shaped 34 vs Diaper 37
Diaper 23 vs Insert 4 Diaper 50 vs Insert 21Day products
Carers could make as many comments as they wished. Comments are included if made by at least three
carers.
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Appendix 19
Trial 2b: comments from carers by resident gender
Design Women (N = 72) Men (N = 27)
Good N Poor N Good N Poor N
Insert Easy on/off/change 33 Not absorbent/ 29 Easy on/off/change 12 Not absorbent/ 10
leaks leaks
Good fit/size 9 Moved around 14 Absorbent 3 Moved around 7
Absorbent/holds  7 Poor size/fit 9 Too small 3
urine
Liked net pants 3 Did not like/ 7 Can be removed  4
problems with  by resident
net pants
Diaper  Absorbent/holds  17 Difficult to put on/ 13 Absorbent/holds  7 Not absorbent/ 8
urine change urine leaks
Good fit/size 10 Too big and bulky 13 Good fit 4
Easy on/off/change 6 Too much plastic/ 12 Comfortable/soft 3
causes sweating
Stays in place 5 Poor fit/size 10 Easy on/off 3
Not absorbent/ 4 Stays in place 3
leaks
Problems with tabs 4 Difficult to remove 3
Pull-up Easy on/off/change 29 Difficult to put on/ 27 Easy to put on/off/ 10 Difficult to put on/ 10
change change change
Comfort/soft  23 Not absorbent/ 7 Comfortable/soft 7 Not absorbent/ 4
leaks leaks
Absorbent/holds 20 Poor  fit/size 4 Absorbent/holds  6
urine urine
Discreet/like pants/ 10 Look good/like  3
dignified pants
Stays in place 7
Resident could  4
manage by self
T-shaped Absorbent/holds  25 Difficult to put on/ 24 Easy to put on/off/ 8 Poor fit/not big  7
urine change change enough
Easy on/off/change 16 Problems with  9 Absorbent/holds  5 Difficult on/change 6
band/tabs urine
Stays in place 10 Not absorbent  7 Poor fit/size 4 Not absorbent  3
enough/leaks enough/leaks
Comfort/soft 8 Poor fit/size 6 Comfortable/soft 2 Tabs did not stick 3
Good fit 7
Good size/shape 7Night products
Carers could make as many comments as they wished. Comments are included if made by at least three
carers.
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Design Women (N = 72) Men (N = 27)
Good N Poor N Good N Poor N
Insert Easy on/off/change 27 Not absorbent  34 Absorbent/holds  6 Not absorbent  15
enough/leaks urine enough/leaks
Absorbent 9 Moves around 13 Easy to change 5 Moves around 8
Can position  3 Dislike/problems  9 Good size/fit 3 Poor size/fit 7
correctly with nets
Poor fit/size 6
Diaper  Absorbent/holds  24 Not absorbent  17 Absorbent/holds  9 Not absorbent  4
urine enough/leaks urine enough/leaks
Easy on/off/change 18 Too much plastic/ 11 Good fit/size 8
sweaty
Good fit/size 12 Too big and bulky 6 Comfortable/soft 6
Comfortable/soft 7 Poor fit/size 6 Easy on/change 4
Stays in place 6 Difficulty on/change 3 Stays in place 4
Do not disturb  3
resident changing 
in night
Pull-up Absorbent/no leaks 15 Difficult on/off/ 25 Easy on/off/change 11 Difficult on/off/ 7
change change
Comfortable/soft 19 Not absorbent  14 Absorbent 7 Not absorbent  5
enough enough/leaks
Good fit/size 17 Poor fit/size 5 Comfortable/soft 7
Easy on/off/change 11 Difficult to remove/ 3
soiled with 
faeces
Stays in place 10
Good appearance/ 7
like pants
T-shaped Easy on/change 26 Not absorbent  13 Absorbent 10 Poor fit/size 6
enough/leaks
Absorbent/no leaks 21 Problem with belt/ 11 Easy on/change 10 Opened/poor tabs/ 6
tabs did not stay on
Good fit/size 10 Difficult on/change 8 Comfortable/soft 4 Difficult on 4
Comfortable/soft 7 Good fit/size 3
Stays in place 6
Keeps skin dry 5Health Technology Assessment 2008; Vol. 12: No. 29
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Appendix 20
Trial 2b: care staff views about the number of staff 
needed to change residents in different positions
Position Design Day Night
n Mean Median SD Range n 1 1.5 2 Mean Median SD Range
Standing Usual product 67 1.67 2 0.512 1–3
T-shaped 67 1.77 2 0.487 1–3
Diaper 67 1.72 2 0.454 1–3
Insert 67 1.63 2 0.553 1–3
Pull-up 67 1.60 2 0.504 1–3
Lying Usual product 85 1.67 2 0.459 1–2 67 15 3 49 1.75 2 0.421 1–2
T-shaped 85 1.65 2 0.463 1–2 70 17 8 45 1.70 2 0.429 1–2
Diaper 85 1.65 2 0.463 1–2 70 18 7 46 1.69 2 0.437 1–2
Insert 85 1.61 2 0.476 1–2 70 20 6 44 1.67 2 0.450 1–2
Pull-up 85 1.65 2 0.463 1–2 70 18 5 47 1.71 2 0.438 1–2Care staff were asked only to consider designs that they considered to be acceptable. They were then
asked: “Bearing in mind that incontinence products are generally purchased by the NHS using money
that we all pay in taxes, would you still think your first choice design was best if it was costing the NHS
£15 (£6 per night) per month more than your second choice? If not – What if it cost £10 (£4 per night)
per month more? If not – What if it cost £5 (£2 per night) per month more?”
Results for comparisons between the second and third choices and between the third and fourth choices
are not shown due to the small number of responses. 
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Appendix 21
Trial 2b: care staff views about the relative value for 
money of different designs
Design: day No. ranking  No. would  No. would  No. would  No. unable 
best still choose  still choose  still choose  to answer 
if £15  if £10  if £5  question
more than  more than  more than 
2nd choice 2nd choice 2nd choice
Pull-ups 44 31 1 1 11
Diapers 22 7 2 2 11
Inserts 18 6 7 1 4
T-shaped 15 3 3 2 7
Design: night No. ranking  No. would  No. would  No. would  No. unable 
best still choose  still choose still choose  to answer 
if £6  if £4  if £2  question
more than  more than  more than 
2nd choice 2nd choice 2nd choice
Diapers 39 10 2 2 25
Pull-ups 33 6 3 2 11
T-shaped 20 11 0 0 9
Inserts 6 3 0 0 3Volume 1, 1997
No. 1
Home parenteral nutrition: a systematic
review.
By Richards DM, Deeks JJ, Sheldon
TA, Shaffer JL.
No. 2
Diagnosis, management and screening
of early localised prostate cancer.
A review by Selley S, Donovan J,
Faulkner A, Coast J, Gillatt D.
No. 3
The diagnosis, management, treatment
and costs of prostate cancer in England
and Wales.
A review by Chamberlain J, Melia J,
Moss S, Brown J.
No. 4
Screening for fragile X syndrome.
A review by Murray J, Cuckle H,
Taylor G, Hewison J.
No. 5
A review of near patient testing in
primary care.
By Hobbs FDR, Delaney BC,
Fitzmaurice DA, Wilson S, Hyde CJ,
Thorpe GH, et al.
No. 6
Systematic review of outpatient services
for chronic pain control.
By McQuay HJ, Moore RA, Eccleston
C, Morley S, de C Williams AC.
No. 7
Neonatal screening for inborn errors of
metabolism: cost, yield and outcome.
A review by Pollitt RJ, Green A,
McCabe CJ, Booth A, Cooper NJ,
Leonard JV, et al.
No. 8
Preschool vision screening.
A review by Snowdon SK, 
Stewart-Brown SL.
No. 9
Implications of socio-cultural contexts
for the ethics of clinical trials.
A review by Ashcroft RE, Chadwick
DW, Clark SRL, Edwards RHT, Frith L,
Hutton JL.
No. 10
A critical review of the role of neonatal
hearing screening in the detection of
congenital hearing impairment.
By Davis A, Bamford J, Wilson I,
Ramkalawan T, Forshaw M, Wright S.
No. 11
Newborn screening for inborn errors of
metabolism: a systematic review.
By Seymour CA, Thomason MJ,
Chalmers RA, Addison GM, Bain MD,
Cockburn F, et al.
No. 12
Routine preoperative testing: 
a systematic review of the evidence.
By Munro J, Booth A, Nicholl J.
No. 13
Systematic review of the effectiveness 
of laxatives in the elderly.
By Petticrew M, Watt I, Sheldon T.
No. 14
When and how to assess fast-changing
technologies: a comparative study of
medical applications of four generic
technologies.
A review by Mowatt G, Bower DJ,
Brebner JA, Cairns JA, Grant AM,
McKee L.
Volume 2, 1998
No. 1
Antenatal screening for Down’s
syndrome.
A review by Wald NJ, Kennard A,
Hackshaw A, McGuire A.
No. 2
Screening for ovarian cancer: 
a systematic review.
By Bell R, Petticrew M, Luengo S,
Sheldon TA.
No. 3
Consensus development methods, and
their use in clinical guideline
development.
A review by Murphy MK, Black NA,
Lamping DL, McKee CM, Sanderson
CFB, Askham J, et al.
No. 4
A cost–utility analysis of interferon 
beta for multiple sclerosis.
By Parkin D, McNamee P, Jacoby A,
Miller P, Thomas S, Bates D.
No. 5
Effectiveness and efficiency of methods
of dialysis therapy for end-stage renal
disease: systematic reviews.
By MacLeod A, Grant A, 
Donaldson C, Khan I, Campbell M,
Daly C, et al.
No. 6
Effectiveness of hip prostheses in
primary total hip replacement: a critical
review of evidence and an economic
model.
By Faulkner A, Kennedy LG, 
Baxter K, Donovan J, Wilkinson M,
Bevan G.
No. 7
Antimicrobial prophylaxis in colorectal
surgery: a systematic review of
randomised controlled trials.
By Song F, Glenny AM.
No. 8
Bone marrow and peripheral blood
stem cell transplantation for malignancy.
A review by Johnson PWM, Simnett SJ,
Sweetenham JW, Morgan GJ, Stewart LA.
No. 9
Screening for speech and language
delay: a systematic review of the
literature.
By Law J, Boyle J, Harris F, Harkness
A, Nye C.
No. 10
Resource allocation for chronic stable
angina: a systematic review of
effectiveness, costs and 
cost-effectiveness of alternative
interventions.
By Sculpher MJ, Petticrew M, 
Kelland JL, Elliott RA, Holdright DR,
Buxton MJ.
No. 11
Detection, adherence and control of
hypertension for the prevention of
stroke: a systematic review.
By Ebrahim S.
No. 12
Postoperative analgesia and vomiting,
with special reference to day-case
surgery: a systematic review.
By McQuay HJ, Moore RA.
No. 13
Choosing between randomised and
nonrandomised studies: a systematic
review.
By Britton A, McKee M, Black N,
McPherson K, Sanderson C, Bain C.
No. 14
Evaluating patient-based outcome
measures for use in clinical 
trials.
A review by Fitzpatrick R, Davey C,
Buxton MJ, Jones DR.
Health Technology Assessment 2008; Vol. 12: No. 29
187
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.
Health Technology Assessment reports 
published to dateNo. 15
Ethical issues in the design and conduct
of randomised controlled trials.
A review by Edwards SJL, Lilford RJ,
Braunholtz DA, Jackson JC, Hewison J,
Thornton J.
No. 16
Qualitative research methods in health
technology assessment: a review of the
literature.
By Murphy E, Dingwall R, Greatbatch
D, Parker S, Watson P.
No. 17
The costs and benefits of paramedic
skills in pre-hospital trauma care.
By Nicholl J, Hughes S, Dixon S,
Turner J, Yates D.
No. 18
Systematic review of endoscopic
ultrasound in gastro-oesophageal
cancer.
By Harris KM, Kelly S, Berry E,
Hutton J, Roderick P, Cullingworth J, et al.
No. 19
Systematic reviews of trials and other
studies.
By Sutton AJ, Abrams KR, Jones DR,
Sheldon TA, Song F.
No. 20
Primary total hip replacement surgery: 
a systematic review of outcomes and
modelling of cost-effectiveness
associated with different prostheses.
A review by Fitzpatrick R, Shortall E,
Sculpher M, Murray D, Morris R, Lodge
M, et al.
Volume 3, 1999
No. 1
Informed decision making: an annotated
bibliography and systematic review.
By Bekker H, Thornton JG, 
Airey CM, Connelly JB, Hewison J,
Robinson MB, et al.
No. 2
Handling uncertainty when performing
economic evaluation of healthcare
interventions.
A review by Briggs AH, Gray AM.
No. 3
The role of expectancies in the placebo
effect and their use in the delivery of
health care: a systematic review.
By Crow R, Gage H, Hampson S,
Hart J, Kimber A, Thomas H.
No. 4
A randomised controlled trial of
different approaches to universal
antenatal HIV testing: uptake and
acceptability. Annex: Antenatal HIV
testing – assessment of a routine
voluntary approach.
By Simpson WM, Johnstone FD, Boyd
FM, Goldberg DJ, Hart GJ, Gormley
SM, et al.
No. 5
Methods for evaluating area-wide and
organisation-based interventions in
health and health care: a systematic
review.
By Ukoumunne OC, Gulliford MC,
Chinn S, Sterne JAC, Burney PGJ.
No. 6
Assessing the costs of healthcare
technologies in clinical trials.
A review by Johnston K, Buxton MJ,
Jones DR, Fitzpatrick R.
No. 7
Cooperatives and their primary care
emergency centres: organisation and
impact.
By Hallam L, Henthorne K.
No. 8
Screening for cystic fibrosis.
A review by Murray J, Cuckle H,
Taylor G, Littlewood J, Hewison J.
No. 9
A review of the use of health status
measures in economic evaluation.
By Brazier J, Deverill M, Green C,
Harper R, Booth A.
No. 10
Methods for the analysis of quality-of-
life and survival data in health
technology assessment.
A review by Billingham LJ, Abrams
KR, Jones DR.
No. 11
Antenatal and neonatal
haemoglobinopathy screening in the
UK: review and economic analysis.
By Zeuner D, Ades AE, Karnon J,
Brown J, Dezateux C, Anionwu EN.
No. 12
Assessing the quality of reports of
randomised trials: implications for the
conduct of meta-analyses.
A review by Moher D, Cook DJ, Jadad
AR, Tugwell P, Moher M, Jones A, et al.
No. 13
‘Early warning systems’ for identifying
new healthcare technologies.
By Robert G, Stevens A, Gabbay J.
No. 14
A systematic review of the role of human
papillomavirus testing within a cervical
screening programme.
By Cuzick J, Sasieni P, Davies P,
Adams J, Normand C, Frater A, et al.
No. 15
Near patient testing in diabetes clinics:
appraising the costs and outcomes.
By Grieve R, Beech R, Vincent J,
Mazurkiewicz J.
No. 16
Positron emission tomography:
establishing priorities for health
technology assessment.
A review by Robert G, Milne R.
No. 17 (Pt 1)
The debridement of chronic wounds: 
a systematic review.
By Bradley M, Cullum N, Sheldon T.
No. 17 (Pt 2)
Systematic reviews of wound care
management: (2) Dressings and topical
agents used in the healing of chronic
wounds.
By Bradley M, Cullum N, Nelson EA,
Petticrew M, Sheldon T, Torgerson D.
No. 18
A systematic literature review of spiral
and electron beam computed
tomography: with particular reference to
clinical applications in hepatic lesions,
pulmonary embolus and coronary artery
disease.
By Berry E, Kelly S, Hutton J, 
Harris KM, Roderick P, Boyce JC, et al.
No. 19
What role for statins? A review and
economic model.
By Ebrahim S, Davey Smith G,
McCabe C, Payne N, Pickin M, Sheldon
TA, et al.
No. 20
Factors that limit the quality, number
and progress of randomised controlled
trials.
A review by Prescott RJ, Counsell CE,
Gillespie WJ, Grant AM, Russell IT,
Kiauka S, et al.
No. 21
Antimicrobial prophylaxis in total hip
replacement: a systematic review.
By Glenny AM, Song F.
No. 22
Health promoting schools and health
promotion in schools: two systematic
reviews.
By Lister-Sharp D, Chapman S,
Stewart-Brown S, Sowden A.
No. 23
Economic evaluation of a primary care-
based education programme for patients
with osteoarthritis of the knee.
A review by Lord J, Victor C,
Littlejohns P, Ross FM, Axford JS.
Volume 4, 2000
No. 1
The estimation of marginal time
preference in a UK-wide sample
(TEMPUS) project.
A review by Cairns JA, van der Pol
MM.
No. 2
Geriatric rehabilitation following
fractures in older people: a systematic
review.
By Cameron I, Crotty M, Currie C,
Finnegan T, Gillespie L, Gillespie W, 
et al.
Health Technology Assessment reports published to date
188No. 3
Screening for sickle cell disease and
thalassaemia: a systematic review with
supplementary research.
By Davies SC, Cronin E, Gill M,
Greengross P, Hickman M, Normand C.
No. 4
Community provision of hearing aids
and related audiology services.
A review by Reeves DJ, Alborz A,
Hickson FS, Bamford JM.
No. 5
False-negative results in screening
programmes: systematic review of
impact and implications.
By Petticrew MP, Sowden AJ, 
Lister-Sharp D, Wright K.
No. 6
Costs and benefits of community
postnatal support workers: a
randomised controlled trial.
By Morrell CJ, Spiby H, Stewart P,
Walters S, Morgan A.
No. 7
Implantable contraceptives (subdermal
implants and hormonally impregnated
intrauterine systems) versus other forms
of reversible contraceptives: two
systematic reviews to assess relative
effectiveness, acceptability, tolerability
and cost-effectiveness.
By French RS, Cowan FM, Mansour
DJA, Morris S, Procter T, Hughes D, 
et al.
No. 8
An introduction to statistical methods
for health technology assessment.
A review by White SJ, Ashby D, 
Brown PJ.
No. 9
Disease-modifying drugs for multiple
sclerosis: a rapid and systematic 
review.
By Clegg A, Bryant J, Milne R.
No. 10
Publication and related biases.
A review by Song F, Eastwood AJ,
Gilbody S, Duley L, Sutton AJ.
No. 11
Cost and outcome implications of the
organisation of vascular services.
By Michaels J, Brazier J, Palfreyman
S, Shackley P, Slack R.
No. 12
Monitoring blood glucose control in
diabetes mellitus: a systematic review.
By Coster S, Gulliford MC, Seed PT,
Powrie JK, Swaminathan R.
No. 13
The effectiveness of domiciliary health
visiting: a systematic review of
international studies 
and a selective review of the British
literature.
By Elkan R, Kendrick D, Hewitt M,
Robinson JJA, Tolley K, Blair M, et al.
No. 14
The determinants of screening uptake
and interventions for increasing uptake:
a systematic review.
By Jepson R, Clegg A, Forbes C,
Lewis R, Sowden A, Kleijnen J.
No. 15
The effectiveness and cost-effectiveness
of prophylactic removal of wisdom
teeth. 
A rapid review by Song F, O’Meara S,
Wilson P, Golder S, Kleijnen J.
No. 16
Ultrasound screening in pregnancy: a
systematic review of the clinical
effectiveness, cost-effectiveness and
women’s views.
By Bricker L, Garcia J, Henderson J,
Mugford M, Neilson J, Roberts T, et al.
No. 17
A rapid and systematic review of the
effectiveness and cost-effectiveness of
the taxanes used in the treatment of
advanced breast and ovarian cancer.
By Lister-Sharp D, McDonagh MS,
Khan KS, Kleijnen J.
No. 18
Liquid-based cytology in cervical
screening: a rapid and systematic review.
By Payne N, Chilcott J, McGoogan E.
No. 19
Randomised controlled trial of non-
directive counselling,
cognitive–behaviour therapy and usual
general practitioner care in the
management of depression as well as
mixed anxiety and depression in
primary care.
By King M, Sibbald B, Ward E, Bower
P, Lloyd M, Gabbay M, et al.
No. 20
Routine referral for radiography of
patients presenting with low back pain:
is patients’ outcome influenced by GPs’
referral for plain radiography?
By Kerry S, Hilton S, Patel S, Dundas
D, Rink E, Lord J.
No. 21
Systematic reviews of wound care
management: (3) antimicrobial agents
for chronic wounds; (4) diabetic foot
ulceration.
By O’Meara S, Cullum N, Majid M,
Sheldon T.
No. 22
Using routine data to complement and
enhance the results of randomised
controlled trials.
By Lewsey JD, Leyland AH, 
Murray GD, Boddy FA.
No. 23
Coronary artery stents in the treatment
of ischaemic heart disease: a rapid and
systematic review.
By Meads C, Cummins C, Jolly K,
Stevens A, Burls A, Hyde C.
No. 24
Outcome measures for adult critical
care: a systematic review.
By Hayes JA, Black NA, 
Jenkinson C, Young JD, Rowan KM,
Daly K, et al.
No. 25
A systematic review to evaluate the
effectiveness of interventions to 
promote the initiation of 
breastfeeding.
By Fairbank L, O’Meara S, Renfrew
MJ, Woolridge M, Sowden AJ, 
Lister-Sharp D.
No. 26
Implantable cardioverter defibrillators:
arrhythmias. A rapid and systematic
review.
By Parkes J, Bryant J, Milne R.
No. 27
Treatments for fatigue in multiple
sclerosis: a rapid and systematic 
review.
By Brañas P, Jordan R, Fry-Smith A,
Burls A, Hyde C.
No. 28
Early asthma prophylaxis, natural
history, skeletal development and
economy (EASE): a pilot randomised
controlled trial.
By Baxter-Jones ADG, Helms PJ,
Russell G, Grant A, Ross S, Cairns JA, 
et al.
No. 29
Screening for hypercholesterolaemia
versus case finding for familial
hypercholesterolaemia: a systematic
review and cost-effectiveness analysis.
By Marks D, Wonderling D,
Thorogood M, Lambert H, Humphries
SE, Neil HAW.
No. 30
A rapid and systematic review of the
clinical effectiveness and cost-
effectiveness of glycoprotein IIb/IIIa
antagonists in the medical management
of unstable angina.
By McDonagh MS, Bachmann LM,
Golder S, Kleijnen J, ter Riet G.
No. 31
A randomised controlled trial of
prehospital intravenous fluid
replacement therapy in serious trauma.
By Turner J, Nicholl J, Webber L,
Cox H, Dixon S, Yates D.
No. 32
Intrathecal pumps for giving opioids in
chronic pain: a systematic review.
By Williams JE, Louw G, Towlerton G.
No. 33
Combination therapy (interferon alfa
and ribavirin) in the treatment of
chronic hepatitis C: a rapid and
systematic review.
By Shepherd J, Waugh N, 
Hewitson P.
Health Technology Assessment 2008; Vol. 12: No. 29
189
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.No. 34
A systematic review of comparisons of
effect sizes derived from randomised
and non-randomised studies.
By MacLehose RR, Reeves BC,
Harvey IM, Sheldon TA, Russell IT,
Black AMS.
No. 35
Intravascular ultrasound-guided
interventions in coronary artery disease:
a systematic literature review, with
decision-analytic modelling, of outcomes
and cost-effectiveness.
By Berry E, Kelly S, Hutton J,
Lindsay HSJ, Blaxill JM, Evans JA, et al.
No. 36
A randomised controlled trial to
evaluate the effectiveness and cost-
effectiveness of counselling patients with
chronic depression.
By Simpson S, Corney R, Fitzgerald P,
Beecham J.
No. 37
Systematic review of treatments for
atopic eczema.
By Hoare C, Li Wan Po A, Williams H.
No. 38
Bayesian methods in health technology
assessment: a review.
By Spiegelhalter DJ, Myles JP, 
Jones DR, Abrams KR.
No. 39
The management of dyspepsia: a
systematic review.
By Delaney B, Moayyedi P, Deeks J,
Innes M, Soo S, Barton P, et al.
No. 40
A systematic review of treatments for
severe psoriasis.
By Griffiths CEM, Clark CM, Chalmers
RJG, Li Wan Po A, Williams HC.
Volume 5, 2001
No. 1
Clinical and cost-effectiveness of
donepezil, rivastigmine and
galantamine for Alzheimer’s disease: a
rapid and systematic review.
By Clegg A, Bryant J, Nicholson T,
McIntyre L, De Broe S, Gerard K, et al.
No. 2
The clinical effectiveness and cost-
effectiveness of riluzole for motor
neurone disease: a rapid and systematic
review.
By Stewart A, Sandercock J, Bryan S,
Hyde C, Barton PM, Fry-Smith A, et al.
No. 3
Equity and the economic evaluation of
healthcare.
By Sassi F, Archard L, Le Grand J.
No. 4
Quality-of-life measures in chronic
diseases of childhood.
By Eiser C, Morse R.
No. 5
Eliciting public preferences for
healthcare: a systematic review of
techniques.
By Ryan M, Scott DA, Reeves C, Bate
A, van Teijlingen ER, Russell EM, et al.
No. 6
General health status measures for
people with cognitive impairment:
learning disability and acquired brain
injury.
By Riemsma RP, Forbes CA, 
Glanville JM, Eastwood AJ, Kleijnen J.
No. 7
An assessment of screening strategies for
fragile X syndrome in the UK.
By Pembrey ME, Barnicoat AJ,
Carmichael B, Bobrow M, Turner G.
No. 8
Issues in methodological research:
perspectives from researchers and
commissioners.
By Lilford RJ, Richardson A, Stevens
A, Fitzpatrick R, Edwards S, Rock F, et al.
No. 9
Systematic reviews of wound care
management: (5) beds; (6) compression;
(7) laser therapy, therapeutic
ultrasound, electrotherapy and
electromagnetic therapy.
By Cullum N, Nelson EA, Flemming
K, Sheldon T.
No. 10
Effects of educational and psychosocial
interventions for adolescents with
diabetes mellitus: a systematic review.
By Hampson SE, Skinner TC, Hart J,
Storey L, Gage H, Foxcroft D, et al.
No. 11
Effectiveness of autologous chondrocyte
transplantation for hyaline cartilage
defects in knees: a rapid and systematic
review.
By Jobanputra P, Parry D, Fry-Smith
A, Burls A.
No. 12
Statistical assessment of the learning
curves of health technologies.
By Ramsay CR, Grant AM, 
Wallace SA, Garthwaite PH, Monk AF,
Russell IT.
No. 13
The effectiveness and cost-effectiveness
of temozolomide for the treatment of
recurrent malignant glioma: a rapid and
systematic review.
By Dinnes J, Cave C, Huang S, 
Major K, Milne R.
No. 14
A rapid and systematic review of the
clinical effectiveness and cost-
effectiveness of debriding agents in
treating surgical wounds healing by
secondary intention.
By Lewis R, Whiting P, ter Riet G,
O’Meara S, Glanville J.
No. 15
Home treatment for mental health
problems: a systematic review.
By Burns T, Knapp M, 
Catty J, Healey A, Henderson J, 
Watt H, et al.
No. 16
How to develop cost-conscious
guidelines.
By Eccles M, Mason J.
No. 17
The role of specialist nurses in multiple
sclerosis: a rapid and systematic review.
By De Broe S, Christopher F, 
Waugh N.
No. 18
A rapid and systematic review of the
clinical effectiveness and cost-
effectiveness of orlistat in the
management of obesity.
By O’Meara S, Riemsma R, 
Shirran L, Mather L, ter Riet G.
No. 19
The clinical effectiveness and cost-
effectiveness of pioglitazone for type 2
diabetes mellitus: a rapid and systematic
review.
By Chilcott J, Wight J, Lloyd Jones
M, Tappenden P.
No. 20
Extended scope of nursing practice: a
multicentre randomised controlled trial
of appropriately trained nurses and
preregistration house officers in pre-
operative assessment in elective general
surgery.
By Kinley H, Czoski-Murray C,
George S, McCabe C, Primrose J, 
Reilly C, et al.
No. 21
Systematic reviews of the effectiveness of
day care for people with severe mental
disorders: (1) Acute day hospital versus
admission; (2) Vocational rehabilitation;
(3) Day hospital versus outpatient 
care.
By Marshall M, Crowther R, Almaraz-
Serrano A, Creed F, Sledge W, 
Kluiter H, et al.
No. 22
The measurement and monitoring of
surgical adverse events.
By Bruce J, Russell EM, Mollison J,
Krukowski ZH.
No. 23
Action research: a systematic review and
guidance for assessment.
By Waterman H, Tillen D, Dickson R,
de Koning K.
No. 24
A rapid and systematic review of the
clinical effectiveness and cost-
effectiveness of gemcitabine for the
treatment of pancreatic cancer.
By Ward S, Morris E, Bansback N,
Calvert N, Crellin A, Forman D, et al.
Health Technology Assessment reports published to date
190No. 25
A rapid and systematic review of the
evidence for the clinical effectiveness
and cost-effectiveness of irinotecan,
oxaliplatin and raltitrexed for the
treatment of advanced colorectal cancer.
By Lloyd Jones M, Hummel S,
Bansback N, Orr B, Seymour M.
No. 26
Comparison of the effectiveness of
inhaler devices in asthma and chronic
obstructive airways disease: a systematic
review of the literature.
By Brocklebank D, Ram F, Wright J,
Barry P, Cates C, Davies L, et al.
No. 27
The cost-effectiveness of magnetic
resonance imaging for investigation of
the knee joint.
By Bryan S, Weatherburn G, Bungay
H, Hatrick C, Salas C, Parry D, et al.
No. 28
A rapid and systematic review of the
clinical effectiveness and cost-
effectiveness of topotecan for ovarian
cancer.
By Forbes C, Shirran L, Bagnall A-M,
Duffy S, ter Riet G.
No. 29
Superseded by a report published in a
later volume.
No. 30
The role of radiography in primary care
patients with low back pain of at least 6
weeks duration: a randomised
(unblinded) controlled trial.
By Kendrick D, Fielding K, Bentley E,
Miller P, Kerslake R, Pringle M.
No. 31
Design and use of questionnaires: a
review of best practice applicable to
surveys of health service staff and
patients.
By McColl E, Jacoby A, Thomas L,
Soutter J, Bamford C, Steen N, et al.
No. 32
A rapid and systematic review of the
clinical effectiveness and cost-
effectiveness of paclitaxel, docetaxel,
gemcitabine and vinorelbine in non-
small-cell lung cancer.
By Clegg A, Scott DA, Sidhu M,
Hewitson P, Waugh N.
No. 33
Subgroup analyses in randomised
controlled trials: quantifying the risks of
false-positives and false-negatives.
By Brookes ST, Whitley E, 
Peters TJ, Mulheran PA, Egger M,
Davey Smith G.
No. 34
Depot antipsychotic medication in the
treatment of patients with schizophrenia:
(1) Meta-review; (2) Patient and nurse
attitudes.
By David AS, Adams C.
No. 35
A systematic review of controlled trials
of the effectiveness and cost-
effectiveness of brief psychological
treatments for depression.
By Churchill R, Hunot V, Corney R,
Knapp M, McGuire H, Tylee A, et al.
No. 36
Cost analysis of child health
surveillance.
By Sanderson D, Wright D, Acton C,
Duree D.
Volume 6, 2002
No. 1
A study of the methods used to select
review criteria for clinical audit.
By Hearnshaw H, Harker R, Cheater
F, Baker R, Grimshaw G.
No. 2
Fludarabine as second-line therapy for
B cell chronic lymphocytic leukaemia: 
a technology assessment.
By Hyde C, Wake B, Bryan S, Barton
P, Fry-Smith A, Davenport C, et al.
No. 3
Rituximab as third-line treatment for
refractory or recurrent Stage III or IV
follicular non-Hodgkin’s lymphoma: a
systematic review and economic
evaluation.
By Wake B, Hyde C, Bryan S, Barton
P, Song F, Fry-Smith A, et al.
No. 4
A systematic review of discharge
arrangements for older people.
By Parker SG, Peet SM, McPherson A,
Cannaby AM, Baker R, Wilson A, et al.
No. 5
The clinical effectiveness and cost-
effectiveness of inhaler devices used in
the routine management of chronic
asthma in older children: a systematic
review and economic evaluation.
By Peters J, Stevenson M, Beverley C,
Lim J, Smith S.
No. 6
The clinical effectiveness and cost-
effectiveness of sibutramine in the
management of obesity: a technology
assessment.
By O’Meara S, Riemsma R, Shirran
L, Mather L, ter Riet G.
No. 7
The cost-effectiveness of magnetic
resonance angiography for carotid
artery stenosis and peripheral vascular
disease: a systematic review.
By Berry E, Kelly S, Westwood ME,
Davies LM, Gough MJ, Bamford JM,
et al.
No. 8
Promoting physical activity in South
Asian Muslim women through ‘exercise
on prescription’.
By Carroll B, Ali N, Azam N.
No. 9
Zanamivir for the treatment of influenza
in adults: a systematic review and
economic evaluation.
By Burls A, Clark W, Stewart T,
Preston C, Bryan S, Jefferson T, et al.
No. 10
A review of the natural history and
epidemiology of multiple sclerosis:
implications for resource allocation and
health economic models.
By Richards RG, Sampson FC, 
Beard SM, Tappenden P.
No. 11
Screening for gestational diabetes: a
systematic review and economic
evaluation.
By Scott DA, Loveman E, McIntyre L,
Waugh N.
No. 12
The clinical effectiveness and cost-
effectiveness of surgery for people with
morbid obesity: a systematic review and
economic evaluation.
By Clegg AJ, Colquitt J, Sidhu MK,
Royle P, Loveman E, Walker A.
No. 13
The clinical effectiveness of trastuzumab
for breast cancer: a systematic review.
By Lewis R, Bagnall A-M, Forbes C,
Shirran E, Duffy S, Kleijnen J, et al.
No. 14
The clinical effectiveness and cost-
effectiveness of vinorelbine for breast
cancer: a systematic review and
economic evaluation.
By Lewis R, Bagnall A-M, King S,
Woolacott N, Forbes C, Shirran L, et al.
No. 15
A systematic review of the effectiveness
and cost-effectiveness of metal-on-metal
hip resurfacing arthroplasty for
treatment of hip disease.
By Vale L, Wyness L, McCormack K,
McKenzie L, Brazzelli M, Stearns SC.
No. 16
The clinical effectiveness and cost-
effectiveness of bupropion and nicotine
replacement therapy for smoking
cessation: a systematic review and
economic evaluation.
By Woolacott NF, Jones L, Forbes CA,
Mather LC, Sowden AJ, Song FJ, et al.
No. 17
A systematic review of effectiveness and
economic evaluation of new drug
treatments for juvenile idiopathic
arthritis: etanercept.
By Cummins C, Connock M, 
Fry-Smith A, Burls A.
No. 18
Clinical effectiveness and cost-
effectiveness of growth hormone in
children: a systematic review and
economic evaluation.
By Bryant J, Cave C, Mihaylova B,
Chase D, McIntyre L, Gerard K, et al.
Health Technology Assessment 2008; Vol. 12: No. 29
191
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.No. 19
Clinical effectiveness and cost-
effectiveness of growth hormone in
adults in relation to impact on quality of
life: a systematic review and economic
evaluation.
By Bryant J, Loveman E, Chase D,
Mihaylova B, Cave C, Gerard K, et al.
No. 20
Clinical medication review by a
pharmacist of patients on repeat
prescriptions in general practice: a
randomised controlled trial.
By Zermansky AG, Petty DR, Raynor
DK, Lowe CJ, Freementle N, Vail A.
No. 21
The effectiveness of infliximab and
etanercept for the treatment of
rheumatoid arthritis: a systematic review
and economic evaluation.
By Jobanputra P, Barton P, Bryan S,
Burls A.
No. 22
A systematic review and economic
evaluation of computerised cognitive
behaviour therapy for depression and
anxiety.
By Kaltenthaler E, Shackley P, Stevens
K, Beverley C, Parry G, Chilcott J.
No. 23
A systematic review and economic
evaluation of pegylated liposomal
doxorubicin hydrochloride for ovarian
cancer.
By Forbes C, Wilby J, Richardson G,
Sculpher M, Mather L, Reimsma R.
No. 24
A systematic review of the effectiveness
of interventions based on a stages-of-
change approach to promote individual
behaviour change.
By Riemsma RP, Pattenden J, Bridle C,
Sowden AJ, Mather L, Watt IS, et al.
No. 25
A systematic review update of the
clinical effectiveness and cost-
effectiveness of glycoprotein IIb/IIIa
antagonists.
By Robinson M, Ginnelly L, Sculpher
M, Jones L, Riemsma R, Palmer S, et al.
No. 26
A systematic review of the effectiveness,
cost-effectiveness and barriers to
implementation of thrombolytic and
neuroprotective therapy for acute
ischaemic stroke in the NHS.
By Sandercock P, Berge E, Dennis M,
Forbes J, Hand P, Kwan J, et al.
No. 27
A randomised controlled crossover 
trial of nurse practitioner versus 
doctor-led outpatient care in a
bronchiectasis clinic.
By Caine N, Sharples LD,
Hollingworth W, French J, Keogan M,
Exley A, et al.
No. 28
Clinical effectiveness and cost –
consequences of selective serotonin
reuptake inhibitors in the treatment of
sex offenders.
By Adi Y, Ashcroft D, Browne K,
Beech A, Fry-Smith A, Hyde C.
No. 29
Treatment of established osteoporosis: 
a systematic review and cost–utility
analysis.
By Kanis JA, Brazier JE, Stevenson M,
Calvert NW, Lloyd Jones M.
No. 30
Which anaesthetic agents are cost-
effective in day surgery? Literature
review, national survey of practice and
randomised controlled trial.
By Elliott RA Payne K, Moore JK,
Davies LM, Harper NJN, St Leger AS,
et al.
No. 31
Screening for hepatitis C among
injecting drug users and in
genitourinary medicine clinics:
systematic reviews of effectiveness,
modelling study and national survey of
current practice.
By Stein K, Dalziel K, Walker A,
McIntyre L, Jenkins B, Horne J, et al.
No. 32
The measurement of satisfaction with
healthcare: implications for practice
from a systematic review of the
literature.
By Crow R, Gage H, Hampson S,
Hart J, Kimber A, Storey L, et al.
No. 33
The effectiveness and cost-effectiveness
of imatinib in chronic myeloid
leukaemia: a systematic review.
By Garside R, Round A, Dalziel K,
Stein K, Royle R.
No. 34
A comparative study of hypertonic
saline, daily and alternate-day 
rhDNase in children with cystic 
fibrosis.
By Suri R, Wallis C, Bush A,
Thompson S, Normand C, Flather M, 
et al.
No. 35
A systematic review of the costs and
effectiveness of different models of
paediatric home care.
By Parker G, Bhakta P, Lovett CA,
Paisley S, Olsen R, Turner D, et al.
Volume 7, 2003
No. 1
How important are comprehensive
literature searches and the assessment of
trial quality in systematic reviews?
Empirical study.
By Egger M, Jüni P, Bartlett C,
Holenstein F, Sterne J.
No. 2
Systematic review of the effectiveness
and cost-effectiveness, and economic
evaluation, of home versus hospital or
satellite unit haemodialysis for people
with end-stage renal failure.
By Mowatt G, Vale L, Perez J, Wyness
L, Fraser C, MacLeod A, et al.
No. 3
Systematic review and economic
evaluation of the effectiveness of
infliximab for the treatment of Crohn’s
disease.
By Clark W, Raftery J, Barton P, 
Song F, Fry-Smith A, Burls A.
No. 4
A review of the clinical effectiveness and
cost-effectiveness of routine anti-D
prophylaxis for pregnant women who
are rhesus negative.
By Chilcott J, Lloyd Jones M, Wight
J, Forman K, Wray J, Beverley C, et al.
No. 5
Systematic review and evaluation of the
use of tumour markers in paediatric
oncology: Ewing’s sarcoma and
neuroblastoma.
By Riley RD, Burchill SA, Abrams KR,
Heney D, Lambert PC, Jones DR, et al.
No. 6
The cost-effectiveness of screening for
Helicobacter pylori to reduce mortality
and morbidity from gastric cancer and
peptic ulcer disease: a discrete-event
simulation model.
By Roderick P, Davies R, Raftery J,
Crabbe D, Pearce R, Bhandari P, et al.
No. 7
The clinical effectiveness and cost-
effectiveness of routine dental checks: a
systematic review and economic
evaluation.
By Davenport C, Elley K, Salas C,
Taylor-Weetman CL, Fry-Smith A, 
Bryan S, et al.
No. 8
A multicentre randomised controlled
trial assessing the costs and benefits of
using structured information and
analysis of women’s preferences in the
management of menorrhagia.
By Kennedy ADM, Sculpher MJ,
Coulter A, Dwyer N, Rees M, 
Horsley S, et al.
No. 9
Clinical effectiveness and cost–utility of
photodynamic therapy for wet age-related
macular degeneration: a systematic review
and economic evaluation.
By Meads C, Salas C, Roberts T,
Moore D, Fry-Smith A, Hyde C.
No. 10
Evaluation of molecular tests for
prenatal diagnosis of chromosome
abnormalities.
By Grimshaw GM, Szczepura A,
Hultén M, MacDonald F, Nevin NC,
Sutton F, et al.
Health Technology Assessment reports published to date
192No. 11
First and second trimester antenatal
screening for Down’s syndrome: the
results of the Serum, Urine and
Ultrasound Screening Study 
(SURUSS).
By Wald NJ, Rodeck C, 
Hackshaw AK, Walters J, Chitty L,
Mackinson AM.
No. 12
The effectiveness and cost-effectiveness
of ultrasound locating devices for
central venous access: a systematic
review and economic evaluation.
By Calvert N, Hind D, McWilliams
RG, Thomas SM, Beverley C, 
Davidson A.
No. 13
A systematic review of atypical
antipsychotics in schizophrenia.
By Bagnall A-M, Jones L, Lewis R,
Ginnelly L, Glanville J, Torgerson D, 
et al.
No. 14
Prostate Testing for Cancer and
Treatment (ProtecT) feasibility 
study.
By Donovan J, Hamdy F, Neal D,
Peters T, Oliver S, Brindle L, et al.
No. 15
Early thrombolysis for the treatment 
of acute myocardial infarction: a
systematic review and economic
evaluation.
By Boland A, Dundar Y, Bagust A,
Haycox A, Hill R, Mujica Mota R,
et al.
No. 16
Screening for fragile X syndrome: 
a literature review and modelling.
By Song FJ, Barton P, Sleightholme V,
Yao GL, Fry-Smith A.
No. 17
Systematic review of endoscopic sinus
surgery for nasal polyps.
By Dalziel K, Stein K, Round A,
Garside R, Royle P. 
No. 18
Towards efficient guidelines: how to
monitor guideline use in primary 
care.
By Hutchinson A, McIntosh A, Cox S,
Gilbert C. 
No. 19
Effectiveness and cost-effectiveness of
acute hospital-based spinal cord injuries
services: systematic review.
By Bagnall A-M, Jones L, 
Richardson G, Duffy S, 
Riemsma R. 
No. 20
Prioritisation of health technology
assessment. The PATHS model:
methods and case studies.
By Townsend J, Buxton M, 
Harper G.
No. 21
Systematic review of the clinical
effectiveness and cost-effectiveness 
of tension-free vaginal tape for
treatment of urinary stress 
incontinence.
By Cody J, Wyness L, Wallace S,
Glazener C, Kilonzo M, Stearns S,
et al.
No. 22
The clinical and cost-effectiveness of
patient education models for diabetes: 
a systematic review and economic
evaluation.
By Loveman E, Cave C, Green C,
Royle P, Dunn N, Waugh N. 
No. 23
The role of modelling in prioritising
and planning clinical trials.
By Chilcott J, Brennan A, Booth A,
Karnon J, Tappenden P. 
No. 24
Cost–benefit evaluation of routine
influenza immunisation in people 65–74
years of age.
By Allsup S, Gosney M, Haycox A,
Regan M. 
No. 25
The clinical and cost-effectiveness of
pulsatile machine perfusion versus cold
storage of kidneys for transplantation
retrieved from heart-beating and non-
heart-beating donors.
By Wight J, Chilcott J, Holmes M,
Brewer N. 
No. 26
Can randomised trials rely on existing
electronic data? A feasibility study to
explore the value of routine data in
health technology assessment.
By Williams JG, Cheung WY, 
Cohen DR, Hutchings HA, Longo MF, 
Russell IT. 
No. 27
Evaluating non-randomised intervention
studies.
By Deeks JJ, Dinnes J, D’Amico R,
Sowden AJ, Sakarovitch C, Song F, et al.
No. 28
A randomised controlled trial to assess
the impact of a package comprising a
patient-orientated, evidence-based self-
help guidebook and patient-centred
consultations on disease management
and satisfaction in inflammatory bowel
disease.
By Kennedy A, Nelson E, Reeves D,
Richardson G, Roberts C, Robinson A,
et al.
No. 29
The effectiveness of diagnostic tests for
the assessment of shoulder pain due to
soft tissue disorders: a systematic review.
By Dinnes J, Loveman E, McIntyre L,
Waugh N.
No. 30
The value of digital imaging in diabetic
retinopathy.
By Sharp PF, Olson J, Strachan F,
Hipwell J, Ludbrook A, O’Donnell M, 
et al.
No. 31
Lowering blood pressure to prevent
myocardial infarction and stroke: 
a new preventive strategy.
By Law M, Wald N, Morris J.
No. 32
Clinical and cost-effectiveness of
capecitabine and tegafur with uracil for
the treatment of metastatic colorectal
cancer: systematic review and economic
evaluation.
By Ward S, Kaltenthaler E, Cowan J,
Brewer N.
No. 33
Clinical and cost-effectiveness of new 
and emerging technologies for early
localised prostate cancer: a systematic
review. 
By Hummel S, Paisley S, Morgan A,
Currie E, Brewer N.
No. 34
Literature searching for clinical and
cost-effectiveness studies used in health
technology assessment reports carried
out for the National Institute for
Clinical Excellence appraisal 
system.
By Royle P, Waugh N.
No. 35
Systematic review and economic
decision modelling for the prevention
and treatment of influenza 
A and B.
By Turner D, Wailoo A, Nicholson K,
Cooper N, Sutton A, Abrams K.
No. 36
A randomised controlled trial to
evaluate the clinical and cost-
effectiveness of Hickman line 
insertions in adult cancer patients by
nurses.
By Boland A, Haycox A, Bagust A,
Fitzsimmons L.
No. 37
Redesigning postnatal care: a
randomised controlled trial of 
protocol-based midwifery-led care
focused on individual women’s 
physical and psychological health 
needs.
By MacArthur C, Winter HR, 
Bick DE, Lilford RJ, Lancashire RJ,
Knowles H, et al.
No. 38
Estimating implied rates of discount in
healthcare decision-making. 
By West RR, McNabb R, 
Thompson AGH, Sheldon TA, 
Grimley Evans J.
Health Technology Assessment 2008; Vol. 12: No. 29
193
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.No. 39
Systematic review of isolation policies in
the hospital management of methicillin-
resistant Staphylococcus aureus: a review of
the literature with epidemiological and
economic modelling. 
By Cooper BS, Stone SP, Kibbler CC,
Cookson BD, Roberts JA, Medley GF, 
et al.
No. 40
Treatments for spasticity and pain in
multiple sclerosis: a systematic review.
By Beard S, Hunn A, Wight J.
No. 41
The inclusion of reports of randomised
trials published in languages other than
English in systematic reviews. 
By Moher D, Pham B, Lawson ML,
Klassen TP.
No. 42
The impact of screening on future
health-promoting behaviours and health
beliefs: a systematic review.
By Bankhead CR, Brett J, Bukach C,
Webster P, Stewart-Brown S, Munafo M,
et al.
Volume 8, 2004
No. 1
What is the best imaging strategy for
acute stroke?
By Wardlaw JM, Keir SL, Seymour J,
Lewis S, Sandercock PAG, Dennis MS, 
et al. 
No. 2
Systematic review and modelling of the
investigation of acute and chronic chest
pain presenting in primary care.
By Mant J, McManus RJ, Oakes RAL,
Delaney BC, Barton PM, Deeks JJ, et al.
No. 3
The effectiveness and cost-effectiveness
of microwave and thermal balloon
endometrial ablation for heavy
menstrual bleeding: a systematic review
and economic modelling. 
By Garside R, Stein K, Wyatt K,
Round A, Price A.
No. 4
A systematic review of the role of
bisphosphonates in metastatic disease. 
By Ross JR, Saunders Y, Edmonds PM,
Patel S, Wonderling D, Normand C, et al. 
No. 5
Systematic review of the clinical
effectiveness and cost-effectiveness of
capecitabine (Xeloda®) for locally
advanced and/or metastatic breast cancer. 
By Jones L, Hawkins N, Westwood M,
Wright K, Richardson G, Riemsma R. 
No. 6
Effectiveness and efficiency of guideline
dissemination and implementation
strategies. 
By Grimshaw JM, Thomas RE,
MacLennan G, Fraser C, Ramsay CR,
Vale L, et al. 
No. 7
Clinical effectiveness and costs of the
Sugarbaker procedure for the treatment
of pseudomyxoma peritonei.
By Bryant J, Clegg AJ, Sidhu MK,
Brodin H, Royle P, Davidson P. 
No. 8
Psychological treatment for insomnia in
the regulation of long-term hypnotic
drug use. 
By Morgan K, Dixon S, Mathers N,
Thompson J, Tomeny M. 
No. 9
Improving the evaluation of therapeutic
interventions in multiple sclerosis:
development of a patient-based measure
of outcome. 
By Hobart JC, Riazi A, Lamping DL,
Fitzpatrick R, Thompson AJ. 
No. 10
A systematic review and economic
evaluation of magnetic resonance
cholangiopancreatography compared
with diagnostic endoscopic retrograde
cholangiopancreatography.
By Kaltenthaler E, Bravo Vergel Y,
Chilcott J, Thomas S, Blakeborough T,
Walters SJ, et al. 
No. 11
The use of modelling to evaluate new
drugs for patients with a chronic
condition: the case of antibodies against
tumour necrosis factor in rheumatoid
arthritis. 
By Barton P, Jobanputra P, Wilson J,
Bryan S, Burls A. 
No. 12
Clinical effectiveness and cost-
effectiveness of neonatal screening for
inborn errors of metabolism using
tandem mass spectrometry: a systematic
review. 
By Pandor A, Eastham J, Beverley C,
Chilcott J, Paisley S.
No. 13
Clinical effectiveness and cost-
effectiveness of pioglitazone and
rosiglitazone in the treatment of 
type 2 diabetes: a systematic 
review and economic 
evaluation. 
By Czoski-Murray C, Warren E,
Chilcott J, Beverley C, Psyllaki MA,
Cowan J. 
No. 14
Routine examination of the newborn:
the EMREN study. Evaluation of an
extension of the midwife role 
including a randomised controlled 
trial of appropriately trained midwives
and paediatric senior house 
officers. 
By Townsend J, Wolke D, Hayes J,
Davé S, Rogers C, Bloomfield L, 
et al. 
No. 15
Involving consumers in research and
development agenda setting for the
NHS: developing an evidence-based
approach. 
By Oliver S, Clarke-Jones L, 
Rees R, Milne R, Buchanan P, 
Gabbay J, et al. 
No. 16
A multi-centre randomised controlled
trial of minimally invasive direct
coronary bypass grafting versus
percutaneous transluminal coronary
angioplasty with stenting for proximal
stenosis of the left anterior descending
coronary artery. 
By Reeves BC, Angelini GD, Bryan
AJ, Taylor FC, Cripps T, Spyt TJ, et al. 
No. 17
Does early magnetic resonance imaging
influence management or improve
outcome in patients referred to
secondary care with low back pain? 
A pragmatic randomised controlled
trial. 
By Gilbert FJ, Grant AM, Gillan
MGC, Vale L, Scott NW, Campbell MK,
et al. 
No. 18
The clinical and cost-effectiveness of
anakinra for the treatment of
rheumatoid arthritis in adults: a
systematic review and economic analysis. 
By Clark W, Jobanputra P, Barton P,
Burls A.
No. 19
A rapid and systematic review and
economic evaluation of the clinical and
cost-effectiveness of newer drugs for
treatment of mania associated with
bipolar affective disorder. 
By Bridle C, Palmer S, Bagnall A-M,
Darba J, Duffy S, Sculpher M, et al. 
No. 20
Liquid-based cytology in cervical
screening: an updated rapid and
systematic review and economic 
analysis.
By Karnon J, Peters J, Platt J, 
Chilcott J, McGoogan E, Brewer N.
No. 21
Systematic review of the long-term
effects and economic consequences of
treatments for obesity and implications
for health improvement. 
By Avenell A, Broom J, Brown TJ,
Poobalan A, Aucott L, Stearns SC, et al.
No. 22
Autoantibody testing in children with
newly diagnosed type 1 diabetes
mellitus. 
By Dretzke J, Cummins C,
Sandercock J, Fry-Smith A, Barrett T,
Burls A.
Health Technology Assessment reports published to date
194No. 23
Clinical effectiveness and cost-
effectiveness of prehospital intravenous
fluids in trauma patients.
By Dretzke J, Sandercock J, Bayliss S,
Burls A. 
No. 24
Newer hypnotic drugs for the short-
term management of insomnia: a
systematic review and economic
evaluation.
By Dündar Y, Boland A, Strobl J,
Dodd S, Haycox A, Bagust A, 
et al. 
No. 25
Development and validation of methods
for assessing the quality of diagnostic
accuracy studies.
By Whiting P, Rutjes AWS, Dinnes J,
Reitsma JB, Bossuyt PMM, Kleijnen J.
No. 26
EVALUATE hysterectomy trial: a
multicentre randomised trial comparing
abdominal, vaginal and laparoscopic
methods of hysterectomy.
By Garry R, Fountain J, Brown J,
Manca A, Mason S, Sculpher M, et al. 
No. 27
Methods for expected value of
information analysis in complex health
economic models: developments on the
health economics of interferon- and
glatiramer acetate for multiple sclerosis.
By Tappenden P, Chilcott JB,
Eggington S, Oakley J, McCabe C.
No. 28
Effectiveness and cost-effectiveness of
imatinib for first-line treatment of
chronic myeloid leukaemia in chronic
phase: a systematic review and economic
analysis. 
By Dalziel K, Round A, Stein K,
Garside R, Price A. 
No. 29
VenUS I: a randomised controlled trial
of two types of bandage for treating
venous leg ulcers. 
By Iglesias C, Nelson EA, Cullum NA,
Torgerson DJ on behalf of the VenUS
Team.
No. 30
Systematic review of the effectiveness
and cost-effectiveness, and economic
evaluation, of myocardial perfusion
scintigraphy for the diagnosis and
management of angina and myocardial
infarction. 
By Mowatt G, Vale L, Brazzelli M,
Hernandez R, Murray A, Scott N, et al. 
No. 31
A pilot study on the use of decision
theory and value of information analysis
as part of the NHS Health Technology
Assessment programme.
By Claxton K on K, Ginnelly L, Sculpher
M, Philips Z, Palmer S. 
No. 32
The Social Support and Family Health
Study: a randomised controlled trial and
economic evaluation of two alternative
forms of postnatal support for mothers
living in disadvantaged inner-city areas. 
By Wiggins M, Oakley A, Roberts I,
Turner H, Rajan L, Austerberry H, et al. 
No. 33
Psychosocial aspects of genetic screening
of pregnant women and newborns: 
a systematic review. 
By Green JM, Hewison J, Bekker HL,
Bryant, Cuckle HS.
No. 34
Evaluation of abnormal uterine
bleeding: comparison of three
outpatient procedures within cohorts
defined by age and menopausal status. 
By Critchley HOD, Warner P, 
Lee AJ, Brechin S, Guise J, Graham B. 
No. 35
Coronary artery stents: a rapid systematic
review and economic evaluation. 
By Hill R, Bagust A, Bakhai A,
Dickson R, Dündar Y, Haycox A, et al. 
No. 36
Review of guidelines for good practice
in decision-analytic modelling in health
technology assessment. 
By Philips Z, Ginnelly L, Sculpher M,
Claxton K, Golder S, Riemsma R, et al.
No. 37
Rituximab (MabThera®) for aggressive
non-Hodgkin’s lymphoma: systematic
review and economic evaluation. 
By Knight C, Hind D, Brewer N,
Abbott V. 
No. 38
Clinical effectiveness and cost-
effectiveness of clopidogrel and
modified-release dipyridamole in the
secondary prevention of occlusive
vascular events: a systematic review and
economic evaluation. 
By Jones L, Griffin S, Palmer S, Main
C, Orton V, Sculpher M, et al.
No. 39
Pegylated interferon -2a and -2b in
combination with ribavirin in the
treatment of chronic hepatitis C: a
systematic review and economic
evaluation. 
By Shepherd J, Brodin H, Cave C,
Waugh N, Price A, Gabbay J. 
No. 40
Clopidogrel used in combination with
aspirin compared with aspirin alone in
the treatment of non-ST-segment-
elevation acute coronary syndromes: a
systematic review and economic
evaluation. 
By Main C, Palmer S, Griffin S, 
Jones L, Orton V, Sculpher M, et al.
No. 41
Provision, uptake and cost of cardiac
rehabilitation programmes: improving
services to under-represented groups. 
By Beswick AD, Rees K, Griebsch I,
Taylor FC, Burke M, West RR, et al.
No. 42
Involving South Asian patients in
clinical trials. 
By Hussain-Gambles M, Leese B,
Atkin K, Brown J, Mason S, Tovey P. 
No. 43
Clinical and cost-effectiveness of
continuous subcutaneous insulin
infusion for diabetes. 
By Colquitt JL, Green C, Sidhu MK,
Hartwell D, Waugh N. 
No. 44
Identification and assessment of
ongoing trials in health technology
assessment reviews. 
By Song FJ, Fry-Smith A, Davenport
C, Bayliss S, Adi Y, Wilson JS, et al. 
No. 45
Systematic review and economic
evaluation of a long-acting insulin
analogue, insulin glargine
By Warren E, Weatherley-Jones E,
Chilcott J, Beverley C. 
No. 46
Supplementation of a home-based
exercise programme with a class-based
programme for people with osteoarthritis
of the knees: a randomised controlled
trial and health economic analysis. 
By McCarthy CJ, Mills PM, 
Pullen R, Richardson G, Hawkins N,
Roberts CR, et al. 
No. 47
Clinical and cost-effectiveness of once-
daily versus more frequent use of same
potency topical corticosteroids for atopic
eczema: a systematic review and
economic evaluation. 
By Green C, Colquitt JL, Kirby J,
Davidson P, Payne E. 
No. 48
Acupuncture of chronic headache
disorders in primary care: randomised
controlled trial and economic analysis. 
By Vickers AJ, Rees RW, Zollman CE,
McCarney R, Smith CM, Ellis N, et al. 
No. 49
Generalisability in economic evaluation
studies in healthcare: a review and case
studies. 
By Sculpher MJ, Pang FS, Manca A,
Drummond MF, Golder S, Urdahl H, 
et al. 
No. 50
Virtual outreach: a randomised
controlled trial and economic evaluation
of joint teleconferenced medical
consultations. 
By Wallace P, Barber J, Clayton W,
Currell R, Fleming K, Garner P, et al. 
Health Technology Assessment 2008; Vol. 12: No. 29
195
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.Volume 9, 2005
No. 1
Randomised controlled multiple
treatment comparison to provide a 
cost-effectiveness rationale for the
selection of antimicrobial therapy in
acne. 
By Ozolins M, Eady EA, Avery A,
Cunliffe WJ, O’Neill C, Simpson NB, 
et al.
No. 2
Do the findings of case series studies
vary significantly according to
methodological characteristics?
By Dalziel K, Round A, Stein K,
Garside R, Castelnuovo E, Payne L.
No. 3
Improving the referral process for
familial breast cancer genetic
counselling: findings of three
randomised controlled trials of two
interventions.
By Wilson BJ, Torrance N, Mollison J,
Wordsworth S, Gray JR, Haites NE, et al.
No. 4
Randomised evaluation of alternative
electrosurgical modalities to treat
bladder outflow obstruction in men with
benign prostatic hyperplasia. 
By Fowler C, McAllister W, Plail R,
Karim O, Yang Q. 
No. 5
A pragmatic randomised controlled trial
of the cost-effectiveness of palliative
therapies for patients with inoperable
oesophageal cancer. 
By Shenfine J, McNamee P, Steen N,
Bond J, Griffin SM. 
No. 6
Impact of computer-aided detection
prompts on the sensitivity and specificity
of screening mammography. 
By Taylor P, Champness J, Given-
Wilson R, Johnston K, Potts H. 
No. 7
Issues in data monitoring and interim
analysis of trials. 
By Grant AM, Altman DG, Babiker
AB, Campbell MK, Clemens FJ,
Darbyshire JH, et al. 
No. 8
Lay public’s understanding of equipoise
and randomisation in randomised
controlled trials.
By Robinson EJ, Kerr CEP, Stevens
AJ, Lilford RJ, Braunholtz DA, Edwards
SJ, et al. 
No. 9
Clinical and cost-effectiveness of
electroconvulsive therapy for depressive
illness, schizophrenia, catatonia and
mania: systematic reviews and economic
modelling studies. 
By Greenhalgh J, Knight C, Hind D,
Beverley C, Walters S. 
No. 10
Measurement of health-related quality
of life for people with dementia:
development of a new instrument
(DEMQOL) and an evaluation of
current methodology. 
By Smith SC, Lamping DL, 
Banerjee S, Harwood R, Foley B, 
Smith P, et al. 
No. 11
Clinical effectiveness and cost-
effectiveness of drotrecogin alfa
(activated) (Xigris®) for the treatment of
severe sepsis in adults: a systematic
review and economic evaluation. 
By Green C, Dinnes J, Takeda A,
Shepherd J, Hartwell D, Cave C, 
et al. 
No. 12
A methodological review of how
heterogeneity has been examined in
systematic reviews of diagnostic test
accuracy. 
By Dinnes J, Deeks J, Kirby J,
Roderick P. 
No. 13
Cervical screening programmes: can
automation help? Evidence from
systematic reviews, an economic analysis
and a simulation modelling exercise
applied to the UK.
By Willis BH, Barton P, Pearmain P,
Bryan S, Hyde C. 
No. 14
Laparoscopic surgery for inguinal
hernia repair: systematic review of
effectiveness and economic evaluation. 
By McCormack K, Wake B, Perez J,
Fraser C, Cook J, McIntosh E, et al. 
No. 15
Clinical effectiveness, tolerability and
cost-effectiveness of newer drugs for
epilepsy in adults: a systematic review
and economic evaluation. 
By Wilby J, Kainth A, Hawkins N,
Epstein D, McIntosh H, McDaid C, et al.
No. 16
A randomised controlled trial to
compare the cost-effectiveness of
tricyclic antidepressants, selective
serotonin reuptake inhibitors and
lofepramine. 
By Peveler R, Kendrick T, Buxton M,
Longworth L, Baldwin D, Moore M, 
et al. 
No. 17
Clinical effectiveness and cost-
effectiveness of immediate angioplasty
for acute myocardial infarction:
systematic review and economic
evaluation. 
By Hartwell D, Colquitt J, Loveman
E, Clegg AJ, Brodin H, Waugh N, 
et al. 
No. 18
A randomised controlled comparison of
alternative strategies in stroke care. 
By Kalra L, Evans A, Perez I, 
Knapp M, Swift C, Donaldson N. 
No. 19
The investigation and analysis of critical
incidents and adverse events in
healthcare. 
By Woloshynowych M, Rogers S,
Taylor-Adams S, Vincent C. 
No. 20
Potential use of routine databases in
health technology assessment. 
By Raftery J, Roderick P, Stevens A. 
No. 21
Clinical and cost-effectiveness of newer
immunosuppressive regimens in renal
transplantation: a systematic review and
modelling study. 
By Woodroffe R, Yao GL, Meads C,
Bayliss S, Ready A, Raftery J, et al. 
No. 22
A systematic review and economic
evaluation of alendronate, etidronate,
risedronate, raloxifene and teriparatide
for the prevention and treatment of
postmenopausal osteoporosis. 
By Stevenson M, Lloyd Jones M, 
De Nigris E, Brewer N, Davis S, 
Oakley J. 
No. 23
A systematic review to examine the
impact of psycho-educational
interventions on health outcomes and
costs in adults and children with difficult
asthma. 
By Smith JR, Mugford M, Holland R,
Candy B, Noble MJ, Harrison BDW, et al. 
No. 24
An evaluation of the costs, effectiveness
and quality of renal replacement
therapy provision in renal satellite units
in England and Wales. 
By Roderick P, Nicholson T, Armitage
A, Mehta R, Mullee M, Gerard K, et al. 
No. 25
Imatinib for the treatment of patients
with unresectable and/or metastatic
gastrointestinal stromal tumours:
systematic review and economic
evaluation.
By Wilson J, Connock M, Song F, Yao
G, Fry-Smith A, Raftery J, et al. 
No. 26
Indirect comparisons of competing
interventions. 
By Glenny AM, Altman DG, Song F,
Sakarovitch C, Deeks JJ, D’Amico R, et al. 
No. 27
Cost-effectiveness of alternative
strategies for the initial medical
management of non-ST elevation acute
coronary syndrome: systematic review
and decision-analytical modelling. 
By Robinson M, Palmer S, Sculpher
M, Philips Z, Ginnelly L, Bowens A, et al. 
Health Technology Assessment reports published to date
196No. 28
Outcomes of electrically stimulated
gracilis neosphincter surgery. 
By Tillin T, Chambers M, Feldman R.
No. 29
The effectiveness and cost-effectiveness
of pimecrolimus and tacrolimus for
atopic eczema: a systematic review and
economic evaluation. 
By Garside R, Stein K, Castelnuovo E,
Pitt M, Ashcroft D, Dimmock P, et al. 
No. 30
Systematic review on urine albumin
testing for early detection of diabetic
complications. 
By Newman DJ, Mattock MB, Dawnay
ABS, Kerry S, McGuire A, Yaqoob M, et al. 
No. 31
Randomised controlled trial of the cost-
effectiveness of water-based therapy for
lower limb osteoarthritis. 
By Cochrane T, Davey RC, 
Matthes Edwards SM. 
No. 32
Longer term clinical and economic
benefits of offering acupuncture care to
patients with chronic low back pain. 
By Thomas KJ, MacPherson H,
Ratcliffe J, Thorpe L, Brazier J,
Campbell M, et al. 
No. 33
Cost-effectiveness and safety of epidural
steroids in the management of sciatica. 
By Price C, Arden N, Coglan L,
Rogers P. 
No. 34
The British Rheumatoid Outcome Study
Group (BROSG) randomised controlled
trial to compare the effectiveness and
cost-effectiveness of aggressive versus
symptomatic therapy in established
rheumatoid arthritis. 
By Symmons D, Tricker K, Roberts C,
Davies L, Dawes P, Scott DL. 
No. 35
Conceptual framework and systematic
review of the effects of participants’ and
professionals’ preferences in randomised
controlled trials. 
By King M, Nazareth I, Lampe F,
Bower P, Chandler M, Morou M, et al. 
No. 36
The clinical and cost-effectiveness of
implantable cardioverter defibrillators: 
a systematic review. 
By Bryant J, Brodin H, Loveman E,
Payne E, Clegg A. 
No. 37
A trial of problem-solving by community
mental health nurses for anxiety,
depression and life difficulties among
general practice patients. The CPN-GP
study. 
By Kendrick T, Simons L, 
Mynors-Wallis L, Gray A, Lathlean J,
Pickering R, et al. 
No. 38
The causes and effects of socio-
demographic exclusions from clinical
trials. 
By Bartlett C, Doyal L, Ebrahim S,
Davey P, Bachmann M, Egger M, 
et al. 
No. 39
Is hydrotherapy cost-effective? A
randomised controlled trial of combined
hydrotherapy programmes compared
with physiotherapy land techniques in
children with juvenile idiopathic
arthritis. 
By Epps H, Ginnelly L, Utley M,
Southwood T, Gallivan S, Sculpher M, 
et al. 
No. 40
A randomised controlled trial and cost-
effectiveness study of systematic
screening (targeted and total population
screening) versus routine practice for
the detection of atrial fibrillation in
people aged 65 and over. The SAFE
study. 
By Hobbs FDR, Fitzmaurice DA,
Mant J, Murray E, Jowett S, Bryan S, 
et al.
No. 41
Displaced intracapsular hip fractures 
in fit, older people: a randomised
comparison of reduction and fixation,
bipolar hemiarthroplasty and total hip
arthroplasty.
By Keating JF, Grant A, Masson M,
Scott NW, Forbes JF. 
No. 42
Long-term outcome of cognitive
behaviour therapy clinical trials in
central Scotland. 
By Durham RC, Chambers JA, 
Power KG, Sharp DM, Macdonald RR,
Major KA, et al. 
No. 43
The effectiveness and cost-effectiveness
of dual-chamber pacemakers compared
with single-chamber pacemakers for
bradycardia due to atrioventricular
block or sick sinus syndrome: 
systematic review and economic
evaluation. 
By Castelnuovo E, Stein K, Pitt M,
Garside R, Payne E. 
No. 44
Newborn screening for congenital heart
defects: a systematic review and 
cost-effectiveness analysis. 
By Knowles R, Griebsch I, Dezateux
C, Brown J, Bull C, Wren C. 
No. 45
The clinical and cost-effectiveness of left
ventricular assist devices for end-stage
heart failure: a systematic review and
economic evaluation.
By Clegg AJ, Scott DA, Loveman E,
Colquitt J, Hutchinson J, Royle P, 
et al. 
No. 46
The effectiveness of the Heidelberg
Retina Tomograph and laser diagnostic
glaucoma scanning system (GDx) in
detecting and monitoring glaucoma.
By Kwartz AJ, Henson DB, 
Harper RA, Spencer AF, 
McLeod D. 
No. 47
Clinical and cost-effectiveness of
autologous chondrocyte implantation
for cartilage defects in knee joints:
systematic review and economic
evaluation. 
By Clar C, Cummins E, McIntyre L,
Thomas S, Lamb J, Bain L, et al. 
No. 48
Systematic review of effectiveness of
different treatments for childhood
retinoblastoma. 
By McDaid C, Hartley S, 
Bagnall A-M, Ritchie G, Light K,
Riemsma R. 
No. 49
Towards evidence-based guidelines 
for the prevention of venous
thromboembolism: systematic 
reviews of mechanical methods, oral
anticoagulation, dextran and regional
anaesthesia as thromboprophylaxis. 
By Roderick P, Ferris G, Wilson K,
Halls H, Jackson D, Collins R,
et al. 
No. 50
The effectiveness and cost-effectiveness
of parent training/education
programmes for the treatment of
conduct disorder, including oppositional
defiant disorder, in children. 
By Dretzke J, Frew E, Davenport C,
Barlow J, Stewart-Brown S, 
Sandercock J, et al. 
Volume 10, 2006
No. 1
The clinical and cost-effectiveness of
donepezil, rivastigmine, galantamine
and memantine for Alzheimer’s 
disease.
By Loveman E, Green C, Kirby J,
Takeda A, Picot J, Payne E, 
et al. 
No. 2
FOOD: a multicentre randomised trial
evaluating feeding policies in patients
admitted to hospital with a recent
stroke. 
By Dennis M, Lewis S, Cranswick G,
Forbes J. 
No. 3
The clinical effectiveness and cost-
effectiveness of computed tomography
screening for lung cancer: systematic
reviews.
By Black C, Bagust A, Boland A,
Walker S, McLeod C, De Verteuil R, 
et al. 
Health Technology Assessment 2008; Vol. 12: No. 29
197
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.No. 4
A systematic review of the effectiveness
and cost-effectiveness of neuroimaging
assessments used to visualise the 
seizure focus in people with refractory
epilepsy being considered for 
surgery. 
By Whiting P, Gupta R, Burch J,
Mujica Mota RE, Wright K, Marson A, 
et al. 
No. 5
Comparison of conference abstracts 
and presentations with full-text 
articles in the health technology
assessments of rapidly evolving
technologies. 
By Dundar Y, Dodd S, Dickson R,
Walley T, Haycox A, Williamson PR. 
No. 6
Systematic review and evaluation of
methods of assessing urinary
incontinence. 
By Martin JL, Williams KS, Abrams
KR, Turner DA, Sutton AJ, Chapple C,
et al.
No. 7
The clinical effectiveness and cost-
effectiveness of newer drugs for children
with epilepsy. A systematic review. 
By Connock M, Frew E, Evans B-W, 
Bryan S, Cummins C, Fry-Smith A, 
et al.
No. 8
Surveillance of Barrett’s oesophagus:
exploring the uncertainty through
systematic review, expert workshop and
economic modelling. 
By Garside R, Pitt M, Somerville M,
Stein K, Price A, Gilbert N. 
No. 9
Topotecan, pegylated liposomal
doxorubicin hydrochloride and
paclitaxel for second-line or subsequent
treatment of advanced ovarian cancer: a
systematic review and economic
evaluation. 
By Main C, Bojke L, Griffin S,
Norman G, Barbieri M, Mather L, 
et al. 
No. 10
Evaluation of molecular techniques 
in prediction and diagnosis of
cytomegalovirus disease in
immunocompromised patients. 
By Szczepura A, Westmoreland D,
Vinogradova Y, Fox J, Clark M. 
No. 11
Screening for thrombophilia in high-risk
situations: systematic review and cost-
effectiveness analysis. The Thrombosis:
Risk and Economic Assessment of
Thrombophilia Screening (TREATS)
study. 
By Wu O, Robertson L, Twaddle S,
Lowe GDO, Clark P, Greaves M, 
et al. 
No. 12
A series of systematic reviews to inform
a decision analysis for sampling and
treating infected diabetic foot 
ulcers. 
By Nelson EA, O’Meara S, Craig D,
Iglesias C, Golder S, Dalton J, 
et al. 
No. 13
Randomised clinical trial, observational
study and assessment of cost-
effectiveness of the treatment of varicose
veins (REACTIV trial). 
By Michaels JA, Campbell WB,
Brazier JE, MacIntyre JB, Palfreyman
SJ, Ratcliffe J, et al. 
No. 14
The cost-effectiveness of screening for
oral cancer in primary care. 
By Speight PM, Palmer S, Moles DR,
Downer MC, Smith DH, Henriksson M
et al. 
No. 15
Measurement of the clinical and cost-
effectiveness of non-invasive diagnostic
testing strategies for deep vein
thrombosis. 
By Goodacre S, Sampson F, Stevenson
M, Wailoo A, Sutton A, Thomas S, et al. 
No. 16
Systematic review of the effectiveness
and cost-effectiveness of HealOzone®
for the treatment of occlusal pit/fissure
caries and root caries. 
By Brazzelli M, McKenzie L, Fielding
S, Fraser C, Clarkson J, Kilonzo M, 
et al. 
No. 17
Randomised controlled trials of
conventional antipsychotic versus new
atypical drugs, and new atypical drugs
versus clozapine, in people with
schizophrenia responding poorly 
to, or intolerant of, current drug
treatment. 
By Lewis SW, Davies L, Jones PB,
Barnes TRE, Murray RM, Kerwin R, 
et al. 
No. 18
Diagnostic tests and algorithms used in
the investigation of haematuria:
systematic reviews and economic
evaluation.
By Rodgers M, Nixon J, Hempel S,
Aho T, Kelly J, Neal D, et al. 
No. 19
Cognitive behavioural therapy in
addition to antispasmodic therapy for
irritable bowel syndrome in primary
care: randomised controlled 
trial.
By Kennedy TM, Chalder T, 
McCrone P, Darnley S, Knapp M, 
Jones RH, et al. 
No. 20
A systematic review of the clinical
effectiveness and cost-effectiveness of
enzyme replacement therapies for
Fabry’s disease and
mucopolysaccharidosis type 1. 
By Connock M, Juarez-Garcia A, Frew
E, Mans A, Dretzke J, Fry-Smith A, et al. 
No. 21
Health benefits of antiviral therapy for
mild chronic hepatitis C: randomised
controlled trial and economic
evaluation. 
By Wright M, Grieve R, Roberts J,
Main J, Thomas HC on behalf of the
UK Mild Hepatitis C Trial Investigators. 
No. 22
Pressure relieving support surfaces: a
randomised evaluation.
By Nixon J, Nelson EA, Cranny G,
Iglesias CP, Hawkins K, Cullum NA, et al. 
No. 23
A systematic review and economic
model of the effectiveness and cost-
effectiveness of methylphenidate,
dexamfetamine and atomoxetine for the
treatment of attention deficit
hyperactivity disorder in children and
adolescents. 
By King S, Griffin S, Hodges Z,
Weatherly H, Asseburg C, Richardson G,
et al.
No. 24
The clinical effectiveness and cost-
effectiveness of enzyme replacement
therapy for Gaucher’s disease: 
a systematic review. 
By Connock M, Burls A, Frew E, 
Fry-Smith A, Juarez-Garcia A, 
McCabe C, et al. 
No. 25
Effectiveness and cost-effectiveness of
salicylic acid and cryotherapy for
cutaneous warts. An economic decision
model. 
By Thomas KS, Keogh-Brown MR,
Chalmers JR, Fordham RJ, Holland RC,
Armstrong SJ, et al. 
No. 26
A systematic literature review of the
effectiveness of non-pharmacological
interventions to prevent wandering in
dementia and evaluation of the ethical
implications and acceptability of their
use. 
By Robinson L, Hutchings D, Corner
L, Beyer F, Dickinson H, Vanoli A, et al. 
No. 27
A review of the evidence on the effects
and costs of implantable cardioverter
defibrillator therapy in different patient
groups, and modelling of cost-
effectiveness and cost–utility for these
groups in a UK context. 
By Buxton M, Caine N, Chase D,
Connelly D, Grace A, Jackson C, et al. 
Health Technology Assessment reports published to date
198No. 28
Adefovir dipivoxil and pegylated
interferon alfa-2a for the treatment of
chronic hepatitis B: a systematic review
and economic evaluation. 
By Shepherd J, Jones J, Takeda A,
Davidson P, Price A. 
No. 29
An evaluation of the clinical and cost-
effectiveness of pulmonary artery
catheters in patient management in
intensive care: a systematic review and a
randomised controlled trial. 
By Harvey S, Stevens K, Harrison D,
Young D, Brampton W, McCabe C, et al. 
No. 30
Accurate, practical and cost-effective
assessment of carotid stenosis in the UK.
By Wardlaw JM, Chappell FM,
Stevenson M, De Nigris E, Thomas S,
Gillard J, et al. 
No. 31
Etanercept and infliximab for the
treatment of psoriatic arthritis: 
a systematic review and economic
evaluation. 
By Woolacott N, Bravo Vergel Y,
Hawkins N, Kainth A, Khadjesari Z,
Misso K, et al. 
No. 32
The cost-effectiveness of testing for
hepatitis C in former injecting drug
users. 
By Castelnuovo E, Thompson-Coon J,
Pitt M, Cramp M, Siebert U, Price A, 
et al. 
No. 33
Computerised cognitive behaviour
therapy for depression and anxiety
update: a systematic review and
economic evaluation. 
By Kaltenthaler E, Brazier J, 
De Nigris E, Tumur I, Ferriter M,
Beverley C, et al. 
No. 34
Cost-effectiveness of using prognostic
information to select women with breast 
cancer for adjuvant systemic therapy. 
By Williams C, Brunskill S, Altman D,
Briggs A, Campbell H, Clarke M, 
et al. 
No. 35
Psychological therapies including
dialectical behaviour therapy for
borderline personality disorder: 
a systematic review and preliminary
economic evaluation. 
By Brazier J, Tumur I, Holmes M,
Ferriter M, Parry G, Dent-Brown K, et al.
No. 36
Clinical effectiveness and cost-
effectiveness of tests for the diagnosis
and investigation of urinary tract
infection in children: a systematic review
and economic model. 
By Whiting P, Westwood M, Bojke L,
Palmer S, Richardson G, Cooper J, et al.
No. 37
Cognitive behavioural therapy in
chronic fatigue syndrome: a randomised
controlled trial of an outpatient group
programme. 
By O’Dowd H, Gladwell P, Rogers CA,
Hollinghurst S, Gregory A. 
No. 38
A comparison of the cost-effectiveness of
five strategies for the prevention of non-
steroidal anti-inflammatory drug-induced
gastrointestinal toxicity: a systematic
review with economic modelling. 
By Brown TJ, Hooper L, Elliott RA,
Payne K, Webb R, Roberts C, et al. 
No. 39
The effectiveness and cost-effectiveness
of computed tomography screening for
coronary artery disease: systematic
review. 
By Waugh N, Black C, Walker S,
McIntyre L, Cummins E, Hillis G. 
No. 40
What are the clinical outcome and cost-
effectiveness of endoscopy undertaken
by nurses when compared with doctors?
A Multi-Institution Nurse Endoscopy
Trial (MINuET). 
By Williams J, Russell I, Durai D,
Cheung W-Y, Farrin A, Bloor K, et al. 
No. 41
The clinical and cost-effectiveness of
oxaliplatin and capecitabine for the
adjuvant treatment of colon cancer:
systematic review and economic
evaluation. 
By Pandor A, Eggington S, Paisley S,
Tappenden P, Sutcliffe P. 
No. 42
A systematic review of the effectiveness
of adalimumab, etanercept and
infliximab for the treatment of
rheumatoid arthritis in adults and an
economic evaluation of their cost-
effectiveness. 
By Chen Y-F, Jobanputra P, Barton P,
Jowett S, Bryan S, Clark W, et al. 
No. 43
Telemedicine in dermatology: 
a randomised controlled trial. 
By Bowns IR, Collins K, Walters SJ,
McDonagh AJG. 
No. 44
Cost-effectiveness of cell salvage and
alternative methods of minimising
perioperative allogeneic blood
transfusion: a systematic review and
economic model. 
By Davies L, Brown TJ, Haynes S,
Payne K, Elliott RA, McCollum C. 
No. 45
Clinical effectiveness and cost-
effectiveness of laparoscopic surgery for
colorectal cancer: systematic reviews and
economic evaluation. 
By Murray A, Lourenco T, 
de Verteuil R, Hernandez R, Fraser C,
McKinley A, et al. 
No. 46
Etanercept and efalizumab for the
treatment of psoriasis: a systematic
review. 
By Woolacott N, Hawkins N, 
Mason A, Kainth A, Khadjesari Z, 
Bravo Vergel Y, et al. 
No. 47
Systematic reviews of clinical decision
tools for acute abdominal pain.
By Liu JLY, Wyatt JC, Deeks JJ,
Clamp S, Keen J, Verde P, et al. 
No. 48
Evaluation of the ventricular assist
device programme in the UK.
By Sharples L, Buxton M, Caine N,
Cafferty F, Demiris N, Dyer M, 
et al. 
No. 49
A systematic review and economic
model of the clinical and cost-
effectiveness of immunosuppressive
therapy for renal transplantation in
children. 
By Yao G, Albon E, Adi Y, Milford D,
Bayliss S, Ready A, et al. 
No. 50
Amniocentesis results: investigation of
anxiety. The ARIA trial. 
By Hewison J, Nixon J, Fountain J,
Cocks K, Jones C, Mason G, et al. 
Volume 11, 2007
No. 1
Pemetrexed disodium for the treatment
of malignant pleural mesothelioma: 
a systematic review and economic
evaluation. 
By Dundar Y, Bagust A, Dickson R,
Dodd S, Green J, Haycox A, et al. 
No. 2
A systematic review and economic
model of the clinical effectiveness and
cost-effectiveness of docetaxel in
combination with prednisone or
prednisolone for the treatment of
hormone-refractory metastatic prostate
cancer. 
By Collins R, Fenwick E, Trowman R,
Perard R, Norman G, Light K, 
et al. 
No. 3
A systematic review of rapid diagnostic
tests for the detection of tuberculosis
infection. 
By Dinnes J, Deeks J, Kunst H,
Gibson A, Cummins E, Waugh N, et al. 
No. 4
The clinical effectiveness and cost-
effectiveness of strontium ranelate for
the prevention of osteoporotic 
fragility fractures in postmenopausal
women. 
By Stevenson M, Davis S, 
Lloyd-Jones M, Beverley C. 
Health Technology Assessment 2008; Vol. 12: No. 29
199
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.No. 5
A systematic review of quantitative and
qualitative research on the role and
effectiveness of written information
available to patients about individual
medicines.
By Raynor DK, Blenkinsopp A,
Knapp P, Grime J, Nicolson DJ, 
Pollock K, et al.
No. 6
Oral naltrexone as a treatment for
relapse prevention in formerly 
opioid-dependent drug users: 
a systematic review and economic
evaluation. 
By Adi Y, Juarez-Garcia A, Wang D,
Jowett S, Frew E, Day E, et al. 
No. 7
Glucocorticoid-induced osteoporosis: 
a systematic review and cost–utility 
analysis. 
By Kanis JA, Stevenson M, 
McCloskey EV, Davis S, Lloyd-Jones M. 
No. 8
Epidemiological, social, diagnostic and
economic evaluation of population
screening for genital chlamydial 
infection. 
By Low N, McCarthy A, Macleod J,
Salisbury C, Campbell R, Roberts TE, 
et al. 
No. 9
Methadone and buprenorphine for the
management of opioid dependence: 
a systematic review and economic
evaluation. 
By Connock M, Juarez-Garcia A,
Jowett S, Frew E, Liu Z, Taylor RJ, 
et al. 
No. 10
Exercise Evaluation Randomised Trial
(EXERT): a randomised trial comparing
GP referral for leisure centre-based
exercise, community-based walking and
advice only.
By Isaacs AJ, Critchley JA, 
See Tai S, Buckingham K, Westley D,
Harridge SDR, et al.
No. 11
Interferon alfa (pegylated and 
non-pegylated) and ribavirin for the
treatment of mild chronic hepatitis C: 
a systematic review and economic
evaluation. 
By Shepherd J, Jones J, Hartwell D,
Davidson P, Price A, Waugh N. 
No. 12
Systematic review and economic
evaluation of bevacizumab and
cetuximab for the treatment of
metastatic colorectal cancer. 
By Tappenden P, Jones R, Paisley S,
Carroll C. 
No. 13
A systematic review and economic
evaluation of epoetin alfa, epoetin beta
and darbepoetin alfa in anaemia
associated with cancer, especially that
attributable to cancer treatment. 
By Wilson J, Yao GL, Raftery J,
Bohlius J, Brunskill S, Sandercock J, 
et al. 
No. 14
A systematic review and economic
evaluation of statins for the prevention
of coronary events. 
By Ward S, Lloyd Jones M, Pandor A,
Holmes M, Ara R, Ryan A, et al. 
No. 15
A systematic review of the effectiveness
and cost-effectiveness of different
models of community-based respite 
care for frail older people and their
carers.
By Mason A, Weatherly H, Spilsbury
K, Arksey H, Golder S, Adamson J, 
et al. 
No. 16
Additional therapy for young children
with spastic cerebral palsy: 
a randomised controlled trial. 
By Weindling AM, Cunningham CC,
Glenn SM, Edwards RT, Reeves DJ. 
No. 17
Screening for type 2 diabetes: literature
review and economic modelling. 
By Waugh N, Scotland G, 
McNamee P, Gillett M, Brennan A,
Goyder E, et al.
No. 18
The effectiveness and cost-effectiveness
of cinacalcet for secondary
hyperparathyroidism in end-stage 
renal disease patients on dialysis: a
systematic review and economic
evaluation.
By Garside R, Pitt M, Anderson R,
Mealing S, Roome C, Snaith A, 
et al. 
No. 19
The clinical effectiveness and 
cost-effectiveness of gemcitabine for
metastatic breast cancer: a systematic
review and economic evaluation. 
By Takeda AL, Jones J, Loveman E,
Tan SC, Clegg AJ. 
No. 20
A systematic review of duplex
ultrasound, magnetic resonance
angiography and computed tomography
angiography for the diagnosis 
and assessment of symptomatic, lower
limb peripheral arterial disease. 
By Collins R, Cranny G, Burch J,
Aguiar-Ibáñez R, Craig D, Wright K, et al. 
No. 21
The clinical effectiveness and cost-
effectiveness of treatments for children
with idiopathic steroid-resistant
nephrotic syndrome: a systematic review. 
By Colquitt JL, Kirby J, Green C,
Cooper K, Trompeter RS. 
No. 22
A systematic review of the routine
monitoring of growth in children of
primary school age to identify 
growth-related conditions. 
By Fayter D, Nixon J, Hartley S,
Rithalia A, Butler G, Rudolf M, et al. 
No. 23
Systematic review of the effectiveness of
preventing and treating Staphylococcus
aureus carriage in reducing peritoneal
catheter-related infections. 
By McCormack K, Rabindranath K,
Kilonzo M, Vale L, Fraser C, McIntyre L,
et al. 
No. 24
The clinical effectiveness and cost of
repetitive transcranial magnetic
stimulation versus electroconvulsive
therapy in severe depression: 
a multicentre pragmatic randomised
controlled trial and economic 
analysis. 
By McLoughlin DM, Mogg A, 
Eranti S, Pluck G, Purvis R, Edwards D,
et al. 
No. 25
A randomised controlled trial and
economic evaluation of direct versus
indirect and individual versus group
modes of speech and language therapy
for children with primary language
impairment. 
By Boyle J, McCartney E, Forbes J,
O’Hare A. 
No. 26
Hormonal therapies for early breast
cancer: systematic review and economic
evaluation. 
By Hind D, Ward S, De Nigris E,
Simpson E, Carroll C, Wyld L. 
No. 27
Cardioprotection against the toxic 
effects of anthracyclines given to
children with cancer: a systematic 
review. 
By Bryant J, Picot J, Levitt G, 
Sullivan I, Baxter L, Clegg A. 
No. 28
Adalimumab, etanercept and infliximab
for the treatment of ankylosing
spondylitis: a systematic review and
economic evaluation. 
By McLeod C, Bagust A, Boland A,
Dagenais P, Dickson R, Dundar Y, et al. 
Health Technology Assessment reports published to date
200No. 29
Prenatal screening and treatment
strategies to prevent group B
streptococcal and other bacterial
infections in early infancy: cost-
effectiveness and expected value of
information analyses.
By Colbourn T, Asseburg C, Bojke L,
Philips Z, Claxton K, Ades AE, et al.
No. 30
Clinical effectiveness and cost-
effectiveness of bone morphogenetic
proteins in the non-healing of fractures
and spinal fusion: a systematic 
review. 
By Garrison KR, Donell S, Ryder J,
Shemilt I, Mugford M, Harvey I, 
et al. 
No. 31
A randomised controlled trial of
postoperative radiotherapy following
breast-conserving surgery in a
minimum-risk older population. The
PRIME trial. 
By Prescott RJ, Kunkler IH, Williams
LJ, King CC, Jack W, van der Pol M, 
et al. 
No. 32
Current practice, accuracy, effectiveness
and cost-effectiveness of the school
entry hearing screen. 
By Bamford J, Fortnum H, Bristow K,
Smith J, Vamvakas G, Davies L, et al. 
No. 33
The clinical effectiveness and 
cost-effectiveness of inhaled insulin 
in diabetes mellitus: a systematic 
review and economic evaluation. 
By Black C, Cummins E, Royle P,
Philip S, Waugh N. 
No. 34
Surveillance of cirrhosis for
hepatocellular carcinoma: systematic
review and economic analysis. 
By Thompson Coon J, Rogers G,
Hewson P, Wright D, Anderson R,
Cramp M, et al. 
No. 35
The Birmingham Rehabilitation Uptake
Maximisation Study (BRUM). Home-
based compared with hospital-based
cardiac rehabilitation in a multi-ethnic
population: cost-effectiveness and
patient adherence. 
By Jolly K, Taylor R, Lip GYH,
Greenfield S, Raftery J, Mant J, et al. 
No. 36
A systematic review of the clinical,
public health and cost-effectiveness 
of rapid diagnostic tests for the
detection and identification of 
bacterial intestinal pathogens in 
faeces and food. 
By Abubakar I, Irvine L, Aldus CF, 
Wyatt GM, Fordham R, Schelenz S, et al.
No. 37
A randomised controlled trial
examining the longer-term outcomes of
standard versus new antiepileptic drugs. 
The SANAD trial.
By Marson AG, Appleton R, Baker GA,
Chadwick DW, Doughty J, Eaton B, et al. 
No. 38
Clinical effectiveness and cost-
effectiveness of different models 
of managing long-term oral
anticoagulation therapy: a systematic
review and economic modelling. 
By Connock M, Stevens C, Fry-Smith A,
Jowett S, Fitzmaurice D, Moore D, et al. 
No. 39
A systematic review and economic
model of the clinical effectiveness and
cost-effectiveness of interventions for
preventing relapse in people with
bipolar disorder. 
By Soares-Weiser K, Bravo Vergel Y,
Beynon S, Dunn G, Barbieri M, Duffy S,
et al. 
No. 40
Taxanes for the adjuvant treatment of
early breast cancer: systematic review
and economic evaluation. 
By Ward S, Simpson E, Davis S, 
Hind D, Rees A, Wilkinson A. 
No. 41
The clinical effectiveness and cost-
effectiveness of screening for open angle
glaucoma: a systematic review and
economic evaluation. 
By Burr JM, Mowatt G, Hernández R,
Siddiqui MAR, Cook J, Lourenco T, 
et al. 
No. 42
Acceptability, benefit and costs of early
screening for hearing disability: a study
of potential screening tests and 
models.
By Davis A, Smith P, Ferguson M,
Stephens D, Gianopoulos I. 
No. 43
Contamination in trials of educational
interventions. 
By Keogh-Brown MR, Bachmann
MO, Shepstone L, Hewitt C, Howe A,
Ramsay CR, et al. 
No. 44
Overview of the clinical effectiveness of
positron emission tomography imaging
in selected cancers. 
By Facey K, Bradbury I, Laking G,
Payne E. 
No. 45
The effectiveness and cost-effectiveness of
carmustine implants and temozolomide
for the treatment of newly diagnosed
high-grade glioma: a systematic review
and economic evaluation. 
By Garside R, Pitt M, Anderson R,
Rogers G, Dyer M, Mealing S, et al. 
No. 46
Drug-eluting stents: a systematic review
and economic evaluation. 
By Hill RA, Boland A, Dickson R, 
Dündar Y, Haycox A, McLeod C, 
et al. 
No. 47
The clinical effectiveness and cost-
effectiveness of cardiac resynchronisation
(biventricular pacing) for heart failure:
systematic review and economic model. 
By Fox M, Mealing S, Anderson R,
Dean J, Stein K, Price A, et al. 
No. 48
Recruitment to randomised trials:
strategies for trial enrolment and
participation study. The STEPS study. 
By Campbell MK, Snowdon C,
Francis D, Elbourne D, McDonald AM,
Knight R, et al. 
No. 49
Cost-effectiveness of functional 
cardiac testing in the diagnosis and
management of coronary artery disease: 
a randomised controlled trial. 
The CECaT trial. 
By Sharples L, Hughes V, Crean A,
Dyer M, Buxton M, Goldsmith K, et al. 
No. 50
Evaluation of diagnostic tests when
there is no gold standard. A review of
methods.
By Rutjes AWS, Reitsma JB,
Coomarasamy A, Khan KS, 
Bossuyt PMM. 
No. 51
Systematic reviews of the clinical
effectiveness and cost-effectiveness of
proton pump inhibitors in acute upper
gastrointestinal bleeding. 
By Leontiadis GI, Sreedharan A,
Dorward S, Barton P, Delaney B,
Howden CW, et al. 
No. 52
A review and critique of modelling in
prioritising and designing screening
programmes.
By Karnon J, Goyder E, Tappenden P,
McPhie S, Towers I, Brazier J, et al. 
No. 53
An assessment of the impact of the 
NHS Health Technology Assessment
Programme. 
By Hanney S, Buxton M, Green C,
Coulson D, Raftery J. 
Volume 12, 2008
No. 1
A systematic review and economic
model of switching from non-
glycopeptide to glycopeptide antibiotic
prophylaxis for surgery.
By Cranny G, Elliott R, Weatherly H,
Chambers D, Hawkins N, Myers L, et al. 
Health Technology Assessment 2008; Vol. 12: No. 29
201
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.No. 2
‘Cut down to quit’ with nicotine
replacement therapies in smoking
cessation: a systematic review of
effectiveness and economic 
analysis. 
By Wang D, Connock M, Barton P,
Fry-Smith A, Aveyard P, Moore D. 
No. 3
A systematic review of the effectiveness
of strategies for reducing fracture risk in
children with juvenile idiopathic
arthritis with additional data on long-
term risk of fracture and cost of disease
management. 
By Thornton J, Ashcroft D, 
O’Neill T, Elliott R, Adams J, Roberts C,
et al. 
No. 4
Does befriending by trained lay workers
improve psychological well-being and
quality of life for carers of people 
with dementia, and at what cost? 
A randomised controlled trial. 
By Charlesworth G, Shepstone L,
Wilson E, Thalanany M, Mugford M,
Poland F. 
No. 5
A multi-centre retrospective cohort study
comparing the efficacy, safety and cost-
effectiveness of hysterectomy and
uterine artery embolisation for the
treatment of symptomatic uterine
fibroids. The HOPEFUL study. 
By Hirst A, Dutton S, Wu O, 
Briggs A, Edwards C, Waldenmaier L, 
et al. 
No. 6
Methods of prediction and prevention
of pre-eclampsia: systematic reviews of
accuracy and effectiveness literature with
economic modelling. 
By Meads CA, Cnossen JS, Meher S,
Juarez-Garcia A, ter Riet G, Duley L, 
et al.
No. 7
The use of economic evaluations in
NHS decision-making: a review and
empirical investigation. 
By Williams I, McIver S, Moore D,
Bryan S. 
No. 8
Stapled haemorrhoidectomy
(haemorrhoidopexy) for the treatment
of haemorrhoids: a systematic review
and economic evaluation.
By Burch J, Epstein D, Baba-Akbari A,
Weatherly H, Fox D, Golder S, et al. 
No. 9
The clinical effectiveness of diabetes
education models for Type 2 diabetes: 
a systematic review. 
By Loveman E, Frampton GK, 
Clegg AJ.
No. 10
Payment to healthcare professionals for
patient recruitment to trials: systematic
review and qualitative study. 
By Raftery J, Bryant J, Powell J, 
Kerr C, Hawker S. 
No. 11
Cyclooxygenase-2 selective non-steroidal
anti-inflammatory drugs (etodolac,
meloxicam, celecoxib, rofecoxib,
etoricoxib, valdecoxib and lumiracoxib)
for osteoarthritis and rheumatoid
arthritis: a systematic review and
economic evaluation. 
By Chen Y-F, Jobanputra P, Barton P,
Bryan S, Fry-Smith A, Harris G, 
et al. 
No. 12
The clinical effectiveness and cost-
effectiveness of central venous catheters
treated with anti-infective agents in
preventing bloodstream infections: 
a systematic review and economic
evaluation.
By Hockenhull JC, Dwan K, Boland
A, Smith G, Bagust A, Dündar Y, et al. 
No. 13
Stepped treatment of older adults on
laxatives. The STOOL trial. 
By Mihaylov S, Stark C, McColl E,
Steen N, Vanoli A, Rubin G, et al. 
No. 14
A randomised controlled trial of
cognitive behaviour therapy in
adolescents with major depression
treated by selective serotonin reuptake
inhibitors. The ADAPT trial. 
By Goodyer IM, Dubicka B, 
Wilkinson P, Kelvin R, Roberts C, 
Byford S, et al. 
No. 15
The use of irinotecan, oxaliplatin and
raltitrexed for the treatment of
advanced colorectal cancer: systematic
review and economic evaluation.
By Hind D, Tappenden P, Tumur I,
Eggington E, Sutcliffe P, Ryan A. 
No. 16
Ranibizumab and pegaptanib for the
treatment of age-related macular
degeneration: a systematic review and
economic evaluation. 
By Colquitt JL, Jones J, Tan SC,
Takeda A, Clegg AJ, Price A. 
No. 17
Systematic review of the clinical
effectiveness and cost-effectiveness of
64-slice or higher computed
tomography angiography as an
alternative to invasive coronary
angiography in the investigation of
coronary artery disease. 
By Mowatt G, Cummins E, Waugh N,
Walker S, Cook J, Jia X, et al. 
No. 18
Structural neuroimaging in psychosis: 
a systematic review and economic
evaluation. 
By Albon E, Tsourapas A, Frew E,
Davenport C, Oyebode F, Bayliss S, 
et al.
No. 19
Systematic review and economic analysis
of the comparative effectiveness of
different inhaled corticosteroids and
their usage with long-acting beta2
agonists for the treatment of chronic
asthma in adults and children aged 
12 years and over. 
By Shepherd J, Rogers G, Anderson R,
Main C, Thompson-Coon J, Hartwell D,
et al. 
No. 20
Systematic review and economic analysis
of the comparative effectiveness of
different inhaled corticosteroids and
their usage with long-acting beta2
agonists for the treatment of chronic
asthma in children under the age 
of 12 years. 
By Main C, Shepherd J, Anderson R,
Rogers G, Thompson-Coon J, Liu Z, 
et al.
No. 21
Ezetimibe for the treatment of
hypercholesterolaemia: a systematic
review and economic evaluation.
By Ara R, Tumur I, Pandor A, 
Duenas A, Williams R, Wilkinson A, 
et al. 
No. 22
Topical or oral ibuprofen for chronic
knee pain in older people. The TOIB
study. 
By Underwood M, Ashby D, Carnes D,
Castelnuovo E, Cross P, Harding G, 
et al.
No. 23
A prospective randomised comparison
of minor surgery in primary and
secondary care. The MiSTIC trial. 
By George S, Pockney P, Primrose J,
Smith H, Little P, Kinley H, et al.
No. 24
A review and critical appraisal of
measures of therapist–patient
interactions in mental health settings. 
By Cahill J, Barkham M, Hardy G,
Gilbody S, Richards D, Bower P, 
et al.
No. 25
The clinical effectiveness and cost-
effectiveness of screening programmes
for amblyopia and strabismus in
children up to the age of 4–5 years: 
a systematic review and economic
evaluation. 
By Carlton J, Karnon J, 
Czoski-Murray C, Smith KJ, Marr J. 
Health Technology Assessment reports published to date
202No. 26
A systematic review of the clinical
effectiveness and cost-effectiveness and
economic modelling of minimal incision
total hip replacement approaches in 
the management of arthritic disease of
the hip. 
By de Verteuil R, Imamura M, Zhu S,
Glazener C, Fraser C, Munro N, et al. 
No. 27
A preliminary model-based assessment
of the cost–utility of a screening
programme for early age-related
macular degeneration. 
By Karnon J, Czoski-Murray C, 
Smith K, Brand C, Chakravarthy U,
Davis S, et al. 
No. 28
Intravenous magnesium sulphate and
sotalol for prevention of atrial
fibrillation after coronary artery bypass
surgery: a systematic review and
economic evaluation. 
By Shepherd J, Jones J, 
Frampton GK, Tanajewski L ´ , 
Turner D, Price A. 
No. 29
Absorbent products for urinary/faecal
incontinence: a comparative evaluation
of key product designs. 
By Fader M, Cottenden A, Getliffe K,
Gage H, Clarke-O’Neill S, Jamieson K,
et al. 
Health Technology Assessment 2008; Vol. 12: No. 29
203
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.Health Technology Assessment 2008; Vol. 12: No. 29
205
Health Technology Assessment
Programme
Prioritisation Strategy Group
Members
Chair,
Professor Tom Walley, 
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool
Professor Bruce Campbell,
Consultant Vascular & General
Surgeon, Royal Devon & Exeter
Hospital
Professor Robin E Ferner,
Consultant Physician and
Director, West Midlands Centre
for Adverse Drug Reactions,
City Hospital NHS Trust,
Birmingham
Dr Edmund Jessop, Medical
Adviser, National Specialist,
Commissioning Advisory Group
(NSCAG), Department of
Health, London
Professor Jon Nicholl, Director,
Medical Care Research Unit,
University of Sheffield, 
School of Health and 
Related Research
Dr Ron Zimmern, Director,
Public Health Genetics Unit,
Strangeways Research
Laboratories, Cambridge
Director, 
Professor Tom Walley, 
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool
Deputy Director, 
Professor Jon Nicholl,
Director, Medical Care Research
Unit, University of Sheffield,
School of Health and Related
Research
HTA Commissioning Board
Members
Programme Director, 
Professor Tom Walley, 
Director, NHS HTA Programme,
Department of Pharmacology &
Therapeutics,
University of Liverpool
Chair,
Professor Jon Nicholl,
Director, Medical Care Research
Unit, University of Sheffield,
School of Health and Related
Research
Deputy Chair, 
Dr Andrew Farmer, 
University Lecturer in General
Practice, Department of 
Primary Health Care, 
University of Oxford
Dr Jeffrey Aronson,
Reader in Clinical
Pharmacology, Department of
Clinical Pharmacology,
Radcliffe Infirmary, Oxford
Professor Deborah Ashby,
Professor of Medical Statistics,
Department of Environmental
and Preventative Medicine,
Queen Mary University of
London
Professor Ann Bowling,
Professor of Health Services
Research, Primary Care and
Population Studies,
University College London
Professor John Cairns, 
Professor of Health Economics,
Public Health Policy, 
London School of Hygiene 
and Tropical Medicine, 
London
Professor Nicky Cullum,
Director of Centre for Evidence
Based Nursing, Department of
Health Sciences, University of
York
Professor Jon Deeks, 
Professor of Health Statistics,
University of Birmingham
Professor Jenny Donovan,
Professor of Social Medicine,
Department of Social Medicine,
University of Bristol
Professor Freddie Hamdy,
Professor of Urology, 
University of Sheffield
Professor Allan House, 
Professor of Liaison Psychiatry,
University of Leeds
Professor Sallie Lamb, Director,
Warwick Clinical Trials Unit,
University of Warwick
Professor Stuart Logan,
Director of Health & Social
Care Research, The Peninsula
Medical School, Universities of
Exeter & Plymouth
Professor Miranda Mugford,
Professor of Health Economics,
University of East Anglia
Dr Linda Patterson, 
Consultant Physician,
Department of Medicine,
Burnley General Hospital
Professor Ian Roberts, 
Professor of Epidemiology &
Public Health, Intervention
Research Unit, London School
of Hygiene and Tropical
Medicine
Professor Mark Sculpher,
Professor of Health Economics,
Centre for Health Economics,
Institute for Research in the
Social Services, 
University of York
Professor Kate Thomas,
Professor of Complementary
and Alternative Medicine,
University of Leeds
Professor David John Torgerson,
Director of York Trial Unit,
Department of Health Sciences,
University of York
Professor Hywel Williams,
Professor of 
Dermato-Epidemiology,
University of Nottingham
Current and past membership details of all HTA ‘committees’ are available from the HTA website (www.hta.ac.uk)
© Queen’s Printer and Controller of HMSO 2008. All rights reserved.Health Technology Assessment Programme
206
Diagnostic Technologies & Screening Panel
Members
Chair,
Dr Ron Zimmern, Director of
the Public Health Genetics Unit,
Strangeways Research
Laboratories, Cambridge
Ms Norma Armston,
Freelance Consumer Advocate,
Bolton
Professor Max Bachmann,
Professor of Health Care
Interfaces, Department of
Health Policy and Practice,
University of East Anglia
Professor Rudy Bilous
Professor of Clinical Medicine &
Consultant Physician,
The Academic Centre,
South Tees Hospitals NHS Trust
Ms Dea Birkett, Service User
Representative, London
Dr Paul Cockcroft, Consultant
Medical Microbiologist and
Clinical Director of Pathology,
Department of Clinical
Microbiology, St Mary's
Hospital, Portsmouth
Professor Adrian K Dixon,
Professor of Radiology,
University Department of
Radiology, University of
Cambridge Clinical School
Dr David Elliman, Consultant in
Community Child Health,
Islington PCT & Great Ormond
Street Hospital, London 
Professor Glyn Elwyn, 
Research Chair, Centre for
Health Sciences Research,
Cardiff University, Department
of General Practice, Cardiff
Professor Paul Glasziou,
Director, Centre for 
Evidence-Based Practice,
University of Oxford
Dr Jennifer J Kurinczuk,
Consultant Clinical
Epidemiologist, National
Perinatal Epidemiology Unit,
Oxford
Dr Susanne M Ludgate, 
Clinical Director, Medicines &
Healthcare Products Regulatory
Agency, London
Mr Stephen Pilling, Director,
Centre for Outcomes, 
Research & Effectiveness, 
Joint Director, National
Collaborating Centre for Mental
Health, University College
London
Mrs Una Rennard, 
Service User Representative,
Oxford
Dr Phil Shackley, Senior
Lecturer in Health Economics,
Academic Vascular Unit,
University of Sheffield
Dr Margaret Somerville,
Director of Public Health
Learning, Peninsula Medical
School, University of Plymouth
Dr Graham Taylor, Scientific
Director & Senior Lecturer,
Regional DNA Laboratory, The
Leeds Teaching Hospitals
Professor Lindsay Wilson
Turnbull, Scientific Director,
Centre for MR Investigations &
YCR Professor of Radiology,
University of Hull
Professor Martin J Whittle,
Clinical Co-director, National
Co-ordinating Centre for
Women’s and Childhealth 
Dr Dennis Wright, 
Consultant Biochemist &
Clinical Director, 
The North West London
Hospitals NHS Trust, 
Middlesex
Pharmaceuticals Panel
Members
Chair,
Professor Robin Ferner,
Consultant Physician and
Director, West Midlands Centre
for Adverse Drug Reactions, 
City Hospital NHS Trust,
Birmingham
Ms Anne Baileff, Consultant
Nurse in First Contact Care,
Southampton City Primary Care
Trust, University of
Southampton
Professor Imti Choonara,
Professor in Child Health,
Academic Division of Child
Health, University of
Nottingham
Professor John Geddes,
Professor of Epidemiological
Psychiatry, University of 
Oxford
Mrs Barbara Greggains, 
Non-Executive Director,
Greggains Management Ltd
Dr Bill Gutteridge, Medical
Adviser, National Specialist
Commissioning Advisory Group
(NSCAG), London
Mrs Sharon Hart, 
Consultant Pharmaceutical
Adviser, Reading
Dr Jonathan Karnon, Senior
Research Fellow, Health
Economics and Decision
Science, University of Sheffield
Dr Yoon Loke, Senior Lecturer
in Clinical Pharmacology,
University of East Anglia
Ms Barbara Meredith,
Lay Member, Epsom 
Dr Andrew Prentice, Senior
Lecturer and Consultant
Obstetrician & Gynaecologist,
Department of Obstetrics &
Gynaecology, University of
Cambridge 
Dr Frances Rotblat, CPMP
Delegate, Medicines &
Healthcare Products Regulatory
Agency, London
Dr Martin Shelly, 
General Practitioner, 
Leeds
Mrs Katrina Simister, Assistant
Director New Medicines,
National Prescribing Centre,
Liverpool
Dr Richard Tiner, Medical
Director, Medical Department,
Association of the British
Pharmaceutical Industry,
London
Current and past membership details of all HTA ‘committees’ are available from the HTA website (www.hta.ac.uk)Health Technology Assessment 2008; Vol. 12: No. 29
207
Therapeutic Procedures Panel
Members
Chair, 
Professor Bruce Campbell,
Consultant Vascular and
General Surgeon, Department
of Surgery, Royal Devon &
Exeter Hospital
Dr Mahmood Adil, Deputy
Regional Director of Public
Health, Department of Health,
Manchester
Dr Aileen Clarke,
Consultant in Public Health,
Public Health Resource Unit,
Oxford
Professor Matthew Cooke,
Professor of Emergency
Medicine, Warwick Emergency
Care and Rehabilitation,
University of Warwick
Mr Mark Emberton, Senior
Lecturer in Oncological
Urology, Institute of Urology,
University College Hospital
Professor Paul Gregg,
Professor of Orthopaedic
Surgical Science, Department of
General Practice and Primary
Care, South Tees Hospital NHS
Trust, Middlesbrough
Ms Maryann L Hardy, 
Lecturer, Division of
Radiography, University of
Bradford
Dr Simon de Lusignan,
Senior Lecturer, Primary Care
Informatics, Department of
Community Health Sciences,
St George’s Hospital Medical
School, London
Dr Peter Martin, Consultant
Neurologist, Addenbrooke’s
Hospital, Cambridge
Professor Neil McIntosh,
Edward Clark Professor of Child
Life & Health, Department of
Child Life & Health, University
of Edinburgh
Professor Jim Neilson,
Professor of Obstetrics and
Gynaecology, Department of
Obstetrics and Gynaecology,
University of Liverpool
Dr John C Pounsford,
Consultant Physician,
Directorate of Medical Services,
North Bristol NHS Trust
Dr Karen Roberts, Nurse
Consultant, Queen Elizabeth
Hospital, Gateshead
Dr Vimal Sharma, Consultant
Psychiatrist/Hon. Senior 
Lecturer, Mental Health
Resource Centre, Cheshire and
Wirral Partnership NHS Trust,
Wallasey 
Professor Scott Weich, 
Professor of Psychiatry, 
Division of Health in the
Community, University of
Warwick
Disease Prevention Panel
Members
Chair, 
Dr Edmund Jessop, Medical
Adviser, National Specialist
Commissioning Advisory Group
(NSCAG), London
Mrs Sheila Clark, Chief
Executive, St James’s Hospital,
Portsmouth
Mr Richard Copeland, 
Lead Pharmacist: Clinical
Economy/Interface, 
Wansbeck General Hospital,
Northumberland
Dr Elizabeth Fellow-Smith,
Medical Director, 
West London Mental Health
Trust, Middlesex
Mr Ian Flack, Director PPI
Forum Support, Council of
Ethnic Minority Voluntary
Sector Organisations, 
Stratford
Dr John Jackson, 
General Practitioner, 
Newcastle upon Tyne
Mrs Veronica James, Chief
Officer, Horsham District Age
Concern, Horsham
Professor Mike Kelly, 
Director, Centre for Public
Health Excellence, 
National Institute for Health
and Clinical Excellence, 
London
Professor Yi Mien Koh, 
Director of Public Health and
Medical Director, London 
NHS (North West London
Strategic Health Authority),
London
Ms Jeanett Martin, 
Director of Clinical Leadership
& Quality, Lewisham PCT,
London
Dr Chris McCall, General
Practitioner, Dorset
Dr David Pencheon, Director,
Eastern Region Public Health
Observatory, Cambridge
Dr Ken Stein, Senior Clinical
Lecturer in Public Health,
Director, Peninsula Technology
Assessment Group, 
University of Exeter, 
Exeter
Dr Carol Tannahill, Director,
Glasgow Centre for Population
Health, Glasgow
Professor Margaret Thorogood,
Professor of Epidemiology,
University of Warwick, 
Coventry
Dr Ewan Wilkinson, 
Consultant in Public Health,
Royal Liverpool University
Hospital, Liverpool
Current and past membership details of all HTA ‘committees’ are available from the HTA website (www.hta.ac.uk)Health Technology Assessment Programme
208
Current and past membership details of all HTA ‘committees’ are available from the HTA website (www.hta.ac.uk)
Expert Advisory Network
Members
Professor Douglas Altman,
Professor of Statistics in
Medicine, Centre for Statistics
in Medicine, University of
Oxford
Professor John Bond,
Director, Centre for Health
Services Research, University of
Newcastle upon Tyne, School of
Population & Health Sciences,
Newcastle upon Tyne
Professor Andrew Bradbury,
Professor of Vascular Surgery,
Solihull Hospital, Birmingham
Mr Shaun Brogan, 
Chief Executive, Ridgeway
Primary Care Group, Aylesbury
Mrs Stella Burnside OBE,
Chief Executive, 
Regulation and Improvement
Authority, Belfast
Ms Tracy Bury, 
Project Manager, World
Confederation for Physical
Therapy, London
Professor Iain T Cameron,
Professor of Obstetrics and
Gynaecology and Head of the
School of Medicine,
University of Southampton
Dr Christine Clark,
Medical Writer & Consultant
Pharmacist, Rossendale
Professor Collette Clifford,
Professor of Nursing & Head of
Research, School of Health
Sciences, University of
Birmingham, Edgbaston,
Birmingham
Professor Barry Cookson,
Director, Laboratory of
Healthcare Associated Infection,
Health Protection Agency,
London
Dr Carl Counsell, Clinical
Senior Lecturer in Neurology,
Department of Medicine &
Therapeutics, University of
Aberdeen
Professor Howard Cuckle,
Professor of Reproductive
Epidemiology, Department of
Paediatrics, Obstetrics &
Gynaecology, University of
Leeds
Dr Katherine Darton, 
Information Unit, MIND – 
The Mental Health Charity,
London
Professor Carol Dezateux, 
Professor of Paediatric
Epidemiology, London
Dr Keith Dodd, Consultant
Paediatrician, Derby
Mr John Dunning,
Consultant Cardiothoracic
Surgeon, Cardiothoracic
Surgical Unit, Papworth
Hospital NHS Trust, Cambridge
Mr Jonothan Earnshaw,
Consultant Vascular Surgeon,
Gloucestershire Royal Hospital,
Gloucester
Professor Martin Eccles, 
Professor of Clinical
Effectiveness, Centre for Health
Services Research, University of
Newcastle upon Tyne
Professor Pam Enderby,
Professor of Community
Rehabilitation, Institute of
General Practice and Primary
Care, University of Sheffield
Professor Gene Feder, Professor
of Primary Care Research &
Development, Centre for Health
Sciences, Barts & The London
Queen Mary’s School of
Medicine & Dentistry, London
Mr Leonard R Fenwick, 
Chief Executive, Newcastle
upon Tyne Hospitals NHS Trust
Mrs Gillian Fletcher, 
Antenatal Teacher & Tutor and
President, National Childbirth
Trust, Henfield
Professor Jayne Franklyn,
Professor of Medicine,
Department of Medicine,
University of Birmingham,
Queen Elizabeth Hospital,
Edgbaston, Birmingham
Dr Neville Goodman, 
Consultant Anaesthetist,
Southmead Hospital, Bristol
Professor Robert E Hawkins, 
CRC Professor and Director of
Medical Oncology, Christie CRC
Research Centre, Christie
Hospital NHS Trust, Manchester
Professor Allen Hutchinson, 
Director of Public Health &
Deputy Dean of ScHARR,
Department of Public Health,
University of Sheffield
Professor Peter Jones, Professor
of Psychiatry, University of
Cambridge, Cambridge
Professor Stan Kaye, Cancer
Research UK Professor of
Medical Oncology, Section of
Medicine, Royal Marsden
Hospital & Institute of Cancer
Research, Surrey
Dr Duncan Keeley,
General Practitioner (Dr Burch
& Ptnrs), The Health Centre,
Thame
Dr Donna Lamping,
Research Degrees Programme
Director & Reader in Psychology,
Health Services Research Unit,
London School of Hygiene and
Tropical Medicine, London
Mr George Levvy,
Chief Executive, Motor 
Neurone Disease Association,
Northampton
Professor James Lindesay,
Professor of Psychiatry for the
Elderly, University of Leicester,
Leicester General Hospital
Professor Julian Little,
Professor of Human Genome
Epidemiology, Department of
Epidemiology & Community
Medicine, University of Ottawa
Professor Rajan Madhok, 
Consultant in Public Health,
South Manchester Primary 
Care Trust, Manchester
Professor Alexander Markham, 
Director, Molecular Medicine
Unit, St James’s University
Hospital, Leeds
Professor Alistaire McGuire,
Professor of Health Economics,
London School of Economics
Dr Peter Moore, 
Freelance Science Writer, Ashtead
Dr Andrew Mortimore, Public
Health Director, Southampton
City Primary Care Trust,
Southampton
Dr Sue Moss, Associate Director,
Cancer Screening Evaluation
Unit, Institute of Cancer
Research, Sutton
Mrs Julietta Patnick, 
Director, NHS Cancer Screening
Programmes, Sheffield
Professor Robert Peveler,
Professor of Liaison Psychiatry,
Royal South Hants Hospital,
Southampton
Professor Chris Price, 
Visiting Professor in Clinical
Biochemistry, University of
Oxford
Professor William Rosenberg,
Professor of Hepatology and
Consultant Physician, University
of Southampton, Southampton
Professor Peter Sandercock,
Professor of Medical Neurology,
Department of Clinical
Neurosciences, University of
Edinburgh
Dr Susan Schonfield, Consultant
in Public Health, Hillingdon
PCT, Middlesex
Dr Eamonn Sheridan,
Consultant in Clinical Genetics,
Genetics Department,
St James’s University Hospital,
Leeds
Professor Sarah Stewart-Brown, 
Professor of Public Health,
University of Warwick, 
Division of Health in the
Community Warwick Medical
School, LWMS, Coventry
Professor Ala Szczepura, 
Professor of Health Service
Research, Centre for Health
Services Studies, University of
Warwick
Dr Ross Taylor, 
Senior Lecturer, Department of
General Practice and Primary
Care, University of Aberdeen
Mrs Joan Webster, 
Consumer member, HTA –
Expert Advisory NetworkHow to obtain copies of this and other HTA Programme reports.
An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of
charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is
also available (see below). 
Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and
private sector purchasers from our Despatch Agents.
Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is
£2 per monograph and for the rest of the world £3 per monograph.
You can order HTA monographs from our Despatch Agents:
– fax (with credit card or ofﬁcial purchase order) 
– post (with credit card or ofﬁcial purchase order or cheque)
– phone during ofﬁce hours (credit card only).
Additionally the HTA website allows you either to pay securely by credit card or to print out your
order and then post or fax it.
Contact details are as follows:
HTA Despatch Email: orders@hta.ac.uk
c/o Direct Mail Works Ltd Tel: 02392 492 000
4 Oakwood Business Centre Fax: 02392 478 555
Downley, HAVANT PO9 2NP , UK Fax from outside the UK: +44 2392 478 555
NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of 
£100 for each volume (normally comprising 30–40 titles). The commercial subscription rate is £300 
per volume. Please see our website for details. Subscriptions can only be purchased for the current or
forthcoming volume.
Payment methods
Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd
and drawn on a bank with a UK address.
Paying by credit card
The following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard,
Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email.
Paying by ofﬁcial purchase order
You can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.
We cannot at present accept purchase orders from commercial companies or from outside the UK.
How do I get a copy of HTA on CD?
Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see
contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.
The website also provides information about the HTA Programme and lists the membership of the various
committees.
HTAA preliminary model-based assessment
of the cost–utility of a screening 
programme for early age-related 
macular degeneration
J Karnon, C Czoski-Murray, K Smith, C Brand, 
U Chakravarthy, S Davis, N Bansback, 
C Beverley, A Bird, S Harding, I Chisholm 
and YC Yang
Health Technology Assessment 2008; Vol. 12: No. 27
HTA
Health Technology Assessment
NHS R&D HTA Programme
www.hta.ac.uk
The National Coordinating Centre for Health Technology Assessment,
Alpha House, Enterprise Road
Southampton Science Park
Chilworth
Southampton SO16 7NS, UK.
Fax: +44 (0) 23 8059 5639 Email: hta@hta.ac.uk
http://www.hta.ac.uk ISSN 1366-5278
Feedback
The HTA Programme and the authors would like to know 
your views about this report.
The Correspondence Page on the HTA website
(http://www.hta.ac.uk) is a convenient way to publish 
your comments. If you prefer, you can send your comments 
to the address below, telling us whether you would like 
us to transfer them to the website.
We look forward to hearing from you.
June 2008
H
e
a
l
t
h
 
T
e
c
h
n
o
l
o
g
y
 
A
s
s
e
s
s
m
e
n
t
 
2
0
0
8
;
V
o
l
.
 
1
2
:
 
N
o
.
 
2
7
C
o
s
t
–
u
t
i
l
i
t
y
 
o
f
 
a
 
s
c
r
e
e
n
i
n
g
 
p
r
o
g
r
a
m
m
e
 
f
o
r
 
e
a
r
l
y
 
a
g
e
-
r
e
l
a
t
e
d
 
m
a
c
u
l
a
r
 
d
e
g
e
n
e
r
a
t
i
o
n